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Abstract 
Pyrimidine uptake has previously been investigated in Trypanosoma brucei 
procyclics and partly investigated in promastigotes of Leishmania major; 
however, no such study has been performed using bloodstream forms of 
Trypanosoma or promastigotes of Leishmania. Here we report a comprehensive 
study of pyrimidine salvage and metabolism in bloodstream forms of 
Trypanosoma and promastigotes of Leishmania species. 
In T. b. brucei bloodstream forms, the uptake of 3H-uracil and 3H-tymidine each 
appeared to be mediated by a single transporter, designated TbU3 and TbT1, 
respectively. The procyclic uracil transporter,TbU1, has a high affinity for uracil, 
with a Km value of 0.46 ± 0.09 μM and Vmax of 0.65 ± 0.008 pmol (10
7cell)-1 s-1. 
These values were similar for TbU3 (Km = 0.54 ± 0.11 µM; Vmax = 0.14 ± 0.03), but 
the main differences between TbU1 and TbU3 are their sensitivity to uridine and 
4-thiouracil. Thymidine uptake is detectable at 10 μM over a period from 5 to 30 
minutes. This uptake was not inhibited by uracil which indicates that TbT1 is a 
novel thymidine transporter. The uptake of other pyrimidines, including uridine 
and 2’-deoxyuridine, by BSF are investigated here but these substrates were also 
transported by TbU3, and no additional pyrimidine transport activities were 
found.  
In L. mexicana and L. major, the uptake of 3H-uracil and 3H-uridine was 
mediated by separate transporters, designated as follows; for uracil uptake 
LmexU1, LmajU1; and for uridine uptake LmexNT1, LmajNT1 and LmajNT2, 
respectively. LmexU1 is a uracil transporter with high affinity to uridine and 
2’deoxyuridine, and the LmexNT1 is a nucleoside transporter with broad 
specificity for purine and pyrimidine nucleosides. L. major uracil transporter 
(LmajU1) has already been reported by others; and here we report that there 
are also two distinct uridine transporters expressed in L. major. LmajNT1 is a 
high affinity uridine transporter which is also inhibited by uracil, inosine and 
adenine; LmajNT2 is low affinity uridine transporter, with very poor affinity for 
uracil, inosine and adenine. However, both transporters are inhibited by 2’-
deoxyuridine, thymidine and adenosine.  
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Several fluorinated pyrimidine analogues were assessed against kinetoplastid 
cells, the most effective compounds, which displayed EC50 values at micromolar 
level, are 5-FU, 5F-2’dUrd, 5-FOA (only against T. brucei BSF) and 5F-Urd (only 
against L. major). We induced resistance to 5-FU, 5-F2’dUrd and 5-FOA by in 
vitro exposure of Tbb-BSF and promastigotes of L. mexicana and L. major. The 
resistance was performed by stepwise increase concentration of the drugs. For 
T. b. brucei BSF, the resistance factors of clonal lines were 131, 825, and 83-
fold, respectively. For L. mexicana and L. major, the resistance factor for 5-FU 
were 147 and 17-fold, and for 5F-2’dUrd were >3500 and 381-fold, respectively. 
We also measured 3H–pyrimidine uptake in these cell lines; the resistant 
bloodstream form strains showed no changes in pyrimidine uptake, with one 
exception, which is a 76% reduction in 5-FU uptake. In contrast, each resistant 
strain of Leishmania spp had lost its natural pyrimidine transporter. For 
example, Leishmania cells resistant to 5-FU had lost uracil transport activity, 
and cells that were resistant to 5F-2’dUrd had lost uridine transport activity. In 
addition, we identified kinetoplastid genes that appeared to be associated with 
resistance to fluorinated pyrimidines. 
Based on these findings, metabolomic analysis of fluorinated pyrimidines in T. b. 
brucei resistant cell lines was performed in comparison with parental wild-type; 
for Leishmania species we only investigated the metabolism of fluorinated 
pyrimidine in wild type cells, as the fluorinated analogues were simply not taken 
up in the resistant clones. The metabolomic analysis data showed that, in T. b. 
brucei, 5-fluorouracil and 5-fluoro orotate are incorporated into a large number 
of metabolites, but likely act through incorporation into RNA. 5F-2’dUrd and 5F-
2’dCtd are not incorporated into nucleic acids but act as prodrugs by inhibiting 
thymidylate synthase after conversion to 5F-dUMP. Cells treated with 5-fluoro-
2’deoxyuridine showed an increase of dUMP, which suggest a block in 
thymidylate synthase or possibly thymidylate kinase. We also present the most 
complete model of pyrimidine salvage in T. brucei to date, supported by 
genome-wide profiling of the predicted pyrimidine biosynthesis and conversion 
enzymes. 
The effect of fluorinated pyrimidine analogues in the two Leishmania species 
was almost identical. Each of the tested drugs (5-FU, 5F-2’dUrd and 5F-Urd) 
produced a limited number of fluorinated metabolites, and their common mode 
J. Ali 2013  iii 
of action was inhibition in thymidylate synthase by 5F-dUMP and thymidine 
kinase by 5F-2’dUrd. Interestingly, we found that the cause of L. mexicana 
resistance to 5F-Urd was due to the absence of the 5F-2’dUrd metabolite, as a 
result of the rapid conversion of 5F-2’dUrd to 5F-dUMP; also we suggest that, in 
L. mexicana, but not in L. major the high affinity salvage of thymidine is 
sufficient to provide the cells with thymidine deoxynucleotides. 
It has been found that pyrimidine salvage is not an essential function for 
Leishmania cells in vitro conditions. However, it is not known whether either, 
pyrimidine salvage or biosynthesis, or both of these systems are essential to the 
trypanosomes in vitro and in vivo study. As T. b. brucei bloodstream forms grew 
unimpeded in vitro in the complete absence of pyrimidines, uptake is clearly not 
essential. Disruption of the pyrimidine biosynthesis pathway by deletion of the 
OMPDCase/OPRTase gene resulted in pyrimidine auxotrophic trypanosomes that 
were unable to grow in the absence of added pyrimidines. The phenotype was 
rescued by addition of uracil, and to a lesser extent by some pyrimidine 
nucleosides. Pyrimidine starvation led rapidly to DNA fragmentation. Adaptations 
to low pyrimidine availability included upregulation of uracil transport capacity 
and of uridine phosphorylase expression. However, pyrimidine auxotrophic T. 
brucei were able to establish a high parasitemia in mice. We therefore conclude 
that pyrimidine salvage was not an essential function for bloodstream T. b. 
brucei. However, trypanosomes lacking de novo pyrimidine biosynthesis are 
completely dependent on an extracellular pyrimidine source, strongly preferring 
uracil, and display reduced infectivity and strongly increased sensitivity to 
fluorinated pyrimidines. As T. brucei are able to salvage sufficient pyrimidines 
from the host environment, the pyrimidine biosynthesis pathway is not a viable 
drug target, although any interruption of pyrimidine supply was lethal. 
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The protozoan order Kinetoplastid contains several parasites and has the 
following systematic position: Phylum Protozoa, Subphylum Sarcomastigiphora, 
Superclass Mastigophora, and Class Zoomastigophora. The crucial genera 
belonging to this group are Trypanosoma and Leishmania, which cause the most 
significant human and veterinary diseases, trypanosomiasis and leishmaniasis, 
respectively. 
1 - Trypanosomiasis 
1.1 Epidemiology and life cycle 
African trypanosomiasis encompasses a number of important animal and human 
diseases and results from infection with protozoan parasites of the genus 
Trypanosoma. The disease occurs in 37 sub-Saharan countries (Figure 1.1), 
where there are suitable habitats for its vector, the tsetse fly. Most of these 
countries are among the least developed in the world (WHO, 2006). African 
trypanosomes are a monophyletic group of unicellular parasitic flagellate 
protozoa and belong to the family Trypanosomatidae, genus Trypanosoma which 
has several species, subspecies and strains. Trypanosomiasis affects both animals 
(animal African trypanosomiasis, AAT) and people (human African 
trypanosomiasis, HAT). 
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Figure 1.1. Human African trypanosomiasis in affected countries. The 
black line denotes the boundary between T. b. gambiense and T. b. 
rhodesiense. Obtained from (Brun et al., 2010). 
AAT is caused by different parasitic species and subspecies of the 
Trypanosoma genus such as T. brucei, T. congolense, T. vivax, T. simiae and T. 
evansi.(Grootenhuis et al., 1990). Animals can also be infected by T. brucei 
gambiense (WHO, 2006). The disease affects many wild and domestic animal 
species. The main effect of AAT on economic development of the rural areas 
concerns domestic animals, especially cattle (in cattle the disease is called 
Nangana). The disease leads to direct losses from AAT in livestock, and costs 
animal producers and consumers an estimated $1340 million per year 
(Kristjanson et al., 1999). The main losses are connected to cattle mortality and 
morbidity, diagnosis, treatment costs and the decrease in agricultural 
production. In Africa, it is estimated that over an area of 8.7 million Km2 
approximately 46 million cattle are exposed to the risk of the disease (Reid et 
al., 1995). The prevalence of AAT is influenced by the age and breed of the 
animal (but not sex) and the season of the year (Kalu, 1995). 
Although untreated animals infected with T. brucei eventually die 
(CFSPH, 2009), this subspecies is non-infectious to humans because of its 
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sensitivity to a human serum factor that lyses the parasite (Hager & Hajduk, 
1997). The trypanolytic activity is linked to high-density lipoprotein (HDL) 
particles (Rifkin, 1978; Rifkin, 1991), especially HDL3 (Lorenz et al., 1995). Two 
proteins in human HDL have been suggested to be the trypanolytic factor (TLF): 
hepatoglobin-related protein (Drain et al., 2001; Lugli et al., 2004) and 
apolipoprotein L1 (Perez-Morga et al., 2005; Vanhamme et al., 2003). 
Trypanosomes transport these particles by receptor-mediated endocytosis and 
the toxicity is related to this uptake. However, separate reports found that, in 
rare cases, trypanosomiasis in man might also be caused by normally non-human 
pathogenic trypanosome species such as T. congolense (Truc et al., 1998), T. 
evansi (Joshi et al., 2005) and T. b. brucei (Deborggraeve et al., 2008). 
HAT, or sleeping sickness, has two classical forms, which mainly differ 
according to incubation time. The acute form is caused by Trypanosoma brucei 
rhodesiense parasites and occurs in eastern and southern Africa, and the chronic 
form is connected to Trypanosoma brucei gambiense found in western and 
central Africa (Figure 1.1). However, the separation between T. b. gambiense 
and T. b. rhodesiense could soon change because the continued spread of T. b. 
rhodesiense in Uganda towards the northwest might lead to an overlap in the 
distribution of the two forms of the disease (Kim et al., 2005). Furthermore, it is 
now recognised that this dichotomy between the two trypanosomes is not fully 
representative of the disease process (Courtin et al., 2008). HAT is usually fatal 
in the absence of treatment. The situation in Africa is that approximately 60 
million people are at risk of infection with 3-4 million people under surveillance 
(Cattand et al., 2001). Although (WHO, 2012) reported a decline in the number 
of new cases in 36 endemic countries by 28% in 2010 compared with 2009 and 
currently it is estimated that there are 30,000 cases of the disease, the 
incidence remains high in some countries such as the Congo (500 reported cases 
in 2010). A recent study has found that around 10000 sleeping sickness cases 
were reported in 2009 (Simarro et al., 2011). The re-emergence of HAT could be 
partly attributed to decreased surveillance and control activities, the 
appearance of parasite and vector chemical resistance, host disease 
susceptibility, war and migrations of populations (Courtin et al., 2008). In 
addition, no successful vaccine against HAT is available (Malvy & Chappuis, 
2011). 
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Transmission 
Trypanosomes are transmitted by blood-feeding tsetse flies, a grey-brown 
insect. Both females and males can transmit the disease from one mammalian 
host to another (Aksoy et al., 2001). Repeated feeding on the same host species 
by a tsetse fly is likely to increase the disease-transmission risk. About 30 
species and subspecies of tsetse flies belong to the genus Glossina, the only 
genus in the family Glossinidae, and they show different abilities to transmit 
trypanosomiasis (Jordan, 1993). Glossina spp infest 10 million Km2 of the 
continent of Africa (Rogers & Randolph, 1986) and occupy an area from 
approximately latitude 14° north to 20° south (Steverding, 2008). Glossina 
palpalis and G. tachinoides transmit chronic trypanosomiasis in West Africa, and 
G. fuscipes in central Africa, whereas G. morstans, G. swynnertoni and G. 
pallidipes are responsible for the acute form of trypanosomiasis (Service, 1996). 
A control of the trypanosomiasis transmission from their invertebrate host is 
important in the disease management. Decades ago, several of trypanosomiasis 
control methods reduced the prevalence of the disease through the use of 
insecticides (i.e. a DDT spray) and the clearance of vegetation. However, these 
tools are undesirable because of the environmental pollution, constrain 
agricultural production and reduce livestock supply. Moreover, the tsetse flies 
become resistance and tolerant to the used dose of chemical insecticides 
(Allsopp, 2001). An alternative method used to save the environment and food 
chain process is trapping insect hosts using fabric traps with attractive shape and 
colour. Recently, sterile insect techniques have been introduced to interrupt the 
transmission of parasites. For instance, sterilizing insect males by irradiation and 
releasing masses of them to target a selected area (where the highest insect 
population is) led to a significant reduction in the invertebrate host number 
(Aksoy, 2003; Vreysen et al., 2000). 
 In addition, transmission of trypanosomiasis can occur by contaminated 
needles or blood transfusion, or the congenital route (Barrett et al., 2003). 
Children can be infected via their mothers by the disease crossing the placenta 
and infecting the foetus causing abortion or perinatal death (De Raadt, 1985; 
Debroise et al., 1968; Lindner & Priotto, 2010). 
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Life cycle 
African trypanosomes undergo several changes during the transmission 
process between the blood of the mammalian host and the gut of the tsetse fly 
(Matthews, 1999;Vickerman, 1985), when the parasite passes from the glucose-
rich environment (the bloodstream in the mammalian host) to the insect midgut, 
its form is changed and the amino acid proline becomes the main source of 
energy (Ford & Bowman, 1973; Overath et al., 1986). Parasites migrate from gut 
to salivary glands and emerge as mammal-infective metacyclic trypanosomes. 
When an infected tsetse fly (genus Glossina) takes blood from a mammalian 
host, it injects metacyclic trypomastigotes into skin tissue. In mammalian cells, 
the parasite proliferates as long slender forms. The most crucial changes in 
parasite cells occur in its mitochondrial system as this adapts via changes in 
their energy metabolism and in the surface membrane to escape the mammalian 
host’s immune defence system (Vickerman, 1971). The attack by parasites 
triggers the mammalian antibody responses, leading to a sequential expression 
of variable surface glycoproteins (VSGs) which are connected to the surface 
membrane by a glycosylphosphatidylinositol anchor (McCulloch, 2004; Pays et 
al., 2004). The trypanosome genome expresses approximately 1000 gene-
encoding sequences for these VSGs (Borst, 2002). Non-proliferative stumpy forms 
replace the slender trypomastigotes as the parasitemia count decreases 
(Matthews et al., 2004; Vickerman, 1985). What is more important is that this 
change arrests stumpy forms in the G1 phase of the cell cycle that serves for the 
re-entry into the cell cycle after transmission to the tsetse fly (Matthews, 2005). 
When bloodstream forms are ingested by Glossina spp, the short stumpy form 
rapidly differentiates into procyclic trypomastigote within the posterior part of 
the tsetse midgut in the endoperitrophic space (Vickerman, 1985), and replaces 
the VSG coat with a less dense surface coat of glycosylphosphatidylinositol-
anchored proteins known as procyclines (Roditi & Liniger, 2002), and the energy 
supply is also changed from glycolysis to a mitochondrion-based respiratory 
system, which demands a complicated metabolomic process (Matthews, 2005). 
After a few days of infection, the procyclic form proliferates, differentiates to 
the long trypomastigote (proventriculus form) and migrates via the oesophagus, 
mouthparts and salivary ducts to establish infection in the salivary glands, then 
transforms to epimastigotes (Van Den Abbeele et al., 1999; Vickerman, 1985). 
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Epimastigotes transform into uncoated premetacyclics, which become 
metacyclics - the infective stage. Once the parasite undergoes division arrest 
during the metacyclic stage, it requires a VSG coat and is released into the 
salivary glands, where it is ready to infect new mammalian host (Figure 1.2). 
The cycle in the fly takes about three weeks to progress. 
 
Figure 1.2. life cycle of Trypanosoma species. Reproduced from The Centres for Disease 
Control (http://dpd.cdc.gov/dpdx). 
1.2 Pathology 
In African animal trypanosomiasis, the incubation time takes between four 
days to several weeks, and the signs on the localised site of the insect bite are 
usually unclear (CFSPH, 2009). The parasite rapidly invades the blood in the first 
days of infection. However, describing clinical symptoms of trypanosomes is 
difficult because infections with more than one species of trypanosomes 
frequently occur, as well as infection occurring at the same time with other 
hemo-parasites being common (Nyeko et al., 1990). The most important clinical 
symptom is anaemia, which becomes severe two months post-infection, with 
other clinical signs being intermittent fever, weight loss, oedema, diarrhoea and 
appetite loss (CFSPH, 2009). In the cases of HAT, trypanosomes are located 
inside the inoculation lesion of the bite for several days, and then multiply in 
J. Ali 2013 Chapter 1 8 
blood and lymph tissues. The chancre is usually the first symptom of HAT, 
primarily for T. b. rhodesiense. African trypanosomiasis is classified into two 
stages: the first stage of the disease is known as the haemolymphatic phase and 
it occurs during parasite proliferation in the blood and lymph systems. Within 
stage I, several nonspecific features may occur such as intermittent fever 
because of the high and low number of parasites, and various parasitemia as a 
result of various antigenic reactions. Other symptoms may be encountered: 
lymphadenopathy, pruritus, oedemas, headaches, anorexia, anaemia and 
hyperesthesia. According to stage I duration, the HAT occur in two forms. In 
acute infection, stage I may last for only a few weeks, whilst in the chronic form 
it lasts several years (Barrett et al., 2003). 
The following stage is the neurological phase and this begins when the 
parasite crosses the blood brain barrier (BBB) and invades the central nervous 
system. A characteristic disturbance of the sleep cycle, which gives the disease 
its name, is an important feature of the second stage of the disease. Symptoms 
related to African trypanosomiasis infection vary according to parasite strains 
and species, host type and environmental factors (Courtin et al., 2008). For 
example, procyclic forms of T. b. gambiense do not cross the in vitro model of 
the human BBB, whereas human-infective bloodstream forms cross it much more 
efficiently than animal-infective T. b. brucei (Nikolskaia et al., 2006). In West 
African forms of sleeping sickness, the expansion of the neurological stage does 
not occur for decades. However, invasion of the CNS in East African sleeping 
sickness occur within weeks. The appearance of neurological problems exists 
mainly in stage II and includes sleeping disorders, hyperesthesia, neuroendocrine 
dysfunctions, cachexia and finally coma (Courtin et al., 2008). 
Diagnosis 
Despite exhibiting various symptoms, AAT is difficult to diagnose unless 
the parasite is detected via detecting the parasite under microscope 
examination of the blood or by serological reaction (CFSPH, 2009). There are 
many parasite detection methods that are currently available for field use. 
Parasitological diagnosis is based on microscopic examination of the blood. This 
is simply done by staining the organism in a blood film using Giemsa’s stain. 
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Unfortunately, this parasitological method is limited by the irregular number of 
trypanosomes, especially in case of T. b. gambiense infection where the 
numbers are typically 103 and sometimes fall below 102 cells/ml (Chappuis et 
al., 2005). 
The blood concentration technique of microhematocrit centrifugation 
(mHCT) to investigate HAT has been developed decades ago (Woo, 1971), but it 
is still in use. In this method, a high speed centrifugation of hematocrit capillary 
tubes can concentrate the parasites between the plasma and the erythrocytes. 
However, this simple technique is considered time-consuming and needs skilled 
workers (Chappuis et al., 2005). The mini-anion-exchange centrifugation 
technique (mAECT) introduced by (Lumsden et al., 1979) is more sensitive than 
the thick blood film and mHCT techniques, especially when the method was 
updated by (Zillmann et al., 1996). The techniques are based on isolating the 
parasites from blood veins by anion-exchange chromatography, the isolate is 
slowly centrifuged, then the trypanosomes can be examined using a microscope, 
but the manipulations in this technique are tedious and time-consuming. In vitro 
culture and animal inoculation is also used as way of diagnosis (Aerts et al., 
1992). However, some obstacles limit this method such as the high cost and the 
long delay before obtaining results. Furthermore, this method is not 
recommended in the case of T. b. gambiense infection because this species 
grows poorly in laboratory rodents (Garcia, 2007). 
In the second stage of HAT, WHO recommends cerebrospinal fluid (CSF) 
examination, which can be obtained by lumber puncture. This test relies on the 
presence of >5 cells per micro litre and/or >370 mg per litre of trypanosomes in 
cerebrospinal fluid (WHO, 1998). These are counted by the dye-binding protein 
assay. Immunofluorescence assays have also been successfully used for HAT 
diagnosis such as enzyme-linked immune-sorbent assay (ELISA) methods, which 
can detect specific antibodies in the salvia from patients to confirm HAT (Lejon 
et al., 2003). 
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1.3 Chemotherapy 
Without treatment, sleeping sickness is thought to be almost invariably 
fatal, especially if it has progressed to the neurological stage. The membrane of 
trypanosomes in mammals is almost completely covered with VSG, which is the 
main antigenic determinant for the human immune system (Sternberg, 1998). In 
addition, the genome of Trypanosoma contains about 103 genes capable of 
coding for VSG genes, which are randomly switched on and off at each 
generation (Donelson et al., 1998). The variant-specific glycoprotein coat 
enables the parasite to escape destruction by the host immune system 
(Matthews, 2005) and ultimately cause a fatal invasion of the CNS. Due to the 
highly variable nature of the glycoprotein coat, all attempts to discover an 
efficient vaccine have met with little success. This immune mechanism is a 
major obstacle to developing a successful vaccine. Therefore, the only available 
option to control HAT is through chemotherapy or vector control. Although 
chemotherapy for trypanosomiasis has been available since the early 20th 
century, no ideal drugs have been discovered. There are four trypanosomal drugs 
currently licensed for the treatment of HAT. 
1.3.1 Pentamidine 
 
Figure 1.3. Chemical structure of pentamidine. 
Pentamidine (Figure 1.3), which is a water-soluble aromatic diamidine 
drug, was introduced in 1941 to treat early stage trypanosomiasis. The drug is 
given by intramuscular injections of 4 mg/kg (Jannin & Cattand, 2004). It has 
been reported that the drug can be taken up by three different transporters: the 
P2 aminopurine transporter (Carter et al., 1995), the high affinity pentamidine 
transporter (HAPT1) and the low affinity pentamidine transporter (LAPT1) (De 
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Koning, 2001). Many studies have focused on the mode of action of pentamidine 
and the consensus is now that it has a multifactorial impact; as such, its target 
has not conclusively been defined. Pentamidine is known to bind to 
mitochondrial DNA and eventually leads to the development of dyskinetoplastic 
forms (Barrett et al., 2007), but the drug has no effect on nuclear DNA. 
Recently, (Moreno et al., 2010) found that pentamidine targets the minor groove 
of DNA where the level of purine nucleobase adenine and its counterpart 
pyrimidine nucleobase thymine are highly concentrated. Other targets previously 
studied in trypanosomes were the inhibition of the polyamine biosynthetic 
pathway, glycolysis and lipid metabolism, as well as effects on amino acid 
transport and ion exchange. However, it has been reported that pentamidine is 
effective against early stage T. b. gambiense infection, but it is less effective 
against T. b. rhodesiense infection, and is ineffective against the late stage 
disease (Barrett et al., 2007; Wang, 1995). In addition, the drug has some side 
effects such as vomiting, abdominal pain and hypoglycaemia (Legros et al., 
2002). 
Another aromatic diamidine drug is diminazene aceturate (berenil), which 
has been developed and licensed for veterinary use. It has also been found that 
the drug is effective against the early stage of T. b. gambiense and T. b. 
rhodesiense infections. Moreover, it has been used in combination with 
melarsoprol for the late stage of the disease. Diminazene uptake via the P2 
transporter has been confirmed by using 3H-diminazene (De Koning et al., 2004) 
or TbAT1 knockout cells (Matovu et al., 2003), indicating that the P2 transporter 
is the main route of the drug uptake. Like pentamidine, berenil mode of action 
is linked to kinetoplast DNA binding (Wang, 1995). However, it is proposed that 
the drug can inhibit topoisomerase II and is believed to interfere in the 
trypanothione metabolism by inhibiting the decarboxylation of S-
adenosylmethionine (Gomes-Cardoso et al., 1999). Although diminazene uptake 
occurs via the P2 transporter, the other pentamidine transporters, LAPT1 and 
HAPT1, seem to play a minor role in its transportation (De Koning,2001). 
However, there is little published on the toxicity of diminazene (Delespaux & De 
Koning,2007). 
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1.3.2 Suramin 
 
Figure 1.4. chemical structure of suramin  
Suramin (Figure 1.4) is a sulfonated naphthylamine polyanionic compound. 
It has been used to treat the early stage of HAT, particularly of disease caused 
by T. b. rhodesiense, for almost a century, but not the neurologic stage, 
because the drug does not cross the BBB in concentrations that are able to kill 
the parasites in the cerebrospinal fluid at doses given to treat the early stage 
disease. The used dose of suramin is 20 mg/kg/day for five days (Jannin & 
Cattand, 2004). The main route of suramin entry is through endocytosis 
(Fairlamb & Bowman, 1980). The drug is negatively charged at physiological pH 
and is intensively bound to a number of serum proteins, including low-density 
lipoprotein LDL (Vansterkenburg et al., 1993). Although some suggest that 
suramin enters during binding to LDL (Bastin et al., 1996; Coppens & Courtoy, 
2000), one study suggests that suramin action is not dependent on the LDL 
receptor (Pal et al., 2002). A recent study reported that suramin action might be 
mediated via the ISG75 protein family in bloodstream forms (Alsford et al., 
2012). It has been found that suramin is a potent inhibitor for 6-
phosphogluconate dehydrogenase, which catalyses the oxidative decarboxylation 
of 6-phosphogluconate to ribulose 5-phosphate in the pentose phosphate 
pathway (Hanau et al., 1996). Common side effects of the drug are neuropathy, 
rash, fatigue, anaemia, hyperglycaemia, hypocalcaemia, coagulopathies, 
neutropenia, renal failure (Barrett et al., 2007) and hypoesthesia, which 
involved a reduced sense of touch, or a partial loss of sensitivity to sensory 
stimuli (Legros et al., 2002). 
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1.3.3 Melarsoprol 
 
Figure 1.5. Chemical structure of melarsoprol. 
Melarsoprol (Figure 1.5), a melaminophenyl-based organic arsenical, was 
discovered at around the middle of the 20th century (Friedheim, 1949) to treat 
the late stage of HAT because of its ability to cross the BBB and accumulate in 
the CNS (Burri et al., 1993). Therefore, it remains the most widely used drug to 
treat late stages of HAT. It is administered as a 3.6% solution in propylene glycol 
and the used regimen dose is 2.2 mg/kg for ten consecutive daily intravenous 
injections (Burri et al., 2000). The drug is amphipathic so that it can diffuse 
across cellular membranes and rapidly convert to hydrophilic melarsen oxide in 
plasma (Burri et al., 1993), both melarsoprol and its metabolites cross the BBB. 
However, the levels of the drug in cerebrospinal fluid might be insufficient to 
kill all parasites, at least in all patients (Hunter et al., 1992; Jennings, 1995). 
Several studies proposed that melarsen oxide enters T. brucei via the P2 
transporter (Carter & Fairlamb, 1993; Maser et al., 1999) or that other 
transporters are able to carry the drug (Matovu et al., 2003). Melarsoprol, being 
lipophylic can diffuse across the parasite plasma membrane, but its metabolite 
melarsen oxide does not do so (Scott et al., 1997). Although exposing 
trypanosomes to melarsoprol leads to immediate cell lysis (Carter et al., 1995), 
the mode of action of the drug is still unclear. However, some suggest that 
melarsen oxide interferes with the glycolytic pathway (Flynn & Bowman, 1974) 
and inhibits enzymes that produce ATP (Denise & Barrett, 2001). Among the 
enzymes affected by melarsen oxide is pyruvate kinase. In vitro and in vivo 
study found that dihydrotrypanothione combined with melarsen oxide to form a 
competitive inhibitor of trypanothione reductase (Fairlamb et al., 1989). 
Melarsoprol has many severe side effects such as a reactive encephalopathy and 
heart failure (Blum et al., 2001). Other reported common features include fever, 
headache, pruritus and thrombocytopenia. 
J. Ali 2013 Chapter 1 14 
1.3.4 Eflornithine 
 
Figure 1.6. Chemical structure of eflornithine 
Eflornithine or α-difluoromethylomithine (DFMO; Figure 1.6) is an 
analogue of the amino acid ornithine. The drug is currently considered as the 
first-line treatment for late stage T. b. gambiense sleeping sickness 
(Balasegaram et al., 2006). DFMO inhibits the polyamine biosynthetic enzyme 
ornithine decarboxylase (Bacchi et al., 1980). The recommended dose is 400 
mg/kg/day intravenously at 6 hour intervals for 14 days (Barrett et al., 2007). 
Eflornithine is taken up in mammalian cells by passive diffusion (Erwin & Pegg, 
1982) and was believed to cross the plasma membrane of bloodstream 
trypanosomes via passive diffusion (Bitonti et al., 1986). However, recent 
separate studies have found that the T. b. brucei AAT6 amino acid transporter is 
involved in DFMO uptake (Baker et al., 2011; Schumann Burkard et al., 
2011;Vincent et al., 2010), the same manuscripts attributed DFMO drug 
resistance to loss of AAT6 transporter. DFMO action on polyamine biosynthesis 
causes an increase of S-adenosyl methionine at the cellular level (Yarlett & 
Bacchi, 1988), which leads to unsuitable methylation of cell elements such as 
nucleic acids, lipids and proteins. (Fairlamb et al., 1987) reported a decrease of 
trypanothione levels after treatment with DFMO. One drawback of eflornithine 
could be its similar efficacy on both the parasite and mammalian host ornithine 
decarboxylase (ODC) (Garofalo et al., 1982; Phillips et al., 1988), and it binds 
either enzyme irreversibly. The selective action against T. brucei is the result of 
the trypanosomal enzyme being very stable, whereas mammalian ODC is very 
rapidly replaced (Delespaux & De Koning, 2007). The side effects of eflornithine 
are diarrhoea, hallucinations, pancytopenia and convulsions (Legros et al., 
2002). 
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1.3.5 Nifurtimox 
 
Figure 1.7. Chemical structure of nifurtimox 
Nifurtimox (Figure 1.7) was discovered empirically decades ago 
(Cerecetto & Gonzalez, 2002) and it is a 5-nitrofuran derivative used as a front 
line drug to treat Chagas’ disease caused by Trypanosoma cruzi in South America 
(Docampo, 1990; Gutteridge, 1985). However, as a mono-therapy against T. b. 
gambiense in West Africa, the drug has limited efficacy (Pepin et al., 1989). 
Against T. cruzi infections, 15 mg/kg/day in three divided doses for two months 
was the recommended dose (Burri et al., 2004; Ministério & Saúde, 2005; Rassi, 
et al., 2010). The drug can accumulate across the BBB (Jeganathan et al., 2011). 
African trypanosomes were not highly vulnerable to nifurtimox in a typical in 
vitro study, with IC50 values at around 5 µM (Enanga et al., 2003). Nifurtimox 
uptake in T. cruzi has been found to proceed via passive diffusion across the cell 
membrane (Tsuhako et al., 1991), but transport of the drug in T. brucei has not 
yet been investigated (Barrett & Gilbert, 2006). 
On the other hand, a promising use of nifurtimox in combinations to cure 
trypanosomiasis has been reported to have succeeded (Bisser et al., 2007; 
Jennings, 1991; Priotto et al., 2006). For example, (Priotto et al., 2006) 
combined nifurtimox and eflornithine to treat trypanosomiasis in clinical trials 
and reported cure rates of more than 94%, but combining melarsoprol with 
nifurtimox is considered to be toxic and the cure rates were less than half 
(44.4%). The combination of nifurtimox and eflornithine to treat the late stage 
of sleeping sickness has also been confirmed by (Checchi et al., 2007) in a 
clinical study in Uganda and is considered to be the most promising new 
development for years. It has been published that the nifurtimox mechanism of 
action is due to free-radical generation through its metabolism; this mechanism 
starts with a reduction of the NO2-group to a nitro-anion radical (Maya et al., 
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2007) and finally produces oxidative stress in the organism itself. Recently, it 
has been found that 2-electron reduction of nifurtimox is catalysed by type I 
nitroreductase and produced toxic metabolites (Wilkinson et al., 2011). Although 
this nitroreductase is a trypanosomal enzyme with no close human homologue, 
toxic side effects of nifurtimox on the nervous system have been reported 
(Castro et al., 2006). In addition, the typical dose of the drug used to treat 
Chagas’ disease caused some problems such as nausea and vomiting (Barrett et 
al., 2007). 
1.4 Drug resistance 
The resistance to current anti-trypanocidal drugs has become a big public 
health problem, which may prevent the successful treatment of the disease. In 
addition, the mechanism of resistance to most chemical trypanocides is still 
unclear. An increasing incidence of resistance to current drugs has been 
reported in some parts of sub-Saharan Africa (Afewerk et al., 2000). In some 
cases, the proposed mechanism of the parasite’s resistance to drugs is due to 
the loss of one or more transport functions in the parasite’s cell membrane (De 
Koning, 2001). Other parasite resistance mechanisms (Figure 1.8) include 
inactivation, excretion or modification of the drug in the cytoplasm of the 
parasite (Borst & Ouellette, 1995). 
 
Figure 1.8: The main biochemical mechanisms responsible for drug resistance in protozoal 
diseases. (Borst & Ouellette, 1995). 
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It has been demonstrated that the loss of the P2 adenosine transporter function, 
which mediates the uptake of melarsoprol and diamidines, leads to T. brucei 
resistance to these drugs (Barrett et al., 1995; De Koning & Jarvis, 1999), but 
pentamidine can enter via other transporters once P2 is lost (De Koning, 2001), 
which makes the search for the method of resistance developed against this drug 
difficult. Recently, (Baker et al., 2012) reported that the melarsoprol-resistance 
trypanosomes with cross resistance to pentamidine is associated with the loss of 
function of aquaglyceroporins, specifically AQP2; very recently, the same 
authors have published that this mechanism of resistance may be applicable in 
clinical conditions (Baker et al., 2013), but in veterinary use the resistance to 
the drug has been reported in Trypanosoma species, such as T. evansi (El Rayah 
et al., 1999; Mutugi et al., 1994). In addition, the selection of cell lines resistant 
to suramin in the laboratory can readily be achieved (Scott et al., 1997), and the 
resistance to melarsoprol has been reported in bloodstream forms of T. brucei 
rhodesiense (Bernhard et al., 2007). The resistance mechanism to melarsoprol is 
related to the selective uptake of organo-arsenicals and to the purine salvage 
pathway. In strains resistant to melarsen oxide, the loss of P2 transport activity 
has been reported (Carter & Fairlamb, 1993; Delespaux & De Koning, 2007). The 
(WHO, 1998) reported an increasing resistance to melarsoprol, reaching 30% in 
central Africa. In addition, relapse after melarsoprol treatment has been 
reported in the field (Brun et al., 2001; Legros et al., 1999; Moore & Richer, 
2001; Stanghellini & Josenando, 2001). Most parasites selected for resistance to 
melarsoprol in the laboratory have lost the drug carrier, the P2 transporter 
(Barrett & Fairlamb, 1999; Carter & Fairlamb, 1993; Maser et al., 1999; Stewart 
et al., 2005), and isolated parasites from relapse patients have defective 
aminopurine P2 transporter (Maser et al., 1999; Matovu et al., 2001; Stewart et 
al., 2005). 
Decreased eflornithine uptake has been reported in procyclic forms of 
Trypanosoma (Bellofatto et al., 1987) and they attributed this to the 
intracellular concentration of N1, N8-bis-(glutathionyl)-spermidine. Recently, it 
was shown that eflornithine resistance in trypanosomes is linked to the loss of 
Tb927.8.5450: an amino acid transporter gene (Baker et al., 2011; Schumann et 
al., 2011; Vincent et al., 2010). No drug resistance has been observed in the 
field (Simarro et al., 2012). T. cruzi resistance to nifurtimox has been well 
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confirmed (Murta et al., 1998); treatment of T. brucei has only just recently 
been introduced, but (Sokolova et al., 2010) reported that the bloodstream 
forms’ resistance to nifurtimox can easily be achieved by in vitro induction. In 
the absence of alternative drugs and successful vaccine programs, the delay in 
resistance to available trypanocides should be taken seriously. 
2- Leishmaniasis 
2.1 Epidemiology and life cycle 
Leishmaniasis is a group of parasitic diseases caused by members of the 
genus Leishmania; the parasites were first seen by Cunningham in 1885, and 
described by Leishman and Donovan in 1903, working separately (Herwaldt, 
1999). However, the connection of Leishmania to the disease kala-azar was 
discovered by Bautley in 1904 (Bhamrah & Juneja, 2001). The parasites cause a 
range of diseases, encompassing cutaneous, mucocutaneous and visceral 
leishmaniasis. Human and animal leishmaniasis show a wide geographic 
distribution (Figure 1.9). Leishmaniasis is endemic in 22 countries in the 
Americas and 88 countries in the rest of the world, most of them in the tropics 
and subtropical areas (Desjeux, 1996), but it is not endemic in Southeast Asia 
and Australia (Herwaldt, 1999). With the estimated yearly incidence, there are 
between 1.5-2 million cases of cutaneous leishmaniasis and half a million cases 
of visceral leishmaniasis. (Desjeux, 1996) estimated that 350 million people are 
at risk of leishmaniasis in the world population. More than 90% of the world’s 
cases of visceral leishmaniasis (VL) occur in five countries: India, Bangladesh, 
Nepal, Sudan and Brazil, whereas 90% of disease caused by cutaneous 
leishmaniasis (CL) appears in nine countries: Afghanistan, Pakistan, Syria, Saudi 
Arabia, Algeria, Brazil, Iran and Peru (Desjeux, 2004). The incidence of 
leishmaniasis has significantly increased over the last few decades (Arias et al., 
1996). The prevalence of the disease is more common in men than in women, 
but this may reflect increased exposure to sand flies. Untreated VL causes a 
mortality rate of 75–95%, whereas CL may affect the mucosa resulting in death 
from secondary infection (CFSPH, 2009). 
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Figure 1.9. Geographical distribution of leishmaniasis. Obtained from (Davies et al., 
2003). 
Leishmaniasis is considered to be an opportunistic infection that affects HIV-
infected people; the majority of co-infection entails the VL form (Desjeux & 
UNAIDS, 1998). To date, co-infection with leishmaniasis and HIV has been 
reported in 34 countries in Africa, Asia, Europe and South America (Figure 1.10). 
In the case of HIV infection, the leishmaniasis cause the symptoms of HIV to 
occur earlier than expected by increasing immunosuppression and by stimulating 
multiplication of the virus (Harms & Feldmeier, 2005). This co-existence is 
increasingly severe, for instance, in Mediterranean European countries about 70% 
of adult cases of VL are co-infected with AIDS (WHO, 2012). 
 
Figure 1.10. World-wide distribution of leishmaniasis    and countries reporting 
Leishmania/HIV co-infection     , obtained from (Desjeux & Alvar, 2003). 
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Transmission 
The distribution of leishmaniasis is connected to the prevalence of the 
vector. The disease is transmitted from the reservoir host to human beings and 
animals by the bite of some types of female phlebotomine sand flies – dipteran 
insects (Bates & Rogers, 2004). 700 species of the insects have been reported, 
and of these, about 10% have been described as vectors of leishmaniasis (Lane, 
1993). The proven vectors of the Leishmania parasites are the blood-sucking 
female of the genus Lutzomyia in the Americas and Phlebotomus spp in the Old 
World (Murray et al., 2005). These include P. argentipes in India, P. martini and 
P. orientalis in Africa and the Mediterranean basin, P. chinensis and P. alexandri 
in China and Lutzomyia longipalpis in the New World. The host reservoirs of 
leishmaniasis are animals such as canines and rodents, and humans (Zijlstra & El-
Hassan, 2001). Other animals in the surrounding area can become infected and 
those are referred to as secondary hosts (Arias et al., 1996). Several studies 
have attempted to reduce leishmaniasis transmissions by targeting the host 
vector using different methods such as environmental control (i.e. using 
insecticides such as deltamethrin, malathion and propoxur), prophylactic 
methods, biological control and remote sensing (WHO, 2010). 
 Life cycle 
The life cycle of Leishmania species switches between two shapes (Figure 
1.11): flagellated promastigotes in the insect vectors and intracellular 
amastigotes in the mammalian host (Gossage et al., 2003). Based on Leishmania 
development within the host vector, the genus was subdivided into two 
subgenera: members of the subgenus Leishmania develop exclusively in the 
midgut and foregut of sand flies, whereas members of the subgenus Viannia 
include a phase of development in the hindgut of their vectors (Lainson & Shaw, 
1987). Many species, subspecies and strains infect several mammalian organisms 
including Homo sapiens and are transmitted by the bite of phlebotomine sand 
flies. The sand-fly vector becomes infected when feeding on the blood of an 
infected person or an animal reservoir host. Leishmania parasites live in the 
phagolysosomes of macrophages of vertebrate hosts as round-shaped, non-motile 
amastigotes (3–7 µm in diameter). During the blood meal of the fly, it creates a 
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wound, which releases skin macrophages and/or freed amastigotes into the pool 
of blood, and enables their subsequent uptake into the stomach of insects (Lane, 
1993). Moving from the bloodstream condition to the transmission vector causes 
changes in the parasite’s life condition such as a decrease in temperature and an 
increase in the pH, which leads to the development of the parasite in the insect 
(Bates & Rogers, 2004; Kamhawi, 2006). The first stage in the vector is called 
procyclic promastigotes. After a few days, the parasite begins to differentiate 
into elongate forms, non-dividing nectomonad promastigotes, which migrate and 
accumulate in the alimentary tract of the fly. Some suggest that N-
acetylglucosaminidase and chitinase are degraded in the chitin of vertebrate 
hosts (Schlein et al., 1991). When they move towards the anterior midgut, the 
nectomonad promastigotes transform into leptomonad promastigotes, which 
begins the process of parasite multiplication (Gossage et al., 2003). Some of the 
leptomonads transform to strictly non-dividing metacyclic promastigotes which 
are the mammal-infective stages (Rogers et al., 2002). 
 
Figure 1.11 Leishmania life cycle (Cited from Protozoa as Human Parasites website 
http://course1.winona.edu/kbates/Parasitology/Images/Leishlifecycle.gif). 
The transmission to vertebrate hosts occurs when the infective females 
feed on the blood of another host leading to the distribution of the disease. In 
mammalian cells, the macrophage is the main host for the Leishmania 
amastigotes. When the metacyclic promastigotes get into the pool of blood they 
attach to mononuclear phagocytes by a receptor-mediated mechanism and are 
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swallowed up via phagocytisis into a phagosome, which combines with lysosomes 
to form the phagolysosome (Handman & Bullen, 2002). This reaction causes 
considerable changes to promastigotes and they develop into the intracellular 
form of the parasite, the amastigote. Once amastigotes are released from the 
macrophages, they can occupy other macrophages and invade fibroblasts and 
dendritic cells (Rittig & Bogdan, 2000). Phagocytosis of promastigotes by 
macrophages, initiated by the attachment of the parasite to receptors on the 
phagocyte, creates additional receptors on the surrounding membrane (Rittig et 
al., 1998). However, the mechanism of exit of the amastigotes from the infected 
macrophages is still poorly described. One accepted idea is that the 
macrophages burst and release the amastigotes after several hours of infection 
(Rittig & Bogdan, 2000). 
2.2 Pathology  
Human leishmaniasis has several clinical aspects. The pattern of the 
disease is based on the type of Leishmania species and on the expressed 
zymodeme (electrophoretic isoenzyme pattern) in that species. Thus, one 
isoenzyme may cause CL while another enzyme of the same species may cause 
VL (Gradoni et al., 1991). 
VL is the most severe form of leishmaniases and its incubation period ranges 
from three to eight months (De Alencar & Neves, 1982). The disease is caused by 
L. infantum in Southern Europe and North Africa and by L. chagasi in the New 
World whereas in India and Kenya it is caused by L. donovani (Piscopo & Mallia, 
2006). The general symptoms are fever, weight loss, hepatosplenmegaly, 
lemphadenopathy, pancytopenia and hypergamaglobuliaemia (Zijlstra & El-
Hassan, 2001). The disease usually has a chronic pattern and leads to death if 
left untreated, especially during severe secondary bacterial infections in 
advanced cases. VL can develop to post-kala-azar dermal leishmaniasis (PKDL) 
after subsidence of VL. The PKDL is often due to infection by the L. donovani 
sensu stricto (Zijlstra & El-Hassan, 2001), and the skin ulcers usually spread from 
the perioral area to other areas of the body. 
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CL is known by different names according to the geographical distribution of the 
disease. CL is caused by many species of the genus Leishmania such as L. major, 
L. tropica, L. aethiopica and rarely L. infantum. In the New World, species such 
as L. mexicana complex, L. braziliensis complex and L. guyanensis complex are 
responsible for CL infections, especially in the forests from Mexico to northern 
Argentina. 
CL has different clinical features and courses of illness such as chronic skin sores 
which can be on a single part of the skin or from a large number of lesions 
(Minodier & Parola, 2007). The disease starts as a pimple at the site of the 
sandfly bite, the papule increases in size, then crusts and finally ulcerates. The 
incubation time varies from two weeks to several months. It has been reported 
in the Old World that CL incubation time can last up to three years (Zijlstra & El-
Hassan, 2001). In the Americas, the incubation period is usually from two to 
eight weeks (Marsden, 1975). However, CL may take from 3 to 18 months to cure 
in the majority of patients (Mandell et al., 2005). 
CL is characterized by a totally curing lesion and intense granuloma occurrence 
that is called leishmaniasis recidivans; this lesion does not heal, occasionally for 
several years. In diffuse CL, the amastigote forms of L. aethiopica and a few 
subspecies of L. mexicana (L. m. pifanoi and maybe L. m. amazonenzsis) 
disseminate through the skin and cause this severe condition. 
Another leishmanial manifestation is mucocutaneous leishmaniasis (MCL; 
espundia), which is distributed across central and South America. The incubation 
period of MCL is 1–3 months, but it may occur after many years post-healing of 
the initial cutaneous ulcers. Approximately 5% of patients with CL develop this 
disease after several months to 30 years from the initial infection (Matlashewski, 
2001). This disease is caused by L. panamensis, L. braziliensis and L. guyanensis. 
The development of mucosal leishmaniasis depends on the size and the numbers 
of the primary lesion/s. The disease commonly starts in the nasal septum and 
mutilates it, and then it may invade other mucous membranes such as the lips, 
palate, pharynx and tonsils (Grevelink & Lerner, 1996). 
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Diagnosis 
Diagnosis of VL is sometimes confused by the symptoms of other diseases 
such as malaria, tropical splenomegaly, histoplasmosis and bacterial endocarditis 
(Singh & Sivakumar, 2003). CL should also be distinguished from some common 
features such as tropical ulcers, leprosy and impetigo (Herwaldt, 1999; Lainson 
& Shaw, 1987). There are also some common symptoms that should be 
recognised from CL infection such as infected insect bites, impetigo and skin 
cancer due to other causes (Herwaldt, 1999). An early lesion of MCL can also be 
difficult to differentiate from histoplasmosis, lymphoma, paracoccidioidomycosis 
and polymorphic reticulosis (Herwaldt, 1999; Zijlstra & El-Hassan, 2001). In 
addition, the diagnostic methods used for each leishmanial form vary, but the 
main idea in each case remains to confirm the clinical suspicion. The diagnosis of 
VL in an endemic area is usually based on microscopic detection of amastigotes 
in biopsy samples or smears of tissue such as lymph nodes, bone marrow, liver 
and spleen. Sometimes parasites taken from microscopy-negative tissue samples 
can be cultured on special medium (Jhingran et al., 2008; Markell et al., 1999) 
or inoculated into animals such as hamsters. VL can also be detected by 
serological tests such as the direct agglutination test, which can detect 
leishmanial antibodies. A variety of nucleic acid detection methods can detect 
parasite DNA or RNA a few weeks ahead of the occurrence of any clinical 
symptoms (Singh & Sivakumar, 2003). Some DNA sequences in the Leishmania 
genome can be detected using polymerase chain reaction (PCR) techniques such 
as for the recombinant Leishmania glycoprotein (rgp63) locus (Shreffler et al., 
1993), internal transcribed spacer (ITS) region (Schonian et al., 2001; Schonian 
et al., 2003) and telomeric sequences (Chiurillo et al., 2001). 
The diagnosis of CL is usually based on biopsy specimens taken from the edge of 
lesions or microscopical examination of skin scrapings, but cultures of lesions 
may be contaminated by bacterial or fungal elements. Furthermore, each 
species has different growth requirements. The Montenegro skin test, which 
detects specific cutaneous delayed type hypersensitivity, has been limited 
because of its inability to distinguish between new and old infections (De Lima 
Barros et al., 2005). Isoenzyme electrophoresis and monoclonal antibodies can 
be used to identify Leishmania species and strains, but a direct analysis of 
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clinical specimens using PCR techniques is rapid and achieved with high 
specificity and better sensitivity (De Oliveira et al., 2003). 
The most common, sensitive and specific test is ELISA but the sensitivity and 
specificity of ELISA is influenced by the antigen used. Many recombinant 
antigens have been developed over the last few years such as rgp63, rk90 and 
rk26 from L. chagasi, rORFF from L. infantum and rGBP from L. donovani 
(Piscopo & Mallia, 2006). ELISA is also used to distinguish between CL and VL due 
to the absence of the gp63 antigen in the former and its presence in the latter 
(Shreffler et al., 1993). 
2.3 Chemotherapy 
Leishmaniasis is assumed to be a treatable disease, and sometimes self-
healing in a few months, especially as CL, so that treatment is occasionally not 
needed. However, some leishmanial lesions diffuse and exist for longer. VL is 
commonly fatal if not treated. Therefore, several highly effective anti-
leishmanial drugs have been introduced, and antimony drugs are considered to 
be the first line of treatment. 
2.3.1 Antimony compounds 
Pentavalent antimonials (SbVs) have been used for more than half a 
century as front line drugs to treat leishmaniasis. Converting SbV to trivalent 
antimonials (SbIII) is necessary in order to fulfil their anti-leishmanial potential 
(Shaked-Mishan et al., 2001). There are two different forms of antimonial: 
glucantime (meglumine antimoniate) and pentostam (sodium stibogluconate), 
and these compounds are non-covalent chelates of SbV (Castillo et al., 2010). It 
is suggested that meglumine antimonite consists of antimony and N-methyl-D-
glucamine alternatively arranged in chain form, where each N-methyl-D-
glucamine moiety is linked on both sides by the antimony molecules (Figure 
1.12). 
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Figure 1.12 The proposed structure of pentavalent antimonial drugs. 
Obtained from (Frezard et al., 2008). 
Initially, antimonials were given at 10 mg/kg for 6–10 days. However, after 
treatment failures first appeared in India, physicians introduced higher doses 
and prolonged schemes (up to 20 mg/kg for 30 days) (Sundar et al., 2000). 
Generally, it has been accepted that SbVs are a prodrug. However, the site and 
the mechanism of reduction remain unclear (Denton et al., 2004) and the mode 
of action of these drugs is poorly understood (Castillo et al., 2010). Early studies 
suggested that pentostam is able to interfere with glycolysis and the β-oxidation 
of fatty acids in the amastigote stages of different species of Leishmania, 
causing a depletion of the ATP level in the parasite (Berman et al., 1985; 
Berman et al., 1987). SbIII and SbV have been found to induce apoptosis and 
death by DNA fragmentation and externalization of phosphatidylserine 
(Sudhandiran & Shaha, 2003). However, specific drug targets have not been 
identified. (Wyllie et al., 2004) designed a model for the mode of action of 
antimonial drugs in Leishmania (Figure 1.13) and they showed that trivalent 
antimony intervenes with trypanothione metabolism in the parasite cells via two 
reactions: SbIII reduced thiol buffering capacity via the equal efflux of 
intracellular trypanothione and glutathione; SbIII inhibited trypanothione 
reductase. Furthermore, pentavalent antimony binds to the ribose moiety and 
forms stable complexes with adenine nucleosides, which act as inhibitors of 
Leishmania purine transporters (Demicheli et al., 2002). 
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Figure 1.13 A model for the mode of action of antimonial drugs on 
Leishmania amastigotes. Om = ornithine, ODC = ornithine decarboxylase, 
Spd = spermidine, TryS = trypanothione synthase, Cys = cystine, GSH = 
Glutathione, γGCS = γ-glutamyl cystine synthase, suggested by (Wyllie et 
al., 2004). 
However, the use of the standard pentavalent antimonial drugs is now 
threatened because of the emergence of drug resistance (Castillo et al., 2010). 
In addition, vomiting, malaise and anorexia are the early side effects of 
pentavalent antimonials. Although the WHO limitation avoids the presence of 
antimonial side effects, (Balana-Fouce et al., 1998) reported that antimonial 
drugs were not particularly safe. Furthermore, it has been reported that in 
patients with increased medication some side effects are common such as 
headache, anorexia and nausea (Navin et al., 1992). As a result of 
chemotherapy, the common side effects of antimonials are cardio-toxicity and 
pancreatitis (Sundar & Chakravarty, 2010). 
Combination drugs with different modes of action have also been used. 
Combinations of sodium stibogluconate with paromomycin (Davidson et al., 
2009; Melaku et al., 2007) or allopurinol (Chunge et al., 1985) increased the 
efficacy against VL. It has also been proven that a combination of glucantime 
with the specific blocker of the ABC transporter, glibenclamide, decreased the 
infection rate of Leishmania major-infected macrophages (Padron-Nieves et al., 
2009). 
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The preferred second-line drugs (Figure 1.14) include amphotericin B, 
miltefosine, paromomycin and pentamidine (Croft et al., 2006; WHO, 2000). 
 
Figure 1.14 Drugs currently used in the treatment of leishmaniasis. Obtained 
from (Croft et al., 2006). 
2.3.2 Amphotericin B 
Amphotericin B (AmB) is used for all types of leishmaniases, particularly in 
HIV-positive patients (Molyneux, 2007). The therapeutic dose of the drug is from 
0.5 to 1 mg/kg intravenously on alternate days for a total of 30 days, but a 96% 
cure rate with a dose of 0.75 mg/kg/day for 15 days has been reported in India 
(Sundar et al., 2007). Half of the AmB molecule consists of double bonds and is 
hydrophobic, whereas the other half contains a series of hydroxyl groups and is 
hydrophilic. Amphotericin molecules can gather in a cluster and interact with 
the aquaphobic centre of the cell membrane. The cluster is lined with the 
hydroxyl groups allowing the polar contents of the cell to escape causing cell 
lysis via the osmotic mechanism. The mode of action of the drug is based on an 
increase in membrane permeability of leishmanial parasites by affecting sterol 
metabolism and changing the cell membrane construction (Balana-Fouce et al., 
1998; Singh, 2006). Several AmB formulations have been developed to decrease 
the toxicity, and at the same time increase its effectiveness, for instance, via 
colloidal depressions and liposomes. Lipid formulations of AmB are specifically 
taken up by the reticulo-endothelial system and show a highly localised 
amplified antileishmanial action (Maltezou, 2010). A recent study has assumed 
that AmB interferes with ergosterol of Leishmania and cholesterol of host 
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macrophages (Paila et al., 2010). The drug is highly toxic and its side effects in 
mammals are caused by the internalization of AmB-lipoprotein complexes 
mediated by low-density lipoprotein receptors (Wasan et al., 1994). Prolonged 
administration and the high cost of the drugs have become the major 
disadvantage. In addition, it can have some catastrophic effects such as 
nephrotoxicity, hypokalaemia and infusion-related fevers and chills (Sundar et 
al., 2007). 
2.3.3 Miltefosine 
Miltefosine is a phosphorylcholine ester of hexadecanol. The drug, which 
is used as an anti-cancer agent, was found to be a very effective oral agent for 
VL (Croft et al., 2005). To date, miltefosine is licensed in India, Germany and 
Colombia (Maltezou, 2010). The recommended dose of the drug is 2.5 
mg/kg/day for 28 days (Sundar et al., 2002). The precise antileishmanial action 
of the drug remains unknown. (Perez-Victoria et al., 2006) suggested three steps 
for the intracellular accumulation of miltefosine including engaging with the 
parasite cell membrane, incorporation of the drug in the cell and intracellular 
directing and metabolism. Others suggested anti-leishmaniasis action of the drug 
is due to generating a disturbance in ether-lipid reconstruction (Lux et al., 
2000). Although miltefosine is tolerated compared to antimonials and 
amphotericin, it has a limited use because of its potential teratogenicity (Olliaro 
et al., 2002) and prolonged half-life. Moreover, diarrhoea and hepatotoxicity are 
common during the first two weeks of treatment (Sundar et al., 1999). 
2.3.4 Paromomycin 
Paromomycin is an aminoglycoside antibiotic that has been used for 
various clinical infections including VL and CL, especially in highly antimony 
resistant VL (Sundar, 2001). The optimal dose of paromomycin is 14–16 
mg/kg/day for three weeks (Thakur et al., 2000). (Maarouf et al., 1997b; 
Maarouf et al., 1995; Maarouf et al., 1997a) suggested that the mode of action 
of the drug in Leishmania spp is coupled with respiratory dysfunction, 
mitochondrial membrane potential and ribosomes. (Jhingran et al., 2009) 
reported that paromomycin could target mitochondrial membrane potential in L. 
donovani. A molecular study proved that paromomycin effects targeted 
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translation process of Leishmania parasites but not their mammalian host 
(Fernandez et al., 2011). However, it was found that the drug produces nerve 
toxicity, nephrotoxicity (Sundar, 2001), ototoxicity and pain at the injection site 
(Sundar et al., 2007). Since the drug has not been used for a long time to treat 
leishmaniasis, no clinical resistance has been induced. 
2.3.5 Pentamidine 
Pentamidine is not a widely used antileishmanial drug, but it is used in 
the case of antimony-failed VL. The used dose of pentamidine is intramuscular 
injections of 2–4 mg/kg, three times a week for 3–5 weeks (Balana-Fouce et al., 
1998). The antileishmanial mechanism of action of pentamidine is still unclear. 
However, suggested modes of action of the drug include inhibition of polyamine 
biosynthesis, DNA minor groove binding preferentially binding to AT sequences in 
kinetoplast DNA (Wilson et al., 2008), inhibition of mitochondrial topoisomerase 
I (Jean-Moreno et al., 2006), effect on mitochondrial inner membrane potential 
(Bray et al., 2003; Mukherjee et al., 2006) and may lead to the destruction of 
the mitochondrion and disintegration of the kinetoplast (Mehta & Shaha, 2004). 
Several side effects have been reported for this drug such as hyperglycaemia, 
hypoglycaemia and nephrotoxicity (Balana-Fouce et al., 1998). The pentamidine 
analogue, diminazene, has also been reported to treat clinical CL (Lynen & Van 
Damme, 1992). Its mechanism of action is similar to pentamidine. 
2.4 Drug resistance 
The role of drug resistance in treatment failure is difficult to understand 
because therapeutic response is multifactorial, and the efficacy of drugs in 
treatment of leishmaniasis depends on differences in drug sensitivity of 
Leishmania species, the immune status of the patient and the pharmacokinetic 
properties of the drug (Croft et al., 2006). 
 In addition to the limited use of antileishmanial agents due to the cost and 
toxicity, emerging resistance to these drugs has become a serious problem in 
terms of being able to control different diseases caused by Leishmania parasites. 
Although antimonial compounds have been used for many years, several studies 
have reported the resistance of Leishmania species to these drugs in different 
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areas. More than half of all patients failed to be treated by antimonials in 
northern India where VL is highly distributed (Sundar, 2001). In South America 
(Rojas et al., 2006) and Iran (Hadighi et al., 2006), it has been found that CL 
patients failed to be treated by antimony. A study in an endemic region of 
eastern Sudan has reported antimonial resistance (Abdo et al., 2003). Resistance 
to antimonials is multifactorial; therefore, several mechanisms have been 
proposed to explain the resistance to antimonial drugs such as drug efflux and 
metabolism (Croft et al., 2006). (Wyllie et al., 2008) suggested that the main 
feature of the resistance mechanism to antimonial drugs could be due to an 
amplified antioxidant defence via overexpression of tryparedoxin peroxidase. 
Antimonials also have reduced activity in the absence of a T-cell immune 
response, which has an impact on the treatment of HIV and VL co-infection cases 
(Cruz et al., 2006; Laguna, 2003). Amphotericin and its formulations have been 
considered as the second line of treatment since the 1960s, and present 
excellent activity against VL in India. Resistance to amphotericin in Leishmania 
patients has not yet been recorded, but it has been selected for in vitro (Mbongo 
et al., 1998). Failure of treatment with these drugs is minimal, unless 
leishmaniasis occurs in HIV-infected patients (Lachaud et al., 2009). 
Resistance to miltefosine can be reached easily in vitro by single point mutations 
(Seifert et al., 2007). The common feature of Leishmania resistance to 
miltefosine is due to declining drug uptake, an increase in drug efflux rate, 
accelerated metabolism or changes in cell membrane permeability (Maltezou, 
2010). A study reported that the cure rate for miltefosine in Guatemalan CL-
infected patients was about 50% (Soto et al., 2004). A VL case relapsed 10 
months after a complete cure with miltefosine in a Nepalese patient (Pandey et 
al., 2009). These facts imply that drug resistance could develop quickly. An 
isolated gene from L. infantum showed protection against both miltefosine and 
SbIII (Choudhury et al., 2008). In one laboratory study, exposing L donovani to 
paromomycin in vitro showed a decrease in drug uptake compared with the wild-
type counterparts (Maarouf et al., 1997b). Pentamidine treatment-resistant 
cases of kala-azar have been reported in an Indian clinical study (Jha et al., 
1991). In one in vitro study, pentamidine resistance in promastigote forms have 
been reported in L. donovani and L. amazonensis due to decreasing drug uptake 
by 18- and 75-fold, respectively (Basselin et al., 2002). 
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3. Pyrimidine biosynthesis in kinetoplastids 
3.1. De novo biosynthesis of UMP 
Purine and pyrimidine nucleotides perform many functions in cells, 
including being the precursors of nucleic acids (DNA and RNA), modulators of 
enzyme activities, and as components of several co-enzymes (ATP, GTP, NADH, 
coenzyme A) and second messenger molecules (cAMP and cGMP) (Hammond & 
Gutteridge, 1982; Hammond & Gutteridge, 1984). Kinetoplastids differ from 
their mammalian and insect hosts in terms of purine metabolism, and must rely 
upon their host to acquire purines. However, no purine-based chemotherapy has 
emerged for kinetoplastid parasites, in large part because there is so much 
redundancy in purine transporters and salvage pathways that the inhibition of 
any one transporter (De Koning et al., 2005) or enzyme (Berg et al., 
2010;Luscher et al., 2007) has little or no effect on parasite survival. 
In contrast, kinetoplastids can synthesise pyrimidines in pathways similar to their 
mammalian host, but these parasites can also obtain pyrimidines by uptake from 
the environment. Although this phenomenon appears to render pyrimidine 
metabolism less amenable to therapeutic intervention, the selective inhibition 
of pyrimidine biosynthetic enzymes and/or the blocking of pyrimidine 
transporter/s may offer new therapeutic agents. 
Pyrimidine biosynthesis pathways seem to be common in most parasitic protozoa 
(Gutteridge & Coombs, 1977) and mammals (Jones, 1980; Levine et al., 1974). In 
kinetoplastids, the pathway involves the sequential action of six enzymes (Figure 
1.15) and begins with the production of carbamoylphosphate from glutamine, 
ATP and HCO3 catalysed by carbamoylphosphate synthetase (EC 2.7.2.5). The 
condensation of aspartate and carbamoylphosphate is then catalyzed by 
aspartate transcarbamoylase (2.1.3.2). The next reaction is catalysed by 
dihydroorotase (EC 3.5.2.3), removing a water molecule from 
carbamoylaspartate to produce dihydroorotate; in this step, the pyrimidine ring 
is being closed. The next step is the oxidation of dihydroorotate to orotate by 
dihydroorotate oxidase (1.3.3.1). The 5-phosophoribosyl 1-pyrophosphate (PRPP) 
is added by orotate phosphoribosyltransferase (EC 2.4.2.10) to form orotidine-5-
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monophosphate (OMP), which is decarboxylated by OMP decarboxylase (4.1.1.23) 
to produce uridine monophosphate (UMP). 
 
Figure 1.15 Pyrimidine biosynthesis pathways, adapted from 
(Hammond & Gutteridge, 1984). 
Although there are similarities between kinetoplastid parasites and their 
mammalian hosts in terms of pyrimidine biosynthetic enzyme activity, there are 
still significant differences related to their organization into polypeptides, 
allosteric regulation, use of cofactors and cellular localisation (Carter et al., 
2008). For instance, the first three pyrimidine biosynthetic enzymes in humans 
are encoded by a single gene (Carrey, 1995), while the kinetoplastid’s enzymes 
are encoded by isolated genes (Gene DB). Another example is that in humans, 
the dihydroorotate dehydrogenase is located in mitochondria and needs 
ubiquinone to be activated (Gero & O'Sullivan, 1985). Paradoxically, in a 
kinetoplastid it is a cytoplasmic enzyme (Hammond & Gutteridge, 1982) and 
requires fumarate as a cofactor (Feliciano et al., 2006). 
J. Ali 2013 Chapter 1 34 
3.2. Interconversion and salvage pathways of pyrimidines 
Although all kinetoplastids described to date can synthesise pyrimidines 
de novo, most of the studied species have some salvage pathways, which are 
used as a source of pyrimidine nucleotides (Hassan & Coombs, 1988). Pyrimidine 
nucleosides can be converted to their corresponding nucleobases or nucleotides 
by pyrimidine nucleoside phosphorylase or pyrimidine nucleoside kinase, 
respectively (Hassan & Coombs, 1988). All pyrimidines entering into the 
parasites, except thymidine and thymine, are probably converted to uracil, 
which is phosphoribosylated to UMP by uracil phosphoribosyl transferase (Figure 
1.16). Therefore, UMP, the product of both the biosynthetic and salvage 
pathways, is considered as a precursor for most pyrimidine nucleotides (Carter 
et al., 2003). 
 
Figure 1.16 Pyrimidine salvage pathways, adapted from (Hammond & Gutteridge, 1984). 
UMP can be phosphorylated through uridine diphosphate (UDP) to uridine 
triphosphate (UTP) by uridine nucleoside kinases in a two-step reaction using 
ATP as the phosphate donor. UTP is then aminated to CTP by CTP synthetase, 
which utilises glutamine as the amine donor (Hofer et al., 2001). Kinetoplastids 
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also possess deaminase activity (Hassan & Coombs, 1986; Kidder, 1984) that can 
convert cytosine, cytidine and deoxycytidine to uracil, uridine and deoxyuridine, 
respectively (Hassan & Coombs, 1986). Uridine can then be converted to uracil 
by uridine phosphorylase (Shi et al., 1999). UMP can be synthesised directly from 
uridine by uridine kinase, but there is an argument about the presence of this 
enzyme in kinetoplastid parasites (Carter et al., 2008). Nevertheless, a gene 
encoding a putative uridine kinase activity is present in the genome database of 
Leishmania major (LmjF.31.2470), L. infantum (LinJ.31.2560) and in L. 
mexicana it is encoded by pseudogene (LmxM. 30.2470). Thymidine, which is 
incorporated into DNA, can be phosphorylated to TMP by thymidine kinase, for 
which the relevant genes are believed to be present in Trypanosoma and 
Leishmania. Thymidine and thymine can be converted reversibly through the 
action of pyrimidine phosphorylase to produce thymine and thymidine, 
respectively. 
Deoxyribonucleoside triphosphates are needed in DNA synthesis. 
Deoxyribonucleotides are produced from ribonucleoside diphosphates via 
ribonucleotide reductase (Figure 1.17). 
 
Figure 1.17. Interconversions of pyrimidines, adapted from (Hammond & Gutteridge, 1984). 
Consequently, UDP and CDP can be converted to dUDP and dCDP, which are 
converted reversibly to dUMP and dCMP. In addition, both dUDP and dCDP can be 
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transformed to dUTP and dCTP respectively, by nucleotide diphosphokinase. 
Thymidine is crucial for DNA replication. dTMP is produced from thymidine by 
thymidine kinase (EC 2.7.1.21). However, the other route to supply cells with 
dTMP is by methylating dUMP with thymidylate synthase utilising 
methylenetetrahydrofolate as the methyl donor (Figure 1.18). In this reaction, a 
one-carbon group and two reducing equivalents are transferred from N5, N10-
methylenetetrahydrofolate to dUMP to produce dTMP and dihydrofolate. 
Regeneration of tetrahydrofolate occurs in a reaction catalysed by dihydrofolate 
reductase with NADPH as the electron donor (Hassan & Coombs, 1988). In 
apicoplast parasites, thymidylate synthase and dihydrofolate reductase exist on 
the same polypeptide as a bifunctional protein (Chalabi & Gutteridge, 1977; 
Garrett et al., 1984; Ivanetich & Santi, 1990). Trypanosomatids are auxotrophic 
for folate metabolites (Kaur et al., 1988; Scott et al., 1987), and rely on their 
transport of this cofactor from their mammalian host. DHFR and thymidylate 
synthase are validated drug targets for antifolate drugs including methotrexate. 
 
Figure 1.18. dTMP synthesis cycle showing the sequential reactions and metabolic 
relationships of TS (thymidylate synthase), DHFR (dihydrofolate reductase), and STH 
(serine transhydroxymethylase). Obtained from (Ivanetich & Santi, 1990). 
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3.3. Pyrimidine metabolism as a drug target  
Rapidly divided cells, such as tumour cells, and plasmodium parasites 
during the intraerythrocytic stage, increase the requirement of nucleotides to 
synthesis nucleic acids. Deoxynucleoside triphosphates (dCTP, dTTP, dATP and 
dGTP) and nucleoside triphosphates (UTP, CTP, ATP and GTP) are the main 
substrates for the synthesis of nucleic acids DNA and RNA, respectively. Several 
of these compounds and their derivatives are especially crucial as sources of 
cellular energy (ATP, GTP), coenzymes (NAD, NADP, FAD), and metabolic 
regulation (cAMP, cGMP). These participations in cell activity make purine and 
pyrimidine biosynthesis pathways very good drug targets in different organisms. 
Specifically, drugs that successfully block pyrimidine biosynthesis have been 
introduced as antiviral, anticancer and potential anti-protozoal agents. 
3.3.1. Antiviral activity 
Viruses do not have their own nucleoside metabolism, and rely on a host 
cell to make their DNA and RNA; therefore, they can only reproduce naturally 
inside a host cell (Wimmer et al., 2009). Some compounds have antiviral activity 
that inhibits the viral proteins or host cell proteins that are needed for virus 
growth. 
Both the pyrimidine salvage mechanism and the pyrimidine de novo biosynthesis 
pathway produce the precursor of all pyrimidine nucleotides, uridine 
monophosphate (UMP), which is needed for RNA (UTP and CTP) and DNA (dTTP 
and dCTP) synthesis (Li et al., 2007). Some antiviral drugs act by targeting 
pyrimidine metabolism of host cells and/or depleting pyrimidine pools, which 
are important for efficient virus replication. For example, dihydroorotate 
dehydrogenase (DHODH) converts dihydroorotate to orotate in the pyrimidine 
biosynthesis pathway with the aid of a flavin cofactor and an electron acceptor. 
This biosynthesis pathway is a target cellular enzyme for brequinar and 
leflunomide. Both of these antiviral compounds clearly inhibit human DHODH 
(Greene et al., 1995; Liu et al., 2000; McLean et al., 2001). Recently, a new 
class of DHODH inhibitors was found by binding the 4-hydrox-1,2,5-oxadiazol-3-yl 
(hydroxyfurazanyl) scaffold with substituted biphenyl moieties via an amide 
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bridge (Lolli et al., 2012). Furthermore, a compound called A3 was identified in 
a high-throughput screen for inhibitors (HTS) of influenza virus replication that 
act on pyrimidine metabolism. Virus divisions rely on large nucleotide pools, and 
the antiviral efficacy of compound A3 is due to pyrimidine depletion. It was also 
shown that the effect of A3 can be reversed, specifically by uracil and orotate 
(Hoffmann et al., 2011). In addition, the antiviral thymidine analogue, 3’-azido-
3’-deoxythymidine (zidovudine or AZT), was found to inhibit thymidine 
phosphorylation by 50% at a concentration of 5.5 ± 1.7 μM in the brain 
mitochondria (McCann et al., 2012). Antiviral pyrimidine nucleoside analogues 
have also been used against viral infections. For example, lamivudine (cytidine 
analogue; 2',3'-dideoxy-3'-thiacytidine) and stavudine (thymidine analogue; 2'-3'-
didehydro-2'-3'-dideoxythymidine) inhibit reverse transcriptase of HIV and lead 
to termination of DNA synthesis in viruses (Eholie et al., 2012; Srivastav et al., 
2010). 
3.3.2. Cancer chemotherapy 
The topic of pyrimidine analogues that are useful or potentially so in 
cancer chemotherapy is too enormous to be completely reviewed in this part of 
the Introduction. However, (Heidelberger, 1967) summarised cancer 
chemotherapy by purine and pyrimidine analogues from 1965 until 1966. That 
overview showed that the most-used pyrimidine analogues to treat cancers at 
the time were 6-azapyrimidines and 5-fluoro-pyrimidines. More recently, several 
pyrimidine nucleoside analogues have been used to treat cancers. For instance, 
cytarabine, a deoxycytidine with the presence of a hydroxyl group in the β-
configuration at the 2’ position of the sugar moiety, was used extensively to 
treat acute leukaemia (Arlin et al., 1988). Cytarabine triphosphate incorporates 
into DNA in competition with deoxycytidine triphosphate this incorporation leads 
to chain termination and results in blocking DNA synthesis and cell cycle arrest 
at S-phase (Major et al., 1981; Major et al., 1982). Gemcitabine is also a 
deoxycytidine analogue, but with two fluorine atoms in the 2’ position of the 
sugar moiety, used in the treatment of solid tumours (Burris et al., 1997; Kaye, 
1994). Gemcitabine is first phosphorylated to its monophosphate derivative, 
then subsequently phosphorylated by pyrimidine nucleotide kinases to the active 
5’-diphosphate and triphosphate derivatives (Abbruzzese et al., 1991). 
Gemcitabine is able to incorporate into both nucleic acids, DNA and RNA (Ruiz 
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van Haperen et al., 1993). The most used fluorinated pyrimidine analogue is 5-
FU. As such, its mechanism of action in human cancer cells has been well 
characterized; several sources described that the main drug toxicity involved the 
inhibition of thymidylate synthase, by its metabolite 5F-dUMP (Grivicich et al., 
2001; Figure 1.19). 
 
Figure 1.19: Metabolic pathways and mechanism of action of 5-fluorouracil (5-FU) in human 
cancer cells. Enzymes catalyzing these reactions are 1, orotate phosphoribosyltransferase; 2, 
uridine phosphorylase; 3, thymidine phosphorylase; 4, uridine kinase; 5, thymidine kinase; 6, 
thymidylate synthase; 7, dihydrofolate reductase; 8, dihydropyrimidine dehydrogenase; 9, 
ribonucleotide reductase; 10, 5'-nucleotidases and phosphatases. Abbreviations: FUMP, FUDP, 
FUTP: fluorouridine -5'-mono-, di-, and triphosphate, respectively; FdUMP, FdUDP, FdUTP: 
fluorodeoxyuridine-5'-mono-, di-, and triphosphate, respectively; dUMP: deoxyuridine-5'-
monophosphate; dTMP, dTDP, dTTP: deoxythymidine-5'-mono-, di-, and triphosphate, 
respectively; PRPP: 5-phosphoribosyl-1-pyrophosphate; FUR: fluorouridine; FUdR: 
fluorodeoxyuridine; F-BAL: -fluoro-ß-alanine; F-UPA: fluoroureidopropionate; F-DHU: 5-
fluorodihydrouracil; DHF: dihydrofolate; THF: tetrahydrofolate; TdR: thymidine; PPi: pyrophosphate. 
Adapted from Grivicich et al., 2001; Peters & Jansen, 1996. 
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3.3.3. Potential for antiprotozoal agents 
Most protozoa parasites are able to synthesis the pyrimidine ring de novo 
(Berens et al., 1995), and yet are also capable of salvaging pyrimidine 
nucleosides and/or nucleobases (Aronow et al., 1987; De Koning et al., 2003; 
Gudin et al., 2006; Papageorgiou et al., 2005). Exceptions are Plasmodium 
species, which are unable to use preformed pyrimidines from the host 
environment, and rely on biosynthesis alone (De Koning et al., 2005; Van Dyke et 
al., 1970), and the amitochondriate protozoa Trichomonas vaginalis, 
Tritrichomonas foetus, and Giardia spp, which lack the de novo biosynthesis 
pathway (Hassan & Coombs, 1988; Wang & Cheng, 1984). 
Several studies targeted pyrimidine metabolism enzymes to provide new routes 
for anti-parasitic drugs. (Cassera et al., 2011) reviewed several pyrimidine 
pathway enzymes that have been targeted in P. falciparum using pyrimidine 
analogues. In an in vitro study, P. falciparum growth was inhibited to half when 
exposed to 6 nM of 5-fluoroorotic acid (Rathod et al., 1989); also on the same 
species, triazolopyrimidine-based dihydroorotate dehydrogenase inhibitors 
(Figure 1.20A) recorded an EC50 at nanomolar levels (Phillips et al., 2008). 
Another pyrimidine pathway inhibitor is L-6-thiohydroorotate, which moderately 
inhibited dihydroorotase of malaria (Seymour et al., 1994). (Baldwin et al., 
2005) introduced an inhibitor of P. falciparum dihydroorotate dehydrogenase 
with an IC50 value of 16 nM. Other inhibitors of dihydroorotate dehydrogenase in 
Plasmodium species have also been identified, for instance, tricyclic aromatic 
amines (Heikkila et al., 2007). 
In addition, the growth of T. vaginalis was reported to be inhibited by 
deoxyuridine analogues, such as 5-methyl-4'-thio-2'-deoxyuridine and 5-iodo-4'-
thio-2'-deoxyuridine, with IC50 at molecular level concentrations (Strosselli et 
al., 1998). Benzimidazole derivatives (Figure 1.20B), which modified the second 
position of the pyrimidine ring, showed anti-parasitic activity against Trichinella 
spiralis, Paramecium caudatum and Lamblia muris (Mavrova et al., 2010). Also, 
hydrophilic derivatives of that pyrimidine analogue, 2,4-diaminothieno[2,3-d]-
pyrimidine lipophilic antifolates (Figure 1.20C), inhibited dihydrofolate 
reductase activity of Pneumocystis carinii, Toxoplasma gondii (Rosowsky et al., 
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1997), and trypomastigotes and amastigotes of T. cruzi (Senkovich et al., 2005). 
The drug was found to be a good substrate of human DHFR enzyme. However, 
the structures in Figure 1.20 could just as easily be described as purine 
analogues than as pyrimidine analogues. 
A. Triazolo-pyrimidine 
  
B. Benzimidazole  
 
C. 2,4-diaminothieno[2,3-d]pyrimidine 
 
Figure 1.20: Structures of 
pyrimidine analogues. A. Triazolo-
pyrimidine, B. Benzimidazole, C. 
2,4-diaminothieno [2,3-d]pyrimidine. 
From: www.ChemSpider.com. 
In kinetoplastids parasites, (Nakajima-Shimada et al., 1996) found that T. cruzi 
growth in vivo was significantly reduced by 3’-azido-3’-deoxythymidine (Figure 
1.21A; AZT) at a concentration around the micromolar level in in vitro cultures 
and also considered that zidovudine may be incorporated into parasite DNA. The 
growth of Trypanosoma cruzi, particularly the amastigote stage, was 
significantly reduced during genetic interruption of the first pyrimidine pathway 
enzyme, carbamoyl-phosphate synthetase II (Hashimoto et al., 2012). It was also 
found that the activity of the fourth enzyme of the pyrimidine pathway (DHOD) 
was reduced by extracts from two types of brown algae in T. cruzi (Nara et al., 
2005). Although trypanosomatids are considered folate auxotrophic (Ouellette et 
al., 2002), enzymes involved in the folate cycle to convert dUMP to dTMP have 
been of interest as drug targets in these parasites. Several compounds have 
shown inhibition activities against DHFR of kinetoplastids these include 2,4-
diaminopyrimidines (Figure 1.21B) (Pez et al., 2003) and 2,4-
diaminoquinazolines (Figure 1.21C) (Khabnadideh et al., 2005). Recently, 
(Mercer et al., 2011) have reported that 2,4-diaminopyrimidines derivatives can 
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kill T. b. brucei under both in vitro and in vivo conditions, presumably by 
targeting mitogen-activated protein kinases and cdc2-related kinases. 
A. 3’-azido-3’-deoxythymidine 
 
B. 2,4-diaminopyrimidines 
 
C. 2,4-diaminoquinazoline 
 
Figure 1.21: Structures of pyrimidine 
analogues. A. Zidovudine (AZT),  
B. 2,4-diaminopyrimidines, C. 2,4-
diaminoquinazolines. 
From: www.ChemSpider.com. 
The derived forms from 5-(substituted-benzyl)-2-4-diaminopyrimidine (Figure 
1.22A) inhibited leishmanial dihydrofolate reductase with IC50 values between 
0.2-11 μM (Sirawaraporn et al., 1988). In L. major, 5-fluorouracil appeared to be 
a good substrate for uracil phosphoribosyl transferase, and recorded an IC50 
value at the micromolar level (Papageorgiou et al., 2005).Acivicin (Figure 
1.22B), which inhibits glutamine utilisation, was able to clear L. donovani 
promastigote and amastigote forms (Mukherjee et al., 1990). In the early 1950s, 
a folic acid analogue, methotrexate (4-amino-N10-methyl-pteroylglutamic acid; 
Figure 1.22C), was introduced to treat leukaemia (Farber et al., 1948; Meyer et 
al., 1950), and later found to treat several other mammalian diseases. In 
mammalian cells (Ingraham et al., 1986), amastigotes of T. cruzi (Zuccotto et 
al., 1999) and promastigotes of L. major (Gallego et al., 2005) the drug inhibited 
dihydrofolate reductase and reduced dTTP synthesis, which led to a rise in dUTP 
that incorporated into DNA. At 400 nM the drug caused 80% inhibition of the 
growth of wild type promastigotes of L. major. 
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Figure 1.22: Structures of pyrimidine metabolism inhibitors. A. substituted 2,4-
diaminopyrimidines, B. Acivicin, a glutamine analogue, C. Methotrexate (4-amino-N10-
methyl-pteroylglutamic acid, a folate analogue. From: www.ChemSpider.com. 
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4. Nucleoside and nucleobase transporters of 
kinetoplastids 
4.1. Classification of transporters 
Biological organisms consist of cells built of proteins, carbohydrates, 
lipids and nucleic acids. Chemical analysis of several kinds of membranes reveals 
that most contain up to 50% protein and 50% lipid. However, organisms might 
have percentages that different from this 1:1 ratio. About one-third of the 
proteins of a cell are embedded in biological membranes, and about one-third of 
these function to catalyze the transport of molecules from one side of the 
membrane to the other side. The plasma membranes function to isolate the 
inside of the cell from its environment. The crucial role for transport processes 
to biological systems was recognized many years ago (Gale & Taylor, 1947; 
Mitchell, 1949). Membrane proteins serve the cell in several ways: the uptake of 
essential materials into the cytoplasm then into organelles, the regulation of 
metabolites and the active release of drug and other toxic substances (Saier, 
2000a). Transport proteins are known to uptake solutes by several mechanisms, 
and a variety of energy combining mechanisms are known to control the active 
transport and/or extrusion of specific compounds (Fath & Kolter, 1993; Kramer, 
1994; Paulsen et al., 1996a; Paulsen et al., 1996b). All uptake across membranes 
falls into one of two fundamental mechanisms: passive diffusion and active 
transport. In passive transports, cells do not use any energy to move molecules 
and substrates diffuse down concentration gradient, while in active transport 
mechanisms they use energy to pass molecules into or out of the cell against the 
gradient. Interestingly, membrane transport proteins, which are integral 
membrane proteins involved in the movement of ions, small or macro molecules 
across a cell membrane, have the two forms of transport mechanisms, passive 
and active transport. In transport protein mechanism, the uptake requires the 
assistance of a transport protein in the membrane to cross the lipid bilayer. 
Numerous studies have classified membrane transport proteins in several 
families according to different aspects. (Saier, 2000b) listed all the recognized 
families of transporters. Of these, there are two main families of transport 
proteins that mediate the movement of nucleobases and nucleosides across 
eukaryotic plasma membrane. The two unique families are the concentrative 
nucleoside transporters (CNT) and the equilibrative nucleoside transporters 
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(ENT). The CNT, designated SLC29, has three human family members (CNT1, 
CNT2 and CNT3). They couple nucleoside uptake to the cellular Na+ or H+ 
gradient, and have 13 predicted transmembrane segments. CNTs can be found in 
many specialized mammalian cell types, such as kidney and intestine, also the 
first eukaryotic nucleoside transporters whose genes were cloned (Baldwin et 
al., 1999) belonged to this family. Although CNT family members are widely 
distributed in both bacteria and eukaryotes, no members of this family have 
been found to date among the protozoa (De Koning & Diallinas, 2000). The ENT 
family was designated SLC28. Four human family members of SLC28 have been 
identified to date (ENT1, ENT2, ENT3 and ENT4); they transport nucleosides 
across plasma membrane bidirectionally in a Na+-independent manner. These 
transporters are distinguished by an overall similarity in predicted topology and 
characteristically possess 11 transmembrane domains (Figure 1.23). Thus far, all 
defined protozoan nucleoside and nucleobase transporter genes appertain to the 
ENT family (Landfear et al., 2004). 
 
Figure 1.23 Predicted topology of ENT and CNT families. Adapted from (Lee et al., 2001).and 
(Cass et al., 1998). 
The identification and classification of these families are based primarily on 
sequence homology. Both ENT and CNT families play critical roles in nucleoside 
salvage pathways. CNT1 prefers pyrimidine nucleosides, CNT2 is purine-
nucleoside preferring and CNT3 takes up both pyrimidine and purine nucleosides 
(Gray et al., 2004). ENTs transport nucleosides and their analogues through 
facilitated diffusion (Hyde et al., 2001). For instance, in humans, ENTs are likely 
to mediate the uptake of most of nucleoside analogues (Acimovic & Coe, 2002). 
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4.2 Characterisation of nucleoside and nucleobase 
transporters of kinetoplastid parasites 
Purine and pyrimidine nucleotides are both considered as nutrients and 
as modulators of cell homeostasis. These molecules are not only monomeric 
nucleic acid precursors, but also key determinants of energy metabolism 
involved in many biosynthetic pathways such as UDP-glucose in glycogen 
synthesis, CDP-diacylglycerol in phospholipid metabolism and S-
adenosylmethionine in essential transmethylation reactions. Also as energy 
transfer units such as ATP and GTP, as well as adenine nucleotides as component 
parts of NAD(P)+, FAD and CoA (Aymerich et al., 2005). Furthermore, some 
nucleosides (adenosine) and nucleotides (ATP) are ligands for purinergic 
receptors (P1 and P2) (Dal et al., 2011). Moreover, they act as second messenger 
molecules in cell signals pathways, e.g. cyclic AMP and cyclic GMP (Carter et al., 
2003). Since nucleosides and nucleobases are hydrophilic molecules, plasma 
membrane transporters are required for this process to occur. To clarify, these 
molecules cannot diffuse across the membrane lipid bilayer, therefore, they use 
integral membrane proteins (ENTs) to move down their concentration gradients. 
4.2.1 Purine transporters 
Among the many metabolic differences between protozoan parasites and 
their mammalian hosts is the fact that they cannot synthesise purine 
nucleosides. While the unicellular organisms are incapable of purine ring 
synthesis, their mammalian hosts are capable of de novo synthesis from amino 
acids and other small molecules. Therefore, Trypanosoma and Leishmania rely 
solely on the uptake mechanisms of these external nutrients. Consequently, the 
purine salvage pathways are required for parasite viability in all life cycle 
stages. The transporters also mediate the uptake of a variety of cytotoxic drugs 
(Geiser et al., 2005). Over the last decades, this phenomenon has led to 
intensive studies on purine uptake and metabolism in several protozoa parasites 
(De Koning et al., 2005). On the other hand, it has been generally demonstrated 
that kinetoplastid parasites are able to synthesis the pyrimidine ring de novo 
(Gudin et al., 2006). However, it is often difficult to study purine/pyrimidine 
transporters within the live parasites, as abundant separate transporter genes 
are expressed simultaneously and specific inhibitors for individual transporters 
are not available (Gudin et al., 2006). Nucleoside and nucleobase transporters in 
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kinetoplastid species are still eliciting considerable attention due to their 
central role in the uptake of antimetabolites. 
4.2.1.1 Trypanosoma spp. 
The first two high-affinity adenosine transport systems in T. brucei were 
identified and designated P1 and P2 (Carter & Fairlamb, 1993), which also 
accumulate inosine and adenine, respectively. The P1 and P2 transporters have 
been widely studied since they were first described. P1 is considered to be a 
conventional purine nucleoside transporter and has a very low affinity for purine 
nucleobases (De Koning & Jarvis, 1999). In addition, the same authors also found 
that bloodstream forms of T. b. brucei transport hypoxanthine via two distinct 
transporters differentiated as guanosine-sensitive and insensitive, and defined as 
purine nucleobase transporter H2 and H3, respectively (De Koning & Jarvis, 
1997a). On the other hand, it was demonstrated that the P2 nucleoside 
transporter mediated the uptake of diamidine drugs, including the widely used 
trypanocide pentamidine (Carter et al., 1995; De Koning, 2001). The 
trypanosome expresses two additional transporters: a high affinity pentamidine 
transporter (HAPT) and a low affinity pentamidine transporter (LAPT), which 
also contribute as pathways for the uptake of pentamidine (De Koning, 2001). 
Since P2 is a member of the equilibrative nucleoside transporters (Ortiz et al., 
2009a) assumed that it is likely the other ENT family members in T. brucei may 
also mediate the uptake of diamidines. 
4.2.1.2 Leishmania spp. 
An early study, conducted by (Hansen et al., 1982), on the uptake of 
purine nucleosides and nucleobases in Leishmania braziliensis promastigotes, 
reported on three transport activities, for adenosine, inosine and the last one 
for the purine bases adenine and hypoxanthine. This model is still being used in 
purine transport for promastigotes. Another study by (Aronow et al., 1987) 
investigated the functions of Leishmania donovani nucleoside transporters and 
found that the parasite possesses two independent purine nucleoside 
transporters that mediate the uptake of adenosine and pyrimidine nucleosides 
(uridine, cytidine and thymidine) in one case, and of inosine and guanosine in 
the other case, with Km values in the micromolar range.  Various nucleoside and 
nucleobase analogues display good activities in vitro and/or in vivo, but to date 
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only the purine nucleobase analogue allopurinol has been used in combination 
therapy against leishmaniasis. It was combined with meglumine antimoniate to 
treat cutaneous leishmaniasis (Momeni et al., 2002) and with pentamidine to 
cure visceral leishmaniasis (Das et al., 2001). 
In general, Leishmania and Trypanosoma have shown many similarities in 
purine nucleobase and nucleoside transporters that mediate the transport purine 
bases, nucleosides and analogues (Al-Salabi et al., 2003; Burchmore et al., 
2003). Moreover, on the level of pyrimidine transporters, both genera express a 
similar high-affinity uracil transporter, designated LmajU1 (Papageorgiou et al., 
2005) and TbU1 (De Koning & Jarvis, 1998), respectively. 
4.2.2 Pyrimidine transporters 
In contrast to purines, only a few studies have been conducted on 
pyrimidine uptake in kinetoplastid parasites (Gudin et al., 2006). This might be 
attributed to the parasites’ ability to synthesise the pyrimidine ring, which 
makes it less attractive to scientists interested in chemotherapy than purine 
transporter studies. In general, purine transporters can mediate the uptake of 
purine and/or pyrimidine antimetabolites in kinetoplastid parasites (De Koning & 
Jarvis, 1998; Papageorgiou et al., 2005; Wallace et al., 2002). (De Koning & 
Jarvis, 1997a) reported hypoxanthine uptake by the H2 transporter in T. b. 
brucei bloodstream forms was inhibited by uracil and thymine, with Ki values of 
60 and 82 µM, respectively. The same authors (De Koning & Jarvis, 1998) 
described the first high-affinity uracil transporter in kinetoplastid, designated 
TbU1, with a Km value of 0.4 µM. The Leishmania major transporter, LmajU1, 
was found to be highly similar to the TbU1 transporter of T. b. brucei 
(Papageorgiou et al., 2005). It has been confirmed that the pyrimidine analogue 
5-fluorouracil is an effective agent against both Leishmania and Trypanosoma 
parasites (Gudin et al., 2006; Papageorgiou et al., 2005), which suggested a 
correlation between efficient salvage and therapeutic effect. Also 5-fluorouracil 
was found as a good inhibitor of both LmajU1 and TbU1 transporters (Gudin et 
al., 2006). Therefore, it might be possible to develop a new chemotherapy for 
trypanosomiasis, if this cytotoxic nucleobase has the same effect on uptake 
systems of the mammalian-infective. 
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4.3. Cloning of nucleoside and nucleobase transporters 
Since nucleoside transporters are responsible for the accumulation of 
chemotherapeutic agents of many diseases, several permeases have been 
characterised from a number of species, ranging from prokaryotic to humans. 
Because of the difficulty to isolate and identify the contribution of a single 
transporter using radio-labeled permeants and whole organisms, scientists 
depend on cloning and expressing the gene encoding the putative transporter in 
a suitable heterologous system (Burchmore et al., 2003). However, the progress 
on molecular level studies of nucleoside and/or nucleobase transporters from 
kinetoplastid started only in the late 1990s, and to date all of the protozoan 
nucleoside and nucleobase transporters identified belong to the ENT family (De 
Koning et al., 2005). With the completion of the T. b. brucei and L. major 
genomes, it is now known how many ENT-family genes each parasite encodes. 
The genome of L major contains a total of 8272 genes (Ivens et al., 2005), 
whereas the T. brucei genome contains 9068 genes (Berriman et al., 2005). Of 
these, T. b. brucei encodes 16 ENT genes (Ortiz et al., 2009a) whereas the 
Leishmania spp genome contains 5 ENT genes (Ortiz et al., 2007). 
4.3.1 Mammals 
The first identified mammalian nucleoside/nucleobase transporter 
proteins were hENT1 and its rat ortholog rENT1, they were expressed in Xenopus 
laevis oocytes and efficiently transported hypoxanthine, adenine, guanine, 
uracil and thymine (Yao et al., 2002). The same authors have demonstrated that 
hENT1 transports thymine, adenine, uracil and guanine. Recently, it has been 
shown that uridine nucleoside inhibits hypoxanthine uptake (Yao et al., 2011). A 
novel human nucleoside transporter 1, designated hNT1, has been described and 
functionally characterized at the molecular level (Umemoto et al., 2009). The 
gene, encoding hNT1 transporter was cloned from human breast cancer cells and 
expressed in Xenopus oocytes. The carrier was able to transport the 
antineoplastic agent, 5-fluorouracil with a very highly affinity (Km value = 69.2 
nM). In addition, hNT1 transporter was strongly inhibited by several nucleosides 
(uridine, thymidine, cytidine, guanosine, inosine, and adenosine) and the 
pyrimidine nucleobase, uracil. However, despite the details given in that 
manuscript it seems doubtful that this gene product of only 82 amino acids 
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encodes a genuine solute transporter. The TM PRED Server and TMHMM Server 
did not identify any transmembrane segments in this protein. No homologous 
genes were present in the Trypanosoma or Leishmania genomes. (Yamamoto et 
al., 2010) described the first genuine nucleobase transporter in mammals, 
defined as Rattus norvegicus slc23A4: an mRNA for encoding sodium-dependent 
nucleobase transporter 1, and designated as rSNBT1. The mRNA of the rSNBT1 
contains 1989 base pair and the protein sequence of this transporter consists of 
599 amino acids. The transporter was found to be able to take up uracil 
efficiently, as well as the other nucleobases thymine, guanine, hypoxanthine and 
xanthine, but adenine, cytosine and nucleosides are not or poorly recognized. 
Furthermore, inhibitory studies on the rSNBT1 found that the transporter can 
recognize the nucleobase analog, 5-fluorouracil. However, it was also reported 
that the gene orthologous to the rSNBT1 gene is genetically not present in 
human. The rSNBT gene is part of the NAT-families, which has no protozoan 
equivalents either (De Koning & Diallinas, 2000; Gournas et al., 2008). 
4.3.2 Trypanosoma spp 
The first cloned nucleoside transporter gene from this species was 
designed Adenosine Transporter 1 (TbAT1) (Maser et al., 1999). The gene was 
functionally expressed in a purine uptake and biosynthesis deficient yeast 
mutant; the result showed that TbAT1 possessed high affinity transport activities 
for adenine and adenosine, TbAT1 was shown to encode the P2 transporter. The 
second transporter, Nucleoside Transporter 2 (TbNT2) (Sanchez et al., 1999), is 
a P1-type transporter. The TbNT2 gene was expressed in Xenopus oocytes and it 
can take up adenosine, inosine and guanosine. (Sanchez et al., 2002) identified 
an array of six genes on chromosome 2 of T. b. brucei strain 927, consisting of 
TbNT2 up to TbNT7. The open reading frames of these genes exhibit high 
identity to each other. Expressing these six genes in Xenopus oocytes showed 
that NT2/927, NT5, NT6 and NT7 seem to possess high affinity to adenosine, 
inosine and guanosine with Km values of (0.3 – 4.3 µM). Unlike NT2/927, those 
transporters are also able to transport hypoxanthine to a limited extent. On the 
other hand, no substrates were identified for the TbNT3 and TbNT4 transporters 
when expressed in Xenopus oocytes, and their function, if any, is as yet 
unknown. It is important to note that these transporters failed to accumulate 
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pyrimidines, including uracil, thymine, thymidine, and uridine (Sanchez et al., 
2002). 
A related gene, designated TbNBT1 (Burchmore et al., 2003), from T. b. brucei 
was identified and expressed both in a strain of yeast lacking purine 
transporters, and in Xenopus oocytes, and assayed for transport of nucleosides 
and nucleobases. TbNBT1 was the first cloned nucleobase transporter gene, with 
high affinity for adenine, hypoxanthine, guanine and xanthine. TbNBT1 also 
transported guanosine, albeit with affinity lower than its corresponding base, 
whereas affinities for inosine and adenosine were very much lower. Generally, 
rates of uptake for nucleosides were also much lower than for nucleobases. A 
similar study was conducted by (Henriques et al., 2003), which identified 
another bona fide nucleobase transporter gene from T. b. brucei, designated 
TbNT8.1. Both genes, TbNBT1 and TbNT8.1, which differ in only 3 amino acids, 
mediate the uptake of the same four purine substrates. Further investigations of 
the T. b. brucei database have identified another four ENT family members, 
TbNT9 (Al-Salabi et al., 2007), TbNT10 (Sanchez et al., 2004), and 
TbNT11/TbNT12 (Ortiz et al., 2009a). TbNT9 and TbNT10 were cloned and 
shown to transport purine nucleosides, adenosine, inosine and guanosine in a 
very similar way as TbNT2. The genes encoding TbNT11 and TbNT12 were 
expressed in a Leishmania donovani line deficient in purine nucleoside or 
nucleobase uptake, and identified as purine nucleobase transporters. Both 
transporters were also shown to have a high affinity to diamidine drug 
pentamidine.  
4.3.3 Leishmania spp 
The first protozoan nucleoside transporter genes, LdNT1 (Vasudevan et 
al., 1998) and LdNT2 (Carter et al., 2000) were cloned from Leishmania 
donovani by functional rescue of a transport-deficient mutant. LdNT1 was 
expressed in Xenopus oocytes and in adenosine transport-deficient L. donovani. 
This approach identified two almost identical genes, designated LdNT1.1 and 
LdNT1.2, which transport adenosine and the pyrimidine nucleosides with a 
micromolar range of Km values. LdNT2 was also expressed in Xenopus oocytes 
and in a mutant cell line of L. donovani deficient in inosine and guanosine 
transport activities, and confirmed that LdNT2 appeared as a single gene 
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encoding 499 amino acids, which has a highly affinity for its substrates and 
mediates the uptake of the oxopurine nucleosides, inosine and guanosine, with 
sub-micromolar of Km values. The first nucleobase transporter to be cloned and 
functionally expressed from L. major was LmaNT3 (Sanchez et al., 2003), which 
shared 33% amino acid identity with LdNT1.1. LmaNT3 displays high rates of 
adenine, guanine, xanthine and hypoxanthine transport, with a range of Km 
values ranging from 8.5 to 16.5 µM. The final member of the ENT family 
identified in the Leishmania major genome database is LmaNT4 (Ortiz et al., 
2007). When the LmaNT4 gene was expressed in a nt3(-/-) null mutant, it was 
shown that LmaNT4 was able to transport adenine but with low affinity. 
5. Research strategy and aims 
The current chemotherapies against kinetoplastid parasites have several 
important disadvantages as mention above. Therefore, searching for new routes 
to treat these neglected diseases is urgently needed. This study will attempt to 
study pyrimidine transporters and metabolism. One of the more promising 
approaches to identify pathways involved in the action of potential pyrimidine 
antimetabolites is to study resistance mechanisms to this compound. Therefore, 
we studied the mechanism of resistance and mode of action of pyrimidine 
analogues in kinetoplastid parasites. The study also focuses on the essentiality of 
pyrimidine de novo biosynthesis or salvage to the survival of the parasite. The 
specific aims are: 
1. To assess the uptake of all natural pyrimidine nucleobases and nucleosides 
into kinetoplastid parasites and identify the pyrimidine transporters, 
thereby increasing our understanding of pyrimidine salvages in protozoa 
parasites. 
2. To evaluate pyrimidines as subversive chemotherapeutic agents against 
kinetoplastid parasites, and establish for each their mode of action and 
their metabolites, as well as to develop and characterise kinetoplastid 
strains resistant to fluorinated pyrimidines. 
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3. To present an improved model of pyrimidine salvage and metabolism in 
kinetoplastids, supported by genome-wide profiling of the predicted 
pyrimidine biosynthesis and conversion enzymes. 
4. To establish whether pyrimidine de novo biosynthesis is or is not essential 
for infectivity of African trypanosomes. 
5. To identify kinetoplastid genes associated with resistance to fluorinated 
pyrimidines. 
CHAPTER TWO 
Material and Methods 
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2.1 Culturing Kinetoplastid cells 
Parasite cells were kept in liquid nitrogen stores. Before starting this project, 
the genotypes of used kinetoplastid cell cultures were confirmed by members of 
the De Koning Lab. Genotyping of wild type bloodstream forms of T. b. brucei 
was proved using multiplex polymerase chain reaction (PCR), and the genotyping 
of wild type promastigotes of Leishmania mexicana and Leishmania major was 
confirmed by restriction analysis of the amplified ITS1 region. 
2.1.1 Trypanosome brucei brucei bloodstream forms 
T. b. brucei bloodstream forms in vitro 
The standard culture of T. b. brucei, bloodstream forms of strain 427-wild type 
were incubated in sterile culture flasks at 37 °C and 5% CO2 in HMI-9 medium 
(obtained from Invitrogen) supplemented with 10% Heated-Inactivated fetal 
bovine serum (FBS) as described by (Hirumi & Hirumi, 1989). The medium was 
made by dissolving a sachet of HMI-9 powder and 500 ml of FBS in 4.5 liter of 
distilled water using a magnetic stirrer overnight at 4 °C. Next, 71.5 μl of 14.3 M 
β-mercaptoethanol was added to the medium and the pH was adjusted to 7.4. 
The medium was sterilized through a Millipore Stericup filter with pore size 0.22 
μm inside a flow cabinet. Mid-logarithmic stage of bloodstream forms were 
regularly passaged (every second day) in small vented-culture flasks containing 
10 ml fresh HMI-9 medium. 
T. b. brucei bloodstream forms in vivo 
A number of 200 g adult female Wistar rats (Harlan, UK) were injected 
intraperitoneally with 2 ml HMI-9 medium inoculated to a density of 105 cells/ml 
of bloodstream forms of T. b. brucei s427-wild type. Parasitemia was checked 
daily by examination of a tail venipuncture. The raped matching method 
(Herbert & Lumsden, 1976) was used to estimate the number of parasites in the 
blood samples. When parasitemia reached around 109 cells/ml the animal was 
anesthetized using CO2 and the blood from infected animal was collected into 50 
ml falcon tube supplemented with 500 units/ml of heparin suspended in Carter’s 
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balanced salt solution (CBSS; D-glucose 11.1 mM, HEPES 25 mM, KCl 5.4 mM, 
NaCl 120 mM, Na2HPO4 5.6 mM, CaCl2 0.55 mM, MgSO4 0.4 mM, the pH adjust to 
7.4). The blood was centrifuged at 2500 rpm at 4 °C for 15 minutes to separate 
its components. Parasites, which lay between the red blood cells and plasma in a 
buffy coat layer, were resuspended in phosphate-buffered saline plus glucose 
(PSG buffer; 13.48g Na2HPO4 (anhydrous), 0.78g NaH2PO4.2H2O and 4.25 g NaCl, 
in distilled water with 1% glucose, adjusted to pH 8.0). The contents were 
applied to the DEAE cellulose (DE-52) anion-exchanger column (Lanham, 1968) 
where the red blood cells were negatively charged and stick to the cellulose and 
the trypanosomes were positively charged and pass through the column. Then 
parasite cells were washed twice more in uptake assay buffer (section 2.3), and 
resuspended in the same buffer at 108 cells/ml for transport assays. 
2.1.2 L. mexicana and L. major promastigotes in vitro 
Promastigotes of L. mexicana (MNY/BZ/62/M379 strain) and L. major, (Friedlin 
strain) were incubated at 25 °C in sterilized small vented flasks. Five ml of 
HOMEM culture medium (Gibco) pH 7.4 provided with 10% FBS were seeded with 
105 cells/ml of mid-log phase culture. The cells were allowed to grow up to 
reach late-log stage and then passaged again in fresh medium. 
2.1.3 Pyrimidine auxotrophic T. b. brucei  
Pyrimidine auxotrophic T. b. brucei in vitro 
Pyrimidine auxotrophic line of T. b. brucei bloodstream forms is a genetic 
deletion mutant lacking the final step of the pyrimidine biosynthesis pathway, 
which in trypanosomes is a fusion of the two enzymes orotidine monophosphate 
decarboxylase (pyr6-OMPDCase) and orotate phosphoribosyl transferase (pyr5-
OPRTase). Pyrimidine auxotrophic trypanosomes strain (pyr6-5-/-) was routinely 
grown in HMI-9 medium, exactly as described for wild-type T. b. brucei 
bloodstream forms. Where indicated, Pyr6-5-/- cell cultures grown in a 
pyrimidine-free medium that was identical to the standard HMI-9 except that it 
did not contain thymidine; this medium was lab-made and abbreviated HMI-9-tmd 
(Appendix I). The thymidine-free HMI-9 medium was supplemented by 10% 
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dialysed serum (first thoroughly dialysed and to become pyrimidine-free serum). 
Dialysis tubing for serum was obtained from Medicell International Ltd, with 
molecular weight cut off 12-14 kDa. Before use, the tubing was boiled in 4 liters 
of dialysis buffer (10 mM NaHCO3 and 1mM EDTA adjust pH 8.0) for 30 minutes, 
rinsed thoroughly in distilled water, then boiled again for 10 minutes in 1 mM 
EDTA pH 8.0. Tubing was stored in 20% ethanol at 4 °C with tubing submerged. 
To dialyse FBS, the dialysis tubing was clipped at one end and 50 ml of the 
serum solution was pipetted into the tubing then the other end was clipped. The 
FBS was dialysed against PBS pH 7.4 and stirred with magnetic stirrer at 4 °C. 
The BPS was replaced every 12 hours and the dialysis process continued for 
around 60 hours. 
Pyrimidine auxotrophic T. b. brucei in vivo 
Six-weeks-old female ICR (CD1) Swiss outbred mice (Harlan, UK) were fed a 
standard diet for more than a week to adapt the new environment. These mice 
were divided into 3 groups of six mice each and injected intraperitoneally with 
200 μl of HMI-9 medium seeded with 105 cells/ml of bloodstream forms of T. b. 
brucei strains: 427-WT, Pyr6-5+/- (single knockout) and Pyr6-5-/- (double 
knockout). The HMI-9 medium was supplemented with 10% FBS. To quantify 
parasitemia, 1 μl of blood was daily harvested from the tail of each infected 
mouse and appropriately diluted in Red Blood Cell Lysis Buffer (Roche). 10 μl of 
the diluted cells was examined under a light microscope at 40-fold magnification 
using a haemocytometer and parasitemia was expressed as a number of parasites 
per ml of blood. 
Growth of pyrimidine auxotrophic trypanosomes on 
different pyrimidine sources 
Growth of pyrimidine auxotrophic (PYR6-5-/-) and/or bloodstream forms of T. b. 
brucei s427-wild type strains were assessed in standard HMI-9 medium provided 
with 10% FBS and/or HMI-9-tmd supplemented with 10% dialysed serum (section 
2.1.3). Cells were seeded at 1 × 105 and/or 5 × 105 cells/ml and grown in 12-well 
plates. Incubation was in appropriate media at 37 °C and 5% CO2. Monitoring of 
cells growth using cell counts was performed in triplicate every 12 or 24 hours. 
The experiments were performed independently on three separate occasions. 
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2.1.4 Adaptation of kinetoplastid parasites to tolerance 
for pyrimidine analogues 
Kinetoplastid resistant cell lines were established in order to study pyrimidine 
analogues metabolism, understand fluorinated pyrimidine mode of action, 
investigate the resistance factor/s and identify pyrimidine transporters in 
kinetoplastid cells. 
Resistance induction in T. b. brucei bloodstream forms 
T. b. brucei BSF wild type s427 cells were grown in HMI-9 medium as described 
previously. Strains adapted to selected pyrimidine analogues were derived from 
s427-WT through in vitro exposure to increasing levels of the drugs over several 
months. The pyrimidine analogues used were the three most effective 
fluorinated pyrimidines (5-fluorouracil, 5-fluoro-2’-deoxyuridine and 5-
fluoroorotic acid), which displayed micromolar level EC50 values (Effective 
Concentration which inhibits growth by 50%). The first drug concentrations used, 
starting the adaptation process, were the half EC50 values of each drug. Surviving 
cells were passaged to three flasks, one flask contained drug free, other flask 
contained the same sub-lethal concentration and the last flask contained twice 
the previous concentration. The procedure was repeated until a high level of 
tolerance to the drug was obtained. 
Resistance induction in Leishmania promastigotes 
Promastigotes of Wild type strains of M379 L. mexicana promastigotes and 
Friedlin L. major were grown in HOMEM medium as described above. Separate 
cultures were exposed to non-lethal concentrations (1/2 EC50) of 5-fluorouracil 
and 5-fluoro-2’-deoxyuridine. The cells were then visually observed for viability 
and sub-passaged to tolerated concentration of the drugs as mentioned above. 
2.1.5 Cloning of kinetoplastid cells 
When the strains became viable in higher concentrations of the drugs, adapted 
strains were cloned out (derived from a single cell) by limiting doubling dilution. 
This consists of taking a dilute culture (3 × 105 cells/ml) and serially diluting 
them two-fold across a 96-well transparent plate. The plates were incubated in 
appropriate conditions for several days, colonies that were grown in the wells 
J. Ali 2013 Chapter 2 59 
numbered 15-24 are considered as a single cell when the previous wells (at least 
two wells) are free of growth. The selected clones were then re-cloned again at 
least twice in the same way. The successful clones were given the following 
abbreviations: Trypanosoma strains adapted to 5-FU, 5-FOA and 5-F2’dUrd 
referred to as Tbb-5FURes, Tbb-5FOARes and Tbb-5F2’dURes, respectively. L. 
mexicana strains adapted to 5-FU and F2’dUrd were called Lmex-5FURes and 
Lmex-5F2’dURes; the L. major lines adapted to the same drugs were 
abbreviated Lmaj-5FURes and Lmaj-5F2’dURes, respectively. 
2.1.6 Establishing stabilates 
Clonal population of parasites were diluted 1:1 in their relative fresh media 
(HMI-9 medium for trypanosomes and HOMEM for leishmanias) containing 30% 
sterilized glycerol. The cells were thus stabilated in 15% glycerol and frozen at -
80 °C before being transferred to liquid nitrogen for long term storage. New 
stabilates were brought from the store, thawed at room temperature and 
passaged to the appropriate medium. Throughout the study, the cell cultures 
were renewed by bringing out new stabilates after ≤20 passages. 
2.2 Chemicals 
2.2.1 Radiolabeled compounds 
The following radiolabeled substances were used through the study: [5,6-3H]-
Uracil (40.3 Ci/mmol) was purchased from Perkin Elmer. [5,6-3H]-Uridine (30 
Ci/mmol), [5-3H]-2’-deoxycytidine (20 Ci/mmol) and [2-3H]-Adenosine (40 
Ci/mmol) were from American Radiolabel Chemicals Inc. All other radioactive 
isotopes including: [methyl-3H]-Thymidine (84 Ci/mmol), [methyl-3H]-Thymine 
(56.3 Ci/mmol), [5-3H]-Cytidine (25.6 Ci/mmol), [5-3H]-Cytosine (25.6), [6-3H]-
2’-deoxyuridine (17.8 Ci/mmol), [6-3H]-5-fluorouracil (20 Ci/mmol), [5-3H]-
Orotic Acid (23 Ci/mmol) and  [2,8-3H]-Inosine (20 Ci/mmol) were from Moravek 
Biochemicals. 
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2.2.2 Purines, pyrimidines and their analogues 
Uracil, 5-fluorouracil, 5-fluorouridine, uridine, 2-deoxyuridine, 5-chlorouracil, 
thymine, thymidine, orotic acid, 5-fluoro orotic acid, cytosine, cytidine, 2’-
deoxycytidine, 5-fluoro-2’-deoxycytidine, adenine,  adenosine, hypoxanthine, 
inosine, xanthine, 5-iodouridine, 3-deoxythymidine, uridine-5-triphosphate 
sodium salt, uridine-5-diphosphate sodium salt, uridine-5-monophosphate 
sodium salt, 3-deazauridine, 2’-4’- dihydroxy-6-methylpyrimidine, 1-
methyluracil, 6-methyluracil, 2-mercaptopyrimidine, 3-deazauracil, 4(3H)-
pyrimidone, 4-thiouracil, 5-Iodouracil, 5,6-dihydrouracil and  6-azauracil were 
from Aldrich Sigma. 5-bromouracil, 5-bromouridine and 5-iodo-2’-deoxyuridine 
were from Avocado Organic. 3’-deoxyuridine, 2-thiouridine and 4-thiouridine 
were from TriLink Bio Tech. 5-fluorocytidine, 5-chlorouridine, 5’-deoxyuridine, 
5’-deoxy-5’-flurouridine, 2’-3’-dideoxyuridine and 2’-deoxy-5-fluorocytidine 
were from Carbosynth. 5-fluoro-2’-deoxyuridine and 5-fluorocytosine were from 
Fluka. 2-thiouracil was from ICN Biomedicals. 3’4’- dihydroxy-6-
methylpyrimidine was from Merck.  
2.2.3 Media and growth chemicals 
Hirumi's modified Iscove‘s (HMI-9) medium was purchased from Invitrogen. 
Eagle’s minimal essential medium (HOMEM) was from GIBCO. Heat-inactivated 
fetal bovine serum was from PAA Laboratories. Potassium chloride, sodium 
dihydrogen phosphate hydrate and (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) were from BDH Prolabo Chemicals. Di-n-
butylphalate, mineral oil and scintillation fluid [Optiphase HiSafe III] were from 
Perkin-Elmer. Sodium chloride, sodium hydrogen carbonate, glucose and glycine 
were from Fisher. Sodium selenite and serine were from Fluka. Threonine was 
from Acros Organics. Acetonitrile was from Fisher Scientific. Exonulease III was 
from Takara Biotechnology, Trizol was from Life Technologies. Restriction 
enzymes, primers and molecular reagents were purchased from Promega. All 
other chemicals were available from Sigma. 
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2.3 Transport assays 
2.3.1 Preliminary uptake assay establishing the required 
range (time course): 
Assays for transport of [3H]-pyrimidines and/or purines by kinetoplastid cells 
were performed exactly as described by (Gudin et al., 2006). Cells in the mid to 
late logarithmic stage of growth were harvested by centrifugation at 2500 rpm 
for 10 min and washed twice with transport assay buffer (Glucose 2.53 g, HEPES 
8.0 g, MOPS 5.0 g, NaHCO3 2.0 g, KCl 0.3475 g, MgCl.6H2O 0.0625 g, NaCl 5.7 g, 
NaH2PO4.2H2O 0.9135 g, CaCl2.2H2O 0.0407 g, and MgSO4.H2O 0.0199 g dissolved 
in 1 litter distilled water, adjusted to pH 7.3 and stored at 4°C). The cells were 
resuspended at a density of 108 parasite cells/ml in the same buffer prior to use 
in transport experiments. Suspended parasites were left for 20-30 minutes to 
recover centrifugation stress. Cells were examined and counted in 16 
haemocytometer sections of 0.1 mm3 using a light microscope at 40-fold 
magnification. Transport was measured at 22 °C, essentially as described by (De 
Koning  & Jarvis, 1997b). Tritium concentration of tested pyrimidines was 
prepared at 4× in uptake assay buffer. The same volume of 4× radiolabel and the 
assay buffer were mixed in a clean 15 ml polystyrene tube. In parallel, another 
volume of 4× radiolabel was mixed with the same volume of 4× related 
unlabelled pyrimidine in order to bring concentrations down to half in both 
cases. A volume of 100 µl of cells at 108 cells/ml was added to an eppendorf 
tube containing 300 µl of mixture oil (1:7 mixture of mineral oil and di-n-butyl 
phthalate) and 100 µl of the 2× diluted tritium compound. The reaction was 
incubated at ambient temperature for predetermined times. The uptake was 
terminated by adding 1 ml of ice cold buffer containing saturating levels of 
unlabeled permeant. Cells were separated from extracellular label by immediate 
centrifugation at 13000 rpm for 45 seconds in a bench top centrifuge. The cells 
were spun through the oil layer to form a pellet in the bottom of the tube, 
isolated from the radiolabel in the aqueous phase above the oil. The entire 
reaction tube was then flash frozen in liquid nitrogen. The pellets were cut off 
and collected in scintillation vials, 250 μl of 2% sodium dodecyl sulphate (SDS; 
10g sodium dodecyl sulphate in 500 ml distilled water) was added to each vial, 
and pellets were left for 20 minutes at room temperature. A volume of 3 ml 
scintillation fluid (Optiphase HiSafe III) was added to the samples and these left 
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overnight at room temperature to observe the radio activity from the sample 
and convert that energy to light which is detected by the counter. Parallel 
triplicate determinations of 4× tritium permeant and 2% SDS were included to 
calculate the saturable mediated uptake in pmoles per 107 cells per sec. The 
presence of radioactivity was measured in a Beckman LS6000 TA scintillation 
counter and corrected for non-specific association of the label with the cell 
pellet. Cells numbers, viability and motility were checked under a phase 
contrast microscope after each uptake assay experiment. 
2.3.2 Dose response assay 
Serial two-fold dilutions were prepared, starting at concentrations up to 4 × 10 
mM down to 4 × 10 nM giving up to 13 separate dilutions of unlabeled compound 
(inhibitor). Next, 100 µl of a 1:1 mixture of 4 × label and 4 × inhibitor dilutions 
were layered over 300 μl of oil in an eppendorf tube, resulting in a mixture 
containing both the label and the inhibitor at 2 × concentration. The mixture 
was centrifuged for 20 seconds to collect it in one layer. As a negative control, 
100 μl of 2 x radiolabeled compound without inhibitor was pipetted into an 
eppendorf tube containing 300 μl oil. The transport assay itself started when 100 
μl of 108 parasite cells/ml was added to the aqueous phase of 2 × radiolabel. The 
reaction was incubated for a predetermined time as appropriate for each 
experiment, but always within the linear phase of transport, which was 
determined from time course experiments before inhibition experiments were 
undertaken. The uptake was terminated by the addition of 1 ml ice-cold 
unlabeled test compound at 1–5 mM in assay buffer. The cells were then isolated 
from the radiolabel in the assay buffer by full speed (13,000×g) centrifugation 
through the oil, and collected in the bottom of the tube. The experiment 
continued just as described above (section 2.3.1). The dose response assays 
were performed to determine the Km (Michaelis-Menten constant) and Vmax 
(Maximum velocity) values of the test compounds, as well as Ki values (Inhibition 
constants) for potential inhibitors. Inhibition data and time courses were plotted 
to equations for hyperbolic, sigmoid lines or linear regression, as appropriate, 
using Prism 5.0 (GraphPad). 
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2.4. Drug sensitivity assay 
Several methods have been used to test the susceptibility of kinetoplastid 
parasites to drugs and other test compounds. The Alamar Blue (resazurin sodium 
salt; Sigma) assay was used in this thesis and is a method that has been used 
widely to determine the sensitivity of kinetoplastid cells to anti-parasitic 
compounds. This assay depends on metabolic functions of the cells, where live 
cells can metabolize the dye resazurin from dark blue and non-fluorescence to 
fluorescent resorufin with a pink colour. This study used Alamar Blue assay to 
determine the cytotoxicity of several pyrimidine analogues on kinetoplastid 
cells. Pyrimidine analogues were dissolved in dimethyl sulfoxide (DMSO) and 
diluted in the appropriate medium for use, with DMSO ≤1%. 
2.4.1 Drug sensitivity assay in bloodstream forms of 
trypanosomes 
Drug sensitivity assay in trypanosomes using Alamar Blue dye was performed as 
described by (Raz et al., 1997). A volume of 100 μl of HMI-9 medium 
supplemented with 10% FBS was loaded in a white-bottomed 96-well plate 
(Greiner) except the first well, which was left empty. Known concentrations of 
tested drugs were diluted in HMI-9 medium and added in the first well at a 
volume of 200 μl; up to four drugs could be tested in one plate, each being 
diluted over two rows. The four drugs were doubly diluted, and gently mixed, 
over 23 wells per drug leaving the last well of each dilution as a negative control 
(drug free). Pentamidine or diminazene were used as positive controls 
throughout the study. 100 μl of bloodstream forms of T. b. brucei at a density of 
2 × 105 cells/ml were inoculated into each well to reach a final density of 1 × 105 
cells/ml. In the case of T. b. brucei pyrimidine auxotrophic cells, Alamar Blue 
experiments were performed in the presence of 2 μg/ml of hygromycin, to keep 
selective pressure on the knockout construct. After 48 hours of incubation the 
plates at 37 °C and 5% CO2, 20 μl of Alamar Blue assay buffer was added to each 
well (12.5 mg of resazurin sodium salt dissolved in 100 ml of PBS, mixed by 
stirring for half an hour, filtered with a 0.22 μm filter in an aseptic environment, 
stored at -20 °C and well-protected from light). Plates were incubated for a 
further 24 hours in the same conditions. Live cells reduce the dark blue dye to a 
pink colour. The concomitant change in fluorescence was measured using a 
J. Ali 2013 Chapter 2 64 
FLUOstar Optima plate reader (BMG Labtech, Durham, NC) at wavelengths of 544 
nm for excitation and 620 nm for emission. The EC50 values were calculated by 
analysing the data with the Prism 5.0 software. Each experiment was performed 
at least on three independent occasions. 
2.4.2 Drug sensitivity assay in promastigotes of 
Leishmania spp 
Alamar Blue assay in Leishmania spp (Mikus & Steverding, 2000) was performed 
as described for trypanosomes (section 2.4.1) with few changes. HOMEM medium 
supplemented with 10% FBS was used for culturing L. major and L. mexicana 
promastigotes. A preliminary cell culture was diluted to a density of 2 × 106 
cells/ml for a final density of 1 × 106 cells/ml. The 96-well plates were 
incubated at 25 °C for 72 hours before adding the Alamar Blue dye. Since 
leishmania parasites metabolise the Alamar Blue dye slower than trypanosomes 
(Gould et al., 2008), the cells were incubated with the dye for a further of 48 
hours. Fluorescence measurements and EC50 calculations were performed as 
described above (section 2.4.1). 
2.5 Trypanosomes cell cycle using flow cytometry analysis 
Flow cytometry assay can be used to assess the effects of anti-protozoan 
compounds on African trypanosomes cell cycle (Hammarton, 2003; Mutomba et 
al., 1997). However, the method in this study was used to investigate the DNA 
content of individual, fixed, pyrimidine auxotrophic trypanosomes grown in 
different natural pyrimidine sources. Pyrimidine auxotrophic trypanosomes 
(PYR6-5-/-) were incubated in 25 ml flasks containing 10 ml of HMI-9-tmd 
supplemented with 10% dialysed serum; each flask was provided with 0.1 mM of 
only one natural pyrimidine source. The supplemented natural pyrimidine 
sources included nucleobases (uracil, cytosine, thymine), ribonucleosides 
(uridine, cytidine, thymidine) or 2’-deoxynucleosides (2’-deoxyuridine, 2’-
deoxycytidine). The flasks were incubated for various time points (24, 36 and 48 
hours), a sample was taken from each culture in a clean autoclaved tube for 
assessment of DNA content as described by (Ibrahim et al., 2011). The cells were 
centrifuged at 1000 rpm for 10 minutes at 4 °C. Next, the pellet was 
resuspended and fixed in 1 ml of 70% methanol diluted in PBS pH 7.4 and kept 
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overnight at 4 °C. The fixed cells were spun at 2500 rpm for 10 minutes at 4 °C 
and washed twice in 1 ml of PBS. Subsequently, the pellet was resuspended in 1 
ml of PBS containing 10 μg/ml of propidium iodide and the same concentration 
of RNase A. Stained samples were kept in the dark for 45 minutes at 37 °C prior 
the analysis. DNA contents assessed by a Becton Dickinson Fluorescence 
Activated Cell Sorter Calibur (FACSCalibur) using the FL2-Area detector and 
CellQuest software. ModFit software was used for cell cycle analysis and 
quantification (ERITY 1995-1996 Software House Inc). 
2.6 Molecular techniques 
The nucleotide and amino acid sequences for genes were found by searching in 
GeneDB or TriTrypDB websites. These websites were used for searching with the 
Basic Local Alignment Search Tool (BLAST) to compare genes sequences. In 
addition, the TMHMM server at http://www.cbs.dtu.dk/services/TMHMM/ was 
used to estimate the number of transmembrane domains in indicated genes. Also 
the CLC workbench software was used to create sequence alignments. 
2.6.1 Generation and confirmation of pyrimidine 
auxotrophic trypanosomes 
The plasmid pLHTL-PYR6-5 (Scahill et al., 2008) was generously donated by 
Professor George Cross of Rockefeller University, New York, USA. This construct 
contained a hygromycin resistance cassette (hygromycin phosphotransferase) 
and a negative selection marker, Herpes simplex Thymidine Kinase (HSVTK) open 
reading frame (ORF) between loxP domains (Sternberg et al., 1981) and was 
targeted to the PYR6-5 locus by flanking sequences of 496 base pair (bp) 
immediately downstream of the target locus and of 365 bp commencing 134 bp 
upstream of the ORF. Bloodstream forms of T. brucei s427-WT were cultivated 
to a density of ~1-2 × 107 cells/ml and washed into Human T-Cell lysis buffer 
(Schumann et al., 2011; 90 mM Na3PO4, 5 mM KCl, 0.15 mM CaCl, 50 mM HEPES, 
pH 7.3) for transfection with the LHTL-PYR6-5 cassette (liberated by digestion 
with PvuII) using an Amaxa Nucleofector electroporator exactly as described by 
(Scahill et al., 2008), creating a single knockout (PYR6-5+/-) strain. 
Transformants were grown and cloned out in standard HMI-9 medium 
supplemented with 10% FBS containing 2 μg/ml hygromycin. The loss of the 
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second PYR6-5 allele was induced by exposure of the clonal lines to 100 μM of 5-
fluoroorotic acid, resulting in a double knockout strain (PYR6-5-/-) that was 
cloned by limiting dilution. PYR6-5 single and double knockout clones were 
confirmed by PCR and Southern blot technique. 
PCR confirmation of double knockout 
DNA was extracted from WT-s427, and from single and double knockout 
auxotrophic strains using a standard Qiagen DNeasy Blood and Tissue Kit, 
following the manufacturer’s instruction. Primers were designed to amplify an 
870 bp part of the PYR6-5 gene. PCR was performed on 200 nanograms (ng) of 
the isolated DNA using 0.75 μl of forward primer (5´ GTTCTCGAGTGCAAGCGGAT) 
and 0.75 μl reverse primer (5´CACAATGCGGTCAAACTGCA). Each reaction 
contained 4.0 μl 5× reaction buffer, 1 μl of 10 mM dNTPs (dATP, dCTP, dGTP and 
dTTP) and 0.2 μl Go Taq polemerase. The PCR reaction was made up to 20 μl 
with distilled water. Amplification was performed on PCR System (G-STORM, 
Thermo Scientific). Primers were annealing at 56 °C for 30 seconds and 
extension at 72 °C for 60 seconds. Agarose gel was prepared in 100 ml TAE 
buffer (84.4g Trizma base, 100 mM EDTA in 1 liter distilled water, adjust pH 8.0 
with glacial acid) with 1% agarose and 8 μl of SYBR Safe stain (10,000 x 
Invitrogen). The DNA samples were run on the gel at 80–100 mV alongside 1 kb 
ladder for about one hour. DNA in the gel was visualised by ultraviolet light on a 
trans-illuminator (UVP Laboratory Products). 
Southern blot confirmation of double knockout 
A Southern blot was also performed to confirm knockouts, using restriction 
digest of 10 μg DNA and blotting performed as described by (Martin & Smith, 
2006), using DNA probes specific for the PYR6-5 and hygromycin B 
phosphotransferase genes. The PYR6-5 probe was generated using the primers 
and conditions given above for the PCR confirmation, whilst the hygromycin 
probe was generated by a PCR to amplify 1029 bp using forward primer 
(5’ATGAAAAAGCCTGAACTCAC) and reverse primer 
(5’ACTCTATTCCTTTGCCCTCG). Primers were allowed to anneal at 55 °C for 30 
seconds and extension was performed at 72 °C for 60 seconds. Whole PCR 
products were run on 1% agarose gel alongside 1 kb ladder as an appropriate DNA 
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marker. DNA fragments that appeared of the right size were cut off using a clean 
scalpel and transferred to a sterile tube. The DNA was then extracted using a 
Qiagen gel extraction Kit, following the manufacturer’s instruction. DNA 
concentrations were measured using a NanoDrop device. 
Approximately 10 μg of extracted DNA from s427-WT, and single and double 
knockout were digested at 37 °C for overnight using restriction enzymes ClaI and 
SpeI. Digested DNAs were run on 400 ml of 0.7% agarose gel and run at 30 volts 
cm-1 overnight. The gel was then immersed in 500 ml of depurination solution 
(22.7 ml of 11 M HCl in 1 liter distilled water) for ~10 minutes. Denatured DNA 
was performed by immersing the gel in 500 ml of a denaturing solution (20 g 
NaOH and 87.664 g NaCl in 1 L distilled water) for 15 minutes. Next was 
immersion of the gel in 500 ml of neutralising solution (87.6 g NaCl and 78.8 g 
Tris base in 1 L distilled water, pH 7.4) for 15 minutes. All these steps were 
performed at room temperature with gentle shaking. The DNAs were then 
transferred from the gel to nylon membrane (HybondTM–N, Amersham 
Biosciences) at room temperature overnight. Membrane was stained with 
methylene blue for 10 minutes, rinsed several times for one minute by distilled 
water until the DNA bands became visible, wrapped in clingfilm and stored at 4 
°C. Membrane was then pre-hybridised for 2 hours at 42 °C on the rotational 
shaker using hybridization solution (15 ml 50% formamide, 7.5 ml 5× SSC (sodium 
chloride and sodium citrate solution)), 6 ml 50× Denhardt’s solution, 0.3 ml 10% 
SDS, 0.6 ml 1 M NaH2PO4 pH6.5, 0.3 ml 0.5 M EDTA pH 8, 0.6 ml 10 mg/ml 
Herring Sperm DNA denatured for 5 minutes at 95 °C). Next, a radioactive probe 
(Prime-it II Random Primer Labelling (Stratagene)) was prepared by mixing 25 ng 
probe DNA with 10 μl random oligo primers, made up to 37 μl with ddH2O and 
heated at 95 °C for 5 minutes. After a brief centrifugation the following mixture 
(10 μl 5× primer buffer, 2 μl γ32P dATP and 1 μl Klenow (5 U/μl)) was added and 
incubated at 37 – 40 °C for 10 minutes. The probes were purified by 
resuspending resin in column by vortexing and adding the labeled probe (25 - 50 
μl) to top centre of the resin and spinning for 3 minutes. The probe was then 
denatured for 5 minutes, added to the tube containing the hybridisation solution 
and membrane and incubated for more than 16 hours. Next, the hybridization 
mixture was washed into washing buffer (0.1 × SSC and 0.1% SDS) at room 
temperature.  Some of the wash buffer (200 ml) was pre-heated to 55 °C in the 
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shaking water bath and 20 ml of pre-heated wash buffer was added to the tube 
and incubated at 55 °C for 20 minutes for the first wash and 45 minutes for the 
second wash. The filter was monitored with a Geiger counter and the probe 
should hybridise to the DNA on the filter. A sheet of MXB Film was added in the 
dark room then exposed to X-ray at -80 °C. Finally, auto-radiographs were 
developed using the Xomat according to the manufacturer’s instructions. 
2.6.2 Quantitative PCR of uridine phosphorylase 
RNA isolated from T. b. brucei s427-WT and PYR6-5-/- cells was quantified using 
a NanoDrop device; 2 μg of RNA was diluted in RNase-free water to a total 
volume of 25 μl. Complementary DNA (cDNA) was produced using a Reverse 
Transcriptase (RT) kit (Primerdesign, UK). cDNA for each sample was diluted 
1:10 and then used for Real Time-PCR. Amplification of cDNA was performed in a 
7500 Real Time PCR System (G-STORM, Thermo Scientific). The dissociation 
curve was used to ensure the amplification of only one product; samples without 
RT or cDNA were used as controls. A constitutively expressed gene, GPI8 (Lillico 
et al., 2003), was used as internal control, with primer sequences 5´- 
TCTGAACCCGCGCACTTC and 5´- CCACTCACGGACTGCGTTT. For uridine 
phosphorylase (UP), the ∆∆CT method was used for relative quantification (RQ) 
using WT cells in HMI-9 as a calibrator or internal control. Data was analyzed 
using Applied Biosystems 7500 SDS Real-Time PCR systems software. Primers 
used for the amplification of UP were 5´-TTTGACCCCTCCACCATGA and 5´-
GATTCAGCAGGTGAGCCACAA. The entire experiment was performed on three 
independent occasions, starting from independent cell cultures and RNA 
isolation. This experiment was performed in our laboratory in collaboration with 
Daniel Tagoe. 
2.6.3 Extraction of DNA from T. b. brucei 
Kinetoplastid cells were grown in a large culture flask to mid log phase. The 
cells were spun down for 5 minutes at 2500 rpm. The pellet was resuspended in 
1 ml of PBS and transferred to eppendorf tube and spun again for 5 minutes at 
1500 rpm. After removing the supernatant, a volume of 500 μl lysis buffer (100 
mM NaCl, 10 mM Tris-HCl pH 8.0 and 5 mM EDTA), 25 μl of 10% SDS and 50 μl of 
10 mg/ml RNase A was added to the sample and incubated overnight at 37 °C. 
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The sample was washed twice in an equal volume of phenol:chloroform:isoamyl-
alcohol (25:24:1; saturated with 10 mM Tris, pH 8.0 and 10 mM EDTA). The 
sample was shaken gently for 5 minutes then spun for 5 minutes at high speed. 
The aqueous phase was washed again twice more in an equal volume of 
chloroform, shaken and spun for 5 minutes. Next, the aqueous phase was 
transferred to a clear 15 ml polystyrene tube contains 1.5 ml absolute ethanol. 
The cloud of DNA was removed and transferred to 1 ml of 70% ethanol in a 
centrifuge tube. The DNA was spun down at top speed for 10 minutes, then the 
supernatant was removed and the precipitated DNA was drained off. Finally, 
DNA was resuspended in 30-50 μl of 1× Tris-EDTA buffer (10 mM Tris-HCl, pH 7.5 
and 1 mM EDTA) and left overnight at 4 °C (without mixing). 
2.6.4 Isolation of RNA from T. b. brucei 
Cell culture at 2× 106 was collected by centrifugation at 2500 rpm for 10 minutes 
at 4 °C. Supernatant was removed and cell pellet was resuspended thoroughly in 
1 ml of Trizol (Life Technologies; contains guanidine isothiocyanate which is a 
protein denaturant in which RNases are not active, and phenol where soluble 
RNA can be separated from the phenol soluble protein), RNases are thus 
separated from RNA. After 5 minutes of incubation at room temperature, a 
volume of 200 μl of chloroform was added and mixed by inverting continuously 
for 1 minute. The homogenised sample was centrifuged at full speed for 20 
minutes at 4 °C. After centrifugation, the mixture was separated into lower red, 
phenol-chloroform phase, an interphase and colourless upper aqueous phase. 
RNA remained exclusively in the aqueous phase. Since RNases are of biological 
origin all reagents and plastics should be RNase free to avoid reintroducing 
RNase by simple precautions. The aqueous phase was transferred to 500 μl of 
isopropanol, incubated at room temperature for 10 minutes and centrifuged at 
full speed for 20 minutes at 4 °C. The RNA precipitated in the side of the bottom 
of the tube. RNA was washed in 1 ml of 75% ethanol and vortexed until the 
pellet was loosened from the wall of the tube. Next, the sample was centrifuged 
at full speed for 5 minutes at 4 °C and the supernatant was removed carefully. 
The pellet was air dried on the bench for 10 minutes. 50-100 μl of autoclaved 
water treated by diethyl pyrocarbonate (DEPC; 500 μl of DEPC with 500 ml 
ddH2O was shaken and left overnight at room temperature, then autoclaved and 
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kept at room temperature) was added to the RNA and heated at 65 °C for 10 
minutes. Dissolved RNA was pulse spun and stored at –80 °C until use. 
2.6.5 Full genome sequences 
DNAs from parasite cells were extracted as described in section (2.6.4). The 
used DNA was 2-5 μg of double stranded DNA in TE buffer at a concentration 
greater than 20 ng/μl, in a volume of 20 - 100 μl, and in fragments >500 bp. In 
collaboration with the Sanger Institute in Hinxton, UK we sequenced the 
extracted DNA from several cell lines: bloodstream forms of T. b. brucei 
including s427-WT, Tbb-5FURes, Tbb-5FOARes and Tbb-5F2’dURes; 
promastigotes of Leishmania spp including L. mexicana sM379-WT, Lmex-5FURes 
intermediate adapted to 5-FU, Lmex-5FURes (highly adapted), L. major 
sFriedlin-WT, Lmaj-5FURes and Lmaj-5F2’dURes. 
Illumina sequencing and SNP analysis: genomic DNA preparations were used to 
create Illumina paired-end sequencing libraries that were sequenced on Illumina 
HiSeq machines using standard procedures yielding paired sequence reads of 75 
bases length. For each parasite strain, the data yield from the sequencing 
machines (passing the default purity filter) was between 12.5 million and 36.6 
million read pairs (median of 17.3 million) which corresponds to a nominal 
genome coverage of between 58.5-fold and 171.1-fold (median of 81.6-fold). 
Mapping of the paired sequencing reads to the genome reference sequences 
from GeneDB (Trypanosoma brucei TREU927, Leishmania major Friedlin, and L. 
mexicana-M379) was carried out with SMALT 
(http://www.sanger.ac.uk/resources/software/smalt/), version 0.5.7 using the 
following parameters: wordlength -k = 13, skipstep -s = 7, maximum insert size -i 
= 1000, minimum Smith-Waterman score -m = 65, and with the exhaustive search 
option (-x) enabled. Of the sequencing reads, the following percentages were 
thus mapped as "proper pairs" (i.e. with the two mates of a sequence read pair 
mapped within the expected distance and in the correct orientation) to the 
genome reference sequences: between 42.3% and 42.8% of reads for T. brucei, 
between 76.6% and 78.8% for L. major, and between 61.1% and 72.9% for L. 
mexicana. The median insert size between read pairs was between 467 and 601 
nucleotides. Only sequence reads mapped as "proper pairs" were used for 
subsequent analyses and the first 5 and last 15 nucleotides were clipped from all 
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reads prior to subsequent analysis. Genotypes for every genomic position were 
determined with SAMtools version 0.1.17 (Li et al., 2009) by using the "samtools 
mpileup" command with minimum baseQ/BAQ ratio of 15 (-Q) followed by 
SAMtools' "bcftools view" command with options -c and -g enabled. For a given 
parasite strain, single nucleotide polymorphisms (SNPs) were identified by 
comparison with the parental wild-type parasite strain and by filtering all 
genotype calls according to the following criteria: a minimum of 8 high-quality 
base calls (DP4), a maximum coverage depth (DP) of the median plus 3 times the 
standard deviation, a minimum quality score (QUAL) of 23, a minimum mapping 
quality (MQ) of 23, a minimum second best genotype likelihood value (PL) of 35, 
a maximum fraction of conflicting base calls for homozygous genotype calls of 
10%, and a minimum percentage of 5% for base calls (as a fraction of all base 
calls for a given genotype) that map either to the forward or the reverse strand 
of the reference sequence. 
2.7 Metabolomic technologies 
Metabolite extraction techniques have been developed by (TKindt et al., 2010) 
and (Saunders et al., 2010), and very recently, methodological advances in 
metabolomics have been applied to kinetoplastid parasites (Creek et al., 2011; 
Creek et al., 2012a). 
2.7.1 Metabolomic sample preparation 
Kinetoplastid parasites were grown in an appropriate medium to log phase stage, 
resuspended at 2× 106 cells/ml in 50 ml relevant medium (HMI-9 for 
trypanosomes and HOMEM for leishmania) provided with 10% FBS in culture flask 
and incubated with 100 μM of the test compound for 8 hours in excellent 
appropriate conditions. Cells were transferred to a 50-ml centrifuge tube and 
instantly cooled down to 4 °C using a dry ice/ethanol bath. This culture was 
centrifuged at 2500 rpm for 10 min at 4 °C and the pellet was lysed by addition 
of 200 μl of chloroform/methanol/water (1:3:1 v/v/v) with internal standards 
for mass spectrometry (1 µM each of theophylline, Cl-phenyl-cAMP, N-methyl 
glucamine, canavanine and piperazine), followed by vigorous mixing for one hour 
at 4 °C. Precipitated proteins and cellular debris were removed from 
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metabolites by centrifugation at 13000 rpm for 3 minutes. Metabolite extracts 
were stored in HPLC vials at -80 °C until use. Control samples were also 
performed in parallel, including untreated cells grown in parallel, unused growth 
medium, 100 µM of the test compound prepared in relevant medium and 
extraction solvent blanks. All experiments were established separately in 
triplicate. 
2.7.2 Metabolomics sample analysis 
Metabolomic samples were analyzed by hydrophilic interaction liquid 
chromatography (HILIC-LC) coupled to high resolution mass spectrometry (MS). 
LC separation utilized a zwitterionic ZIC-pHILIC column (Merck Sequant) with 
ammonium carbonate alkaline gradient as recently described by (Zhang et al., 
2012). The method was performed on a Dionex RSLC3000 (Thermo Fisher) LC 
system coupled to an Exactive Orbitrap (Thermo Fisher) operating at 50,000 
resolution in positive and negative mode ESI (rapid switching) with MS 
parameters as previously published (Creek et al., 2011). Mass calibration was 
performed immediately before the batch, followed by analysis of authentic 
metabolite standards to determine standard retention times (Creek et al., 
2011). Samples were analyzed in random order and signal stability assessed by 
periodic analysis of pooled quality control samples. Data from each sample were 
manually inspected and irreproducible samples excluded from analysis based on 
total ion chromatogram (TIC) signals and internal standards. 
2.7.3 Metabolomic data analysis 
Metabolomics data was analyzed using the IDEOM application 
(http://mzmatch.sourceforge.net/ideom.php) with default parameters (Creek et 
al., 2012b) after selecting the pHILIC chromatography method, raw files were 
converted to mzXML format and peaks were detected using the XCMS Centwave 
algorithm (Tautenhahn et al., 2008). Peak data for all samples was combined, 
filtered and saved in peakmL files using mzMatch (Scheltema et al., 2011). Noise 
filtering and putative metabolite identification was performed in IDEOM based 
on accurate mass and retention time, parameters are available in the 
supplementary IDEOM file. In addition to the automated identification of 
metabolites from the IDEOM database, data were screened for novel fluorinated 
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metabolites by the addition of 17.9906 to all known metabolite masses, which 
detected peaks with accurate mass and retention times consistent with 5-fluoro-
UDP, 5-fluoro-UTP, fluoro-N-carbamoyl-L-aspartate, 5-fluoro-orotic acid 
(detected primarily as the CO2–loss fragment) and fluorinated UDP-hexose and 
UDP-N-acetyl-hexosamine (putatively identified as 5-fluoro-UDP-glucose and 5-
fluoro-UDP-N-acetylglucosamine). LC-MS peak heights were used for semi-
quantitative analysis of metabolite abundances, and statistical analyses 
comprised pair-wise comparisons of study groups by unpaired rank products 
analyses with P-values for probability of false positives based on 200 
permutations. 
2.8 DNA degradation 
Pyrimidine auxotrophic trypanosomes (Pyr6-5-/-) were incubated with 100 μM of 
5-fluoro-2’-deoxyuridine or 5-fluorouracil for 12 hours in HMI-9-tmd supplemental 
with 10% dialysis serum (section 2.1.3). In parallel, untreated control cells were 
cultured in the same medium. Extracted DNA from these cultures was 
resuspended in 30 μl TE buffer and quantified using a NanoDrop device, typically 
containing 4–5 μg DNA/ml. 10 μl of 10× exonulease III buffer, 1000 units of 
Exonulease III enzyme and 85 μl distilled water were added to the resuspended 
DNA. The reaction was followed by incubation at 37 °C for 48 hours. From the 
digest 20 μl was mixed vigorously with 60 μl of chloroform/methanol/water 
(section 2.7.1) and centrifuged at high speed for 5 minutes. The supernatant was 
stored at -80 °C until use in metabolomic analysis. 
2.9 RNA degradation 
Pyrimidine auxotrophic T. b. brucei (Pyr6-5-/-) were exposed to 100 μM of 5-
fluorouracil for 12 hours using HMI-9 free pyrimidine medium (section 2.1.3). 
Extracted RNAs from those cells were incubated overnight at 37 °C with 10 μl of 
10 mg/ml phosphodiesterase II (3’exonuclease). The RNAs extracted from 
untreated cells grown in parallel were used as negative control. The digested 
RNA was mixed with 80 μl chloroform/methanol/water (section 2.8.1) and 
centrifuged for 5 minutes at high speed. Supernatant was stored at -80 °C until 
use in metabolomic analysis. 
J. Ali 2013 Chapter 2 74 
2.10 Construction of a profile library for enzymes of the 
pyrimidine pathways 
Reference sequences for the enzymes of pyrimidine metabolism were 
downloaded from UniProt (www.uniprot.org), searching by enzyme code number 
(EC) in the manually annotated SwissProt section. Each of the obtained sets of 
sequences was redundancy reduced by ≤50% identity, aligned with ClustalW 
(Thompson et al., 2002), and converted into a HMM-profile with hmmbuild of 
the HMMer 3.0 package (Eddy, 2009). The profiles were concatenated to a 
library. Predicted proteomes were downloaded from Integr8 
(www.ebi.ac.uk/integr8) and searched with hmmscan of the HMMer package. 
Hierarchical clustering of proteomes based on the best scores obtained to each 
of the profiles was performed with the R package pvclust (Suzuki & Shimodaira, 
2006), using Canberra distance and the McQuitty algorithm. This part was 
performed by our collaborator Pascal Mäser (Swiss Tropical and Public Health 
Institute, Basel, Switserland. 
2.11 Effect of 5-FU on glycosylation in T. b. brucei 
Bloodstreams of T. b. brucei WT-s427 and pyrimidine auxotrophic cultures were 
adjusted to 1× 106 cell/ml and incubated for 12 hours in HMI-9 medium 
supplemented with 10% FBS in the presence or absence of 100 µM 5-FU or 5F-
2’dUrd. Cell cultures were spun down at 2500 rpm at 4 °C and washed three 
times in sterilized PBS. Consequently, the pellets were suspended at a density of 
107 cells/ml in 100 μl protein gel loading buffer (50 mM Tris-HCl pH 6.8; 2% SDS; 
10% glycerol; 1% β-mercaptoethanol; 12.5 mM EDTA and 0.02% bromophenol 
blue). The samples were then incubated at 95 °C for 15 minutes and stored at -
20 °C until use. Interaction of glycoproteins with lectins was visualized by 
separating proteins by reducing SDS-PAGE (using 10% gels and 107 cell 
equivalents/lane) and then Western blotting onto Immobilon-P transfer 
membranes (Millipore). Gels were stained with Brilliant Blue electrophoresis 
reagent to check for equal cell loading and for visualization of protein bands. 
Membranes were stained using Erythrina cristigalli lectin (1:1,000) or Ricinus 
communis lectin (1:1,000) (both obtained from Vector Laboratories) and washed 
extensively before incubation with streptavidin-HRP (1:7,000) (Thermo 
Scientific) as recently described by (Mehlert et al., 2012). Further extensive 
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washing was followed by visualization of bands using ECL reagents (GE 
Healthcare). This experiment was performed in the laboratory of our 
collaborator Mark Field at the University of Cambridge, UK. 
 
 
CHAPTER THREE 
Trypanosoma brucei: Pyrimidine transporters and 
trypanocidal pyrimidine analogues 
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3.1 Introduction 
Membrane transporters have been involved in many drug uptake 
processes, thus studying this phenomenon requires the identification, detailed 
characterization and cloning of parasite-specific high-affinity transporters for 
substrates with a low concentration in the host tissues. The kinetoplastid 
transporters for purines and pyrimidines seem to meet these criteria. Since 
trypanosome parasites are unable to synthesize the purine ring de novo , these 
purine transporters have been studied extensively (Gudin et al., 2006). To date, 
sixteen members of the equilibrative nucleoside transporter (ENT) family, which 
encodes all the protozoan plasma membrane purine transporters, have been 
identified and cloned in Trypanosoma spp. Although purine transporters can 
mediate the uptake of purine and/or pyrimidine antimetabolites in kinetoplastid 
parasites (De Koning & Jarvis, 1998; Papageorgiou et al., 2005; Wallace et al., 
2002), pyrimidine nucleosides and nucleobases failed to inhibit with high affinity 
the uptake of purines in procyclics and bloodstream forms of Trypanosoma 
brucei, suggesting that separate pyrimidine transporters must be present in the 
plasma membrane. 
In contrast to purines, Trypanosoma species are known to possess both 
salvage and biosynthesis routes for pyrimidines (De Koning et al., 2005; 
Hammond & Gutteridge, 1982; Hassan & Coombs, 1986; Papageorgiou et al., 
2005). Only few studies have been conducted on pyrimidine uptake in 
kinetoplastid parasites, this might be attributed to the parasites’ ability to 
synthesise the pyrimidine ring. The first high affinity transporter for uracil was 
described in procyclic forms of T. b. brucei and designated TbU1 (De Koning & 
Jarvis, 1998). The uptake of [3H]-uracil by TbU1 was not inhibited by a broad 
range of purine and pyrimidine nucleosides and nucleobases. (Gudin et al., 2006) 
found that TbU1 transporter was also able to mediate uridine uptake, in their 
survey of pyrimidine transport activities, they identified a very high-affinity 
transporter for cytosine in T. b. brucei procyclic forms which was designated 
TbC1. This transporter was inhibited by cytosine and uracil with high affinity but 
no cytidine uptake was detectable in procyclics. The other pyrimidine 
transporter identified by the same workers in T. b. brucei procyclics is TbU2; 
this transporter was a higher-affinity uridine transporter. To date, those three 
pyrimidine transporters are the only pyrimidine-specific permeases identified 
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and characterized in Trypanosoma spp. The well known anticancer drug 5-
fluorouracil, a halogenated pyrimidine nucleobase, was found to be a good 
inhibitor to [3H]-uracil uptake in Trypanosoma spp, and killed trypanosomes 
efficiently (De Koning & Jarvis, 1998; Gudin et al., 2006; Papageorgiou et al., 
2005). 
Currently information on pyrimidine transporters in bloodstream 
trypanosomes is very incomplete, and no study systematically assessed the 
effect of pyrimidine analogues on bloodstream forms of T. b. brucei. The 
potential for resistance against pyrimidine nucleoside and nucleobase analogues 
by kinetoplastid species has also not been investigated. The lack of information 
about pyrimidine transport activities in bloodstream forms of T. b. brucei s427 
delays efforts to develop a pyrimidine-based chemotherapy. Therefore, this 
study systematically assessed the uptake of all natural pyrimidine nucleobases 
and nucleosides into bloodstream trypanosomes. In addition, we screened the 
potential for the accumulation of some halogenated pyrimidine compounds 
through pyrimidine transporters and generated cell lines resistance to toxic 
pyrimidine analogues in BSF of T. b brucei. 
3.2. Uracil uptake in T. b. brucei BSF-WT 
In procyclic trypanosomes, pyrimidine uptake is mostly mediated by the 
TbU1 transporter, the main substrate of which is uracil. Therefore, this study 
investigated [3H]-uracil transport in bloodstream forms in order to assess 
whether pyrimidines are salvaged in a similar way in this life-cycle stage, and if 
so, whether it could be mediated by the same transporter. 
Transport of 0.15 µM [3H]-uracil was linear for at least 120 seconds (r2 = 
0.99), and significantly different from zero (F test; P<0.0001), with a rate of 
0.034 ± 0.002 pmol∙107 cells-1∙s-1 and was almost entirely inhibited by 1 mM of 
unlabelled uracil (Figure 3.1), transport was reduced by >97% but still 
significantly different from zero (F-test, P = 0.03). This showed that [3H]-uracil 
uptake is transporter-mediated and that simple diffusion does not play a 
significant role in this process, at least at low uracil concentrations. Subsequent 
[3H]-uracil assays used 0.15 µM of label and a 30 seconds incubation time very 
much within the linear phase of uptake. 
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Figure 3.1. Timecourse of [
3
H]-uracil transport in T. b. brucei bloodstream forms over 2 min. 
The figure shows transport of 0.15 µM [
3
H]-uracil (■) was linear and totally inhibited in the 
presence of 1 mM unlabelled uracil (●). Error bars are SE, and when not shown fall inside the 
symbol. The experiment was performed in triplicate and was one of several independent 
experiments with highly similar outcomes. The uptake was terminated by the addition of 1 ml 
ice-cold 1 mM uracil in assay buffer and immediate centrifugation through oil. 
Next determinations were the uracil Km and Vmax values for BSF of T. b. 
brucei. This was possible as all inhibition data were consistent with monophasic 
inhibition with Hill slopes near -1, i.e. a single transporter model. The graph in 
Figure 3.2A shows a representative inhibition profile of [3H]-uracil inhibited by 
unlabeled uracil and shows the conversion to a Michaelis-Menten saturation plot 
(Figure 3.2B). The average Km values over six identical triplicate experiments 
was 0.54 ± 0.11 µM, with a Vmax of 0.14 ± 0.03 pmol∙10
7 cells-1∙s-1. This Km value 
was similar to the value previously reported for TbU1 (0.46 ± 0.09 µM) but the 
Vmax is almost 5-fold lower than in procyclics. 
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Figure 3.2. Characterization of [
3
H]-uracil transport in T. b. brucei BSF. A. 
Inhibition of 0.15 µM [
3
H]-uracil uptake over 30 seconds by various concentrations 
of unlabelled uracil (■). B. Conversion the data from frame A to Michaelis-Menten 
saturation plot (●), for 30 seconds incubations. The uptakes were terminated by the 
addition of 1 ml ice-cold 1 mM uracil in uptake assay buffer and immediate 
centrifugation through oil. Error bars were SE of triplicate determinations. 
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In order to investigate whether the same transport activity was expressed 
in both life cycle forms of T. b. brucei, the affinity of BSF uracil transporter was 
assessed. Whereas TbU1 displayed moderately high affinity (33 μM) for the 
nucleoside uridine (De Koning & Jarvis, 1998), uracil uptake in BSF was virtually 
insensitive to uridine, with 10 mM of the nucleoside uridine inhibiting just 
approximately 50% of 0.15 µM [3H]-uracil uptake (Figure 3.3). However, TbU1 
and TbU3 transporters were similarly sensitive to the fluorinated uracil 
counterpart, 5-fluorouracil (Figure 3.3). The striking difference in uridine 
sensitivity between uracil transport activities in procyclics and BSF showed that 
these were distinct transporters, and we designated the novel BSF uracil 
transporter TbU3. 
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Figure 3.3. Inhibition of 0.15 µM [
3
H]-uracil transport by unlabelled uridine (▲) and 
unlabelled 5-fluorouracil (●) for 30 sec incubations. The inhibition processes were 
terminated by the addition of 1 ml ice-cold 1 mM uracil in assay buffer and immediate 
centrifugation through oil. Error bars were SE of triplicate determinations. 
3.3. Comparing substrate profiles of TbU1 and TbU3 
An overview of pyrimidine transporters in T. b. brucei procyclics and BSF 
was summarized in Table 3.1. The data showed that TbU1 and TbU3 have a very 
similar inhibitor profile, and thus it is highly likely TbU1 and TbU3 bind uracil in 
a very similar way, with the defining difference being the different affinity for 
uridine. The only other notable difference was the lower affinity of TbU3 for 4-
thiouracil with Ki values of 159 ± 24 µM versus 22 ± 7 µM for TbU1 (7.2-fold). On 
the other hand, the Ki values for 2-thiouracil by TbU1 and TbU3 were highly 
similar (640 ± 110 and 700 ± 130 µM, respectively). The lower affinity for 4-
thiouracil is likely to reflect a stronger hydrogen bond at the 4-keto group than 
was the case for TbU1, as a result of a subtle shift in position or a different 
amino acid facing this group. 
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Table 3.1. Substrate profiles of the T. b. brucei strain 427-wild type pyrimidine transporters of 
procyclic forms and bloodstream forms: Km and Ki values in µM. Entries in bold typescript indicate 
Km rather than Ki values. NE, no effect on uptake at concentration indicated. Blanks showed where 
values not determined. Data for procyclic forms were taken from (De Koning & Jarvis, 1998; 
Gudin et al., 2006; Papageorgiou et al., 2005), and included here for comparison. The chemical 
structure of used pyrimidines and their analogues are shown in Appendix II; and the actual single 
values are shown in Appendix III-IV. 
 Procyclic forms Bloodstream forms 
 TbU1 TbU2 TbC1 TbU3 TbT1 
Pyrimidine nucleobases 
Uracil 0.46 ± 0.09  0.36 ± 0.06 0.54 ± 0.11 >2500 
Thymine >1000   >2500 NE, 1000 
Cytosine NE, 1000  0.048 ± 0.009 >2500  
Orotic acid    630 ± 48 NE, 1000 
Pyrimidine nucleosides 
Uridine 33 ± 5 4.1 ± 2.1  9500 ± 2700 199 ± 38 
2’-Deoxyuridine    804 ± 132 320 ± 47 
Thymidine NE, 1000 0.38 ± 0.07  >10000 1240 ± 310 
Cytidine NE, 1000 0.057 ± 0.019 0.42 ± 0.16  >10000 
2’-Deoxycytidine      
Pyrimidine analogues 
1-Methyluracil NE, 10000   >5000  
2-Mercaptopyrimidine NE, 500   1640 ± 510  
2-Thiouracil 640 ± 110   700 ± 130  
3-Deazauracil >2500   >5000  
4(3H)-Pyrimidinone 1670 ± 180   4410 ± 1090  
4-Thiouracil 22 ± 7   159 ± 24  
5-Bromouracil    180 ± 36  
5-Fluorouracil 3.0 ± 0.8   2.6 ± 0.01 >1000 
5-Chlorouracil 900 ± 140   560 ± 180  
5-Iodouracil    1300 ± 70  
5,6-Dihydrouracil 830 ± 200   >5000  
6-Azauracil ~1000   663 ± 125  
6-Methyluracil >2500   >5000  
2’,3’-Dideoxyuridine    2260 ± 540  
2’,5’-Dideoxyuridine    >2500  
5’-Deoxyuridine    >2500  
5-Fluoroorotic acid    330 ± 47  
Purines 
Adenosine NE, 1000    2.3 ± 0.3 
Hypoxanthine NE, 1000   NE, 1000  
Inosine NE, 1000    0.89 ± 0.15 
Xanthine    NE, 1000  
Adenine NE, 1000     
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The many close similarities between TbU1 and TbU3 inhibitor profiles, including 
similar affinity for 5-halogenated uracil analogues (Figure 3.4), seem to indicate 
common transporter structure. However, the specific differences suggest that 
TbU3 has more steric limitations than TbU1 when it comes to binding nucleosides 
rather than nucleobases. The lower Ki value for 2’-deoxyuridine in TbU3 (1150 ± 
340 μM) compared to uridine (Ki = ~10 mM) suggests that the 2’-hydroxyl group is 
a significant factor in the non-binding of uridine. In contrast, the further 
removal of the 3’-hydroxyl group (2’, 3’-dideoxyuridine), or of the 5’-hydroxyl 
(2’, 5’-dideoxyuridine and 5’-deoxyuridine), did not lead to higher affinity. 
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Figure 3.4. Inhibition of 0.15 µM [
3
H]-uracil transport by 5-fluorouracil (▲), 5-chlorouracil (■) 
and 5-bromouracil (●) for 30 seconds incubations. The uptake was terminated by the addition 
of 1 ml ice-cold 1 mM uracil in uptake assay buffer and immediate centrifugation through oil. 
Error bars were SE of triplicate determinations. Experiments were performed in triplicate and 
were representative of three identical experiments performed on different dates. 
3.4 Uridine and 2’-deoxyuridine uptake in T. b .brucei 
BSF-WT 
Procyclic T. b. brucei express a separate uridine transporter designated 
TbU2, in addition to a modest rate of uridine uptake through TbU1, which is 
primarily a uracil transporter. With TbU3 displaying almost no affinity for 
uridine, this study investigated whether a separate uridine transporter was 
expressed in bloodstream forms as well. Saturable transport of [3H]-uridine was 
hardly detectable in bloodstream forms, and not at all at submicromolar 
concentrations (Figure 3.5A) or at short time intervals (2 minutes; Figure 3.5B). 
A measurable rate (pmol∙107 cells-1∙s-1) was obtained at 2.5 μM [3H]-uridine, 
using a timecourse over 30 minutes (Figure 3.5C). 
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Figure 3.5. Timecourse of [
3
H]-uridine uptake 
in T. b. brucei BSF, where closed-circle brown 
bar (●) indicated the presence of [
3
H]-uridine 
and the blue-closed square bar (■) the 
presence of 5 mM unlabelled uridine. A. 
transport of 0.5 µM [
3
H]-uridine over 2 
minutes, B. Transport of 2.5 µM [
3
H]-uridine 
over 2 minutes. C. transport of 2.5 µM [
3
H]-
uridine over 30 minutes. Error bars were SE, 
and when not shown fall inside the symbol. 
Lines were calculated by linear regression 
analysis. 
The subsequent experiments were performed using 2.5 μM [3H]-uridine and 15 
minutes incubation times - very much within the linear phase of uptake. This 
allowed the determination of an apparent Km value of 9500 ± 2700 μM and a Vmax 
of 16 ± 4 pmol∙107 cells-1∙s-1 (Figure 3.6A). This extremely low affinity was 
entirely consistent with uridine being transported by TbU3 only at very high 
concentrations. This was confirmed by inhibition of 2.5 μM [3H]-uridine uptake 
by uracil, with a Ki value of just 1.6 ± 0.2 μM (Figure 3.6B), highly similar to the 
TbU3 Km value for uracil. 
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Figure 3.6. Characterization of [
3
H]-uridine transport in T. b. brucei BSF. A. The inhibition of 2.5 
µM [
3
H]-uridine uptake for 15 minutes incubation by various concentrations of unlabelled uridine 
was converted to a Michaelis-Menten saturation plot to determine Km and Vmax values. The 
inhibition data was taken from frame B (the closed-brown circles). B. Inhibition of 2.5 μM [
3
H]-
uridine transport for 15 minutes incubation by unlabelled uridine (●) and unlabelled uracil (■). The 
uptake was terminated by addition of 1 ml ice-cold 10 mM unlabelled uridine. Error bars were SE of 
triplicate determinations. Lines were calculated using an equation for sigmoid curve; where 
inhibition was above 50% but not complete at the highest inhibitor concentration, the Hill slope was 
set at -1 and the bottom level at zero for the purpose of extrapolation. 
At the low permeant concentration of 0.5 μM [3H]-2’deoxyuridine the rate of 
uptake was barely detectable over 2 minutes, with a rate of 0.00045 pmol∙107 
cells-1∙s-1 (Figure 3.7A), indicating the absence of high affinity transport for 
uridine nucleosides. Transport of 5 μM [3H]-2’deoxyuridine was linear over 4 
minutes with a rate of 0.0051 ± 0.0003 pmol∙107 cells-1∙s-1, which was 76% 
inhibited by 2.5 mM unlabelled 2’-deoxyuridine (Figure 3.7B). 
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Figure 3.7. Transport of [
3
H]-2’deoxyuridine (●) in T. b. brucei BSF in the presence of 2.5 mM 
unlabelled 2’-deoxyuridine (■). A. Transport of 0.5 µM [
3
H]-2’deoxyuridine over 2 minutes B. 
transport of 5 µM [
3
H]- 2’-deoxyuridine over 4 minutes. Error bars were SE, and when not 
shown fall inside the symbol. Lines were calculated by linear regression analysis. 
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Characterization of the transport of 2’-deoxyuridine was performed using 5 μM 
of label and 180 seconds as incubation time. This transport activity displayed a 
Km of 804 ± 132 μM, and a Vmax of 1.3 ± 0.7 pmol∙10
7 cells-1∙s-1 (n=3; Figure 3.8A). 
The uptake of tritium 2’-deoxynucleoside was inhibited by unlabelled uracil with 
a Ki value (1.1 ± 0.1 μM) very close to TbU3 Michaelis constant (Figure 3.8B). 
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Figure 3.8. Characterization of [
3
H]-2’deoxyuridine transport in T. b. brucei BSF. A. The 
inhibition of 5 µM [
3
H]-2’deoxyuridine uptake for 3 minutes incubation by various 
concentrations of unlabelled 2’deoxyuridine was converted to a Michaelis-Menten saturation 
plot to determine Km and Vmax values. The inhibition data was taken from frame B (the closed 
brown circles). B. Inhibition of 5 μM [
3
H]-2’deoxyuridine transport for 3 minutes incubation by 
unlabelled 2’-deoxyuridine (●) and unlabelled uracil (■). The uptake was terminated by 
addition of 1 ml ice-cold 5 mM unlabelled 2’-deoxyuridine. Error bars were SE of triplicate 
determinations. Lines were calculated using an equation for sigmoid curve with variable Hill 
slope; extrapolation of incomplete inhibitions was as described in the legend to Figure 3.6. 
The Ki and Km values of uracil, uridine and 2’-deoxyuridine were entirely 
consistent with all three pyrimidines being taken up by a single transport 
protein, TbU3. However, the low affinity for the nucleosides showed that TbU3 
was a uracil transporter and will not accumulate significant amounts of uridine 
and 2’-deoxyuridine under physiological conditions. 
3.5 Thymidine uptake in T. b. brucei BSF-WT 
No significant amounts of thymidine transport by BSF of T. b. brucei could be 
detected at submicromolar (Figure 3.9A) or low micromolar concentrations 
(Figure 3.9B) over 2 minutes. However, we were able to measure transport of 10 
μM thymidine over a period from 5 to 30 minutes (Figure 3.9C), with a rate of 
0.0015 ± 0.0003 pmol∙107 cells-1∙s-1, which was 80% inhibited by 2.5 mM 
unlabelled thymidine. 
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Figure 3.9. Timecourse of [
3
H]-thymidine 
uptake in T. b. brucei BSF. Brown circles (●) 
indicate the presence of [
3
H]-thymidine only 
and the blue squares (■) indicate the presence 
of added 5 mM unlabelled thymidine. A. 
transport of 0.5 µM [
3
H]-thymidine over 2 
minutes. B. Transport of 10 µM [
3
H]-thymidine 
over 2 minutes. C. Transport of 10 µM [
3
H]-
thymidine up to 30 minutes. All error bars were 
SE of triplicate determinations; where not 
visible error bars fall within the symbol. 
Using 10 μM of [3H]-thymidine and an incubation time of 15 minutes led to a 
possibility to derive reproducible Km values (Figure 3.10A) and inhibition profile 
(Table 3.1). The average Km value was 1240 ± 310 μM and the Vmax was 0.067 ± 
0.008 pmol∙107 cells-1∙s-1 (n=3), yielding an efficiency ratio Vmax/Km of just 
0.0001. Thymidine transport was not sensitive to inhibition by uracil, 
consistently failing to reach 50% inhibition even at 2.5 mM (Figure 3.10B; n=4), 
clearly showing that this is a distinct transporter from TbU3. Therefore, we 
designated bloodstream form thymidine transporter TbT1. 
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Figure 3.10 Characterization of [
3
H]-thymidine transport in T. b. brucei BSF. A. The conversion of 
thymidine inhibition data to a Michaelis-Menten saturation plot was performed to determine Km and 
Vmax, incubations (15 minutes). The inhibition data was taken from frame B (the closed brown 
circles). B. Inhibition of 5 μM [
3
H]-thymidine transport by thymidine (●) and uracil (▲), incubations 
(15 minutes). All data are averages and SEM of triplicate determinations and representative of at 
least three independent experiments. 
 
Moreover, the transporter was completely inhibited by adenosine with a Ki value 
of just 2.3 ± 0.3 µM (Figure 3.11A), whereas adenosine has no effect on TbU1 
mediated uracil transport. Uridine and 2’-deoxyuridine also inhibited this novel 
nucleoside transport activity (Figure 3.11B), but several other pyrimidines 
including orotic acid, thymine, cytidine and 5-fluorouracil had little or no effect 
on thymidine uptake (Table 3.1). 
 
-9 -8 -7 -6 -5 -4 -3 -2
0.0000
0.0005
0.0010
A
log[Inhibitor](M)
T
h
y
m
id
in
e
 U
p
ta
k
e
 (
p
m
o
l.
 (
1
0
7
 c
e
ll
s
)
-1
. 
s
-1
)
 
-10 -8 -6 -4 -2 0
0.000
0.001
0.002
B
log[Inhibitor](M)
T
h
y
m
id
in
e
 U
p
ta
k
e
 (
p
m
o
l.
 (
1
0
7
 c
e
ll
s
)
-1
. 
s
-1
)
 
Figure 3.11 Inhibition of 10 μM [
3
H]-thymidine transport by A. adenosine (□) B. uridine (●) 
and 2’deoxyuridine (○), for 15 minutes incubations. Experiments were performed in triplicate 
and were representative of three identical experiments performed on different dates. 
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The extremely low thymidine affinity and translocation efficiency of TbT1 led us 
to speculate that it would not contribute substantially to pyrimidine salvage in 
vivo, unless it was expressed at very much higher levels of activity in vivo rather 
than under the ‘rich’ in vitro growth conditions of standard HMI-9/FBS. This 
would parallel the situation with the TbAT1/P2 aminopurine transporter, which 
was highly expressed in rodent-grown trypanosomes but barely detectable in in 
vitro cultured trypanosomes (Ward et al., 2011). However, despite a trend 
suggesting a minor increase in [3H]-thymidine uptake from cells grown in vivo 
(Figure 3.12; n=3), the study was unable to detect a clear difference in 
thymidine transport rates in trypanosomes isolated from rat blood or from 
culture in HMI-9/FCS. 
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Figure 3.12 Timecourse of [
3
H]-thymidine uptake by in vivo grown T. b. brucei BSF, 
where closed brown circles (●) show uptake of 10 μM [
3
H]-thymidine and the blue 
squares (■) show uptake of the label in the presence of 2.5 mM unlabelled thymidine. 
Incubations were up to 30 minutes and performed in triplicate. 
The function of this transporter was not primarily the uptake of 
thymidine, but of purines. Considering the high affinity for adenosine, the 
transporter could be the previously described P2 aminopurine transporter (De 
Koning & Jarvis, 1999) or any of a number of P1-type purine nucleoside 
transporters (Al-Salabi et al., 2007; De Koning & Jarvis, 1999). It was thus tested 
whether [3H]-thymidine uptake was sensitive to inosine, and it was found that 
the purine nucleoside inhibited TbT1-mediated thymidine uptake with a Ki value 
of 1.6 ± 0.6 µM (n=3; Figure 3.13A). As P2 is insensitive to even very high levels 
of inosine (De Koning & Jarvis, 1999) this clearly established that the T1 was a 
P1-type nucleoside transporter, although it is currently unclear which one of the 
multiple P1-type transporter genes in the T. b. brucei genome (De Koning et al., 
2005) would encode this activity. To test this hypothesis, the inhibition of [3H]-
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inosine by thymidine was assessed in BSF and it was found that inosine uptake 
was inhibited by thymidine in a monophasic way with a Ki value of 214 ± 51 µM 
(Figure 3.13B). This activity displayed a Km for inosine of 0.89 ± 0.15 µM and Vmax 
0.075 ± 0.015 pmol∙107 cells-1∙s-1 (Figure 3.13C), all completely consistent with 
the hypothesis that TbT1 was a P1-type nucleoside transporter (Al-Salabi et al., 
2007; De Koning et al., 2005; De Koning & Jarvis, 1999). 
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Figure 3.13. Kinetic characterization of a 
P1-type nucleoside transporter in T. b. 
brucei BSF. A. Inhibition of 5 µM [
3
H]-
thymidine uptake over 15 minutes by 
unlabelled inosine (●) B. Inhibition of 0.25 
µM [
3
H]-inosine over 20 seconds by 
unlabelled inosine (●) and thymidine (■) C. 
Conversion of inosine inhibition curve from 
frame B to a Michaelis-Menten saturation 
plot in order to determine Km and Vmax 
values. 
3.6 Uptake of other pyrimidines by T. b. brucei BSF-WT 
Attempts were made to measure transport of other natural pyrimidine 
nucleosides and nucleobases. A very slow accumulation of 0.5 μM [3H]-cytidine 
was measured with incubation times up to 30 minutes. The rate of uptake was 
just 6.5×10-5 ± 4.1×10-6 pmol∙107 cells-1∙s-1 but [3H]-cytidine transport was only 
partly inhibited by 2.5 mM unlabelled cytidine (Figure 3. 14A). Consistent with 
this observation, an effort to determine the Km value for 0.5 μM [
3H]-cytidine, 
using a 20-minutes incubation time, found only partial saturation at 10 mM 
cytidine and the study concluded that bloodstream forms of T. b. brucei do not 
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salvage significant amounts of cytidine through uptake from their environment. 
Similarly, just detectable accumulation of 2.5 μM [3H]-2’deoxycytidine over 15 
minutes was not saturated by 10 mM unlabelled 2’-deoxycytidine (Figure 3. 14B). 
We have also attempted to measure the uptake of 0.25 µM [3H]-cytosine (Figure 
3. 14C) and 1 µM [3H]-thymine (Figure 3. 14D), but they did not detectably 
accumulate in BSF even up to 15 minutes incubation time. 
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Figure. 3. 14. In T. b. brucei BSF the transport of [
3
H]-pyrimidines (●) was not, or 
hardly, inhibited by the corresponding unlabelled permeants (■): A. Uptake of 0.5 μM 
[
3
H]-cytidine inhibited by 2.5 mM unlabelled cytidine over 30 minutes. B. Uptake of 2.5 
μM [
3
H]-2’deoxycytidine inhibited by 10 mM of unlabelled 2’-deoxycytidine over 15 
minutes. C. Uptake of 0.25 μM [
3
H]-cytosine inhibited by 2.5 mM unlabelled cytosine 
over a 15 minute period. D. Uptake of 1 μM [
3
H]-thymine inhibited by 10 mM unlabelled 
thymine for 15 minutes. 
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In summary, under the standard in vitro conditions used, T. b. brucei BSF 
express a high affinity uracil transporter, TbU3, and a P1-type nucleoside 
transporter capable of low affinity uptake of thymidine, TbT1. Uptake of 
uridine, 2’-deoxyuridine, cytidine and 2’-deoxycytidine can all be measured but 
displays very low affinity and efficiency compared to [3H]-uracil transport, and is 
unlikely to play any significant role in pyrimidine metabolism in vivo. 
3.7 Sensitivity of T. b. brucei BSF s427-WT to analogues 
of pyrimidine nucleosides and nucleobases 
The effects of a number of pyrimidine nucleoside and nucleobase analogues 
were tested on bloodstream trypanosomes in order to be evaluated as potential 
drugs and as tools to investigate the pyrimidine salvage pathways (Table 3.2). 
Thiouridines (2-thiouridine, 4-thiouridine), 4-thiouracil, 5-fluorouridine, 3’-
deoxypyrimidine nucleosides (3’-deoxyuridine, 2’,3’-dideoxyuridine, 3’-
deoxythymidine) and 5’-deoxyuridines (5’-deoxyuridine, 5-fluoro-5’deoxyuridine) 
all had no effect up to one millimolar drug concentration. In addition, uracil and 
uridine analogues with 5-position halogenations other than fluorine (i.e. 
chlorine, bromine or iodine) all displayed EC50 values ≥2.5 mM or no effect at all, 
and the other tested pyrimidine analogues including 5-fluorocytosine and 5-
fluorocytidine had no effect at tested concentrations. 
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Table 3.2. The activity of pyrimidine analogues against BSF of T. b. brucei s427-WT 
in vitro culture. Indicated values in the table were EC50 in μM, SE refer to standard 
error. The structure of pyrimidines and their analogues are shown in Appendix II; and 
the actual single values are shown in Appendix V. 
Pyrimidine analogues 
EC50 Value 
AVG SE 
Nucleobase analogues   
5-Fluorouracil 35.9  1.5 
5-Chlorouracil 2500  212 
5-Bromouracil >5000  
5-Iodouracil >5000  
5-Fluorocytosine >5000  
5-Fluoroorotic acid 14.1  0.9 
6-Azauracil 958  34 
4-Thiouracil >5000  
Nucleoside analogues   
5-Fluorouridine >5000  
5-Chlorouridine >5000  
5-Bromouridine >5000  
5-Iodouridine >5000  
5-Fluorocytidine >5000  
2-Thiuridine >5000  
4-Thiouridine >5000  
Deoxynucleoside analogues   
5-Fluoro2’-deoxyuridine 5.2  0.2 
5-Chloro2’-deoxyuridine 54  1.7 
5-Bromo2’-deoxyuridine >5000  
5-Iodo2’-deoxyuridine 2709  209 
5-Fluoro2’deoxycytidine 49.4  3 
5-deoxyuridine 1740  71 
5’-deoxy-5-fluorouridine >5000  
2’-3’-dideoxyuridine >5000  
3’-deoxyuridine >5000  
3’-deoxythymidine >5000  
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The disappointing activity of some of the ribonucleoside analogues on T. 
b. brucei BSF s427-WT may reflect the poor uptake of uridine and its close 
analogues. Therefore, we tested 5-fluorouridine against procyclic forms of T. b. 
brucei of s427-WT, which have previously been shown to take up uridine 
moderately well (Table 3.1). The analogue 5-flurorouridine at 1 mM inhibited 
procyclic growth by approx 60% over several days (Figure 3.15) but this modest 
effect still seems to indicate that 5-fluorouridine is also a poor substrate for 
uridine phosphorylase, which would convert it to 5-fluorouracil in the cell, or 
that this activity is not (highly) expressed in the life cycle stages investigated 
here. 
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Figure. 3.15. The effect of 5-fluorouridine on the growth of T. b. brucei procyclic forms 
s427-WT in semi defined medium 79 (SDM-79; Biosera) supplemented with 10% FBS 
cultured at 28 °C. Cultures containing 10
5
 trypanosomes/ml were incubated in SDM-
79 medium with 0.01 mM (■), 0.1 mM (◊) or 1 mM (▲) of the drug, using drug-free 
medium (●) as a positive control. Every 24 hours time, samples were taken and 
counted microscopically using a haemocytometer. 
The 2’-deoxynucleoside analogues were much more active against BSF 
than corresponding ribonucleosides; 5-fluoro-2’deoxyuridine, 5-chloro-
2’deoxyuridine and 5-fluoro-2’deoxycytidine, all displayed micromolar activity 
against trypanosomes (Fig 3.16A). In addition, pyrimidine nucleobase analogues 
also displayed significant antiprotozoal effects, including 5-fluorouracil and 5-
fluoroorotic acid with EC50 values at micromolar levels (Figure 3.16B). 
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Figure 3.16. Sensitivity of bloodstream forms of T. b. brucei s427-WT to pyrimidine analogues. A. 
Fluorinated deoxynucleosides: 5-fluoro-2’-deoxyuridine (○), 5-fluoro-2’-deoxycytidine (●) and 5-
chloro-2’-deoxyuridine (◊). B. Fluorinated nucleobases: 5-fluoruracil (■), 5-fluoroorotic acid (□) 
and pentamidine (▲) as a control. Using Alamar Blue assay, cell culture at 1×10
5
 cells/ml was 
incubated with the indicated concentrations. 
Although 6-azauracil is an inhibitor of pyrimidine de novo  biosynthesis pathway, 
being an inhibitor of orotidylate decarboxylase in trypanosomes (Jaffe, 1961), its 
EC50 value against BSF of T. b. brucei was around one millimolar. Presumably 
because 6-azauracil was a poor substrate for TbU3 (Table 3.1) and inhibition of 
de novo UMP biosynthesis was non-lethal because of uracil and pyrimidine 
nucleosides salvage. None of the fluorinated pyrimidines killed trypanosomes 
very quickly, even at 500 µM, although they appeared to induce almost 
immediate growth arrest (Figure 3.17). 
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Figure 3.17. Effect of fluorinated pyrimidines on growth of bloodstream forms s427-WT. 
Cultures containing 1×10
5
 or 2×10
5
 trypanosomes/ml were incubated with 500 μM of 5-FU 
(●), 5-FOA (▲), 5-fluoro-2’deoxyuridine (■) or control (◊). At various times samples were 
taken and counted microscopically using a haemocytometer. The inset is the same data as 
in the main figure but including the control (no added drug) culture and on a different scale. 
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3.8 Induction of resistance to selected pyrimidine 
antimetabolites and cross resistance profiles 
To further investigate in which way the most active analogues rely on salvage 
enzymes or transporters, this study induced resistance to 5-fluorouracil (5-FU), 
5-fluoroorotic acid (5-FOA) and 5-fluoro-2’deoxyuridine (5F-2’dUrd) by in vitro 
exposure of T. b. brucei BSF s427-WT to stepwise increasing concentrations of 
the compounds (Figure 3.18). 
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Figure 3.18. Adaptation of s427 BSF of T. b. brucei to high concentrations of 
fluorinated pyrimidines during in vitro culturing. Concentrations indicated were the 
analogue added to the medium, in which the cells managed to survive and multiply. 
When the trypanosomes became resistance to high concentrations of the drugs 
the new strains were cloned out. This resulted in clonal lines Tbb-5FURes 
(Resistance Factor 131 to 5-FU; Figure 3.19A), Tbb-5FOARes (Resistance Factor 
83 to 5-FOA; Figure 3.19B) and Tbb-5F2’dURes (Resistance Factor 825 to 5F-
2’dUrd; Figure 3.19C). The trypanocidal drug pentamidine was used as a positive 
control throughout the assessment. 
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Figure 3.19 Sensitivity of resistant line of T. 
b. brucei to fluorinated pyrimidines (■) 
comparing with s427-WT (○) A. the sensitivity 
of Tbb-5FURes and s427-WT to 5-FU B. the 
sensitivity of Tbb-5FOARes and s427-WT to 
5-FOA C. the sensitivity of Tbb-5F2’dURes 
and s427-WT to 5F-2’dUrd. 
The induced resistant strains were characterized with respect to cross-
resistance to other pyrimidine analogues (Table 3.3). Tbb-5FURes was not cross-
resistant to pyrimidine nucleoside analogues but displayed 6.9-fold resistance to 
5FOA, showing that at least one of multiple changes impacted on a joint 
pathway. Interestingly, Tbb5-FURes displayed increased sensitivity to 6-
azauracil, probably indicating a reduced uracil salvage pathway and increasing 
reliance on de novo synthesis. In addition, Tbb-5FURes was ~15-fold more 
sensitive to 5-chloro-2’deoxyuridine, possibly an indication that this analog also 
inhibits de novo pyrimidine biosynthesis. Similarly, Tbb-5FOARes showed 13-fold 
resistance to 5-FU, a fraction of the resistance to 5-FOA itself, and even less 
resistance to the nucleoside analogues. Tbb-5F2’dURes was not cross-resistant to 
the nucleobase analogues 5-FU, 5-FOA and 6-azauracil showing that the 
resistance was not due to loss of TbU3 activity since its natural pyrimidine 
(2’deoxyuridine) uptake was totally inhibited by the main substrate for TbU3, 
uracil. However, this strain was resistant to 5-fluoro-2’-deoxycytidine to the 
limit tested (5 mM), although not to 5-chloro-2’-deoxyuridine, confirming that 
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the latter has a different mode of action than 5F-2’dUrd. This observation 
strongly suggests that 5-fluoro2’-deoxycytidine is converted to 5F-2’dUrd in the 
cell, presumably by cytidine deaminase, and that its mechanism of action is 
completely dependent on that conversion. 
Table 3.3. Resistance and cross-resistance characterization of T. b. brucei BSF adapted to high 
levels of fluorinated pyrimidines, compared to the parental s427-wild type. Indicated values in the 
table were EC50 in μM. SE stand for standard error, RF symbolize resistance factor which means 
EC50 of resistance cells/ EC50 of s427-WT cells. The actual single values are shown in Appendix V. 
Compounds 
s427-WT Tbb-5FURes Tbb-5FOARes Tbb-5F-2’dURes 
AVG ± SE AVG ± SE RF AVG ± SE RF AVG ± SE RF 
5F-uracil 35.9 ± 1.5 4707 ± 307 131 448 ± 32 13 76.1 ± 2.2 2.1 
5F-orotic acid 14.1 ± 0.9 98 ± 2 6.9 1178 ± 99 83 13.3 ± 0.1 0.94 
5F-2’d-uridine 5.2 ± 0.2 3.2 ± 0.3 0.61 31 ± 2 5.9 4295 ± 267 825 
5Chl-2’d-uridine 54 ± 1.7 3.7 ± 0.2 0.07 91 ± 6 1.7 22.0 ± 1.0 0.4 
5F2’d-cytidine 49.4 ± 3 55 ± 5 1.1 126 ± 10 2.6 >5000 >100 
6-Azauracil 958 ± 34 157 ± 2 0.16 1387 ± 78 1.4 1103 ± 44 1.2 
3.9 Assessment of pyrimidine transport in the resistant 
clones 
We investigated whether Tbb-5FURes cells resistance to 5-FU was linked to 
changes in uracil and/or 5-fluorouracil transport. Whereas transport of 0.5 μM 
[3H]-uracil was almost identical in s427-WT and Tbb-5FURes cells (Figure 3.20A), 
the uptake of the same concentration of [3H]-5FU was reduced in Tbb-5FURes 
cells by 76 ± 6% (n=3; P<0.01, paired Student’s t-test; Figure 3.20B). The Km and 
Vmax value of [
3H]-uracil uptake in Tbb-5FURes cells were unchanged relative to 
s427-WT, as well as were the sensitivity to uridine and 5-FU (the average of Ki 
values were ~10 mM and 3.7 ± 0.7 μM, respectively (Figure 3.20C). 
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Figure 3.20. Transport of 0.5 μM of A. [
3
H]-
uracil B. [
3
H]-5fluorouracil in BSF of T. b. 
brucei WT-s427 (●) and Tbb-5FURes cell 
line (■). C. Inhibition of 0.1 μM [
3
H]-uracil 
transport by (●) uridine and (■) 5-
fluorouracil in Tbb-5FURes cells. 
Incubations of 30 seconds were terminated 
by the addition of 1 ml ice-cold 1 mM uracil 
in assay buffer and immediate centrifugation 
through oil. Error bars were SE of triplicate 
determinations. The graph was 
representative of three similar experiments. 
Lines were calculated by linear regression. 
A subtle change in the TbU3 transporter reduced transport rates for 5-
fluorouracil but not for uracil and without changing affinity for 5-fluorouracil 
(Table 3.4). Consistent with this interpretation, the transport efficiency 
(Vmax/Km) for [
3H]-5fluorouracil in Tbb-5FURes was 0.088 compared with 0.25 for 
[3H]-uracil. In WT cells the difference between the uracil and 5-FU transport 
efficiencies was much lower compared with the difference in Tbb-5FURes cells. 
However, based on the considerable insensitivity of Tbb-5FURes cells to 5FU 
(131-fold), we can assume that the reduction in 5-FU uptake efficiency is small 
and most likely only one contributing factor to the high level of resistance 
observed in Tbb-5FURes. 
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Table 3.4. Kinetic parameters of uracil and 5-fluorouracil transport in T. b. brucei BSF of s427-
WT and Tbb-5FURes. 
Permeant Strains 
Km (μM) Vmax (pmol∙10
7
 cells
-1∙s-1) 
Efficiency 
(Vmax/Km) AVG SE AVG SE 
[
3
H]-Uracil 
s427 WT 1.5 0.3 0.27 0.05 0.18 
Tbb-5FURes 0.66 0.15 0.16 0.02 0.25 
[
3
H]-5Fluorouracil 
s427 WT 2.5 0.01 0.27 0.02 0.11 
Tbb-5FURes 2.3 0.4 0.2 0.02 0.088 
We have also investigated whether reduced uptake of orotic acid might 
partly explain the phenotype of Tbb-5FOARes cells. Uptake of 2.5 μM [3H]-orotic 
acid was linear in BSF of T. b. brucei s427-WT (r2 = 0.98) and significantly 
different from zero (F-test, P = 0.002) with a rate of 2.1×10-4 ± 2.1×10-5 pmol∙107 
cells-1∙s-1. However, uptake appeared to be non-saturable in the presence of ≥1 
mM of unlabelled orotic acid. [3H]-orotic acid uptake was not significantly 
inhibited by uracil and thymidine either (Figure 3.21). As such, it was impossible 
to determine kinetic parameters and characterize orotic acid uptake in 
bloodstream forms of T. b. brucei s427-WT. 
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Figure 3.21. T. b. brucei BSF, representative inhibition transport of 2.5 μM [
3
H]-orotic 
acid by unlabelled orotic acid, uracil and thymidine, using 10 minutes incubations. 
Error bars were SE of triplicate determinations. 
However, it was clear that, when the uptake of 2.5 μM [3H]-orotic acid was 
measured, accumulation of orotic acid was less in Tbb-5FOARes cells than in 
s427-WT cells; in two experiments (each performed in triplicate). The uptake of 
2.5 μM [3H]-orotic acid over 10 minutes was reduced by 68.1% (P<0.01; Figure 
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3.22A) and 62.8% (P<0.001; Figure 3.22B; Student’s t-test). However, it was 
unsafe to attribute this to either reduced transport or a reduced rate of orotic 
acid metabolism as it was difficult to establish an initial rate of mediated 
transport for this permeant and metabolic usage of the [3H]-orotic acid could 
therefore be the rate-determining step. 
0 2 4 6 8 10
0.0
0.5
1.0
1.5
2.0
2.5
A
Time (min)
O
ro
ti
c
 a
c
id
 U
p
ta
k
e
 (
p
m
o
l.
 (
1
0
7
 c
e
ll
s
)
-1
. 
s
-1
)
 
0 2 4 6 8 10
0.0
0.5
1.0
1.5
2.0
2.5
B
Time (min)
O
ro
ti
c
 a
c
id
 U
p
ta
k
e
 (
p
m
o
l.
 (
1
0
7
 c
e
ll
s
)
-1
. 
s
-1
)
 
Figure 3.22. A and B were two identical separate experiments showed 
transport of 2.5 μM [
3
H]-orotic acid over 10 minutes incubations by 
bloodstream forms of T. b. brucei  s427-WT (■) and Tbb-5FOARes cells (●). 
3.10. Discussion 
Pyrimidine analogs have been extremely successful in anti-cancer (Galmarini et 
al., 2003) and anti-viral chemotherapy (Hoffmann et al., 2011). For instance, 
fluorinated pyrimidines capecitabine and 5-fluoro-2’deoxyuridine (Floxuridine), 
are both pro-drugs of the well known anticancer drug 5-fluorouracil. As a first 
step towards a rational evaluation of possible pyrimidine chemotherapy for 
trypanosomatid infections, it is incumbent to understand which natural 
pyrimidines would efficiently reach the target cell’s interior (Luscher et al., 
2007). Natural pyrimidine nucleobases and nucleosides, and many analogues, do 
not have an appreciable diffusion rate and thus require transport proteins to 
enter cells. Therefore, this study attempted to investigate the transport of all 
natural pyrimidines, and of 5-fluorouracil, by bloodstream trypanosomes. 
Evidence was found for only one such transporter, TbU3, with high affinity for 
uracil and very low affinity for uridine and 2’-deoxyuridine. The reciprocal Ki 
and Km values of uracil with uridine and 2’-deoxyuridine are entirely consistent 
with all uptakes of these nucleosides proceeding through the TbU3 transporter, 
but the low affinity for the nucleosides shows that TbU3 is a uracil transporter. 
This is confirmed by comparing the transport efficiencies, expressed as Vmax/Km, 
this index is identical for uridine and 2’deoxyuridine (0.0017) but two orders of 
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magnitude higher for uracil (0.18). No separate transport activity, other than 
TbU3, could be detected for uridine, 2’deoxyuridine, cytidine, 2’-deoxycytidine, 
cytosine, orotate and thymine. Transport of [3H]-thymidine was evident, and 
mediated by a transport activity that was distinct from TbU3 and designated 
TbT1. However, its low affinity for thymidine, its high affinity inhibition by 
adenosine and reciprocal inhibition by inosine clearly shows this thymidine flux 
is mediated by one of the P1-type purine nucleoside transporters expressed in T. 
b. brucei bloodstream forms (Al-Salabi et al., 2007; De Koning et al., 2005; De 
Koning & Jarvis, 1999; Sanchez et al., 2002). 
The uracil transporter found in procyclic forms, TbU1, has been well 
characterized (De Koning & Jarvis, 1998; Papageorgiou et al., 2005) and, like the 
corresponding transporter of L. major, binds its substrate through hydrogen 
bonds to both keto groups and both ring nitrogens in protonated state 
(Papageorgiou et al., 2005). The many close similarities between procyclic TbU1 
and bloodstream form TbU3 inhibitor profiles seem to indicate a common 
transporter structure, but the specific differences, particularly the low affinity 
for uridine by TbU3, suggest that TbU3 has more steric limitations than TbU1 
when it comes to binding nucleosides rather than nucleobases – either in the 
binding site itself or in extracellular access to it. As a Ki value for 2’-
deoxyuridine could be established (1150 ± 340 μM) it appears that the 2’-
hydroxyl group is a significant factor in the non-binding of uridine. In contrast, 
the further removal of the 3’-hydroxyl group (2’,3’-dideoxyuridine), or of the 5’-
hydroxyl (2’,5’-dideoxyuridine and 5’-deoxyuridine), did not lead to higher 
affinity. In addition, the lower affinity for 4-thiouracil in TbU3 is likely to reflect 
a stronger hydrogen bond at the 4-keto group than was the case for TbU1, as a 
result of a subtle shift in position or a different amino acid facing this group. 
Of all the 5-halogenated pyrimidines, 5-fluorouracil seems to be the only 
cytotoxic pyrimidine nucleobase taken up efficiently by BSF trypanosomes. The 
notable affinity of 5-fluorouracil but not (5-chloro and 5-bromo)- uracil for TbU3 
suggests size limitations on position 5 of uracil: fluorine has a small size 
compared to other halogens. Furthermore, the carbon-fluor bond is one of the 
strongest bonds in organic chemistry which contributes to its stability. When 
fluorine, the halogen atom of 5-fluorouracil, was substituted by chloro, iodo, 
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bromo or a methyl group (i.e. thymine) there was no considerable inhibition on 
[3H]-uracil uptake. 
Of particular interest was the observation that 5-FOA displayed >3-fold 
higher activity than 5-FU although the orotate uptake rate was just a fraction 
(≤1%) of the transport rate of [3H]-5-fluorouracil. Interestingly, 5-FOA displays 
even much higher activity against Plasmodium falciparum, with reported in vitro 
EC50 values in the low nanomolar range (Rathod et al., 1989). It seems highly 
likely that the 100-fold higher antimalarial activity of 5-FOA can be attributed to 
the fact that orotic acid is, alone among all pyrimidines, efficiently taken up by 
Plasmodium spp and incorporated into nucleic acids (Gutteridge & Trigg, 1970). 
The strict selectivity of kinetoplastid uracil transporters was also noted for the 
procyclic TbU1 and Leishmania major LmajU1 carriers (De Koning & Jarvis, 1998; 
Papageorgiou et al., 2005) and is in contrast to some of the kinetoplastid 
nucleoside transporters, particularly the aminopurine transporter TbAT1/P2 
which is involved in uptake of many of the current first line trypanosomiasis 
drugs (Al-Salabi et al., 2007; De Koning et al., 2004; De Koning, 2001). 
(Hofer et al., 2001) was unable to detect incorporation of radiolabeled 
cytosine and cytidine into the T. b. brucei nucleotide pool using nanomolar 
concentrations. They concluded that CTP synthase was the only route to obtain 
cytidine nucleotides and the inhibition of the enzyme reduced proliferation both 
in vivo and in vitro (Fijolek et al., 2007; Hofer et al., 2001). The likely 
explanation is the use of submicromolar concentrations of pyrimidines used by 
Hofer; at these concentrations uracil is rapidly taken up and incorporated into 
nucleotide pools, but cytosine and cytidine are taken up very poorly at low 
concentrations, although their uptake is noted at high substrate levels. In 
chapter 7 it will be shown that pyrimidine auxotrophic trypanosomes can survive 
and multiply, albeit poorly, on 1 mM cytidine as sole pyrimidine source. 
In summary, this study assessed pyrimidine salvage by bloodstream forms of T. 
b. brucei and reports that only uracil is efficiently taken up through a high 
affinity transporter, TbU3. The lack of high affinity transporters for most 
pyrimidine antimetabolites (Table 3.1) may limit the achievable trypanocidal 
activity with water-soluble pyrimidines. 
 
 
CHAPTER FOUR 
Leishmania spp: characterisation of pyrimidine 
transporters and analysis of anti-leishmanial action 
of selected pyrimidine analogues 
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4.1. Introduction 
A few microorganisms are incapable of pyrimidine salvage, such as 
Plasmodium (Van Dyke et al., 1970; Gutteridge and Trigg, 1970) or lack de novo 
pyrimidine biosynthesis pathways, such as Trichomonas vaginalis, Trichomonas 
foetus and Giardia spp (Wang & Cheng, 1984). However, most organisms are 
capable of salvage and biosynthesis of pyrimidine molecules, including 
kinetoplastid cells. In addition, most of the inter-conversion pyrimidine 
metabolizing enzymes, and the enzymes of the biosynthesis pathways are shared 
among the various organisms. With respect to salvage, Leishmania and 
Trypanosoma parasites have shown similarities in pyrimidine transport activities. 
For instance, a similar high-affinity uracil transporter was characterized in 
promastigotes of L. major (Papageorgiou et al., 2005), procyclic forms of T. b. 
brucei (De Koning & Jarvis, 1998) and, very recently, bloodstream forms of T. b. 
brucei (Ali et al., 2013a). In addition, all of these uracil transporters showed 
very high affinity to 5-fluorouracil and the drug was effective against the 
parasites, with EC50 values at micromolar concentrations. It was also shown that 
5-FU was incorporated into RNA of bloodstream form of trypanosomes (Ali et al., 
2013a). In this project, we characterized pyrimidine uptake and assessed the 
activity of pyrimidine analogues against Leishmania cells. In addition, we 
created and analysed resistant strains to the most effective pyrimidine 
analogues. 
4.2. Characterization of pyrimidine transporters in L. 
mexicana promastigotes 
The first purine nucleobase transporter in L. mexicana, LmexNBT1, was 
identified and characterized in the amastigote stage; this transporter has high 
affinity to purine nucleobases and low affinity for nucleosides and pyrimidines, 
and was also involved in the uptake of the anti-leishmanial drug allopurinol (Al-
Salabi & De Koning, 2005). At the start of this project, the pyrimidine transport 
activities of L. mexicana promastigotes were unknown, with no information 
regarding the number of individual pyrimidine transporters, or their 
characteristics. Therefore, this study investigated pyrimidine transporters 
expressed in the insect stage of L. mexicana. 
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4.2.1 Uracil uptake in L. mexicana promastigotes 
When testing [3H]-uracil uptake at 1.0 μM over 2 minutes, the rate of [3H]-uracil 
uptake was 0.0028 ± 0.0004 pmol∙107 cells-1∙s-1 (linear regression, r2 = 0.96) and 
was >95% inhibited by 1 mM unlabelled uracil (Figure 4.1A). The first effort to 
characterise the uracil transporter was performed using 0.5 μM [3H]-uracil over 
30 seconds – within the linear phase, but this incubation time was insufficient to 
present a consistent monophasic graph (Figure 4.1B), due to the low amount of 
radiolabel accumulated. Therefore, we next performed the uracil timecourse 
using a maximum 10 minutes incubation time. [3H]-uracil at 0.5 μM was 
transported by L. mexicana promastigotes in linear manner over 10 minutes with 
a rate of uptake of 0.1073 ± 0.01552 pmol∙107 cells-1∙s-1, which was 38.3-fold 
higher than the rate of 1 μM [3H]-uracil for 120 seconds incubation, indicating 
that the transporter has not yet saturated at 1 µM for 120 seconds. The rate of 
0.5 μM [3H]-uracil uptake for 10 minutes incubation was 94% inhibited by 1 mM 
unlabelled uracil (Figure 4.1C). These findings showed that uracil was mediated 
by a saturable protein membrane transporter. All subsequent experiments were 
performed using 0.5 μM [3H]-uracil and 4 minutes incubations – very much within 
the linear phase of uptake. 
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Figure 4.1 The uptake of labelled uracil 
(■) by L. mexicana promastigotes in the 
presence of an additional 1 mM 
unlabelled uracil (●). A. The uptake of 
1.0 μM [
3
H]-uracil over 2 minutes. 
Transport in the presence of unlabelled 
uracil was not significantly different from 
zero (F-test; P=0.76). B. Inhibition of 0.5 
µM [
3
H]-uracil uptake (30 seconds 
incubations) by various concentrations of 
unlabelled uracil. C. The uptake of 0.5 
μM [
3
H]-uracil over 10 minutes. 
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The transport experiments with 0.5 μM [3H]-uracil in promastigotes of L. 
mexicana over a 4 minute period produced sigmoid curves consistent with 
monophasic inhibition, with Hill slopes close to -1. The inhibition of [3H]-uracil 
by increasing concentrations of unlabelled uracil and 5-fluorouracil was 
consistent between experiments, and showed monophasic inhibition with Hill 
slopes near -1, i.e. a single transporter model (Figure 4.2A). The uracil inhibition 
data was converted to Michaelis-Menten plots and displayed an average of Km 
value of 29.7 ± 4.4 μM and average Vmax value of 0.088 ± 0.01 pmol∙10
7 cells-1∙s-1 
(n=3; Figure 4.2B). This was the first pyrimidine nucleobase transporter 
identified in L. mexicana and it was tentatively designated L. mexicana uracil 
transporter 1 (LmexU1). Based on apparent Km and Vmax values of LmexU1, it 
appeared that the transport efficiency for uracil, expressed as Vmax/Km, was very 
low compared with the purine nucleobase transporter, LmexNBT1 (0.003 versus 
0.057, respectively). This is consistent with the greater need for purine salvage 
than for pyrimidine uptake in this species. 
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Figure 4.2. Characterization of [
3
H]-uracil transport in promastigotes of L. mexicana. A. 
Inhibition of 0.5 µM [
3
H]-uracil uptake over 4 minutes by various concentrations of unlabelled 
uracil (■) and 5-fluorouracil (●). B. Conversion uracil inhibition data from frame A to 
Michaelis-Menten saturation plot to determine the Km and Vmax values. 
Purines and pyrimidines were assessed for inhibition of the uptake of 0.5 
μM [3H]-uracil in order to investigate the specificity of LmexU1 (Table 4.1). The 
data from LmexU1 inhibition profile showed that the average Ki value for 5-FU 
inhibition of uracil transport was almost identical to the average of Km values for 
uracil uptake. Thus the anticancer drug 5-fluorouracil was almost as good a 
substrate as uracil for LmexU1 (Figure 4.2A) and displayed anti-leishmanial 
activity at micromolar level (Table 4.3). When the fluor atom of 5-FU was 
replaced with a methyl group to form thymine, the binding of the nucleobase 
with LmexU1 was not observed; this is likely linked to the larger size of the 
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methyl group as compared to the fluor (Schlosser & Michel, 1996). Although 
LmexU1 has high affinity for some pyrimidine nucleobases, cytosine up to 5 mM 
did not show any inhibition of 0.5 μM [3H]-uracil uptake. With respect to purine 
nucleobases, LmexU1 showed low affinity to adenine, which displayed poor 
inhibition activity against uracil uptake and an average Ki value of >0.3 mM 
(Figure 4.3A). The substitute of hydrogen atom on carbon position-5 of uridine 
with a methyl group, to form thymidine, was once again rejected from binding 
with LmexU1, consistent with the observations with thymine. Furthermore, 
neither hypoxanthine nor adenosine was a good substrate for the uracil 
transporter. LmexU1 was very sensitive to uridine nucleosides, thus the apparent 
affinities of LmexU1 for uridine and 2’-deoxyuridine against uracil uptake were 
higher than the affinity of LmexU1for uracil, by 14.8-fold and 3.2-fold, 
respectively (Figure 4.3B). As the data showed that LmexU1 is a uracil 
transporter with high affinity to uridine nucleosides, the uptake of [3H]-uridine 
by L. mexicana promastigotes was investigated next. 
-9 -8 -7 -6 -5 -4 -3 -2
-0.001
0.000
0.001
0.002
0.003
A
log[Inhibitor](M)
U
ra
c
il 
U
p
ta
k
e
 (
p
m
o
l.
 (
1
0
7
 c
e
ll
s
)
-1
. 
s
-1
)
 
-10 -8 -6 -4 -2 0
0.000
0.001
0.002
log[Inhibitor](M)
U
ra
c
il 
U
p
ta
k
e
 (
p
m
o
l.
 (
1
0
7
 c
e
ll
s
)
-1
. 
s
-1
)
B
 
Figure 4.3 Pyrimidine transport in L. mexicana promastigotes. Dose-dependent inhibition 
of 0.5 µM [
3
H]-uracil uptake by increased concentrations of A. unlabelled adenine (∆) B. 
unlabelled uridine (□) and 2’-deoxyuridine (●). The blue closed-square symbol (■) is the 
zero transport in the presence of 1 mM unlabelled uracil. All incubations were over one 
minute and performed in triplicate; average and SE are shown. 
4.2.2 Uridine uptake in L. mexicana promastigotes 
This study assessed the uptake of 0.25 μM [3H]-uridine by promastigotes of L. 
mexicana and found that the transport was linear for at least 2 minutes with a 
rate of 0.004 ± 0.0003 pmol∙107 cells-1∙s-1 (r2= 0.96). The uptake was completely 
inhibited by 1 mM unlabelled uridine indicating that the uptake was saturable 
(Figure 4.4A). The following [3H]-uridine experiments used 0.15 μM of label and 
one minute incubation time – very well inside the linear phase. Uridine transport 
at room temperature complied with the Michaelis-Menten equation as shown in 
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the inset of figure 4.4B. Uridine uptake displayed an apparent Km value of 7.2 ± 
0.9 μM and Vmax value of 0.33 ± 0.11 pmol∙10
7 cells-1∙s-1 (n=5). As all uridine 
inhibition results were consistent with monophasic inhibition with Hill slope very 
close to -1, it is possible that uridine is taken up by a single transporter. 
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Figure 4.4. Transport of [
3
H]-uridine by promastigotes of L. mexicana. A. 
Transport of 0.25 µM [
3
H]-uridine (■) was performed over 2 minutes and entirely 
inhibited by 1 mM unlabelled uridine (●) B. Inhibition of 0.15 µM [
3
H]-uridine 
uptake over one minute by various concentrations of unlabelled uridine. The 
inset indicates conversion of the data to a Michaelis-Menten saturation plot. 
In order to investigate whether the uridine and uracil shared the same 
transporter, the inhibition by various concentrations of unlabelled uracil of 0.15 
μM [3H]-uridine uptake was assessed. In five independent experiments, the 
apparent Ki value for uracil inhibition of uridine transport was statistically equal 
to the uracil Km value for LmexU1 (Figure 4.5A); however, uracil up to 2.5 mM 
inhibited only 55.6 ± 3.1% of 0.15 μM [3H]-uridine uptake, taking inhibition by 1 
mM unlabelled uridine as 100% (n=5). Furthermore, 5 mM of 5-fluorouracil did 
not inhibit 0.15 μM [3H]-uridine transport (Figure 4.5B); therefore, the effect of 
5-FU on uridine transport is very different from its activity against uracil uptake. 
As the partial inhibition by uracil shown in figure 4.5A was very consistent, and 
represented less than 50% inhibition of [3H]-uridine transport, it appears that L. 
mexicana expresses 2 distinct uridine transporters: one being uracil-sensitive 
and one being uracil insensitive. Therefore, the uptake of [3H]-uridine in the 
presence of 1 mM unlabelled uracil was investigated, so as to obtain a 
characterization of the uracil-insensitive uridine transporter in isolation. 
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Figure 4.5. Inhibition of 0.15 µM [
3
H]-uridine uptake over 60 second incubations 
by various concentrations of unlabelled uridine (●), A. unlabelled uracil (□) B. 
unlabelled 5-FU (■). 
The uptake of 0.15 μM [3H]-uridine in presence of 1 mM unlabelled uracil 
over 1 min was inhibited by various concentrations of unlabelled uridine (Figure 
4.6A); the inhibition data was consistent with Michaelis-Menten kinetics (Figure 
4.6B). The Km value for uridine uptake in presence of 1 mM uracil (4.1 ± 0.2 μM) 
was almost identical to the Km value for uridine uptake in the absence of uracil 
(7.2 ± 0.9 μM), also the average Vmax value was equal 0.32 ± 0.07 pmol∙10
7 cells-
1∙s-1. This uracil-insensitive uridine transporter was designated L. mexicana 
Nucleoside Transporter 1 (LmexNT1), whereas the uridine/uracil transporter is 
referred to as LmexU1. Comparing the transport efficiencies the index (Vmax/Km) 
was for LmexNT1 (using uridine as a substrate) was 26-fold higher than for 
LmexU1 (using uracil as a substrate). As the blue closed-circle symbol in figure 
4.6A indicates the level of uridine uptake without additional uracil, in three 
independent experiments we once again confirmed that 1 mM of unlabelled 
uracil inhibited about half of 0.15 μM [3H]-uridine uptake (55 ± 3.5%). Uracil and 
uridine can be transported by both LmexU1 and LmexNT1, albeit with different 
efficiencies. 
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Figure 4.6. L. mexicana promastigotes, characterization of [
3
H]-uridine transport in 
presence of 1 mM unlabelled uracil. A. Inhibition of 0.15 µM [
3
H]-uridine uptake over one 
minute by various concentrations of unlabelled uridine (■), the blue closed-circle symbol 
(●) shows the uptake of 0.15 μM [
3
H]-uridine without uracil. B. The data derived from 
frame A was converted to a Michaelis-Menten saturation plot. Error bars were SE of 
triplicate determinations. 
In order to investigate the specificity of LmexNT1, the effects of several 
purines and pyrimidines were assessed for inhibition of the uptake of 0.15 μM 
[3H]-uridine in the presence of 1 mM unlabelled uracil (Table 4.1). The inhibition 
profiles demonstrated Hill coefficients near -1 and maximum inhibition was 
consistently identical to the level of inhibition of the control (i.e. 1 mM 
unlabelled uridine) – all consistent with the LmexNT1 transport activity 
representing a single gene product. Interestingly, the apparent average Ki value 
for 2’-deoxyuridine was identical to its 5-fluorinated counterpart, and it was 
concluded that the presence or absence of fluor on carbon position 5 of the 
nucleoside has no effect on substrate binding with LmexNT1. The data in figure 
4.7 shows that uptake of [3H]-uridine in the presence of 1 mM unlabelled uracil 
is also sensitive to thymidine (Ki = 10 ± 2.6) and very sensitive to adenosine (Ki = 
0.39 ± 0.09), and the uptake of adenosine was therefore further investigated. 
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Figure 4.7 Dose-dependent inhibition of 0.15 µM [
3
H]-uridine transport in the 
presence of 1 mM unlabelled uracil by unlabelled uridine (●), adenosine (□) and 
thymidine (○). Incubation time was 60 seconds. 
Initial experiments tested the uptake of 0.1 μM [3H]-adenosine over 2 minutes, in 
the presence or absence of 1 mM unlabelled adenosine. However under these 
conditions, the [3H]-adenosine in the media was quickly depleted, resulting in a 
non-linear rate of uptake (Figure 4.8A). Subsequent uptake assay with [3H]-
adenosine was performed using shorter incubations , which presented a linear 
uptake with a rate of 0.20 ± 0.01 pmol∙107 cells-1∙s-1 (r2=0.98) over 25 seconds; 
transport was completely inhibited by 1 mM unlabelled adenosine (Figure 4.8B), 
showing that adenosine uptake is mediated by a saturable transporter rather 
than by simple diffusion. 
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Figure 4.8. L. mexicana promastigotes, timecourse of 0.1 μM [
3
H]-adenosine 
transport over incubation time up to A. 120 seconds B. 30 seconds. 
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The use of 0.05 μM [3H]-adenosine and an incubation time of 15 seconds – within 
the linear phase – allowed us to characterize adenosine uptake. The inhibition 
data of adenosine (Figure 4.9A) was converted to a Michaelis-Menten saturation 
plot to determine the average of Km and Vmax values. Based on adenosine Km of 
0.83 ± 0.16 μM and Vmax of 1.13 ± 0.21 pmol∙10
7 cells-1∙s-1 (Figure 4.9B), the 
difference between the adenosine and uridine transport efficiencies was very 
substantial, being 1.36 versus 0.08, respectively. We conclude that L. mexicana 
promastigotes express a high affinity nucleoside transporter that preferentially 
transports adenosine over uridine. 
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Figure 4.9. Characterization of [
3
H]-adenosine transport in L. mexicana 
promastigotes. A. Inhibitions of 0.05 µM [
3
H]-adenosine uptake over 15 second, by 
various concentrations of unlabelled adenosine. B. Conversion of the inhibition data 
from frame A to a Michaelis-Menten saturation plot. 
The inhibition profiles of labeled adenosine uptake showed Hill 
coefficients close to -1 and the maximum inhibition was equal to the level of 
inhibition of 1 mM unlabelled adenosine. In three independent experiments, 
uridine and thymidine inhibited the uptake of [3H]-adenosine with almost 
identical Ki values, 24.2 ± 2.2 μM and 18.5 ± 0.64 μM, respectively (Figure 
4.10A). As the adenosine Km value is 5-fold lower than the uridine Km (P<0.0001, 
Student’s t-test) and was almost identical to the Ki value for adenosine inhibition 
of [3H]-uridine transport, we conclude that adenosine is taken up by LmexNT1, 
which is a nucleoside transporter with high affinity to adenosine. To prove that 
LmexNT1 is specifically a nucleoside transporter and not a nucleobase 
transporter, the inhibition of [3H]-adenosine by various concentrations of 
unlabelled uracil and adenine were performed in three separate experiments. 
J. Ali 2013 Chapter 4 113 
The results demonstrate that neither uracil nor adenine at 1 mM inhibited the 
uptake of 0.05 μM [3H]-adenosine (Figure 4.10B), confirming LmexNT1 as a 
straightforward nucleoside transporter. Another notable observation was that 
thymidine similarly inhibited the uptake of both labeled uridine and adenosine 
with identical level (9.8 ± 2.6 μM and 18.5 ± 0.64 μM, respectively), showing that 
thymidine is most likely also a LmexNT1 substrate, even though thymidine was 
not a substrate for LmexU1 (see above). To confirm these findings we also 
assessed the uptake of thymidine in promastigotes of L. mexicana. 
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Figure 4.10. Dose-dependent inhibition of 0.05 µM [
3
H]-adenosine uptake by 
unlabelled adenosine (□), A. unlabelled nucleosides, uridine (●) and thymidine (○) B. 
unlabelled nucleobases uracil (■) and adenine (▲). Incubations were for 15 seconds. 
The transport of [3H]-thymidine at 1 μM was determined over 30 seconds 
and showed a linear uptake with a rate of 0.08 ± 0.004 pmol∙107 cells-1∙s-1 
(r2=0.98); it was entirely inhibited by 1 mM unlabelled thymidine (Figure 4.11A). 
These data showed that thymidine enters L. mexicana promastigotes via 
membrane protein(s) and that simple diffusion does not play a significant role in 
this process. All subsequent [3H]-thymidine experiments were performed using 1 
μM label and 20 s incubations – well within the linear phase. In triplicate dose-
response experiments, the results showed that the inhibition activity of [3H]-
thymidine transport displayed Hill coefficients close to -1 and the maximum 
inhibition was identical to the level of inhibition of 1 mM unlabelled thymidine. 
Conversion of the inhibition data to Michaelis-Menten plot displayed an apparent 
Km value of 4.2 ± 0.4 μM and Vmax value of 0.85 ± 0.12 pmol∙10
7 cells-1∙s-1 (Figure 
4.11B). 
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Figure 4.11. Characterization of [
3
H]-thymidine transport in L. mexicana 
promastigotes. A. Timecourse of 1 μM [
3
H]-thymidine transport (■) in the presence of 
1 mM unlabelled thymidine (●); incubation was up to 30 seconds. B. Inhibition of 1 µM 
[
3
H]-thymidine uptake over 20 s by various concentrations of unlabelled thymidine (●). 
The inset indicated conversion the data to Michaelis-Menten saturation plot. 
Inhibition activity for uridine and adenosine against thymidine uptake was very 
consistent and presented Ki values of 6.0 ± 0.6 μM and 0.25 ± 0.04 μM, 
respectively (Figure 4.12A) also against thymidine uptake cytidine showed Ki  
value of 82 ± 5.3 μM, but uracil did not show any activity against 1 μM [3H]-
thymidine uptake even at 2.5 mM unlabelled uracil (Fig 4.12B). 
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Figure 4.12. Dose-dependent inhibition of 1.0 µM [
3
H]-thymidine transport for 20 second 
incubations by unlabelled thymidine (○), A. uridine (●) and adenosine (□) B. uracil (■). 
 
The most consistent findings were that the affinity of LmexNT1 for 
thymidine was very similar to uridine. In addition, the Ki values for adenosine 
inhibition of uridine and thymidine were identical. The thymidine uptake data 
also confirmed that neither uracil nor adenine was a good substrate for 
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LmexNT1. Therefore, we can conclude that LmexNT1 is specifically a nucleoside 
transporter and substrate binding depends very much on the presence of the 
ribose ring. However, the data from inhibition experiments showed that 2’-
deoxyuridine inhibited [3H]-uridine uptake with almost the same affinity as 
uridine itself, showing that the absence of the hydroxyl group from ribose ring 
on carbon position-2’ does not play a major role in LmexNT1 substrate binding. 
In conclusion, under the standard in vitro conditions used, L mexicana 
promastigotes express at least two pyrimidine transporters, a nucleoside 
transporter with broad specificity for purine and pyrimidine nucleosides 
(LmexNT1), and a uracil/uridine transporter (LmexU1). 
Table 4.1 Substrate profile of LmexU1 and LmexNT1, the values were expressed in μM. Entries 
in bold typescript indicate Km rather than Ki values. NE, no effect on uptake at concentration 
indicated; blanks were values not determined. The structure of pyrimidines and their analogues 
are shown in Appendix II; and the actual single values are shown in Appendix III-IV. 
Substrates LmexU1 LmexNT1 
Nucleobases   
Uracil 29.7 ± 4.4 25.7 ± 6.6 
Cytosine NE, >5000  
Thymine 563 ± 193  
Hypoxanthine NE, >500  
Adenine 288 ± 67 NE, >1000 
Nucleosides   
Uridine 2 ± 0.5 4.1 ± 0.2 
2’-deoxyuridine 9.3 ± 2.6 7.2 ± 0.78 
Thymidine NE, >10000 4.2 ± 0.4 
Cytidine  78 ± 15.1 
Adenosine NE, >3500 0.83 ± 0.16 
Inosine  1010 ± 193 
Pyrimidine analogs   
5-fluorouracil 56.3 ± 6.4 >5000 
5-fluoro-2’deoxyuridine  7 ± 0.11 
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4.3. Characterization of pyrimidine transporters in L. 
major promastigotes 
4.3.1 Uracil uptake in L. major promastigotes 
The first pyrimidine nucleobase transporter in Leishmania cells was previously 
identified in promastigotes of L. major and designated LmajU1 with Km value of 
0.32 ± 0.07 μM and Vmax value of 0.68 ± 0.15 pmol∙10
7 cells-1∙s-1 (Papageorgiou et 
al., 2005). The transporter was highly sensitive to uracil and 5-fluorouracil, but 
moderately inhibited by uridine; however, the authors of that study did not 
investigate the uptake of [3H]-uridine by those cells. Yet, uridine transport in 
promastigotes of Leishmania donovani has been well described and proceeds 
efficiently via the LdNT1 adenosine/ pyrimidine nucleoside transporter (Aronow 
et al., 1987;Vasudevan et al., 1998), although for this species pyrimidine 
nucleobase transport was not investigated. Amastigotes of the same species also 
express a high affinity adenosine/pyrimidine nucleoside transporter, designated 
T1 (Ghosh & Mukherjee, 2000). Therefore, we assess here uridine transport by L. 
major promastigotes in order to understand whether uridine is taken up by the 
same or different transporter(s) and obtain the complete model of pyrimidine 
transport for Leishmania major. The combined data of pyrimidine uptake in 
multiple Leishmania spp will establish how well conserved 
nucleoside/nucleobase transport is across the Leishmania species. This is 
essential information if a pyrimidine-based anti-leishmanial therapy is to be 
developed, which must be similarly active against most, if not all, subspecies. 
4.3.2 Uridine uptake in L. major promastigotes 
The uptake of 0.25 μM [3H]-uridine by L. major promastigotes was linear over 15 
minutes with a rate of uptake of 0.14 ± 0.01 pmol∙107 cells-1∙s-1 (r2= 0.96); 
transport was completely inhibited by 1 mM unlabelled uridine (Figure 4.13A). 
Subsequent experiments were performed using 0.25 μM [3H]-uridine and 
incubations for 7 min - very much within the linear phase of uptake. Inhibition of 
0.25 μM [3H]-uridine uptake by various concentrations of unlabelled uridine was 
monophasic with average Hill-coefficients near -1 (Figure 4.13B). The inhibition 
data was converted to a Michaelis-Menten saturation plot and showed an average 
of Km value of 3.1 ± 0.6 μM and Vmax value of 0.036 ± 0.004 pmol∙10
7 cells-1∙s-1. 
Figure 4.13B also shows that 1 mM of unlabelled uracil inhibited 77.3 ± 2.7% of 
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0.25 μM [3H]-uridine uptake with a Ki value similar to the Km value for uridine. 
While this confirms that the majority of uridine uptake is through a uracil-
sensitive nucleoside transporter, designated LmajNT1, the uracil-insensitive part 
(22.7%) of uridine influx is possibly mediated by another transporter, designated 
LmajNT2. 
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Figure 4.13. [
3
H]-uridine uptake by L. major promastigotes A. Timecourse of 0.25 μM 
[
3
H]-uridine transport (●) in the presence of 1 mM unlabelled uridine (■) over 15 
minutes. B. Dose-dependent inhibition of 0.25 µM [
3
H]-uridine uptake by unlabelled 
uridine (●) and uracil (□) for 7 minute incubations. Inset: conversion the uridine inhibition 
data in frame B to Michaelis-Menten saturation plot to calculate the Km and Vmax values. 
In order to determine the specificity of LmajNT1, the study assessed the effect 
of several pyrimidines and purines against labelled 0.25 μM [3H]-uridine uptake 
(Table 4.2). The inhibition profile for LmajNT1 showed that nucleosides 
(thymidine, 2’deoxyuridine and adenosine) completely inhibited the uptake of 
labelled uridine in a monophasic manner (Figure 4.14A), with the level of 
inhibition by 1 mM of these nucleosides similar to the effect of 1 mM unlabelled 
uridine (closed-green square symbol in figure 4.14). Interestingly, adenine and 
inosine (up to 1 mM) only partially inhibited (60 ± 4.1% and 50 ± 7%, respectively) 
[3H]-uridine uptake compared to 1 mM of unlabelled uridine (Figure 4.14B). 
Consistently, a mixture of 1 mM adenine and 1 mM inosine, represented by the 
upside-down closed black triangle symbol in figure 4.14B, inhibited uridine 
uptakes exactly as 1 mM unlabelled adenine activity, showing that adenine and 
inosine both inhibit the same part of the uridine flux, and dividing this into an 
adenine/inosine-sensitive uptake activity and an adenine/inosine-insensitive 
activity - both of which are equally sensitive to adenosine, thymidine and 
2’deoxyuridine. 
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Figure 4.14. Dose-dependent inhibition of 0.25 μM [
3
H]-uridine in L. major 
promastigotes by a concentration of 1 mM unlabelled uridine (■) in presence of 
various concentrations of unlabelled substrates. A. thymidine (●), 2’deoxyuridine (▲), 
adenosine (○), B. adenine (□), inosine (*). The black closed upside-down triangle is 
adenine and inosine together, each at 1mM. 
Thus, the part of [3H]-uridine uptake that is not inhibited by uracil, adenine and 
inosine shows that L. major expressed at least two pyrimidine nucleoside 
transporters: a high affinity uridine transporter (LmajNT1), which has high 
affinity for uracil, adenine and inosine; and a lower affinity uridine 
transporter(LmajNT2), which is insensitive to uracil, adenine and inosine. Both 
transporters are sensitive to 2’-deoxyuridine, thymidine and adenosine. In order 
to differentiate the two uridine activities, the uridine inhibition data from figure 
4.13B was converted to a Lineweaver-Burk plot (Lineweaver & Burk, 1934); this 
conversion identified high and low uridine affinity transport activities. The data 
showed that the Km value of the high affinity uridine transporter was 10-fold 
lower than the value for the low affinity transporter (3.1 ± 0.6 μM against 33.5 ± 
7 μM, respectively). The average Vmax was higher in the latter than in the former 
(0.036 ± 0.004 versus 0.152 ± 0.038 pmol∙107 cells-1∙s-1; Figure 4.15), and the 
transport efficiency index (Vmax/ Km for the former was 2.5-fold higher than for 
the latter. 
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Figure 4.15. Conversion of unlabelled uridine inhibition data against [
3
H]-uridine uptake 
from figure 4.11B to Lineweaver-Burk plot. The data best fitted a two-transporter model 
(LmajNT1 and LmajNT2), with linear regression through 4 and through 5 points, 
respectively. The experiment was performed in triplicate and representative of three 
identical repeats. The red dashed line represents linear regression of all data points for 
comparison. 
In conclusion, L. major expresses at least two nucleoside transporters with 
different affinities to uridine; a high affinity uridine transporter LmajNT1, which 
was sensitive to inhibition by uridine, uracil, inosine and adenine; and a low 
affinity uridine transporter, designated LmajNT2, which has lower affinity to 
uridine and is insensitive to uracil, inosine and adenine. Both transporters are 
inhibited by 2’-deoxyuridine, thymidine and adenosine. Table 4.2 gives the Ki 
values for these inhibitors in the LmajNT1 column as the large majority of [3H]-
uridine uptake was through this transporter, but LmajNT2 must have similar 
values. These could be separately determined in the presence of 1 mM inosine, 
for example. 
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Table 4.2 Substrate profile of LmajU1, LmajNT1 and LmajNT2 the value was expressed in μM. 
Entries in bold typescript indicate Km rather than Ki values. NE, no effect on uptake at 
concentration indicated in µM; where left blank, the values were not determined. Data for LmajU1 
were taken from (Papageorgiou et al., 2005) and included for comparison. The structure of 
pyrimidines and their analogues are shown in Appendix II; and the actual single values are shown 
in Appendix III-IV. 
Substrates LmajU1 LmajNT1 LmajNT2 
Nucleobases    
Uracil 0.32 ± 0.07 2.5 ± 0.6  
Adenine NE, 200 5.1 ± 2.1  
Nucleosides    
Uridine 10.9 ±3.2 3.1 ± 0.6 33.5 ± 7 
2’-deoxyuridine  12.4 ± 4.5  
Thymidine NE, 200 110 ± 20  
Adenosine  1.9 ± 0.5  
Inosine  0.14 ± 0.004  
Pyrimidine analogs    
5-fluorouracil 0.66 ± 0.14   
4.4 Anti-leishmanial activity of pyrimidine analogues 
4.4.1 The activity of pyrimidine analogues against L. 
mexicana promastigotes 
The EC50 values of several pyrimidine analogues on Leishmania cells were 
determined using the Alamar Blue fluorescence assay. Pentamidine and 
diminazene were used as positive controls throughout the assessment. The 
nucleobase analogues 5-chlorouracil, 5-bromouracil, 5-iodouracil, 5-
fluorocytosine, 5-fluoroorotic acid, 6-azauracil and 4-thiouracil, and the 
nucleoside analogues 5-fluorouridine, 5-chlorouridine, 5-bromouridine, 5-
iodouridine, 5-fluorocytidine, 2-thiuridine and 4-thiouridine, as well as the 
deoxynucleoside analogues 5-chloro-2’-deoxyuridine, 5-bromo-2’-deoxyuridine, 
5-iodo-2’-deoxyuridine, 5’-deoxy-5-fluorouridine, 2’-3’-dideoxyuridine, 3’-
deoxyuridine and 3’-deoxythymidine, all had no effect on L. mexicana 
promastigotes up to at least 1 mM of compound. The only tested pyrimidine 
analogues to show activity against L. mexicana promastigotes were 5-
fluorouracil, 5-fluoro-2’deoxyuridine and 5-fluoro-2’deoxycytidine; these 
analogues displayed EC50 value at micromolar level (Table 4.3). In addition, 5’-
deoxyuridine showed an average EC50 value 461 ± 80 μM. Interestingly, despite 
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the fact that L. mexicana pyrimidine transporters were much more sensitive to 
nucleosides than nucleobases, ribonucleoside analogues did not show anti-
leishmanial activity against these cells even at millimolar concentrations. 
Pentamidine and diminazene as positive controls against promastigotes of L. 
mexicana cells demonstrated EC50 values of 1.0 ± 0.1 μM and 7.4 ± 0.3 μM, 
respectively. 
Table 4.3. The EC50 values per μM of effective 5-fluoro-pyrimidines on L. mexicana and L. 
major promastigotes using Alamar Blue fluorescent assays. The structure of pyrimidines and 
their analogues are shown in Appendix II; and the actual single values are shown in 
Appendix V. 
 L. mexicana L. major 
5-Fluorouracil 9.3 ± 0.6 8.5 ± 0.6 
5-Fluorouridine >5000 18 ± 1.6 
5-Fluoro-2’deoxyuridine 1.4 ± 0.06 1.7 ± 0.1 
5-Fluoro-2’deoxycytidine 17.3 ± 1.8 38 ± 1.7 
5’-Deoxyuridine 461 ± 80 525 ± 46 
Pentamidine 1.0 ± 0.1 3.3 ± 0.2 
Diminazene 7.4 ± 0.3 9.8 ± 0.3 
4.4.2 The activity of pyrimidine analogues against L. 
major promastigotes 
The activity of the above listed pyrimidine analogues against promastigotes of L. 
major was also determined. The sensitivity of L. major to these compounds was 
very similar to L. mexicana. The effect of pyrimidine analogues on L. major 
showed that only four compounds displayed an average of EC50 values at 
micromolar level, whereas 21 of 25 compounds were nontoxic up to 1 mM of the 
reagent (Table 4.3). The main difference was 5-fluorouridine, which displayed 
no activity against L. mexicana at concentrations up to 5 mM (Figure 4.16A), but 
killed promastigotes of L. major at concentrations below 20 μM (Figure 4.16B). 
In contrast, the average of EC50 values of 5’-deoxyuridine was very similar (525 ± 
46 μM for L. major). The effects of pentamidine (3.3 ± 0.2 μM) and diminazene 
(9.8 ± 0.3 μM) on promastigotes of L. major were also identical to L. mexicana 
cells. However, the sensitivity of L. major promastigotes to 5-fluoro-
2’deoxycytidine was >2-fold lower than for L. mexicana. 
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Figure 4.16. The sensitivity of A. L. mexicana promastigotes and B. L. major 
promastigotes to 5-FU (●), 5F-2’dUrd (▲) and 5F-Urd (■), using Alamar Blue assays. 
4.4.3 The effect of fluorinated pyrimidines on growth of 
Leishmania spp 
The effective fluorinated pyrimidines identified above were tested for effect on 
the growth of promastigotes during in vitro culture of L. mexicana and L. major 
by exposing the cells to 0.5 mM of each drug separately. The density of 
Leishmania promastigotes cultures at mid-log phase were adjusted to 106 
cells/ml in 10 ml culture flasks, and 500 μM of one of the effective drugs (5-FU, 
5F-2’dUrd and 5F-Urd) was added. The cell count was monitored until the death 
of the parasite populations. For L. mexicana, the nucleobase and 
deoxynucleoside analogues killed the cells after a few days of exposure to the 
indicated drugs. However, these cells were insensitive to 5F-Urd (Figure 4.17A), 
although the drug arrested the growth for few days, after which the cells started 
multiplying. This observation was entirely consistent with the Alamar Blue data. 
L. major promastigotes were sensitive to all fluorinated pyrimidines tested 
(Figure 4.17B), and the drugs arrested the growth of the cells before killing them 
off. None of the pyrimidine analogues killed Leishmania cells very quickly, which 
is the same observation made in trypanosomes. 
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Figure 4.17. The effect of fluorinated pyrimidines on the growth of A. L. mexicana sM379-
WT B. L. major Friedlin-WT. Cultures containing 10
6
 promastigotes/ml were incubated in 
HOMEM medium with 0.5 mM of 5-FU (●), 5F-Urd (■) or 5F-2’dUrd (▲). The inset for 
each figure shows the growth of Leishmania in drug free standard HOMEM medium. 
4.5. Induction of resistance to selected pyrimidine 
analogues and cross-resistance profiles 
To assess the extent to which anti-leishmanial pyrimidine analogues depend on 
salvage enzymes and/or transporters, resistance to 5-fluorouracil and 5-fluoro-
2’deoxyuridine was induced by in vitro exposure of wild type L. mexicana sM379 
and L. major sFriedlin promastigotes to stepwise increasing concentrations of 
the drugs (Figure 4.18). It was noted that Leishmania cells adapted to 5F-2’dUrd 
more quickly than to 5-FU; while Leishmania cells became insensitive to high 
concentrations of 5F-2’dUrd in a few months, the resistance induction to 5-FU 
required around a year. Clonal lines were generated from each strain that 
displayed resistance to high concentrations of 5-FU or 5F2’dUrd. 5-FU-adapted 
clones from L. mexicana and L. major were abbreviated Lmex-5FURes and Lmaj-
5FURes, whereas cells adapted to 5F-2’dUrd were called Lmex-5F2’dURes and 
Lmaj-5F2’dURes, respectively. Regarding the Lmex-5FURes strain, an 
intermediate strain, which was able to survive and proliferate in 500 μM of 5-FU, 
was also cloned out in order to be able to investigate intervening changes. 
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Figure 4.18. Adaptation of promastigotes of Leishmania spp to high concentrations of 
fluorinated pyrimidine analogues during in vitro culturing. Concentrations indicated are 
the concentrations of analog added to the medium, in which the cells managed to survive 
and multiply., i.e. 5-fluorouracil to generate the adapted cell line 5FURes, and 5F-2’dUrd 
to generate the cell line 5F-dURes; After adaptation of the cultures the promastigotes 
were cloned out by limiting dilution so that the eventual cell lines that were characterized 
were all grown from a single cell. 
 
The anti-leishmanial activity and the cross-resistance patterns of cytotoxic 
pyrimidine analogues were investigated for each adapted cell line; the 
assessment was performed in parallel with the parental wild-type strains. Using 
Alamar Blue assays average EC50 values were generated for several pyrimidine 
analogues against resistant strains (Table 4.4). These determinations allowed us 
to identify possible cross-resistance, which in turn is indicative of common 
mechanisms of action. In general, resistant clones exhibited a high level of 
resistance to each individual drug as well as some cross-resistance to other 
fluorinated pyrimidines, but resistant clones were not cross-resistant to 
pentamidine and diminazene. 
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Lmex-5FURes cells displayed high levels of resistance to 5-FU, but retained the 
same sensitivity to 5-fluoro-2’deoxy-pyrimidines. On the other hand, Lmex-
5F2’dURes were completely adapted to tested concentration of 5-fluoro-
2’deoxy-pyrimidines, and were slightly more resistant to 5-FU than Lmex-5FURes 
(RF 190 versus 147). L. major promastigotes adapted to 5-fluoro-pyrimidines 
were different from L. mexicana in terms of resistance factors and cross-
resistance pattern and particularly with respect to the sensitivity to 5-
fluorouridine. However, both Lmex-5FURes and Lmaj-5FURes cells displayed 
almost the same sensitivity to fluorinated nucleosides as their respective 
parental cell lines. The main difference is that whereas L. mexicana cells 
adapted to high levels of fluorinated pyrimidine nucleosides such as 5F-2’dUrd 
were also highly resistant to 5-FU, Lmaj-5F2’dURes cells were not at all cross 
resistance to 5-FU. To understand in which way the resistance response of 
Leishmania species to pyrimidine analogous rely on salvage enzymes or 
transporters, the study attempted to compare the transport of [3H]-pyrimidines 
in the adapted lines with the wild type promastigotes of each species. 
 
 
Table 4.4. Phenotype of Leishmania promastigotes strains adapted to high level resistance to 
fluorinated pyrimidines. All EC50 values were obtained using the Alamar blue assay and are 
given in µM. WT = wild-type sensitive control strain. Resistance Factor = EC50 (resistant 
clone)/ EC50 (WT). The actual single values are shown in Appendix V 
Strains/drugs 5-FU 5F2’dUrd 5F2’dCyd 5FUrd 
L. mexicana-WT 9.3 ± 0.6 1.4 ± 0.06 17.3 ± 1.8 >5000 
Lmex5FURes 1374 ± 123 1.5 ± 0.2 24 ± 0.9 >5000 
RF 147 1 1.38 1 
Lmex5F2’dURes 1773 ± 301 >5000 >5000 >5000 
RF 190 >3500 >289 1 
L. major-WT 8.5 ± 0.6 1.7 ± 0.1 38 ± 1.7 18 ± 1.6 
Lmaj5FURes 150 ± 5.2 6.1 ± 0.5 17 ± 1.8 110 ± 17 
RF 17 3.6 0.4 6 
Lmaj5F2’dURes 12 ± 1.0 381 ± 83 3870 ± 621 1232 ± 341 
RF 1.3 224 101 68 
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4.6. Assessment of pyrimidine uptakes in Leishmania 
resistant strains 
4.6.1. Leishmania strains adapted to 5-fluorouracil 
The uptake of 0.5 μM of [3H]-uracil (Figure 4.19A) or [3H]-5-fluorouracil (Figure 
4.19B) over 10 minutes in the presence or absence of 1 mM unlabelled uracil or 
5-FU was assessed in Lmex-5FURes promastigotes in parallel with their WT 
counterparts. [3H]-uracil and 5-FU uptakes were linear for 10 minutes in L. 
mexicana M379-WT cells with a rate of 0.11 ± 0.01, and 0.30 ± 0.03 pmol∙107 
cells-1∙s-1, respectively. However, the uptake of both labeled uracil and 5-
fluorouracil in Lmex-5FURes was profoundly reduced and became identical to 
the [3H]-uptakes in the presence of 1 mM unlabeled nucleobases, meaning that 
there was no evidence for transporter-mediated uracil or 5-FU uptake in Lmex-
5FURes. This observation very much confirmed that uracil and 5-FU share the 
same transporter, LmexU1, and that this transport activity is lost through 
adaptation to 5-FU without an obvious in vitro growth phenotype. 
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Figure 4.19. [
3
H]-pyrimidine transport by promastigotes of L. mexicana strains. A. 
Transport of 0.5 μM [
3
H]-uracil by Lmex-5FURes (●) and sM379-WT (▲) in the 
presence or absent of 1 mM unlabelled uracil, (○) and (■), respectively. B. Transport of 
0.5 μM [
3
H]-5fluorouracil by Lmex-5FURes (●) and sM379-WT (▲) in the presence of 
1 mM unlabelled 5-FU (■) and (○), respectively. Incubations were for up to 10 minutes. 
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Transport of 0.5 μM [3H]-uridine was also investigated in Lmex-5FURes and 
compared with M379-WT (Figure 4.20). The results showed that the rate of 0.5 
μM [3H]-uridine uptake in Lmex-5FURes and M379-WT was almost identical (0.65 
± 0.05 pmol∙107 cells-1∙s-1 versus 0.68 ± 0.1 pmol∙107 cells-1∙s-1, respectively); in 
both strains [3H]-uridine transport was completely inhibited in the presence of 1 
mM unlabelled uridine. These findings show very clearly that uracil and uridine 
are taken up by separate transporters in L. mexicana promastigotes, and that 
meant that Lmex-5FURes had lost the nucleobase transporter (LmexU1), but not 
the nucleoside transporter (LmexNT1). This suggestion is also confirmed by the 
lack of resistance of Lmex-5FURes to fluorinated nucleosides. 
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Figure 4.20. [
3
H]-uridine transport in promastigotes of L. mexicana 
strains. Transport of 0.5 μM [
3
H]-uridine by Lmex-5FURes (●) and 
sM379-WT (▲) was measured over 10 minutes in the presence or 
absence of 1 mM unlabelled uridine, (■) and (○), respectively. 
For L. major promastigotes, the uptake of 0.5 μM [3H]-uracil and [3H]-
uridine in Lmaj-5FURes cells, in comparison with sFriedlin-WT, was also 
investigated. The uptake of labeled uracil was performed in the presence and 
absence of 1 mM unlabeled uracil over 10 minutes. Figure 4.21A showed that 
[3H]-uracil transport in sFriedlin-WT was linear with a rate of uptake 0.3 ± 0.009 
pmol∙107 cells-1∙s-1 (r2=0.99). However, [3H]-uracil uptake was 96% reduced in the 
resistant clone and was almost equal to [3H]-uracil uptake in the presence of 1 
mM unlabelled uracil, uracil uptake was still significantly non-zero (P<0.027; F-
test). We can assume that the strain Lmaj-5FURes cells have totally lost uracil 
activity (LmajU1) and have become unable to salvage this nucleobase, with the 
minor uracil flux being attributable to LmajNT1, which has a relatively low 
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affinity for uracil (Table 4.2). However, as [3H]-uridine transport was compared 
in Lmaj-5FURes and sFriedlin-WT, it was found that in two separate experiments 
transport of 0.5 μM [3H]-uridine in these strains was clearly different. While the 
uptake was linear in sFriedlin-WT cells with a rate of 0.08 ± 0.007 pmol∙107 cells-
1∙s-1, in Lmaj-5FURes the uptake was nonlinear and saturable over the indicated 
time with an apparent rate of 0.29 ± 0.07 pmol∙107 cells-1∙s-1 over the first five 
minutes, becoming subsequently saturable with a rate of just 0.058 ±0.003 
pmol∙107 cells-1∙s-1 for the rest of the 10 minute incubations (Figure 4.21B). 
These findings agree with the Alamar Blue data (Table 4.4, above) which showed 
that Lmaj-5FURes cells were still sensitive to cytotoxic pyrimidine nucleosides. 
As Lmaj-5FURes has lost the high affinity uracil transporter (LmajU1), the Lmaj-
5FURes strain relies on the nucleoside transporter(s) to provide the cells with 
pyrimidine sources; the apparent increase in the rate of uridine uptake during 
the initial incubations could be due to up-regulation of LmajNT1/LmajNT2; the 
non-linearity suggests that, under the assay conditions, the rate of uridine 
uptake in Lmaj-5FURes exceeded its metabolic usage, resulting in a high initial 
rate of transport, and a lower secondary rate representing uridine metabolism, 
which became rate limiting for overall uptake after a few minutes. 
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Figure 4.21. [
3
H]-pyrimidine uptake in L. major  strains. A. Transport of 0.5 μM [
3
H]-uracil 
by Lmaj-5FURes (●) and sFriedlin-WT (▲) in the presence of 1 mM unlabelled uracil (■) 
and (○), respectively. B. Uptake of 0.5 μM [
3
H]-uridine by Lmaj-5FURes (●) and sFriedlin-
WT (▲) over 15 minutes in the presence of 1 mM unlabelled uridine (■) and (○), 
respectively. The dashed line is showing the rate of uptake without linear regression 
calculation. 
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4.6.2 Leishmania strains adapted to 5-fluoro-2’-
deoxyuridine 
In section 4.2.2 it was shown that L. mexicana promastigotes take up 
uridine and adenosine through the nucleoside transporter LmexNT1, and that the 
uptake can be inhibited by 2’-deoxyuridine, which is the natural 
deoxynucleoside equivalent of 5F-2’dUrd. Specifically, the Km values for uridine 
(7.15 ± 0.9 μM) and the Ki values for 2’deoxyuridine (7.2 ± 0.78 μM) were shown 
to be identical. In this section the uptake of 0.5 μM [3H]-uridine and of 0.1 μM 
[3H]-adenosine was investigated in Lmex-F2’dURes, and compared with the 
parental strain M379-WT. The uptake of [3H]-uridine (Figure 4.22A) and [3H]-
adenosine (Figure 4.22B) was linear over the 600 s (uridine) and the 25 s 
(adenosine) duration of the experiment in L. mexicana M379-WT with a rate of 
0.68 ± 0.1 pmol∙107 cells-1∙s-1 and 0.037 ± 0.002 pmol∙107 cells-1∙s-1, respectively. 
In contrast, the transport of [3H]-uridine by Lmex-F2’dURes was completely 
reduced and became identical to the uptake in the presence of 1 mM unlabeled 
uridine, so that it is believed that the Lmex-5F2’dURes cells have lost the 
uridine transport activity (LmexNT1). Furthermore, the uptake of [3H]-adenosine 
by Lmex-5F2’dURes was reduced by 81% compared with M379-WT cells; thus very 
low level (19%) of adenosine uptake could be maintained by an unknown low 
affinity adenosine transporter. As Lmex-5F2’dURes cells showed cross-resistance 
with 5-FU we decided to assess uracil uptake in those cells as well. 
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Figure 4.22. [
3
H]-pyrimidine uptake by promastigotes of L. mexicana strains. A. 
Transport of 0.5 μM [
3
H]-uridine by Lmex-5F2’dURes (●) and sM379-WT (▲) in the 
presence of 1 mM unlabelled uridine (○) and (■), respectively. B. Transport of 0.1 μM 
[
3
H]-adenosine by Lmex-5F2’dURes (●) and sM379-WT (▲) in the presence of 1 mM 
unlabelled adenosine (■) and (○), respectively. 
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In order to test the rate of 0.5 μM [3H]-uracil transport in Lmex-F2’dURes 
against wild type promastigotes of L. mexicana, uracil uptake was determined at 
various intervals over 10 minutes. The results show that the rate of 0.5 μM [3H]-
uracil uptake in Lmex-5F2’dURes was completely identical to the rate in M379-
WT, with an average of 0.096 ± 0.01 pmol∙107 cells-1∙s-1 and 0.097 ± 0.01 
pmol∙107 cells-1∙s-1, respectively (Figure 4.23); uptake of 0.5 μM labeled uracil in 
both strains was equally sensitive to 1 mM of unlabeled uracil. It is clear that 
Lmex-5F2’dURes are still maintaining the uracil transport activity Lmex-U1, but 
lost uridine transporters. Notwithstanding the observation that uridine and uracil 
transporters had overlapping inhibition profiles (section 4.2), these data clarify 
that uracil and uridine are taken up by different transport proteins (LmexU1 and 
LmexNT1, respectively). 
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Figure 4.23 [
3
H]-pyrimidine uptake by promastigotes of L. mexicana strains. 
Uptake of 0.5 μM [
3
H]-uracil by Lmex-F2’dURes (●) and M379-WT (▲) over 
10 minutes in the presence of 1 mM unlabelled uracil, (■) and (●), 
respectively; n=3. 
Uridine uptake in Lmaj-5F2’dURes in parallel with sFriedlin-WT was 
investigated in two separate experiments. The study found that the uptake of 
0.5 μM [3H]-uridine was linear over 10 minutes in sFriedlin-WT cells with a rate 
of uptake of 0.11 ± 0.01 pmol∙107 cells-1∙s-1, which was totally inhibited by 1 mM 
unlabeled uridine (Figure 4.24A). However, the transport of [3H]-uridine was 
reduced by 83% in Lmaj-F2’dURes cells. It can be argued that Lmaj-5F2’dURes 
strain had lost the most part of uridine activity. As described previously (section 
4.3.2), L. major promastigotes expressed two uridine activities (high and low 
affinity uridine transporters); therefore it is suggested that Lmaj-5F2’dURes cells 
have lost one of the uridine transporters (LmajNT1 or LmajNT2), but retain a 
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reduced capacity for uridine uptake through the other uridine transporter, and 
possibly through LmajU1. These findings prompted us to assess uracil uptake in 
Lmaj-5F2’dURes. 
The transport of 0.5 μM [3H]-uracil in Lmaj-5F2’dURes were performed in 
parallel with sFriedlin-WT over 10 minutes. The uptake of [3H]-uracil by 
sFriedlin-WT cells was linear for 10 minutes with a rate of 0.54 ± 0.02 pmol∙107 
cells-1∙s-1, and the transport was totally inhibited by 1 mM unlabelled uracil. 
However, the uptake of [3H]-uracil was reduced by 82% in Lmaj-5F2’dURes cells 
compared with sFriedlin-WT, with a rate of uptake 0.10 ± 0.02 pmol∙107 cells-1∙s-
1 (Figure 4.24B). The most interesting observation was that uracil and uridine 
transport were equally reduced in Lmaj-5F2’dURes cells (17% and 18%, 
respectively), compared with sFriedlin-WT. This suggests that the low affinity 
uridine transporter (LmajNT2) is potentially the only active pyrimidine 
transporter in Lmaj-5F2’dURes. 
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Figure 4.24 [
3
H]-pyrimidine uptake in L. major  strains. A. Transport of 0.5 μM [
3
H]-
uridine by Lmaj-5F2’dURes (●) and sFriedlin-WT (▲) over 10 minutes in the 
presence of 1 mM unlabelled uracil (■) and (○), respectively. B. Transport of  0.5 μM 
[
3
H]-uracil by Lmaj-5F2’dURes (●) and sFriedlin-WT (▲) over 10 minutes in the 
presence of 1 mM unlabelled uridine (■) and (○), respectively. 
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4.7. Discussion 
As membrane transporters are involved in drug uptake, the study of this 
phenomenon thus requires the identification, detailed characterization and 
cloning of parasite-specific high-affinity transporters for substrates with a low 
concentration in the host tissues. The kinetoplastid transporters for purines and 
pyrimidines appear to meet this description. Because kinetoplastid parasites are 
unable to synthesise the purine ring de novo, purine metabolism and transport 
were studied extensively (Boitz et al., 2012a; Boitz et al., 2012b; Carter et al., 
2010; Carter et al., 2008; De Koning et al., 2005; Looker et al., 1983; Ortiz et 
al., 2007). On the other hand, the majority of protozoan parasites synthesise 
pyrimidines in pathways similar to their mammalian host (Berens et al., 1995), 
and can also obtain pyrimidines by uptake from their environment (Aronow et 
al., 1987; De Koning et al., 2005; De Koning et al., 2003; Gudin et al., 2006; 
Papageorgiou et al., 2005). Although this phenomenon appears to render 
pyrimidine metabolism less amenable to therapeutic intervention than purine 
salvage, the selective inhibition of pyrimidine biosynthetic enzymes and/or the 
blocking of pyrimidine transporters may offer new therapeutic avenues. 
The bond lengths of fluorine and of hydrogen with carbon are very similar; 
the fluorine (1.35Å) - carbon bond has a length of 1.26-1.41Å, and the hydrogen 
(1.1Å) – carbon bond requires 1.08-1.1Å (Heidelberger et al., 1957), so that 
substituting hydrogen with fluorine may lead to a very small change in the 
substrate size, and intruding on the steric limitations of the transporter’s 
binding pocket. About half a century ago, Heidelberger designed the widely used 
anticancer drugs 5-FU and 5F-2’dUrd (Heidelberger et al., 1958), these drugs 
were found to be metabolized in a similar way to their natural counterparts. 
This study has proved that in Leishmania promastigotes 5-FU shares a 
transporter with uracil, and the fluorinated ribo- and 2’-deoxy-nucleosides 
prefer nucleoside transporter(s). Fluorinated pyrimidines need transport and 
metabolic activation to their active forms before they can exert their 
cytotoxicity. Pyrimidine nucleosides and nucleobases do not show appreciable 
diffusion rates; therefore, they need carrier proteins to move into the cells. In 
order to identify which cytotoxic pyrimidine analogues would efficiently target 
the interior of Leishmania cells, we attempted to investigate the efficient 
transport of natural pyrimidines by promastigotes of Leishmania. We also 
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induced resistance clones to anti-leishmanial pyrimidine analogues to understand 
how the resistance to these analogues depends on salvage enzymes or 
transporters. 
Several previous studies have been performed on purine transport in 
Leishmania parasites, the first purine nucleobase transporters identified in 
Leishmania species were LmajNBT1 in promastigotes of L. major (Al-Salabi et 
al., 2003) and LmexNBT1 in amastigotes of L. mexicana (Al-Salabi & De Koning, 
2005). However, the only pyrimidine specific transporter in Leishmania 
promastigotes was LmajU1 (Papageorgiou et al., 2005). To date, no study has 
been performed to evaluate the uptake of pyrimidines by L. mexicana 
promastigotes. As a first effort to evaluate potential pyrimidine chemotherapy 
against Leishmania cells, it is necessary to be aware of which natural 
pyrimidines and cytotoxic analogues would efficiently cross the cell membrane 
and reach the parasite’s interior. Therefore, we studied the uptake of natural 
pyrimidines, particularly uracil and uridine, by promastigotes of Leishmania. We 
found evidence that L. mexicana and L. major promastigotes are taking up 
natural nucleosides and nucleobases with various efficiencies, and we 
demonstrated that Leishmania cells transport pyrimidine nucleobases and 
nucleosides via distinct transporters, but these pyrimidine transporters have 
some overlapping inhibitor profiles, which may indicate a common transporter 
structure. For nucleobase uptake, LmajU1 has higher affinity for uracil and 5-FU 
than LmexU1; both transporters also displayed different Ki values for uridine 
(Figure 4.25A&B). 
Nucleoside uptake was also diverse among Leishmania spp; LmexNT1 has 
the same affinity for uridine and thymidine, and was very sensitive to adenosine; 
L. major expressed both high and a low affinity uridine transporters. L. major’s 
high and low affinity transporters were sensitive to nucleosides but they differ in 
their affinity for uridine; additionally, whereas the high affinity uridine 
transporter was sensitive to nucleobases (uracil, adenine) and strongly inhibited 
by inosine, the low affinity uridine transporter was insensitive to these 
compounds. 
In general, while the L. mexicana NT1 transporter has higher affinity for 
pyrimidine nucleosides and their fluorinated analogous than the corresponding L. 
major NT1 nucleoside transporter, the latter was much more sensitive to uracil 
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and 5-FU than the former (Figure 4.25A&B). As pyrimidine transporters have not 
yet been identified at the genetic level, it is not possible to attribute distinct 
characteristics of pyrimidine transporters to differences in sequence. It is 
unlikely that the nucleoside and nucleobase transporters are encoded by 
members of the same gene family, because the nucleoside transport activities 
are encoded by the Equilibrative Nucleoside Transporter (ENT) family, and all 
the kinetoplastid ENT family members have been cloned and characterised to 
different degrees; none were shown to be pyrimidine-specific transporters (De 
Koning, 2008). However, the different substrate and inhibitor profiles among the 
transporters could be a result of a shift in amino acid position, or (a) different 
amino acid(s) facing the active site of the substrates or translocation. The 
correlation of different substrate affinities to primary sequence will have to wait 
until the gene for each transporter is identified. 
Fluorinated pyrimidines have been introduced as pyrimidine salvage inhibitors 
against T. gondii (Youn et al., 1990) and L. amazonensis (Katakura et al., 2004). 
As the toxicity of fluorinated pyrimidines depends on the concentration and 
duration of exposure, these factors were standardised to compare the effect of 
active drugs against kinetoplastid cells. Fluorinated pyrimidines were not 
systematically proposed as clinical anti-leishmanials; however, this study is the 
first effort to evaluate the toxicity of pyrimidine anti-metabolites on Leishmania 
parasites. In terms of the sensitivity to pyrimidine analogues, it seems that 
promastigotes of Leishmania are similar to bloodstream form trypanosomes. For 
example, 5-FU, 5F-2’dUrd and 5F-2’dCyd were much more active against these 
strains than any of the other halogenated pyrimidines tested. In contrast, 5-
fluoroorotic acid, which its EC50 at micromolar level on trypanosomes, showed 
no activity at all against Leishmania species. These findings agree with French et 
al., 2011 who found that pyrimidine auxotrophic of L. donovani are unable to 
grow in 100 μM orotate as sole pyrimidine source. Notwithstanding the 
observation that most fluorinated pyrimidines have identical cytotoxicity against 
multiple Leishmania species, the effect of 5-fluorouridine was an exception. The 
drug was active against L. major promastigotes, and killed them at 
concentrations below 20 μM; however, L. mexicana cells were very insensitive to 
5F-Urd. It is reported above (chapter 3) that bloodstream form trypanosomes are 
also naturally resistant to 5F-Urd. 
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Leishmania cells become resistant to high concentrations of fluorinated 
deoxynucleosides faster than to fluorinated nucleobases. In addition, all cells 
that are resistant to 5F-2’dUrd became also highly resistant to 5-fluoro-
2’deoxycytidine; this observation is very similar to the case of trypanosomes and 
shows that these deoxynucleoside pyrimidine analogues have the same mode of 
action, with 5F-2’dCtd converted to 5F-2’dUrd by cytidine deaminase. Lmex-
5FURes were unable to take up uracil, but the rate of uridine uptake was 
identical to L. mexicana M379-WT cells. As L. mexicana promastigotes 
metabolize 5-FU and 5F-2’dUrd through almost the same pathway and end up 
with the same fluorinated pyrimidine metabolites (chapter 6) we could not 
attribute the mechanism of resistance in Lmex-5FURes to changes in pyrimidine 
metabolism. This clearly shows that Lmex-5FURes cells have lost their uracil 
transport activity completely, and that this is the cause of their resistance, 
while retaining wild-type sensitivity to fluorinated pyrimidine nucleosides, which 
are taken up by a different transporter. 
Although Lmex-5FURes cells were not cross-resistant to deoxynucleoside 
analogues, Lmex-5F2’dURes cells were very cross-resistant to 5-FU; but the 
uracil rate of uptake by Lmex-5F2’dURes was equal to promastigotes of L. 
mexicana M379-WT. Here we can assume that the high level of resistance (190-
fold) of Lmex-5F2’dURes to 5-FU is not due to the lack of uracil transport 
activity, but rather to changes in 5-FU metabolism, which might be mutations in 
thymidylate synthase and/or thymidine kinase. It must be noted that we 
assessed uracil not 5-FU uptake by Lmex-5F2’dURes, so changes in affinity of 
LmexU1 specifically to 5-FU could reduce uptake rates for 5-FU but not for 
uracil. However, we present no evidence for this possibility and since the 
adaptation was to 5F-2’dUrd rather than to 5-FU we believe it is much more 
likely that the resistance mechanism to 5-FU by Lmex-5F2’dURes cells is related 
to adaption in pyrimidine-metabolising enzymes rather than to changes in 
transport activity, particularly the part of the pyrimidine metabolomic pathway 
shared by 5-FU and 5F-2’dUrd, i.e. thymidine kinase and thymidylate synthase. 
The Alamar blue experiments showed that 5-FU and 5F-2’dUrd have almost the 
same activity against L. major promastigotes as against L. mexicana. However, 
the L. major strains adapted to these compounds resistant barely showed cross-
resistance between fluorinated nucleobases and nucleosides. Lmaj-5FURes cells 
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were 17-fold resistant to 5-FU compared with the wild-type control, but the rate 
of uracil uptake by Lmaj-5FURes cells was almost completely flat for 10 minutes, 
clearly showing that Lmaj-5FURes cells have lost uracil activity (LmajU1), just 
like LmexU1 was lost through adaptation to 5-FU. Yet, a small but significant 
uptake rate of uracil could still be detected in these cells, and was attributed to 
LmajNT1; this explains the relatively low level of 5-FU resistance in Lmaj-
5FURes, and the lack of strong cross-resistance with the fluoro-nucleosides. 
Lmaj-5F2’dURes cells are resistant to all fluorinated pyrimidine nucleosides, but 
are not at all resistant to 5-FU. Uptake of low concentrations of uridine and 
uracil was equally reduced, by just over 80%, compatible with loss of both the 
LmajU1 and one of the uridine transport activities (LmajNT1 or LmajNT2), yet 
the remaining capacity of 5-FU uptake was clearly sufficient for its anti-
leishmanial activity, indicating uptake through a lower-affinity, high capacity 
transporter that is therefore more active at the ~10 µM concentration of the 5-
FU EC50. We suggest that these cells may have lost LmajNT2, which is the uracil-
insensitive nucleoside transporter, but more experiments would clearly be 
required for a definitive answer to this puzzle. Nor can we currently do more 
than speculate as to the selective mechanism of resistance to the fluoro-
nucleosides by Lmaj-5F2’dURes, as a significant nucleoside transport capacity is 
retained and the mechanism of action is shared with 5-FU. The only explanation 
for the resistance pattern that presents itself to us is that LmajNT2 has very low 
tolerance for the 5-fluoro substitution, compared to LmajNT1. Experiments to 
verify this hypothesis are being scheduled. 
Notwithstanding that sensitivity and cross-resistance to fluorinated pyrimidines 
was similar among kinetoplastid cells, the mechanism of resistance to these 
analogues is totally different within trypanosomes and Leishmania cells. 
Bloodstream form trypanosomes adapted to high concentrations of pyrimidine 
analogues through changes in the level of some pyrimidine pathway enzymes, as 
well as a limited reduction in the uptake of 5-FU, which was observed only in 
Tbb-5FURes cells. In contrast, all resistant Leishmania promastigotes responded 
to increased concentrations of pyrimidine analogues by a significant or complete 
reduction in the transport capacity for natural pyrimidines. The apparent ease 
by which Leishmania promastigotes ‘loose’ a pyrimidine transport activity is 
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possibly related to the fact that they have several, whereas bloodstream 
trypanosomes express only TbU3 (Ali et al., 2013a; and this thesis). 
Although Leishmania promastigotes showed different mechanisms of 
resistance to fluorinated pyrimidine analogues, through loss of different 
transporters, mostly, there were many close similarities between the cellular 
effects of fluorinated pyrimidine analogues (5-FU, 5F-2’dUrd and 5F-Urd), 
indicating a common mode of action on L. mexicana and L. major. The specific 
difference was the effect of 5F-Urd, particularly in that L. mexicana was 
extremely resistant to the compound, whereas the other species was very 
sensitive. This cannot be attributed to differences in uridine transport between 
the species, which, if anything, seems to be higher affinity and more efficient in 
L. mexicana (Tables 4.1 and 4.2). Nor can it be argued that LmexNT1 does not 
transport substrates with the 5-fluoro substitution, as 5F-2’dUrd displayed the 
exact same affinity as 2’dUrd for this carrier (Table 4.1), and 5F-2’dUrd was 
highly active against L. mexicana promastigotes (Table 4.4). This phenomenon 
will be interpreted in Chapter six. 
  
J. Ali 2013 Chapter 4 138 
 
 
 
Figure 4.25. The model of pyrimidine uptake in A. L. mexicana and B. L. major. 
Entries in bold typescript indicate Km or Ki≤ 10 μM, rather Km or Ki≥ 10 μM. 
  
CHAPTER FIVE 
Metabolomic investigations of the mechanisms of 
action and resistance of fluorinated pyrimidines on 
trypanosomes 
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5.1. Introduction 
African trypanosomes are a complex of single-celled protozoan parasites, 
as these blood-borne parasites must continually divide to stay ahead of the host 
immune system, nucleotide metabolism is one obvious drug target, particularly 
as all protozoan parasites are unable to synthesize the purine ring de novo and 
thus necessarily rely on salvage from the host environment (De Koning et al., 
2005). However, no purine-based chemotherapy has emerged for kinetoplastid 
parasites, in large part because there is so much redundancy in purine 
transporters and salvage pathways that the inhibition of any one transporter (De 
Koning et al., 2005) or enzyme (Berg et al., 2010; Luscher et al., 2007) has little 
or no effect on parasite survival. 
 The organization of pyrimidine nucleotide metabolism is rather more 
diverse in protozoan parasites. Plasmodium species, for example, are unable to 
use preformed pyrimidines from the host environment, and rely on biosynthesis 
alone (De Koning et al., 2005; Van Dyke et al., 1970). Kinetoplastid parasites, 
including major pathogens such as the Leishmania and Trypanosoma species, are 
known to possess both salvage and biosynthesis routes for pyrimidines (De Koning 
et al., 2005; Hammond & Gutteridge, 1982; Hassan & Coombs, 1986; 
Papageorgiou et al., 2005) and it has recently become clear that some enzymes 
of the pyrimidine inter-conversion pathways may be good drug targets in T. 
brucei. One validated target in the pyrimidine pathways is deoxyuridine 5’-
triphosphate nucleotidohydrolase (dUTPase), as RNAi knockdown of this enzyme 
reduces growth rates and causes DNA breaks by allowing a toxic build-up of dUTP 
in T. b. brucei cells (Castillo-Acosta et al., 2008, 2013). Similarly, knockout of 
dihydrofolate reductase - thymidylate synthase (DHFR-TS) is lethal in T. b. 
brucei unless rescued by very high levels of thymidine in vitro (Sienkiewicz et 
al., 2008). (Arakaki et al., 2008) showed that under conditions of limited 
pyrimidine salvage RNAi knockdown of dihydroorotate dehydrogenase (DHODH), 
one of the enzymes in the pyrimidine biosynthesis pathway, caused severe 
growth defects for bloodstream trypanosomes. 
It thus appears, from a combination of genetic and pharmacological 
evidence, that pyrimidine metabolism in African trypanosomes is replete with 
drug targets and that a systematic evaluation of pyrimidine salvage mechanisms 
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is long overdue. The incomplete study about individual pyrimidine metabolites 
within trypanosome cells, and the poor information about changes that occur in 
response to pyrimidine analogues in T. b. brucei BSF delay efforts to develop a 
pyrimidine-based chemotherapy, either consisting of inhibitors of the key 
enzymes of pyrimidine metabolism, or of subversive substrates that would be 
activated to cytotoxic nucleotides and possibly be incorporated into nucleic 
acids. 
Here, a metabolomic approach was used to assess: (1) whether nucleotide 
levels or pathways were changed during the process of adaptation to fluoro-
pyrimidines; (2) what metabolites are formed from the fluoro-pyrimidine 
analogues in T. b. brucei s427-WT and resistant cells; (3) the mechanisms of 
action and resistance to these compounds (4) whether these analogues are 
incorporated into nucleic acids. These metabolomic techniques allowed us to 
identify the mode of action and metabolites of several trypanocidal pyrimidines. 
We thus present a first evaluation of pyrimidines as subversive chemotherapeutic 
agents against these parasites and a much improved model of pyrimidine salvage 
and metabolism in African trypanosomes (Figure 5.1). 
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Figure 5.1. Scheme of pyrimidine biosynthesis and metabolism in T. b. brucei. The double curved line represents the plasma membrane and arrows 
across its (potential) transport activities. Red boxes indicate metabolites, of which fluorinated analogues were detected by metabolomic techniques; 
black boxes indicate metabolites not detected in fluorinated form. Numbers above arrows indicate the following enzymes, listed here with EC numbers. 
1, carbamoyl phosphate synthase (6.3.5.5); 2, aspartate carbamoyl transferase (2.1.3.2); 3, dihydroorotase (3.5.2.3); 4, dihydroorotate dehydrogenase 
(1.3.3.1); 5, orotate phosphoribosyltransferase (2.4.2.10); 6, orotidine 5-phosphate decarboxylase (4.1.1.23); 7, uracil phosphoribosyltransferase 
(2.4.2.9); 8, nucleoside diphosphatase (3.6.1.6). 9, nucleoside diphosphate kinase (2.7.4.6). 10, cytidine triphosphate synthase (6.3.4.2); 11, 
ribonucleoside-diphosphate reductase (1.17.4.1); 12, uridine phosphorylase (2.4.2.3); 13, dUTPase (3.6.1.23); 14, thymidylate kinase (2.7.4.9); 15, 
thymidine kinase (2.7.1.21); 16, thymidylate synthase (2.1.1.45); 17, cytidine deaminase (3.5.4.5); 18, UDP-glucose pyrophosphorylase (2.7.7.9); 19, 
UDP-glucose epimerase (5.1.3.2); 20, adenylate kinase (2.7.4.10); 21, phosphatidate cytidylyltransferase (2.7.7.41); 22, ethanolamine-phosphate 
cytidylyltransferase (2.7.7.14); 23, choline-phosphate cytidylyltransferase (2.7.7.15); 24, orotate reductase (1.3.1.14, not present); 25, dihydroorotate 
dehydrogenase (1.3.5.2, not present); 26, pseudouridylate synthase (4.2.1.70); 27, UTP:N-acetyl-a-D-glucosamine-1-phosphate uridylyltransferase 
(2.7.7.23); 28, a-1,6-N-acetylglucosaminyltransferase. Abbreviations: Gln, glutamine; Carb-P carbamoyl phosphate; Asp, aspartate; Carb-Asp, N-
carbamoyl-L-aspartate; DHO, dihydroorotate; OMP, orotidine-5-phosphate; Urd, uridine; Tmd, thymidine; 2’dCtd, 2’-deoxycytidine; Glc, glucose; Gal, 
galactose; GlcNAc, N-acetylglucosamine. Lipid metabolism refers to formation of CDP-diacylglycerol (EC 2.7.7.41), CDP-ethanolamine (EC 2.7.7.14) 
and CDP-choline (EC 2.7.7.15). 
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5.2 Metabolomic analysis of fluorinated pyrimidine 
nucleobases in T. b. brucei BSF 
5.2.1 5-Fluorouracil  
T. b. brucei s427-wild type cells treated with 5-FU metabolized the drug to 5F-
UMP, 5F-UDP and 5F-UTP, whereas no 5-fluorouridine or 5-fluoro-2’deoxyuridine 
were detected. These observations strongly suggest that 5-FU is not a substrate 
for T. b. brucei uridine phosphorylase, but is a substrate for T. b. brucei uracil 
phosphoribosyltransferase (Tbb-UPRT), as well as for nucleoside diphosphatase 
and nucleoside diphosphate kinase. No fluorinated deoxyuridine nucleotides 
were detected, making it unlikely that fluorinated pyrimidine nucleotides are a 
substrate for ribonucleotide reductase. However, a different group was able to 
detect 5F-dUTP after incubation of T. b. brucei with 5-FU (T. Smith, St. 
Andrews, UK; personal communication) and this may explain our observation 
that intracellular levels of dUMP were significantly increased in WT and Tbb-
5FURes cells treated with 5-FU, compared to their respective untreated control 
cells. In WT the increase of dUMP was 10.5-fold (P<0.0001) and in Tbb-5FURes it 
was 7.2-fold (P<0.001; Figure 5.2). 
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Figure 5.2 Relative levels of dUMP in T. b. brucei s427-wild-type (solid bars) 
and Tbb5-FURes (hatched bars) cells exposed to 100 µM 5-FU for 8 hours. **, 
P<0.02; by unpaired two-tailed Student’s T-test comparing intensity of a 
particular metabolite in WT and resistant lines; n=3. 
J. Ali 2013 Chapter 5 144 
 
Interestingly, significant amounts of 5F-UDP-glucose were detected, 
showing that 5F-UTP is a substrate for UDP-glucose pyrophosphorylase, which 
couples UTP to glucose-1P. It must be noted that the detection method, based 
on mass-spectrometry, cannot distinguish between UDP-glucose and UDP-
galactose so it is unclear whether 5F-UDP glucose might be a substrate for UDP-
Glc 4’-epimerase. Similarly, highly significant amounts of 5F-UDP-N-acetyl-
glucosamine were detected which may include the equivalent galactose 
residues. This indicates that 5F-UTP is a substrate of UTP-N-acetyl-α-D-
glucosamine-1-phosphate uridylyltransferase which forms UDP-GlcNAc from UTP 
and N-acetyl-α-D-glucosamine 1-phosphate (Figure 5.1). UDP-GlcNAc in turn is a 
substrate of N-acetyl-glucosaminyltransferase, transferring the GlcNAc to 
protein and glycans. It is thus possible that 5-FU interferes with glycosylation 
through the production of 5F-UDP hexoses and or hexosamines. 
 In Tbb-5FURes cells treated with 5-FU the relative amounts of 5-FU, and 
fluorouridine nucleotides, in the cell were all somewhat lower than in WT cells 
exposed to the same concentration of 5-FU (Figure 5.3A), consistent with 
reduced efficiency of 5-FU uptake contributing to some extent to resistance, but 
dUMP levels were still significant elevated. The largest difference, however, was 
6.3-fold and 3.8-fold reduction of 5F-UDP-glucose and of 5F-UDP-GlcNAc in Tbb-
5FURes cells relative to WT cells treated with 5-FU (P<0.05 and P<0.01), 
respectively (Figure 5.3B), suggesting that sugar nucleotide metabolism 
contributes significantly to 5-FU mode of action in T. brucei, and that changes in 
this pathway could make major contributions to 5-FU resistance. 
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Figure 5.3. Relative levels of A. 5-FU and fluorinated nucleotides B. fluorinated 
nucleotide sugars, in T. b. brucei WT (solid bars) and Tbb5-FURes (hatched bars) 
cells exposed to 5-FU. The intensity of the mass spectrometer signal is plotted here 
for the metabolites observed. *, P<0.05; ***, P<0.01 by unpaired two-tailed Student’s 
T-test comparing intensity of a particular metabolite in WT and resistant lines. 
5.2.2 5-Fluoroorotic acid 
Very similar levels of 5-FOA (Figure 5.4) were detected after exposure of s427-
WT and Tbb-5FOARes cells to 100 μM of the drug for 8 hours, indicating that 
uptake was not the main mechanism of resistance, consistent with the non-
saturable orotic acid uptake noted in section 3.9 and in Figure 3.22. In both cell 
types, but particularly in WT, intracellular 5-FU was detected after incubation 
with 5-FOA (Figure 5.4), this was not a contamination of the chemical as it was 
not present in fresh medium samples containing drug, and indicates that UPRT 
can operate to hydrolyse 5F-UMP to 5-FU. 
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Figure 5.4. Relative levels of 5-FOA, and 5-FU in T. b. brucei WT (solid bars) and Tbb-5FOARes 
(hatched bars) cells exposed to 100 μM of 5-FOA. The intensity of the mass spectrometer signal 
was plotted here for the metabolites observed. ***, P<0.01 by unpaired two-tailed Student’s T-test 
comparing intensity of a particular metabolite in s427-WT and Tbb-5FOARes cells. 
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Interestingly, orotate levels were also 3.5-fold higher in untreated Tbb-5FOARes 
cells versus untreated WT cells (P<0.0001), indicating an adaptation by either 
significantly increasing orotate biosynthesis, or a reduction in OPRT activity, or 
both. The same adaptation of increased baseline orotate concentration was also 
observed in the 5-FU resistant cells, making it more likely that the orotate 
increase is the result from increased biosynthesis, as this would ‘dilute’ the 5F-
UMP derived from 5-FU with newly synthesized UMP. 5-FOA was clearly a 
substrate as well as an inhibitor of OPRT and was converted to fluorinated 
uridine nucleotides (Figure 5.5A) and 5F-UDP-glucose and 5F-UDP-GlcNAc (Figure 
5.5B), reaching levels in WT cells well in excess of those after treatment with 5-
FU, consistent with the stronger trypanocidal activity of 5-FOA compared to 5-
FU. In Tbb-5FOARes cells, the level of all fluorinated nucleotides was very much 
reduced with a 50-fold decrease in 5F-UMP, while 5F-UDP and 5F-UTP were 
below detection limits, resulting in >200-fold reduction in 5F-UDP-glucose. 
Another surprise was the detection of fluoro-N-carbamoyl-L-aspartate in both 
cell types (Fig 5.5B), indicating a partial reversal of the pyrimidine biosynthesis 
pathway. This may be caused by a build-up of 5-FOA, which seems to inhibit 
orotate phosphoribosyltransferase (OPRT), leading to an increase in free orotate 
levels in both s427-WT (3.6-fold; P<0.01) and Tbb-5FOARes cells (1.6-fold; 
P<0.05). 
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Figure 5.5. Relative levels of A. 5-fluoro-nucleotides B. F-carb-Asp, 5F-UDP-glu and 5F-
UDP-GlcNAc in T. b. brucei WT (solid bars) and Tbb-5FOARes (hatched bars) cells 
exposed to 100 μM of 5-FOA. The intensity of the mass spectrometer signal was plotted 
here for the metabolites observed. *, P<0.05; **, P<0.02; ***, P<0.01 by unpaired two-
tailed Student’s T-test comparing intensity of a particular metabolite in s427-WT and Tbb-
5FOARes cells. 
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As with 5-FU-treated cells there was a small but significant (2.5-fold; P<0.01) 
increase in dUMP in 5-FOA-treated WT trypanosomes compared to untreated 
cells; this effect was not observed in Tbb-5FOARes cells. No fluorinated cytidine 
or deoxyuridine nucleotides were observed in 5-FOA-treated cells, nor was there 
any effect of this compound on the levels of thymidine nucleotides. It thus can 
be concluded that the main adaptation in Tbb-5FOARes cells is by preventing its 
incorporation into the nucleotide pool, presumably through a change in OPRT, as 
orotidine-5-phosphate was not detected whereas orotate levels were 
significantly increased. 
5.3 Metabolomic analysis of fluorinated pyrimidine 
nucleosides in T. b. brucei 
5.3.1 5-Fluro-2’deoxyuridine 
Intracellular levels of 5F-2’dUrd were not different between s427-WT and 
Tbb-5F2’dURes cells (Figure 5.6), confirming that the resistance mechanism is 
based on metabolism rather than reduced uptake of the drug. 
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Figure 5.6. Relative levels of 5F-2’dUrd in T. b. brucei s427-WT 
(solid bars) and Tbb-5F-2’dURes (hatched bars) cells exposed to 
100 μM of 5F-2’dUrd. 
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No fluorinated pyrimidine analogues, including ribonucleosides, were 
detected in WT trypanosomes treated with 5F-2’dUrd, apart from the drug itself 
(the apparent signal for 5-FU deriving from an in-source fragment of 5F-2’dUrd, 
as confirmed in the spiked medium). This confirms that 5F-2’dUrd is not a 
substrate for T. brucei uridine phosphorylase, as this would have generated 5-FU 
and fluorinated ribonucleotides. Interestingly, the automated data analysis did 
not detect any 5F-dUMP, nor the corresponding di- and tri-phosphonucleotides. 
However, manual inspection of the raw data revealed low levels of 5F-dUMP in 
treated cells, confirming that 5F-2’dUrd is a substrate for thymidine kinase. The 
main difference observed between untreated WT cells and those treated with 
5F-2’dUrd was a 36.5-fold increase in dUMP (P<10-5; Figure 5.7), highly 
suggestive of a block in thymidylate synthase (enzyme 16 in Figure 5.1) 
mediated either by 5F-2’dUrd itself, or by the low levels of 5F-dUMP. 
Significantly, only a 2.5-fold increase in dUMP was observed in the treated Tbb-
5F2’dURes cells relative to untreated wild-type cells (Figure 5.7), clearly 
showing a link between the dUMP increase and the mechanism of action for this 
drug. Indeed, dUMP levels were virtually undetectable in untreated Tbb-
5F2’dURes cells, indicating a down-regulation of 2’-deoxyuridine nucleotide 
synthesis as part of the adaptation to 5F-2’dUrd. However, it must be noted that 
dUMP levels were only two-fold above detection level in untreated WT cells, and 
it is therefore not possible to estimate the extent of the down regulation. 
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Figure 5.7. Relative levels of dUMP in T. b. brucei s427-WT (solid bars) and Tbb-5F-
2’dURes (hatched bars) exposed to 100 μM of 5F-2’dUrd for 8 hours. The intensity of the 
mass spectrometer signal was plotted here for the metabolites observed. *, <0.05; P***, 
P<0.01 by unpaired two-tailed Student’s T-test comparing intensity of a particular 
metabolite in s427-WT and resistant lines. 
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However, thymidine nucleotide levels were not significantly different in 
WT and Tbb-5F2’dURes cells, or after treatment with 5F-2’dUrd (Figure 5.8), 
presumably through salvage of thymidine, which is present at high 
concentrations (20 mg/L, i.e. ~83 µM) in standard HMI-9 medium. This confirms 
(1) that the mode of action is through inhibition of thymidylate synthase rather 
than thymidylate kinase and (2) that under these conditions the cells succumb to 
high levels of deoxyuridine nucleotides rather than from lack of thymidine 
nucleotides. 
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Figure 5.8. Relative levels of TMP in T. b. brucei WT (solid bars) and Tbb-5F2’dURes 
(hatched bars) cells exposed to 100 μM of 5F-2’dUrd. The abundance of TMP, TDP and 
TTP (not shown) was statistically identical in control and Tbb5FdURes cells, whether 5F-
2’dUrd-treated or not. 
 The emerging model of inhibition of thymidylate synthase predicts that 
medium thymidine concentrations could greatly impact on the trypanocidal 
activity of 5F-2’dUrd. Indeed, the presence or absence of thymidine in the 
extracellular media had a profound effect on sensitivity to 5F-2’dUrd, 5F-2’dCtd 
and even 5Cl-2’-dUrd, but not to 5-FU, 5-FOA or diminazene aceturate (Table 
5.1). 
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WT trypanosomes in a thymidine-free version of HMI-9 with dialyzed serum were 
highly sensitive to 5F-2’dUrd (EC50 0.77 ± 0.3 µM); the addition of 100 µM 
thymidine reduced the sensitivity 24-fold (EC50 18.6 ± 3.0 µM; Figure 5.9A). The 
same phenomenon was observed even more prominently using Tbb-5F2’dURes 
cells (>600-fold), and when using 5F-2’dCtd on either cell type (78-fold in WT; 
Tbb-5F2’dURes cells were insensitive up to 5 mM 5F-2’dCtd; Figure 5.9B), 
confirming that the two deoxynucleoside analogues have the same mechanism of 
action, through conversion of 5F-2’dCtd to 5F-2’dUrd. 
Table 5.1 Average EC50 values for fluorinated pyrimidines against T. b. brucei BSF of s427-WT 
and Tbb-5F2’dURes cells in the presence and absence of 100 μM thymidine. Cultures were 
grown in a minimal version of HMI-9 without pyrimidines using dialyzed fetal bovine serum, to 
which either 100 µM thymidine or nothing was added. Normal HMI-9 medium and the anti-
trypanocidal diminazene were used as controls. The results shown were the average of three 
independent experiments; error bars were Standard Error of Mean (SEM). 
Drug/medium 
T. b. brucei BSF s427-WT Tbb-5F2’dURes 
HMI-9 HMI-9+Tmd HMI-9-Tmd HMI-9 HMI-9+Tmd HMI-9-Tmd 
5-FU 35.9 ± 1.5 91.1 ±  8.5 124 ± 8.1 76.1 ± 2.2 15.2 ± 2.0 24.7 ± 2.1 
5-FOA 14.1 ± 0.9 33.5 ± 1.3 9.8 ± 0.8 13.3 ± 0.1 7 ± 0.9 7.1 ± 0.2 
5F-2’dUrd 5.2 ± 0.16 18.6 ± 3.0 0.77 ± 0.3 4295 ±267 2559 ±280 4.1 ± 0.7 
5F-2’dCyd 49.4 ± 3.0 350 ± 27.7 4.5 ± 0.7 >5000 >5000 2.7 ± 0.2 
5Cl-2’dUrd 54 ± 1.7 35 ± 3.0 5.4 ± 1.0 22 ± 1.0 20.5 ± 0.5 0.65 ±0.05 
diminazene 0.12 ± 0.05 0.13 ± 0.04 0.14 ±0.06 0.12 ±0.07 0.11 ±0.03 0.12 ±0.05 
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Figure 5.9. Effect of fluorinated pyrimidines on A. T. b. brucei BSF of WT-s427 and B. 
Tbb5F2’dURes cells in the presence and absence of 100 µM thymidine. Cultures were 
grown in a minimal version of HMI-9 without pyrimidines using dialyzed fetal bovine 
serum, to which either 100 µM thymidine or nothing was added. Normal HMI-9 medium 
on one side and the anti-trypanocidal diminazene on the other side of comparison were 
used as controls. The results shown were the average of three independent 
experiments; error bars were SEM. *, P<0.05; **, P<0.02; ***, P<0.01 by unpaired two-
tailed Student’s T-test. 
 The observation that increased thymidine salvage rescues the effect of 
5F-2’dUrd prompted us to next compare thymidine uptake in s427-WT and Tbb-
5F2’dURes cells. The study found that uptake of 10 µM [3H]-thymidine over half 
an hour in Tbb-5F2’dURes was mediated by a medium-high affinity transporter, 
with significantly different rate of uptake between Tbb-5F2’dURes and s427-WT 
(P= 0.003; Figure 5.10A). We also were able to characterize this activity and 
found that the Km = 22 ± 3 µM and the Vmax = 0.013 ± 0.002 pmol∙10
7 cells-1∙s-1 - a 
>50-fold increase in thymidine affinity of Tbb-5F2’dURes, and a 6-fold increase 
in transport efficiency (Vmax/Km; Figure 5.10B). It is clear that this adaptation 
contributes to the 5F-2’dUrd resistance level; as the TbT1-encoding gene has yet 
to be identified the adaptation could be either the expression of an alternative 
thymidine transporter, or a mutant form of TbT1. 
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Figure 5.10. Characterization of [
3
H]-thymidine transport in Tbb-5F2’dURes. A. Timecourse 
of [
3
H]-thymidine transport in T. b. brucei bloodstream forms over 30 minutes. The figure 
showed transport of 10 µM [
3
H]-thymidine by Tbb-5F2’dURes (■) and s427-WT (●) was 
almost totally inhibited in the presence of 10 mM unlabelled thymidine in BSF of Tbb-
5F2’dURes (◊) and s427-WT (▲). B. Inhibition of 2.5 µM [
3
H]-thymidine uptake in Tbb-
5F2’dURes over 30 minutes by various concentrations of unlabelled thymidine (●). The 
inset was conversion the data from frame A to Michaelis-Menten saturation plot. The 
uptakes were terminated by the addition of 1 ml ice-cold 10 mM thymidine in uptake assay 
buffer and immediate centrifugation through oil. Error bars were SE of triplicate 
determinations. 
5.3.2. 5-Fluoro-2’deoxycytidine 
The metabolomic analysis of s427-WT BSF treated with 5F-2’dCtd provided 
further confirmation that 5F-2’dCtd and 5F-2’dUrd act in a similar way, as the 
main fluorinated metabolite of 5F-2’dCtd was 5F-2’dUrd. A very small amount of 
5F-dUMP was also detected by manual inspection, below the limit of automated 
detection. As with 5F-2’dUrd treatment there was a massive increase in dUMP 
levels in the cell (67-fold; P<10-5. This was accompanied by a 2.9-fold increase in 
2’-deoxyuridine (P<0.01). Conversely, there was a small but significant reduction 
in uridine (41%; P<0.01) and UMP (51%; P<0.01). 
In addition there were significant (P<0.02) effects on cytidine nucleotide 
metabolism. There were significant increases in dCDP (4.6-fold) and dCTP (5.6-
fold), as well as an apparent shift in lipid metabolism intermediates. CDP-
choline and CDP-ethanolamine were reduced by 42% and 39% respectively, while 
increases were observed for metabolite peaks putatively identified as dCDP-
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choline (2.2-fold) and dCDP-ethanolamine (4.5-fold). There were no significant 
differences in the cellular levels of the cytidine ribonucleotides CMP, CDP and 
CTP after incubation with 5F-2’dCtd. These effects were not easily understood 
as we are not aware of a mechanism for (deoxy)-cytidine utilization in 
trypanosomes other than through cytidine deaminase. However, the effect on 
deoxycytidine nucleotide levels may have been through the effects of 
accumulating dUMP on ribonucleoside reductase (enzyme 11 in Figure 5.1), 
which can be allosterically regulated by deoxyribonucleotides (Hofer et al., 
1998). This notion was greatly supported by the fact that similar effects could be 
observed after treatment with 5F-2’dUrd, which caused increases in dCMP (2.8-
fold; P<0.001) and dCDP (3.8-fold; P<0.001) as well as in dCDP-choline (2.0-fold; 
P<0.01); while there was no effect on levels of CMP or CDP. 
5.3.3. 5-Fluorouridine 
This nucleoside analogue had no effect on trypanosome growth when tested in 
the Alamar blue viability assay. Consistent with this observation, only very low 
levels of fluorinated metabolites (5-FU, 5-FUMP, 5-FUDP and 5-FUDP-glucose) 
were observed in WT cells exposed to 100 μM of 5-fluorouridine compared to 5-
FU or 5-FOA. No major changes to cellular metabolism were observed.  
5.4. Incorporation of fluorinated pyrimidines into nucleic 
acids 
5.4.1 DNA 
As part of the investigation of the mechanism of action 5F-2’dUrd on 
trypanosomes the study isolated and digested DNA from 5F-2’dUrd-treated cells. 
No 5F-dUMP was detected in the digest in spite of the four natural 
deoxynucleotides being present at 500 to 5000 fold higher intensity than the 
detection limit. The study can rule out that significant amount of 5-fluoro-
2’deoxyuridine is incorporated into DNA in lieu of thymidine. 
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5.4.2 RNA 
As mentioned above the presence of 5F-UTP raises the possibility of 
incorporation of fluorinated nucleotides into RNA. Following purification and 
digestion of RNA from 5-FU treated cells, qualitative LC-MS analysis detected 
significant amounts of 5F-UMP (~10% of UMP abundance by comparison of LC-MS 
peak heights), in addition to low levels of 5F-CMP, confirming the incorporation 
of significant amounts of fluorinated nucleotides into RNA. This data provides 
evidence that 5F-UTP is a substrate for cytidine triphosphate synthase, as 5F-
CTP was not detected in the original extracts of cellular metabolites; however, 
the purification and digestion of isolated RNA led naturally to a much more 
concentrated mono-nucleotide pool for HPLC/MS analysis. 
5.5. Effect of fluorinated uridines on glycosylation in T. 
b. brucei 
To test whether the detection of significant quantities of 5F-UDP-hexoses and 
hexosamines contribute to trypanocidal action through interference with either 
protein glycosylation or glycosylphosphatidylinositol (GPI) anchor biosynthesis, 
protein extracts of BSFs of T. b. brucei s427-WT and pyrimidine auxotrophic 
trypanosomes, incubated for 12 hours in the presence or absence of 100 µM 5-FU 
or 5F-2’dUrd, were separated by 1D SDS-PAGE and transferred onto Immobilon-P 
membranes. Two separate blots of the same samples were incubated with 
Ricinus communis lectin, which binds specifically to terminal β-galactose 
residues, or with Erythrina crystalgalli lectin, which is specific for N-acetyl 
lactosamine modifications - both are hallmarks of mature N-glucan processing. 
This experiment was performed on three independent occasions but in no case 
was a difference in staining pattern or intensity observed between the extracts 
from treated and untreated trypanosome cultures (Figure 5.11). Furthermore, 
the intensity and migration position of the variant surface glycoprotein band, as 
detected by Coomassie staining of gels, was unaltered. In conclusion, no major 
defects to glycosylation or GPI anchor synthesis took place under the influence 
of fluorinated pyrimidines. Although it is possible that glycosylation of a 
relatively rare glycoprotein could have been affected without this being 
apparent in the blot, it is clear that the bulk of N-glycan and GPI biosynthesis 
are unaltered. 
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Figure 5.11. Lectin blotting of T. b. brucei BSF protein samples after incubation with 5-
fluorouracil or 5fluoro-2’deoxyuridine. Cultures of T. b. brucei BSF and pyrimidine auxotrophic 
trypanosomes (KO) were incubated for 12 hours in the presence or absence of 100 μM of either 
pyrimidine analog, under standard culturing conditions. Protein extracts were separated on 1D 
polyacrylamide gels (left hand-side, Coomassie Blue stained) and transferred to Immobilon-P 
membranes to be incubated with either Erythrina crystalgalli lectin or Ricinus Communis lectin 
(right hand-side). Lectin binding was visualized by using ECL reagents. The abbreviations: wt = 
wild-type drug free; 5FDU = WT treated by 5-F2’deoxyuridine; 5-FU = WT treated by 5-FU; KO 
wt = pyrimidine auxotrophic trypanosomes in free drug medium; KO 5FDU = KO treated by 5-
F2’deoxyuridine; KO 5-FU = KO treated by 5-FU. This experiment was carried out in 
collaboration with Harriet Allison and Mark Field of the University of Cambridge, who performed 
the lectin blotting from extracts made at the University of Glasgow. 
5.6. Genome-wide profiling of trypanosomatid pyrimidine 
metabolism 
The above analyses of pyrimidine metabolism, and of the effects of pyrimidine 
analogues on this system, resulted in a new overview of the pyrimidine salvage 
and biosynthesis pathways in T. b. brucei. To further validate the presence of 
the enzymes predicted in the model shown in figure 5.1, the study constructed a 
library of hidden Markov model (HMM)-based profiles for pyrimidine synthesis 
and salvage enzymes. Selected parasite proteomes were scanned with this 
library, Homo sapiens and Mus musculus served as a reference. The use of the 
same profiles over different proteomes enabled clustering of the respective 
species according to their 'pyrimidine metabolic vectors' (Figure 5.12). 
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Figure 5.12 Analysis of pyrimidine metabolic enzymes in major protozoan pathogens and two 
reference mammalian genomes. Profiles specific for the known pyrimidine metabolic enzymes 
were constructed as described in Methods. The profiles were scanned against selected eukaryote 
proteomes. A. Heat map of the best scores obtained by each proteome against profiles for 
enzymes of pyrimidine synthesis (1-6), salvage (7-17), sugar (18-19), and lipid metabolism (20-23). 
Enzyme numbers were the same as in Figure 5.1. B. Hierarchical clustering of the 'pyrimidine 
metabolic vectors' (top) based on Canberra distance (scale bar); the red numbers are 
'approximately unbiased' confidence (au), where p = (100-au)/100. This analysis was carried out in 
collaboration with Pascal Mäser of the Swiss Tropical and Public Health Institute in Basel, who also 
created this figure. 
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This analysis clearly separated the pyrimidine auxotrophic Giardia 
duodenalis, Entamoeba histolytica, and Trichomonas vaginalis from other 
protozoa. These parasites lack thymidylate synthase (enzyme number 16; EC 
2.1.1.45). Within the pyrimidine prototrophs, the trypanosomatids separated 
from the apicomplexans mainly due to the presence of thymidine kinase 
(enzyme number 15; EC 2.7.1.21), UDP-glucose pyrophosphorylase (enzyme 
number 18; EC 2.7.7.9) and UDP-glucose epimerase (19; EC 5.1.3.2), and the 
absence of orotate reductase (enzyme 24 not present; EC 1.3.1.14) and 
dihydroorotate dehydrogenase (enzyme number 25 not present; EC 1.3.5.2). The 
main distinction between T. brucei and its mammalian hosts was the apparent 
absence of dUTPase (enzyme number 13; EC 3.6.1.23) and dihydroorotate 
dehydrogenase (enzyme number 4; EC 1.3.5.2), in addition to a relatively low 
score for uridine phosphorylase (enzyme number 12; EC 2.4.2.3). 
 The apparent absence of dUTPase, a well-characterized enzyme in T. b. 
brucei (Castillo-Acosta et al., 2008) is explained by the fact that it is highly 
atypical for a eukaryotic dUTPase: it is dimeric rather than trimeric (possibly 
unique among eukaryotes (Castillo-Acosta et al., 2008), with a very different 3D 
structure (Harkiolaki et al., 2004), giving it features different from other 
eukaryotic dUTPases, including recognition of both dUTP and dUDP as substrates 
(Bernier-Villamor et al., 2002). These kinetoplastid dUTPases have been 
classified together with several prokaryotic and bacteriophage dUTPases into an 
all-α NTP pyrophosphatase superfamily (Moroz et al., 2005). Similarly, 
trypanosomal uridine phosphorylase has an unusual quaternary structure, 
although most of its active site layout is conserved (Larson et al., 2010): it is a 
member of the NP-I family of nucleoside phosphorylases but, unusually, not 
organized as a stable trimer of dimmers, but rather as a single dimer stabilized 
by a Ca2+ ion. Dihydroorotate dehydrogenase (EC 1.3.5.2) is indeed absent from 
the T. b. brucei genome, its function in the pyrimidine biosynthesis pathway 
instead being performed by dihydroorotate dehydrogenase (EC 1.3.3.1; Arakaki 
et al., 2008), which the HMM analysis correctly predicts. 
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5.7. Discussion 
The pyrimidine analogues target rapidly dividing cells and kinetoplastid parasites 
similarly depend on high growth rates to outpace the host’s defenses. Here, we 
systematically investigate metabolomic effects of pyrimidine antimetabolites 
and the incorporation of pyrimidine analogues into nucleic acids by 
trypanosomes. Antiprotozoal pyrimidine therapy would start with cytotoxic 
pyrimidines efficiently reaching the target cell’s interior (De Koning , 2001; 
Luscher et al., 2007). 
5-FU and 5-FOA give rise to the same active metabolites, converging 
immediately on 5F-UMP (Figure 5.1). As the cells are more sensitive to 5-FOA 
than to 5-FU, despite a much less efficient uptake, it must be concluded that 
the 2-step conversion of 5-FOA to 5-UMP (by orotate phosphoribosyltransferase 
(OPRT) and orotidine monophosphate decarboxylase (OMPDC) is far more 
efficient than the phosphoribosylation of 5-FU by uracil 
phosphoribosyltransferase (UPRT). The active sites of OPRT and OMPDC clearly 
are more tolerant of the 5-position fluorine than UPRT. 
As predicted by the current knowledge of pyrimidine pathways in T. b. 
brucei (Figure 5.1) incubation with sub-lethal concentrations of 5-FOA and 5-FU 
produced essentially the same set of downstream metabolites, although 5-FOA 
incubation also resulted in detectable levels of fluoro-carbamoylaspartate, 
indicating the pyrimidine biosynthesis pathway can operate in reverse, at least 
from orotate. 5-FOA incubation likewise resulted in production of 5-FU by the 
trypanosomes, thus uracil phosphoribosylation is also reversible. Significant 
amounts of 5F-UMP, 5F-UDP and 5F-UTP were detected in the metabolome, in 
addition to 5F-UDP-glucose or -galactose, and 5F-UDP-N-acetylglucosamine 
and/or 5F-UDP-N-acetylgalactosamine. In contrast, no trace of 5F-
2’deoxyuridine nucleotides were detected, indicating that 5F-UDP was not a 
substrate of T. b. brucei ribonucleoside-diphosphate reductase. Yet, incubation 
with 5-FU did result in an elevation of dUMP levels. The cause of these elevated 
dUMP levels is not clear but is unlikely to be the result of 5F-dUMP inhibition of 
thymidylate synthase, as no 5F-dUMP was detected in the metabolomic analysis, 
nor has any other evidence that fluorinated pyrimidines might be substrates of 
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ribonucleoside-diphosphate reductase (RNR) come to light in this study. It could 
be speculated, however, that there is an allosteric effect of a fluorinated 
nucleotide on RNR, as (Hofer et al., 1998) demonstrated that this key enzyme is 
allosterically regulated by numerous nucleotides in a complex way. The 
complete lack of cross-resistance between 5-FU and 5F-2’deoxynucleosides 
(Table 3.3) seems to definitively show that the increase in dUMP, unlike 5F-
2’dUrd, is not the main mechanism of action for the fluorinated nucleobases. 
These observations suggest therefore (one of) two main mechanisms of action 
for the fluorinated nucleobases: incorporation as 5-fluoronucleotides into RNA, 
or an effect of the 5F-UDP-coupled sugars on glycosylation or GPI anchor 
synthesis. The presence of significant levels of 5F-uridine (and lower levels of 
5F-cytidine) nucleotides in digested RNA (but not DNA), coupled with the 
absence of any observable effect on glycosylation of T. b. brucei membrane 
proteins (>95% Variant Surface Glycoprotein, a GPI-anchored glycoprotein) 
suggest that the incorporation of fluorinated nucleotides into RNA contributes to 
5-FU-induced cell death in trypanosomes but it is highly likely that the 
trypanocidal activity is multifactorial.  
 5F-2’dUrd was a substrate for thymidine kinase (5F-dUMP detected), but 
not for uridine phosphorylase, as no 5-FU or fluorinated uridine ribonucleotides 
were observed in 5F-2’dUrd-exposed trypanosomes. Nor were 5F-dUDP or 5F-
dUTP present in detectable quantities and we conclude that 5F-dUMP was not a 
substrate for thymidylate kinase. The absence of any incorporation of 5F-
deoxynucleotides into DNA supports this conclusion. The notable change in the 
metabolome of 5F-2’dUrd-treated trypanosomes was a large increase (>35-fold) 
in dUMP levels, strongly suggesting that its mechanism of action is the inhibition 
of dihydrofolate reductase-thymidylate synthase. The rescue by excess 
extracellular thymidine supports this conclusion. The small effects on the levels 
of 2’deoxycytidine nucleotide levels may indicate allosteric effects on 
ribonucleoside reductase. Incubation with 5F-2’dCtd caused virtually the same 
metabolomic changes as with 5F-2’dUrd, consistent with the notion of any 
2’deoxycytidine utilization in trypanosome being through deamination to 
2’deoxyuridine that were also indicated by the cross-resistance between 5F-
2’dUrd and 5F-2’dCtd (Table 3.3). Indeed, 5F-2’deoxyuridine was clearly 
detected after incubation with the deoxycytidine analogue, as were small 
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quantities of 5F-dUMP, confirming reports of deoxycytidine incorporation in T. b. 
gambiense (Koenigk, 1976) and of cytidine deaminase activity in several 
kinetoplastid parasites (Hammond & Gutteridge, 1982) but contrast with 
evidence from (Hofer et al., 2001) who were unable to detect incorporation of 
radiolabeled cytosine and cytidine into the T. b. brucei nucleotide pool. The 
likely explanation is the use of submicromolar concentrations of pyrimidines by 
Hofer for the incorporation studies, which would allow rapid uptake and 
utilization of uracil but not of cytosine or cytidine. 
 The metabolomic analysis also supplied further information about a 
possible uridine phosphorylase. Fluorinated uridine nucleosides are at best poor 
substrates for this enzyme, as incubation with 5F-2’dUrd resulted in no 
detectable production of 5-FU or fluorinated ribonucleotides. Incubation with 
5F-Urd did produce some of these metabolites, however, showing that this 
enzyme (EC 2.4.2.3; Tb927.8.4430) is indeed expressed in bloodstream forms as 
suggested by (Hassan & Coombs, 1988) and favors uridine over 2’-deoxyuridine 
as shown by (Larson et al., 2010). There is no evidence for a uridine kinase 
activity in kinetoplastids (Figure 5.12) (Hammond & Gutteridge, 1982).  
This study has for the first time established the metabolic space of 
pyrimidine antimetabolites in kinetoplastid parasites. A surprising number of 
metabolites were detected, showing that the fluorination on position 5 has 
limited effect on many enzymes of the pyrimidine pathways. Pyrimidine 
antimetabolites may be incorporated into RNA, into precursors for lipid 
biosynthesis and activated sugar metabolism, potentially impacting on VSG 
glycosylation or GPI anchors - all essential functions to trypanosomes (Donelson, 
2003). However, it is equally instructive to observe which into which part of the 
pyrimidine ‘system’ the analogues did not penetrate: 5-FU was not a substrate 
for uridine phosphorylase or ribonucleotide reductase. This is very different from 
5-FU metabolism in human cells (Longley et al., 2003), where 5-FU incorporation 
into deoxynucleotides is mediated by human ribonucleotide reductase, and by 
uridine phosphorylase and pyrimidine phosphorylase followed by thymidine 
kinase (forming 5F-2’dUMP) [Note: it is possible that the non-detection of 
fluorinated deoxyuridine nucleotides after 5-FU exposure is partly due to 
technical limitations as another group appears to have detected 5F-dUTP as a 5-
FU metabolite in trypanosomes (T. Smith, personal communication)]. The 
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formation of fluorinated deoxynucleotides in human cells leads to their 
incorporation into DNA and inhibition of thymidylate synthase leading to double 
strand breaks; 5F-UMP is similarly incorporated into human RNA. It is believed 
that the inhibition of thymidylate synthase is the main action of 5-FU and its 
prodrugs on human cells (Ceilley, 2010; Longley et al., 2003), leading to an 
imbalance between deoxyuridine nucleotides and thymidine nucleotides and the 
miss-incorporation of the former into DNA. This mechanism is identical to that 
described here for the trypanocidal action of 5F-2’dUrd and 5F-2’dCtd. 
 Untargeted metabolomics and HMM profiling were used to map the 
pyrimidine salvage system, and the passage of pyrimidine antimetabolites 
through it. This approach proved to be extremely powerful, highlighting even 
apparently minor metabolites in pathways such as GPI anchor biosynthesis and 
lipid biosynthesis pathways. In addition, the untargeted metabolomics further 
highlighted important changes in metabolites that were not directly derived 
from the active analogue under investigation, such as the accumulation of dUMP 
after treatment with 5F-2’dUrd, resulting in a much-improved understanding of 
pyrimidine salvage systems in kinetoplastids, and a first evaluation of its utility 
in a strategy of antimetabolites for antiprotozoal chemotherapy. 
  
CHAPTER SIX 
Metabolomic investigations of the mechanisms of 
action of fluorinated pyrimidines on Leishmania 
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6.1. Introduction 
Most organisms are capable of salvage and biosynthesis of pyrimidine molecules, 
including kinetoplastid cells. In addition, most of the inter-conversion pyrimidine 
metabolizing enzymes, and the enzymes of the biosynthesis pathways are shared 
among the various organisms. The six pyrimidine biosynthesis enzymes in 
Leishmania were detected, as well as identification and characterization of 
several pyrimidine pathway enzymes have been studied at molecular level 
(Wilson et al., 2012). Although Leishmania cells are pyrimidine prototrophic, 
several studies have targeted pyrimidine biosynthesis enzymes. Recently, 
knockout of UMP synthase in L. donovani promastigotes led to totally non-viable 
cells in the absence of pyrimidines in vitro conditions, and they were able to 
grow on low levels of pyrimidines (French et al., 2011).To date, no study has 
investigated the metabolites and the mode of action of 5-FU (or even any other 
pyrimidine analogues) in Leishmania cells; moreover, the metabolism of 
individual pyrimidines inside these cells has not been investigated. The 
incompleteness of this knowledge delays the development of an anti-leishmanial 
pyrimidine-based chemotherapy. Therefore, the current study used a 
metabolomic approach to assess: (1) the mechanism of action to 5-fluoro-
pyrimidines (2) what metabolites are formed from 5-fluoro-pyrimidines in 
promastigotes of Leishmania spp (3) whether these analogues utilise the same 
metabolomic pathways in leishmania and trypanosomes. In addition, the 
considerable differences between L. mexicana and L. major in terms of 5F-Urd 
toxicity were investigated here. We selected the active fluorinated pyrimidines 
(5-FU, 5F-2’dUrd and 5F-Urd), and excluded 5F-2’dCyd as its metabolism in 
trypanosomes was identical to that of 5F-2’dUrd (chapter 5). We selected the 
wild type strain of L. mexicana sM379 and L. major sFriedlin to perform this 
experiment, and excluded the derived strains resistant to fluorinated 
pyrimidines from metabolomic assessment as they had lost their natural 
pyrimidine transporters (Chapter 4). 
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6.2 Metabolomic analysis of 5-fluorouracil in 
promastigotes of Leishmania spp 
Promastigotes of L. mexicana and L. major incubated with 100 μM of 5-
fluorouracil for 8 hours showed a considerable amount of intracellular 5-FU 
(Figure 6.1A). Neither fresh medium nor intracellular untreated controls showed 
fluorinated pyrimidines, showing that the identifications were correct. Only low 
levels of 5F-2’dUrd were detected in L. major; however, for L. mexicana the 
level was much lower and below the level at which it could confidently be 
detected and identified by the automated paradigm used (Figure 6.1B). In 
contrast, almost identical levels of 5F-dUMP were observed in both Leishmania 
species (Figure 6.1C). The detection limit of 5F-2’dUrd and 5F-dUMP was not a 
contamination of the drug as added to the cultures, as it was not present in 
fresh medium samples containing 5-FU. It was notable that promastigotes of 
both Leishmania species produced highly similar levels of the same fluorinated 
metabolites. Another common aspect between the promastigotes of Leishmania 
was that neither 5-fluorouridine nor fluorinated uridine nucleotides (F-UMP, F-
UDP and F-UTP) were observed in extracted cells exposed to the indicated 
concentration of 5-FU, in complete contrast to the metabolism in T. brucei. 
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Figure 6.1 Metabolomic profiles of L. 
mexicana (hatched bars) and L. major 
(solid bars) exposed to 100 µM of 5-FU 
for 8 hours; n=3 relative levels of A. 5-
fluorouracil (5-FU) B. 5-fluoro-2’-
deoxyuridine (5F-2’dUrd) C. 5-fluoro-2’-
deoxyuridine monophosphate (5F-
dUMP). 
The detection levels of 5F-2’dUrd and 5F-dUMP clarify that leishmania 
metabolised 5-FU by uridine phosphorylase to 5-F2’dUrd (but not to 5F-uridine), 
which was subsequently phosphorylated by thymidine kinase to 5F-dUMP, which 
inhibited thymidylate synthase. Consistent with observations in human cells, 5F-
dUMP then inhibited thymidine kinase and/or thymidylate synthase and block 
deoxythymidine nucleotides biosynthesis. In sharp contrast with 5-FU 
metabolism in T. b. brucei, the drug does not appear to be a substrate for 
Leishmania uracil phosphoribosyl transferase. 
Another interesting observation in the pyrimidine pathways of Leishmania 
cells exposed to 5-FU was a change in the level of deoxy-pyrimidine nucleotides. 
The intracellular levels of dUMP in treated Leishmania species were massively 
increased compared with respective untreated controls, which were very low in 
comparison, particularly in L. mexicana where the level in untreated cells was 
below automatic detection; therefore, no statistical analysis could be performed 
(Figure 6.2A). In addition, 5-FU caused a reduction in the intensity of dTMP and 
dTTP peaks in L. mexicana promastigotes (P=0.05 and P=0.03, respectively) 
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compared with respective untreated control (Figure 6.2B and C). It should be 
noted that in treated L. major cells the reduced level of deoxythymidine 
nucleotides was not significant, although the reduced dTTP level was observed 
in two out of three replicates. However, exposure of L. major cells to 5-FU 
showed no significant changes in the level of the nucleoside thymidine compared 
with untreated controls. The subsequent reduction in 2’deoxy-thymidine 
nucleotides in Leishmania species is thus probably due to the inhibition of 
thymidine kinase by 5-FU and/or its metabolites. It should be considered that 
the level of dTMP in L. mexicana untreated cells was 3.7-fold higher than in the 
L. major untreated control, whilst the levels of dTTP in the former were 2.2-fold 
lower than the latter. No traces of dTDP were detected in either treated or 
untreated promastigotes of Leishmania cells. 
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Figure 6.2. Metabolomic profiles of L. 
mexicana (hatched bars) and L. major (solid 
bars) treated with 100 μM 5-FU for 8 hours; 
relative levels of A. 2’deoxyuridine 
monophosphate B. 2’deoxythymidine 
monophosphate C. 2’deoxythymidine 
triphosphate. The results shown are the 
mean of three independent experiments; 
error bars are S.E.M; n=3. *P<0.05 by 
unpaired Student’s t test. 
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Other changes that occurred in both L. mexicana and L. major treated 
with 5-FU were an elevation of the levels of deoxynucleosides of uridine (Figure 
6.3A; P= 0.06 and 0.05, respectively) and adenosine (Figure 6.3B; not significant 
in both species) compared to untreated controls. We also observed increases in 
the intensity of 2’deoxycytidine nucleotides (dCMP, dCDP, dCTP) and 
2’deoxyadenosine nucleotides (dAMP, dADP) relative to respective untreated 
controls. It must be noted that the level of 2’deoxycytidine and 
2’deoxyadenosine nucleotides were barely detected in leishmania untreated 
controls; dATP was undetectable in both treated and untreated cells. 
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Figure 6.3. Metabolomic profiles of L. mexicana (hatched bars) and L. major (solid bars) 
treated with 100 μM 5-FU for 8 hours; n=3; relative levels of A. 2’deoxyuridine B. 
2’deoxyadenosine. The results shown are the mean of three independent experiments; 
error bars are S.E.M. The differences were insignificant by unpaired Student’s t test. 
In trypanosomes, 5-FU was incorporated into sugar nucleotides such as 
UDP-glucose, potentially affecting glycosylation. No direct evidence for a 
disruption of glycosylation was found in a preliminary investigation but 5-FU 
resistance coincided with a strongly reduced incorporation into this pathway (Ali 
et al., 2013a). However, 5-FU showed no effect on the levels of UDP-glucose in 
Leishmania cells, and although the drug increased the intensities of UDP-N-
acetyl-D-glucosamine, the increase was not statistically significant. 
The levels of other natural pyrimidine and purine nucleotides, nucleosides 
and nucleobases were generally unchanged in promastigotes of Leishmania spp 
treated by 5-FU, relative to their respective untreated controls. However, the 
intensity of ATP appeared to be higher in treated L. mexicana cells than in their 
control (but insignificant, P=0.06). In addition, the levels of cytidine and 
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thymine in L. major were significantly reduced (P=0.025 and 0.002, respectively) 
compared with their untreated counterparts. 
The untreated controls of L. mexicana and L. major commonly displayed 
the same level of pyrimidine derivatives; however, a few significant differences 
were observed. For instance, dUMP was clearly detected in L. major, even 
though it was very much below detection limit in L. mexicana. The 
monophosphate nucleotides level (CMP, AMP, and GMP) were significantly higher 
in L. mexicana than in L. major (P values were 0.028, 0.002, 0.025, 
respectively), but the intensity of triphosphate nucleotides (UTP, CTP and ATP) 
were considerably lower in the former than the latter (P values were 0.008, 
0.042 and 0.004, respectively). Other variations were in the levels of cytidine, 
thymidine and guanine, which were significantly higher in L major than L. 
mexicana (P=0.029, P=0.023, P=0.002, respectively). 
6.3. Metabolomic analysis of 5-fluoro-2’deoxyuridine in 
promastigotes of Leishmania spp 
Almost the same amount of 5F-2’dUrd was detected in cells of both Leishmania 
species after being exposed to 100 μM of 5F-2’dUrd. In addition, high levels of 5-
FU were found after the treatments (Figure 6.4A), with the level of 5-FU in L. 
mexicana slightly higher than in L. major; this is most likely the result of 
conversion of 5F-2’dUrd to 5-FU by uridine phosphorylase. Furthermore, the 
level of 5F-dUMP in L. mexicana was >9-fold higher than in L. major (n=3, 
P<0.028, Student’s t-test, Figure 6. 4B). The significant difference between the 
two species of Leishmania treated by 5F-2’dUrd, using identical conditions in a 
parallel experiment, could either be due to a higher activity of thymidine kinase 
(TK) in L. mexicana, or to a higher affinity for 5F-2’dUrd by L. mexicana-TK than 
by L. major-TK - both would result in a quick phosphorylation of 5F-2’dUrd in L. 
mexicana. As no 5-fluorouridine was detected in Leishmania cells treated by 5F-
2’dUrd, we conclude that the drug is converted to 5-FU, in a reversible reaction, 
and that Leishmania uridine phosphorylase specifically generates 2’-
deoxyuridine rather than uridine. These findings are consistent with the 
observations with 5-FU-treated cells (see previous section). 
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Figure 6.4 Metabolomic profiles of L. mexicana (hatched bars) and L. major 
(solid bars) exposed to 100 µM of 5-fluoro-2’deoxyuridine for 8 hours; n=3; 
relative levels of A. 5F-2’dUrd and 5-FU B. F-d-UMP in both Leishmania 
species; n=3. *P< 0.05 by unpaired Student’s t test. 
The dUMP levels of Leishmania cells were considerably increased after 
exposure to 5F-2’dUrd (Figure 6.5A), with the drug causing a 67-fold increase in 
the level of dUMP of L. major (P<0.001, unpaired Student’s t-test), and an even 
more significant increase in L. mexicana cells. In contrast, exposure of L. 
mexicana or L. major to 5F-2’dUrd caused a significant reduction in the 
intensities of dTMP (P= 0.005, P= 0.042, respectively; Figure 6.5B) and dTTP 
(Figure 6.5C; in L. major P<0.001); it should be noted that in L. mexicana no 
statistical analysis can be performed here and onwards as the levels of dTTP for 
5F-2’dUrd-treated cells, and of dUMP in control cells, was very much below the 
detection limit, but the same trends were strongly observed in both Leishmania 
species. The elevations in dUMP and the reductions in deoxythymidine 
nucleotides were similar to the changes observed in Leishmania cells after 5-FU 
treatment, strongly suggesting that, in Leishmania, 5-FU and 5F-2’dUrd have a 
very similar mode of action. 
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Figure 6.5. Metabolomic profiles of L. 
mexicana (hatched bars) and L. major (solid 
bars) treated with 100 μM of 5F-2’dUrd for 8 
hours, the controls were untreated 
counterparts; n=3; relative levels of A. d-
UMP B. d-TMP C. d-TTP. *P< 0.05; 0.02; 
***P<, 0.01 by unpaired Student’s t test. 
Other significant changes that occurred in cells treated with 5F-2’dUrd 
compared to their respective untreated controls were increases in the level of 
2’deoxyuridine of both L. mexicana and L. major (Figure 6.6A; P=0.002 and 
0.005, respectively), indicating inhibition of thymidine kinase, and an increase in 
the 2’deoxyadenosine intensity (Figure 6.6B; insignificant in L. mexicana, 
P=0.027 in L. major). It was further found that 5F-2’dUrd lead to a significant 
increase in the levels of 2’deoxy-cytidine nucleotides (dCMP, dCDP, dCTP) and 
2’deoxyadenosine nucleotides (dAMP, dADP). 
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Figure 6.6. Metabolomic profiles of L. mexicana (hatched bars) and L. major (solid bars) 
treated with 100 μM 5-F2’dUrd for 8 hours; n=3; relative levels of A. 2’deoxyuridine B. 
2’deoxyadenosine. The results shown are the mean of three independent experiments; error 
bars are S.E.M. *P< 0.05; ***P<, 0.01 by unpaired Student’s t test. 
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Interestingly, even though 5F-2’dUrd and 5F-dUMP were the only 
fluorinated pyrimidines detected, the treatment led to a significant elevation in 
the intensities of UDP-N-acetyl-D-glucosamine of L. mexicana and L. major 
(P=0.045, P=0.034, respectively; Figure 6.7), possibly through effect/s on 
nucleotide reductase by build up dUMP, increasing availability of uridine 
nucleotides and flux through some UTP-dependent pathways. Once again these 
differences between 5F-2’dUrd-treated and untreated controls were identical to 
the changes caused by 5-FU, which confirms the common mode of action of the 
drugs. 
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Figure 6.7 Metabolomic profiles of L. mexicana (hatched bars) and L. 
major (solid bars) exposed to 100 µM of 5-fluoro-2’deoxyuridine for 8 
hours; n=3; relative levels of UDP-N-acetyl-D-glucosamine in both 
Leishmania species. *P< 0.05 by unpaired Student’s t test. 
The rest of the natural pyrimidines and purines were generally not 
changed in Leishmania promastigotes treated by 5F-2’dUrd compared with their 
respective untreated controls. However, for L. mexicana promastigotes, 5F-
2’dUrd reduced the level of CMP (P=0.049) and increased the level of cytosine 
(P=0.035) compared with untreated control, suggesting either reduced 
production of CMP or increased CMP catabolism by a nucleoside hydrolase. In L. 
major, the drug significantly elevated the intensity of guanine (P=0.002). 
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6.4. Metabolomic analysis of 5-fluorouridine in 
promastigotes of Leishmania spp 
Exposure of Leishmania promastigotes to 100 μM of 5-fluorouridine (5F-Urd) for 8 
hours produced various levels of 5-FU (Figure 6.8A), 5F-Urd and 5F-2’dUrd 
(Figure 6.8B), as well as 5F-dUMP (Figure 6.8C), showing that 5-fluorouridine is a 
substrate of uridine phosphorylase even if it is not a significant product of the 
enzyme (see above). The most interesting point in this process is the resistance 
of L. mexicana to 5F-Urd (chapter 4): no 5F-2’Urd was detected in L. mexicana 
cells although it was detected at low levels in L. major. Notwithstanding the 
fact that the level of 5F-Urd was ~3-fold higher in L. major than in L. mexicana, 
the intensity of 5-FU and 5F-dUMP were considerably higher in L. mexicana than 
in L. major (P=0.001 for 5-FU; no detectable intensity of 5F-dUMP in L. major to 
analyse the difference statistically). It thus can be recapitulated that L. 
mexicana and L. major both take up 5F-Urd quite well. This observation, along 
with their inability to convert 5F-2’dUrd to 5F-Urd (see above), again shows that 
5-fluorouridine is a very poor substrate for uridine phosphorylase, and is 
probably not a substrate for thymidine kinase at all, the 2’-hydroxyl group of 5F-
Urd preventing this interaction. The small amount of 5F-dUMP detected in 5-
fluorouridine treated L. mexicana promastigotes seems to be the result of total 
conversion of the small amount of 5F-2’dUrd by L. mexicana-TK, whereas this 
apparently did not (detectably) happen in L. major. 
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Figure 6.8. Metabolomic profiles of fluorinated 
pyrimidines in L. mexicana (hatched bars) and L. 
major (solid bars) treated with 5-fluorouridine. 
Relative levels of A. 5-FU B. 5F-Urd and 5F-
2’dUrd C. 5F-dUMP, exposed to 100 µM 5F-Urd 
for 8 hours; n=3. 
Promastigotes treated with 5F-Urd led to a significant increase in dUMP 
levels compared to respective untreated controls in which the dUMP levels were 
very low. The intensity of dUMP in L. mexicana treated cells was 5-fold higher 
than in L. major (Figure 6.9A). It follows that 5F-Urd inhibits thymidylate 
synthase (TS) in both Leishmania species, so that 5F-Urd acts possibly like 5-FU 
and 5F-2’dUrd. For L. major promastigotes, the drug caused a decrease in the 
level of dTMP as well (P= 0.06, n=3; Figure 6.9B) and a considerable reduction in 
dTTP intensity (P<0.001; Figure 6.9C). Interestingly, no significant changes were 
observed in dTMP and dTTP levels of L. mexicana cells exposed to 5F-Urd, 
suggesting that L. mexicana is better able to compensate for loss of TS activity, 
probably by thymidine salvage from the medium and the activity of TK. 
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Other changes after 5F-Urd exposure were almost identical to the changes 
caused by 5-FU and 5F-2’dUrd, such as an increase in the level of 2’deoxyuridine 
in L. mexicana and L. major. Moreover, it was also found that in both 
Leishmania species 5F-Urd caused a significant increase in the levels of 
2’deoxynucleotides of cytidine and adenosine compared with respective 
untreated controls; these changes were similar to the effects of 5-FU and 5F-
2’dUrd on Leishmania cells. 
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Figure 6.9 Metabolomic profiles of 
pyrimidine deoxynucleotides in L. 
mexicana (hatched bars) and L. major 
(solid bars) exposed to 100 μM of 5F-Urd 
for 8 hours, the controls were untreated 
counterparts; relative levels of A. d-UMP 
B. d-TMP C. d-TTP. ***P<, 0.01 by 
unpaired Student’s t test. 
5-Fluorouridine increased the level of 2’-deoxyuridine in L. mexicana and 
L. major (P=0.001 and P=0.012, respectively; Figure 6.10A) that was similar to 5-
FU and 5F-2’dUrd effect. Exposure of L. mexicana to 100 μM of 5F-Urd for 8 
hours did not change the level of 2’deoxyadenosine, but did lead to a significant 
increase of 2’deoxyadenosine in L. major promastigotes (P<0.001;  Figure 
6.10B). This observation might be related to the low sensitivity of L. mexicana to 
5F-Urd as it seems to indicate a difference in regulation of the dinucleotide 
reductase in the two species. Another notable difference between L. mexicana 
and L. major after 5F-Urd treatment was a significant variation in thymidine 
intensity; while the level of thymidine in L. mexicana was significantly elevated 
(P=0.006) after 5F-Urd exposure, the drug led to a considerably decreased 
thymidine intensity in L. major (P=0.017; Figure 6.10C). 
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Figure 6.10 Metabolomic profiles of L. 
mexicana (hatched bars) and L. major 
(solid bars) exposed to 100 µM of 5F-Urd 
for 8 hours, n=3; relative levels of A. 
2’deoxyuridine B. 2’deoxyadenosine C. 
thymidine. **P<, 0.02; ***P<, 0.01 by 
unpaired Student’s t test. 
The other natural pyrimidine and purine metabolites were mostly 
unchanged in Leishmania promastigotes treated by 5F-Urd compared with their 
relative untreated controls. The only common change in L. mexicana and L. 
major species treated by 5F-Urd was a significant increase in the level of uracil 
(P=0.029, P= 0.044, respectively), this increase was also observed in case of 5F-
2’dUrd treatment. This elevation could perhaps be attributed to the inhibition of 
thymidylate synthase of Leishmania spp. Furthermore, there were some other 
common effects on each species of Leishmania by the tested fluorinated 
pyrimidines. For instance, the level of ATP in L. mexicana was elevated by 5-FU, 
5F-2’dUrd and 5F-Urd, (P=0.06, 0.09, and 0.025, respectively); all three drugs 
also increased the level of cytosine intensity (P=0.06, 0.05, and 0.01, 
respectively); for L. major, the drugs led to clear reductions in the level of 
thymine (P=0.025, 0.01, and 0.003, respectively) and cytidine (P=0.025, 0.017, 
and 0.1, respectively), and also caused a significant increase in the intensity of 
guanine (P=0.06, 0.05, and 0.01, respectively). 
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6.5. Discussion 
In order to identify which cytotoxic pyrimidine metabolites would 
efficiently target Leishmania‘s pyrimidine pathway enzymes, we attempted to 
investigate the conversion of most effective pyrimidine analogues into 
metabolites to form harmful chemicals. The metabolism of fluorinated 
pyrimidine analogues in Leishmania species showed some differences compared 
to T. b. brucei. Although 5-FU and 5F-2’dUrd followed different routes of 
metabolism in trypanosomes, they follow a similar pathway of metabolism in 
Leishmania cells. The different fluorinated pyrimidines were also differentially 
metabolised in mammalian cells. For instance, when human L1210 leukaemia 
cells were exposed separately to 5-FU and 5F-2’dUrd, the drugs showed different 
metabolic pathways and had different modes of action (Roobol et al., 1984). 5-
FU incorporated into the RNA of trypanosomes and into precursors for 
glycosylation (Ali et al., 2013a), but exposing Leishmania cells to effective 
pyrimidine analogues showed no detectable fluorinated ribonucleotides and we 
conclude that Leishmania uracil phosphoribosyltransferase does not accept 5-FU 
as a substrate. In fact, the number of detected fluorinated pyrimidine 
metabolites was very limited after exposing Leishmania cells to 100 μM of 
fluorinated pyrimidine analogues. 
However, there were a surprising number of changes detected in natural 
purine and pyrimidine metabolites, showing that the 5-fluoro- analogues have 
some (indirect) effect on much of the nucleoside/nucleotide metabolism. 
Leishmania cells, like trypanosomes, are unable to produce 5F-Urd from 5-FU or 
5F-2’dUrd, but they can produce very high levels of 5-FU following sub-lethal 
doses of 5F-Urd. The only fluorinated pyrimidine nucleoside detected after 5-FU 
treatment was 5F-2’dUrd at a very low level, so that uridine phosphorylase in 
Leishmania seems a reversible enzyme, at least for the 2’dUrd/uracil reaction. 
Indeed, 5F-2’dUrd and 5F-Urd are efficiently metabolized to 5-FU, which means 
that these drugs are good substrates for uridine phoshporylase. Notwithstanding 
the fact that the uracil transporter is >20-fold more sensitive to 5-FU in L. major 
cells than in L. mexicana (Chapter 4), both strains showed the same intensity of 
5-FU in the metabolomic profile, after exposure to the same concentration of 
the drug and for an equal incubation period. However, it is not possible to 
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directly compare the two groups quantitatively without the use of internal 
controls of known quantity. 
The observation that 5-FU is not a substrate for Leishmania uracil 
phosphoribosyltransferase (UPRT), but is for Leishmania uridine phosphorylase 
(UP) indicates changes in the way uracil is bound by these two enzymes, with 
UPRT more sensitive to 5-position substitutions. 
Surprisingly, all of the pyrimidine analogues, 5-FU, 5F-2’dUrd and 5F-Urd, 
were principally converted to 5F-dUMP, in contrast to the situation in T. brucei 
(Ali et al., 2013a). Leishmania cells metabolized 5-fluorouracil and 5-
fluorouridine to 5-fluoro-2’deoxyuridine, which was phosphorylated by thymidine 
kinase to produce 5F-dUMP; no fluorinated uridine nucleotides were detected in 
the metabolome of the fluorinated pyrimidines-exposed Leishmania, nor were 
5F-dUDP or 5F-dUTP present in detectable quantities, so it must be concluded 
that 5F-dUMP is not a substrate for thymidylate kinase. Instead the most 
important alteration in the metabolome of the fluorinated pyrimidines-treated 
Leishmania species was a large increase in dUMP levels, strongly suggesting that 
the mechanism of action of these pyrimidine analogues is the inhibition of 
dihydrofolate reductase-thymidylate synthase (DHFR-TS), blocking the 
conversion of dUMP to dTMP. This observation is very similar to the effect of 5-
FU on human cancer cells (Longley et al., 2003). TS of mammalian cells transfers 
the methyl group from methylene tetrahydrofolate to carbon in position 5 of 
dUMP to form dTMP (Santi & McHenry, 1972). In the case of 5F-dUMP, the 
presence of the fluorine atom at that position prevents the transmethylation and 
thus stalls the folate cycle; it seems that Leishmania thymidylate synthase is 
unable to break the strong carbon-fluorine bond to allow the methylation to take 
place. The inhibition of TS thus caused a build-up of dUMP and a concomitant 
decrease in thymidine nucleotides. The depletion of thymidine nucleotides may 
be further enhanced by inhibition of thymidylate kinase by 5F-dUMP, a structural 
analogue of the dTMP substrate, in addition to potential inhibition of thymidine 
kinase by 5F-2’dUrd. 
The combined effect of these enzyme inhibitions is an imbalance between 
deoxyuridine nucleotides and thymidine nucleotides. It seems that the depletion 
of deoxythymidine nucleotides activates changes in nucleoside and nucleotide 
J. Ali 2013 Chapter 6 178 
 
pools. There were clear increases in the intensity of deoxyuridine and 
deoxycytidine nucleotides, but these were probably secondary to the dUMP 
elevation. Furthermore, thymidine deoxynucleotide (dTMP and dTTP) levels 
were decreased in Leishmania promastigotes after exposing to 100 μM of 5-
fluoro-pyrimidine analogues (with the exception 5F-Urd on promastigotes of L. 
mexicana). The significant increase in the levels of deoxyuridine might be 
attributed to the inhibition of thymidine kinase which led to an increase in the 
free deoxynucleoside levels in fluorinated pyrimidine-treated cells. However, 
very recently 2-deoxyuridine has been found as a very poor substrate for TK 
(Castillo-Acosta et al., 2013). Therefore, we suggest that the elevations in 
2’deoxy purine and pyrimidine nucleosides and nucleotides in promastigotes of 
Leishmania cells that were exposed to fluorinated pyrimidines could be related 
to activation of the allosterically regulated enzyme ribonucleoside reductase 
(RNR). As a result, the enzyme may produce too much dNDP product, which was 
not being used. Therefore, these are broken down to dNMPs and subsequently to 
free 2’deoxynucleosides. Particularly, the conversion of dNDPs to dNTPs is highly 
regulated. 
Although Leishmania promastigotes showed different mechanisms of 
resistance to fluorinated pyrimidine analogues, through loss of different 
transporters (chapter 4), mostly, there were many close similarities between the 
cellular effects of fluorinated pyrimidine analogues (5-FU, 5F-2’dUrd and 5F-
Urd), indicating a common mode of action on L. mexicana and L. major. The 
specific difference was the effect of 5F-Urd, particularly in that L. mexicana was 
extremely resistant to the compound, whereas the other species was very 
sensitive. This cannot be attributed to differences in uridine transport between 
the species, which, if anything, seems to be higher affinity and more efficient in 
L. mexicana (Tables 4.1 and 4.2). Nor can it be argued that LmexNT1 does not 
transport substrates with the 5F substitution, as 5F-2’dUrd displayed the exact 
same affinity as 2’dUrd for this carrier (Table 4.1), and 5F-2’dUrd was highly 
active against L. mexicana promastigotes (Table 4.4). In addition, 5F-uridine was 
detected in the metabolomic profile of L. mexicana, after exposure to this 
compound, albeit at a lower mass-spectrometric intensity than in L. major. 
However, a notable difference in the metabolomic profile of the two species was 
that after 5-fluorouridine treatment no 5F-2’dUrd was detectable in L. 
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mexicana, whereas this was clearly present in L. major, despite the fact that 5-
FU was clearly generated from 5F-Urd in both species, and in comparable 
amounts. More surprisingly, the level of 5F-dUMP in L. mexicana was 9.2-fold 
higher than in L. major (P= 0.028; Figure 6.7C), which can only have been 
generated from 5F-2’dUrd; this is accompanied by the predicted build-up of 
dUMP (higher in L. mexicana) by inhibition of TS (Figure 6.9A). 
It thus follows that, whereas both species generate 5F-2’dUrd from 5F-Urd 
by the double action of uridine phosphorylase (with 5-FU as intermediate 
product), this is more rapidly converted by thymidine kinase to 5F-dUMP in L. 
mexicana than in L. major, explaining both the absence of the substrate and the 
higher level of the product in L. mexicana promastigotes. The other evidence is 
that the level of 5F-2’dUrd was below detection limit in L. mexicana treated 
with 5-FU, which shows the rapid conversion of 5F-2’dUrd to 5F-dUMP by 
promastigotes of this species. However, this still does not appear to explain the 
insensitivity of L. mexicana to 5F-Urd. The key observation for this is that 
thymidine nucleotide levels in L. major are substantially reduced relative to 
untreated controls, but are not significantly different in L. mexicana, in which 
dTMP levels in any case were much higher than in L. major (Figure 6.8B). We 
conclude that the biosynthesis of thymidine is substantially inhibited in L. major, 
through inhibition of both TS in the de novo pathway (by 5F-dUMP) and TK in the 
salvage pathway (by 5F-2’dUrd), whereas there is no inhibition of TK in L. 
mexicana due to the absence of 5F-2’dUrd, allowing a bypass from the inhibition 
of TS and a sufficient synthesis of thymidine nucleotides. This interpretation is 
corroborated by the fact that LmajNT1 has only low affinity for thymidine, 
allowing at best a poor rate of salvage, whereas LmexNT1 displays a Km of just 
4.2 ± 0.4 µM for thymidine, identical to its affinity for uridine (Table 4.1); the 
source of the thymidine for salvage is the 10% of FBS in the HOMEM medium. This 
model also explains why 5F-2’dUrd is active against L. mexicana, as this agent 
generates a sufficiently high concentration of 5F-2’dUrd in the cell to also block 
TK, despite the efficient conversion to 5F-dUMP. Our overall conclusion is that 5-
fluoropyrimidines exert their anti-leishmanial activity through inhibition of both 
thymidylate synthase and thymidine kinase (Figure 6.11). 
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Figure 6.11. The metabolism of fluorinated pyrimidines in promastigotes of A. L. mexicana and 
B. L. major. The double green line refers to cell membrane. The blue arrows refer to pyrimidine 
salvage or conversion, when thick show high flow and when dotted show poor uptake; the red 
curved-arrows refer to the block of thymidine kinase by 5F-2’dUrd, the dotted line means low 
amount and inadequate to block TK when the treatment is with 5F-Urd, although sufficient when 
the treatment is 5-FU or 5F-2’dUrd. Abbreviations above the blue arrows are referred to: UP = 
uridine phosphorylase, TK = thymidine kinase, TdlK = thymidylate kinase, TS = thymidylate 
synthase, NDK = nucleoside diphosphate kinase. 
 
 
 
CHAPTER SEVEN 
Construction and characterisation of a pyrimidine 
auxotrophic Trypanosoma brucei clone 
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7.1 Introduction 
Trypanosomes possess both the pyrimidine biosynthesis and salvage routes, and 
that would appear to make pyrimidine metabolism an unattractive drug target. 
Until the start of this project, it has not been established whether either 
pyrimidine biosynthesis or salvage is essential in African trypanosomes. 
Moreover, the salvage and biosynthesis pathways actually share most of the 
pyrimidine metabolizing enzymes, many of which have now been shown to be 
essential because (in contrast to purine metabolism) there is little or no 
redundancy in the pathways. For example, dihydrofolate reductase - thymidylate 
synthase (DHFR-TS) is essential in trypanosomes and its knockout can only be 
rescued by high levels of thymidine (Sienkiewicz et al., 2008), and CTP 
synthetase is essential as T. b. brucei are unable to incorporate extracellular 
cytosine or cytidine in their nucleic acids (Hofer et al., 2001). Furthermore, T. 
b. brucei deoxyuridine 5’-triphosphate nucleotidohydrolase (dUTPase) was 
recently shown to be essential (Castillo-Acosta et al., 2008, 2013) and it is clear 
that several other enzymes of the same pathways may equally be good drug 
targets. 
However, it is as yet unclear whether either the uptake of extracellular 
pyrimidines or the de novo biosynthesis of the first pyrimidine nucleotide, UMP, 
is essential in kinetoplastid parasites. It has been previously shown that in 
procyclic T. b. brucei pyrimidines are mainly taken up through the TbU1 uracil 
transporter (De Koning & Jarvis, 1998; Gudin et al., 2006) and recently we have 
completed a study of pyrimidine transport activities in bloodstream form T. b. 
brucei showing the presence of only one high affinity uracil transporter, TbU3, 
and almost no uptake of other pyrimidines at physiological levels (Ali et al., 
2013a). A previous study, by (Arakaki et al., 2008) showed that RNAi disruption 
of one of the biosynthesis enzymes, dihydroorotate dehydrogenase, led to 
impaired growth which could be compensated for by pyrimidine uptake. The 
rescue by extracellular uracil, however, was not observed in the presence of the 
TbU3 inhibitor 5-fluorouracil (Arakaki et al., 2008). In the present study we 
simulated complete inhibition of pyrimidine salvage by in vitro growth in 
pyrimidine-free medium and inhibition of de novo biosynthesis through the 
construction of a genetic deletion mutant lacking the final step of the 
pyrimidine biosynthesis pathway, which in trypanosomes is a fusion of the two 
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enzymes orotidine monophosphate decarboxylase (PYR6, OMPDCase) and orotate  
phosphoribosyl-transferase (PYR5, OPRT) (Gao et al., 1999; Scahill et al., 2008). 
The PYR6-5-/- trypanosomes were characterized in vitro and in vivo. While they 
were completely non-viable in the absence of pyrimidines in vitro, they were 
able to grow on low levels of pyrimidines, similar as reported for L. donovani 
promastigotes (French et al., 2011). In this chapter we investigated the activity 
of the TbU3 transporter and expression of uridine-phosphorylase in pyrimidine 
auxotrophic trypanosomes. We also assessed the sensitivity of PYR6-5-/- cells to 
fluorinated pyrimidine analogues, and determined the DNA content of these 
bloodstream forms. In addition, the study established an infection of PYR6-5-/- 
trypanosomes in mice. We exclude Leishmania species from this project as 
(Wilson et al., 2012) have very recently published a paper addressing this issue 
in L. donovani. 
7.2. Generation and confirmation of pyrimidine 
auxotrophic T. b. brucei s427 mutants 
A schematic representation of the generation of a PYR6-5-/- strain is shown in 
Figure 7.1A. Plasmids with the positive selection marker hygromycin 
phosphotransferase (HYG) and the negative selection marker Herpes simplex 
virus thymidine kinase (HSVTK) (generous donation from George Cross, 
Rockefeller University, New York) were used. Bloodstream forms of T. b. brucei 
s427 (1×106 cells ml-1) were transformed with the loxP-HYG-HSVTK-loxP cassette 
using an Amaxa Nucleofector. The transformants were grown in selective 
medium containing 4.5 µg ml-1 hygromycin (Sigma) and were cloned using 
limiting dilution, creating a heterozygote PYR6-5+/- strain. Viable clones with the 
desired insert were subjected to increasing drug pressure with 5-fluoroorotic 
acid (5-FOA) leading to loss of the second PYR6-5 gene (loss of heterozygosity) at 
100 M (Figure 7.1B). Loss of heterozygosity (LOH) and the generated 
homozygous PYR6-5-/- were further confirmed using Southern blot (Figure 7.1C). 
J. Ali 2013 Chapter 7 184 
 
 
  
Figure 7.1. Generation of Pyr6-5 Knockouts. A. Schematic representation of the generation of 
Orotidine Monophosphate Decarboxylase (OMPDCase) knockout. The first step is replacement of 
one PYR6-5 allele with a construct containing both positive selection marker hygromycin 
phosphotransferase (HYG) and negative marker Herpes simplex virus thymidine kinase (HSVTK) 
between 34-bp loxP elements. The second step creates the homozygous PYR6-5
-/-
 through drug 
pressure with 5-fluoroorotic acid, causing loss of heterozygosity. B. PCR analysis of the PYR6-5 
gene, generating an 870 bp amplicon as described in the Materials and Methods section 
confirmed the absence of the gene in Pyr6-5
-/- 
(lane 1) and its continued presence in Pyr6-5
+/-
 
(lane 2); and lane 3 which is the control with WT s427 DNA. C. Southern blot confirming knockout 
strategy, using probes for the PYR6-5 locus and for the HYG-HSVTK cassette. Lane 1, Pyr6-5
-/-
, 
lane 2, Pyr6-5
+/-
, Lane 3, WT s427; and ‘a’ is PYR6-5, band ‘b’ is HYG-HSVTK. 
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7.3. Growth of pyrimidine auxotrophs on different 
pyrimidine sources 
Under standard culture conditions there was no clear growth phenotype 
associated with loss of the PYR6-5 locus, as growth of the knockout cells in 
standard HMI-9 was similar to that of WT-s427 trypanosomes in HMI-9-tmd 
supplemented with 10% dialysed FBS (Figure 7.2). PYR6-5-/- cells were grown 
either in standard HMI-9 or in HMI-9-tmd, which does not contain any pyrimidines 
but does contain 1 mM hypoxanthine as a purine source (Appendix I) and is 
supplemented with FBS that was extensively dialysed to remove small molecules 
such as nucleosides. 
 
Figure 7.2. Growth of PYR6-5
-/-
 T. b. brucei bloodstream forms in standard HMI-9 
and s427-WT in HMI-9
-tmd
 supplemented with 10% dialyzed FBS. Seeding density 
was 1 × 10
5
 cells ml
-1
 and cells were manually counted every 24 hours. On day 3 
cells were sub-passaged to relevant fresh medium, again at 1 × 10
5
 cells ml
-1
. 
As expected, PYR6-5-/- cells were unable to grow in this semi-defined 
medium without pyrimidines, and the trypanosome population rapidly declined 
after 24 hours (Figure 7.3A,B). In contrast, a shift to purine-free conditions only 
caused growth arrest after approximately 48 hours (Figure 7.3B), consistent with 
previous observations in procyclic T. brucei (De Koning & Diallinas, 2000) and 
promastigotes of L. donovani (Carter et al., 2010). Evidently, any interruption in 
pyrimidine supply rapidly makes trypanosomes non-viable and we investigated 
how quickly the damage becomes irreversible (Figure 7.3A), by adding back 100 
µM uracil at various times after passage of PYR6-5-/- to HMI-9-tmd. Cells grew to 
the same density as in standard HMI-9 when uracil was added immediately after 
passage (0 hours control) but adding the uracil after as little as 12 hours resulted 
in irreversible growth arrest and the eventual death of the parasite population. 
From 24 hours, the addition of uracil was almost redundant, with the cell 
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population declining as rapidly as in continuously pyrimidine-free conditions 
(Figure 7.3A). 
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Figure 7.3. Growth of bloodstream form T. b. brucei in media with various purine and 
pyrimidine content. A. Pyr5-6
-/-
 trypanosomes were transferred from HMI-9 to HMI-9
-tmd
 
(pyrimidine-free, □) medium to which subsequently uracil was added to a final 
concentration of 100 µM at the indicated time after seeding the culture. Samples were 
taken every 12 h and cell densities determined using a haemocytometer. In cultures with 
conditions that allowed fast growth, the trypanosome population declined after 36 - 48 h 
due to overgrowth. Cell population in the ‘0 hours’ group declined after 60 h due to over-
growth and exhaustion of the medium. B. Comparison of purine-free and pyrimidine 
conditions. WT s427 cells were passaged from mid-log cultures (grown in standard HMI-9 
into fresh cultures with the same medium (control, ▲) or the same medium without 
hypoxanthine and supplemented with dialysed serum (purine free, ●). Pyrimidine-
auxotrophic T. b. brucei (PYR6-5
-/-
) were transferred from standard HMI-9 into HMI-9
-tmd
 
(pyrimidine-free, ■) medium. Cell population in the ‘WT, HMI-9 control’ group declined 
sharply after 36-48 hours due to over-growth and exhaustion of the media. 
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We next tested the ability of these cells to grow on 100 µM or 1 mM 
(Figure 7.4) of each natural pyrimidine nucleoside or nucleobase. At the lower 
concentration, uracil supported near-normal growth but at 1 mM appeared to 
have become somewhat growth inhibitory and growth was less pronounced, 
possibly because the resulting excessive uracil influx could cause an imbalance 
between pyrimidine nucleotides and 2’deoxyribonucleotides, or between purine 
and pyrimidine nucleotides. Uridine also supported growth at 100 µM and even 
better at 1 mM, whereas 2’-deoxyuridine barely had any effect at all at 100 µM. 
Of the other pyrimidines, only cytidine had any effect on growth, and only at 1 
mM. 
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Figure 7.4. Growth of pyrimidine auxotrophic T. b. brucei bloodstream forms 
on various pyrimidine sources. PYR6-5
-/- 
 cell cultures were seeded at a 
density of 1×10
5
 cells ml
-1
 and cultured at 37 °C/5% CO2, either in normal 
HMI-9 or in a simplified pyrimidine version supplemented with dialysed FBS 
and the indicated pyrimidine source at (A) 100 µM or (B) 1 mM. Samples 
were taken every 24 hours and cell densities determined using a 
haemocytometer, in duplicate. The experiment shown is representative of 
several similar experiments with essentially identical results. In cultures with 
conditions that allowed fast growth, the trypanosome population declined 
after 36 - 48 hours due to overgrowth. 
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7.4. [
3
H]-Uracil uptake in pyrimidine auxotrophic T. 
brucei 
We determined uracil uptake rates in Pyr6-5-/- and control s427-WT cells 
to assess whether uracil uptake capacity in bloodstream form T. b. brucei 
increased in the absence of pyrimidine biosynthesis. WT and Pyr6-5-/- were 
grown in standard HMI-9 and uptake of 0.15 µM [3H]-uracil was measured in a 
timecourse over 120 s. The initial rate of uracil uptake was consistently higher in 
the Pyr6-5-/- cells (Figure 7.5A). The rates were 0.0109 ± 0.0001 and 0.0241 ± 
0.0014 pmol (107 cells)-1s-1 for WT and Pyr6-5-/- trypanosomes, respectively (n=3; 
P<0.05, Student’s T-test, unpaired). The increased uptake rate could not be 
attributed to the expression of an additional uracil transporter in the knockout 
strain not present in the WT cells, as Km values were identical in both strains 
(0.31 ± 0.01 and 0.34 ± 0.03 µM, respectively (n=3)) and uracil transport was 
almost completely insensitive to uridine in both strains (Ki values >3 mM, n=3; 
Figure 7.5B). Indeed, uptake of 2.5 µM [3H]-uridine was almost undetectable in 
both strains. However, the Vmax for uracil transport was significantly increased in 
Pyr6-5-/- cells (0.14 ± 0.01 versus 0.087 ± 0.007 pmol (107 cells)-1s-1, respectively; 
n=3, P = 0.012) (Figure 7.5C), consistent with the increased initial rate seen in 
the time course, and probably reflecting a higher number of the uracil 
transporter in the plasma membrane rather than the expression of a different or 
additional transport protein. 
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Figure 7.5. Uracil transport by T. b. brucei bloodstream forms. A. Timecourse of 
0.15 µM [
3
H]-uracil uptake by WT-s427 and by PYR6-5
-/-
 cells, in the presence or 
absence of 1 mM unlabelled uracil, as indicated. Dashed lines represent linear 
regression over the first 50 s, yielding correlation coefficients of 0.97 and 0.92 for 
the knockout and WT strains, respectively. In the presence of excess unlabeled 
uracil uptake was not significantly different from zero (F-test) for both strains. The 
experiment shown is representative of three identical experiments with highly 
similar outcomes and shows average and SE of triplicate determinations. In the 
presence of 1 mM uracil, the lines for WT and PYR6-5
-/-
 were superimposed. B. 
Uptake of [
3
H]-uracil by PYR6-5
-/-
 trypanosomes was measured over 30 s in the 
presence or absence of unlabelled uracil (○) or uridine (■) at the indicated 
concentrations. The data was plotted to a sigmoid curve with variable slope 
which in the case of uridine inhibition was set at zero for its minimum. The data 
are the average and SE of triplicate determinations and the experiment shown is 
representative of several independent experiments with essentially identical 
outcomes. C. Michaelis-Menten saturation plots for uracil uptake of [
3
H]-uracil by 
WT (○) or PYR6-5
-/-
 (■) T. b. brucei bloodstream forms. The data represents the 
average and SE of three identical experiments, each performed in triplicate. 
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7.5. Sensitivity of pyrimidine auxotrophic of T. b. brucei 
to pyrimidine analogues 
We tested whether pyrimidine auxotrophs were more sensitive to cytotoxic 
pyrimidine analogues and found that Pyr6-5-/- cells are approximately one order 
of magnitude more sensitive to most analogues, including 5-fluorouracil and 5-
fluoro-2’deoxyuridine (Table 7.1). The only exception was 5-fluoroorotic acid, 
whose action is dependent on OPRTase and OMPDCase, and to which the Pyr6-5-
/- cells were completely impervious up to 5 mM although WT trypanosomes were 
sensitive to this compound with an EC50 of 13.2 ± 1.2 µM. Interestingly, the Pyr6-
5-/- strain was also sensitized to 5-fluorouridine whereas the WT cells were not 
sensitive to this compound up to the limit tested (5 mM). 
Table 7.1. EC50 values in μM for some pyrimidine analogues tested on WT-s427 and PYR6-5
-/-
 
bloodstream forms grown in standard HMI-9, using a standard protocol based on the 
fluorescent indicator dye Alamar Blue. Resistance Factor (RF) is the ratio of the EC50 values 
(μM) for knockout over WT strains. P value is based on an unpaired Students t-test. 
Pyrimidine analogous 
WTs-427  PYR6-5-/-  
RF P value 
(AVG ± SE) (AVG ± SE) 
5-Fluorouracil 35.9 ± 1.5 2.3 ± 0.07 0.06 <0.001 
5F-2’deoxyuridine 4.6 ± 0.5 0.77 ± 0.10 0.16 0.002 
5F-2’deoxycytidine 43.7 ± 4.4 4.6 ± 0.9 0.105 <0.001 
5-Fluorouridine >5000 472 ± 3 <0.09 <0.001 
5-Fluoroorotic acid 13.2 ± 1.2 >5000 >380 <0.001 
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7.6. Expression of Uridine Phosphorylase in pyrimidine 
auxotrophs  
We observed that cultures of Pyr6-5-/- cells appeared to be able to adapt to 
uridine as a sole pyrimidine source. In order to utilize uridine for the synthesis of 
pyrimidine nucleotides they need to generate uracil from it, using uridine 
phosphorylase (UPase) (Larson et al., 2010). We thus inferred that upregulation 
of UPase could be a possible adaptation to pyrimidine starvation and performed 
quantitative PCR to assess relative UPase mRNA levels in WT and Pyr6-5-/- cells 
grown in different media. As shown in Figure 7.6, UPase expression was identical 
in WT cells grown in standard HMI-9 or in HMI-9-tmd supplemented with 100 µM 
uracil, but was significantly increased after 48 hours growth on HMI-9-tmd 
supplemented with 1 mM uridine (P<0.001). In Pyr6-5-/- cells cultured long-term 
in standard HMI-9 but transferred to HMI-9-tmd/uracil for 48 hours UPase 
expression levels were higher than for s427-WT under the same conditions 
(P<0.001) and the level was further increased for Pyr6-5-/- cells grown 48 hours 
in HMI-9-tmd/uridine (P<0.001). These data appear to indicate that T. b. brucei 
can adjust its UPase expression levels to accommodate growth on uridine as its 
sole pyrimidine source, whether these cells are pyrimidine auxotrophs or 
prototrophs. We next investigated whether Pyr6-5-/- strains can adapt when 
long-term cultured (two months) on uridine as sole pyrimidine source. We found 
that these cells do express significantly higher UPase levels than s427-WT control 
cells grown in standard HMI-9 or on HMI-9-tmd/uracil (P<0.01), but revert quickly 
to control levels of expression when shifted to HMI-9-tmd/uracil (Figure 7.6). 
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Figure 7.6. Comparative expression of uridine phosphorylase in wild-type and pyrimidine 
auxotrophic trypanosomes. Expression of uridine phosphorylase (UPase) was assessed by 
Real Time PCR in WT and PYR6-5
-/-
 strains grown under various conditions. The results are 
presented normalized to the control (group1) and are the average and SE of 8 replicates. 1. 
Control: WT grown in HMI-9; 2. WT grown 48 hours in HMI-9
-tmd
 + 100 µM uracil; 3. WT 
grown 48 hours in HMI-9
-tmd
 + 1 mM uridine; 4. PYR6-5
-/-
 grown 48 hours in HMI-9
-tmd
 + 100 
µM uracil; 5. PYR6-5
-/-
 grown 48 hours in HMI-9
-tmd
 + 1 mM uridine; 6. PYR6-5
-/-
long-term 
adapted to growth on uridine, grown 48 hours in HMI-9
-tmd
 + 100 µM uracil; 7. PYR6-5
-/-
long-
term adapted to growth on uridine, grown 48 hours in HMI-9
-tmd
 + 1 mM uridine. Data were 
analysed with a one-way ANOVA with Tukey’s correction. Horizontal asterisks indicate 
significant differences from control; vertical asterisks indicate significant differences between 
individual bars as indicated. **, P<0.01; ***, P<0.001. 
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7.7. The effect of pyrimidine starvation on DNA content 
and integrity of pyrimidine auxotrophic T. b. brucei 
Pyrimidine auxotrophs die relatively rapidly in the absence of a salvageable 
pyrimidine source (uracil>uridine>2’deoxyuridine>cytidine; see figure 7.4), with 
death of the population progressing soon after 24 hours. To investigate the cause 
of the rapid cell death we examined DNA content of the Pyr6-5-/- cells grown in 
HMI-9-tmd supplemented with 100 µM of various pyrimidines, using flow cytometry 
with the DNA-binding fluorophore propidium iodide; Pyr6-5-/- cells grown in 
normal HMI-9 served as control. We found that DNA content in control cells 
presented a classical distribution of most cells in G1 phase (diploid), a small 
proportion in S-phase undergoing DNA synthesis and finally a percentage of the 
population in G2 phase (double set of chromosomes) (Figure 7.7). This profile 
was stable over the 48 hours of the experiment, although the proportion in G2 
phase increased somewhat over this period, probably reflecting the mid-log 
phase of growth of the population at the end of the experiment, compared to 
early log phase at the start (% in G2 was 4.9 ± 2.8%, 11.6 ± 3.1% and 13.9 ± 1.9% 
at 24 hours, 36 and 48 hours, respectively; quantified using the ModFit software 
package). In sharp contrast, there was a rapid increase in cells displaying an 
incomplete complement of chromosomes in Pyr6-5-/- cells grown in HMI-9-tmd, 
resulting both in cells with less fluorescence (i.e. less DNA) than should be 
associated with normal G1 phase cells, or cells with a DNA content between G1 
and G2 phase (Figure7.7). This clearly indicates that the cells are attempting 
cell division ‘as normal’ but are unable to complete chromosome synthesis due 
to lack of pyrimidine nucleotides, leading to aberrant cells with incomplete and 
fragmented chromosomes that are ultimately non-viable. This phenomenon 
progressed rapidly and at 48 hours few live cells could be detected. The cells 
that could be counted by the flow cytometer almost all contained incomplete 
and presumably fragmented DNA. Highly similar flow cytometry results were 
obtained when supplementing HMI-9-tmd with cytosine, thymine or thymidine, 
whereas supplementation with uracil or uridine produced profiles highly similar 
to the control (growth in standard HMI-9); addition of 2’deoxyuridine, cytidine or 
2’deoxycytidine resulted in intermediate levels of DNA damage over 48 hours. 
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Figure 7.7. Flow cytometry for DNA content in bloodstream form PYR6-5
-/-
 cells. 
Pyrimidine auxotrophic trypanosomes were either incubated in standard HMI-9 or, 
in parallel, in pyrimidine-free HMI-9
-tmd
 for up to 48 hours, stained with propidium 
iodide and prepared for flow cytometric analysis. Whereas control cultures show a 
classical distribution of cells in G1, S and G2 phase, as well as a small percentage 
of cells with less than the normal diploid DNA content (debris, d), cells grown in 
pyrimidine-free medium showed a much higher percentage of cells with partial 
DNA content, and this increased dramatically between 24 and 48 hours. 
In an effort to quantify the emergence of aberrant cells the flow 
cytometry profiles were analyzed with the ModFit software package which 
models the peak area. This was not successful for the 48 hours time points 
because of the lack of viable cells and too extensive DNA damage, which did not 
allow reliable estimates of relevant peaks. However, some results for the 24-
hours and 36 hours time points are shown in figure 7.8. The use of thymidine as 
sole pyrimidine source caused a highly significant increase in cells in G2 phase, 
most likely because of the anticipated imbalance between thymidine nucleotides 
and deoxycytidine nucleosides, which the cell cannot generate from thymidine. 
The peak classified as ‘DNA debris’ increased within 24 hours of pyrimidine-free 
conditions and this was highly significant (P<0.01) after 36 hours; the debris 
amount was also significantly increased by culturing on thymidine (Figure 7.8). 
We conclude that any significant interruption of pyrimidine nucleotide 
availability leads to major defects in DNA synthesis. 
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Figure 7.8. Figure 7.8. Quantitative analysis of DNA content in pyrimidine-starved 
trypanosomes. The peak area of G1, S-phase, G2 and debris of flow cytometric analysis 
of DNA content (Figure 7.7) was determined using the ModFit software package after 24 
or 36 hours of growth under various culturing conditions. Growth was in HMI-9 
(considered as a control in each frame) or in HMI-9
-tmd
 with or without the addition of 100 
µM of one pyrimidine as indicated. The data are the average of 3 - 6 independent 
determinations and statistical analysis was performed using one-way ANOVA with 
Tukey's correction (Prism 5, GraphPad), relative to the HMI-9 control. *, P<0.05; **, 
P<0.01. 
7.8. Infectivity of pyrimidine auxotrophic T. b. brucei in 
mice 
The observation (Figure 7.4) that pyrimidine auxotrophic Pyr6-5-/- cells grow in 
standard HMI-9, which contains only thymidine as a pyrimidine source, but 
cannot grow in thymidine-supplemented medium with dialyzed FBS strongly 
suggest that (1) T. b. brucei cannot use thymidine as its sole pyrimidine source 
and (2) it is able to salvage sufficient amounts of other pyrimidines from the 
non-dialyzed serum. It could thus be speculated that pyrimidine auxotrophic 
trypanosomes should be able to survive in vivo. To test this, we infected groups 
of 6 mice with a high inoculum of 105 trypanosomes of s427-WT, Pyr6-5+/- or 
Pyr6-5-/- strains and followed survival and parasitaemia for 15 days. Figure 7.9A 
shows that WT trypanosomes were the most virulent and killed all mice between 
4 and 8 days. The single allele knockout strain Pyr6-5+/- caused the death of four 
mice by day 5 but two of the animals survived until day 12. In contrast, all the 
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animals inoculated with Pyr6-5-/- survived until day 15, when the experiment was 
terminated. However, the auxotrophs were able to survive and to multiply in the 
host, as evidenced by the average parasitaemia, which reached levels of 106 
cells/ml albeit much more slowly than the other strains (Figure 7.9B). We 
conclude that T. brucei can salvage just enough uracil and/or uridine in vitro to 
maintain an infection. 
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Figure 7.9. Infectivity of pyrimidine auxotrophic T. b. brucei. A. Survival of mice 
in groups of 6, each inoculated with 10
5
 bloodstream form trypanosomes of 
various clonal lines. B. Parasitaemia of the same mice as depicted for survival in 
panel A. The average parasitaemia of the surviving mice is shown. Detection 
was by phase-contrast microscopy and detection limit was 1×10
4
; where the 
infected was sub-patent, a value of 5000 cells ml
-1
 was inserted in order to arrive 
at a reasonable average. Both panels: ○, WT s427; ■, PYR6-5
+/-
; ▲, PYR6-5
-/-
.
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7.9. Discussion 
Kinetoplastid parasites are able to salvage preformed pyrimidine nucleobases 
and/or nucleosides (Al-Salabi et al., 2007; Bellofatto, 2007; De Koning et al., 
2005; Landfear et al., 2004; Papageorgiou et al., 2005) as well as synthesise 
them de novo from glutamine and aspartate (Hammond & Gutteridge, 1982). The 
two pathways converge at UMP, the end-product of the 6-step biosynthesis 
pathway as well as the nexus for salvaged cytidine, uridine, 2’deoxyuridine, 
2’deoxycytidine and uracil, through the actions of cytidine deaminase, uridine 
phosphorylase and uracil phosphoribosyltransferase (UPRT). From UMP the cell 
can then make all pyrimidine ribonucleotides and 2’deoxyribonucleotides that it 
needs, through non-redundant pathways. Salvaged thymidine can be utilised as 
thymidine nucleotides but not to produce any other pyrimidine nucleotides (Ali 
et al., 2013a; Berens et al., 1995; Hassan & Coombs, 1988) and both procyclic 
and bloodstream form trypanosomes take up thymidine very poorly (Ali et al., 
2013a; Gudin et al., 2006). Therefore it is clear that pyrimidine metabolism in 
protozoa must be replete with good drug targets. Indeed, T. b. brucei DHFR-TS, 
CTP synthetase and dUTPase have all been shown already to be essential 
enzymes (Castillo-Acosta et al., 2008; Hofer et al., 2001; Sienkiewicz et al., 
2008). These enzymes are all in the pathways downstream from UMP and thus 
shared by the salvage route and the biosynthesis route. 
 What is less clear is whether either of the two biochemical pathways to 
obtain UMP in the first place might be essential and thus a potential drug target. 
In order to therapeutically target the salvage pathway to UMP it would be 
necessary to inhibit either the uptake of uracil, uridine, 2’deoxyuridine, cytidine 
and 2’deoxycytidine, or to inhibit UPRT. With regards to the former option it 
should be noted that cytidine and 2’deoxycytidine are incorporated very poorly 
into the T. b. brucei nucleotide pool (Ali et al., 2013a; Hofer et al., 2001) and it 
would thus only be necessary to inhibit the carriers for uracil, 2’deoxyuridine 
and uridine, and we recently reported that all three are mediated by the same 
transporter, TbU3, in bloodstream forms (Ali et al., 2013a). However, we report 
here that WT trypanosomes (i.e. pyrimidine prototrophs) grow almost 
unimpeded in the absence of any pyrimidine source and must conclude that 
neither pyrimidine transporters nor UPRT are essential functions in bloodstream 
form T. b. brucei - consistent with a recent report that deletion of UPRT in L. 
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donovani promastigotes created a pyrimidine prototrophic parasite with normal 
in vitro growth (Wilson et al., 2012). It can thus be concluded that pyrimidine 
salvage is not an essential function for trypanosomes. 
 (Arakaki et al., 2008) previously investigated whether the de novo 
biosynthesis route to UMP was essential to T. b. brucei in vitro; they employed 
RNA-interference (RNAi) to reduce expression of T. brucei dihydroorotate 
dehydrogenase (DHODH). These authors reported that knockdown of this enzyme 
did not affect growth in standard HMI-9 but greatly reduced growth in 
pyrimidine-depleted medium using a commercial dialysed serum. Our own 
observations with a PYR6-5-/- strain are entirely consistent with Arakaki’s report: 
the growth rate of pyrimidine auxotrophs is at most slightly affected in normal 
medium with non-dialysed serum. As shown in Appendix I, thymidine (20 mg/L, 
i.e. ~83 µM) is the only pyrimidine added to that medium but since this 
nucleoside cannot be converted to uridine and cytidine nucleotides by T. b. 
brucei, it is redundant (Ali et al., 2013a; Gao et al., 1999) and clearly the serum 
provides sufficient pyrimidines for growth, consistent with the average uracil 
concentration of 0.17 ± 0.05 µM in human plasma (Bi et al., 2000) and high 
affinity uptake of pyrimidines, particularly uracil, by T. brucei (Ali et al., 2013a; 
De Koning & Jarvis, 1998). We thus conclude that pyrimidine biosynthesis is not 
essential for in vitro growth, and the fact that even 10% FBS supplies sufficient 
pyrimidines, seems to indicate that it may not be essential for in vivo growth 
either. 
This was tested by infecting mice with s427-WT, PYR6-5+/- and PYR6-5-/- 
trypanosomes. All three strains were able to maintain an infection and although 
the homozygous knockout strain was clearly less virulent, it unambiguously 
establishes that inhibition of the de novo pyrimidine biosynthesis is not a viable 
therapeutic strategy against African trypanosomes. These findings are very 
similar to those reported for promastigote L. donovani (French et al., 2011) but, 
in contrast to the authors of that report, we contend that the fact that 
disruption of pyrimidine biosynthesis can be compensated for by physiological 
levels of pyrimidines demonstrates that this pathway is not essential in 
kinetoplastids, and not a viable drug target. Indeed, the same authors very 
recently demonstrated that L. donovani that lack carbamoyl phosphate 
synthetase, and are thus pyrimidine auxotrophic, were able to establish a 
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‘robust’ infection in mice (Wilson et al., 2012). It is noteworthy, however, that 
Leishmania species are obligated intracellular parasites and that the current 
report is the first assessment of in vivo growth of an extracellular pyrimidine-
auxotrophic protozoan. This is relevant as the intracellular and extracellular 
nucleoside and nucleobase levels are potentially very different, with the 
intracellular purines and pyrimidines overwhelmingly existing as nucleotides, 
which cannot be taken up directly by protozoan transporters (De Koning et al., 
2005). In addition, a previous report on pyrimidine-auxotrophic Toxoplasma 
gondii, another obligate intracellular protozoan, showed that these parasites 
were completely avirulent even in immune-compromised mice (Fox & Bzik, 2002) 
- a phenotype attributed to the lack of free pyrimidines within animal cells 
which also prevents growth of pyrimidine auxotrophic bacteria (Fields et al., 
1986). 
Inhibition of the pyrimidine biosynthesis pathway in T. b. brucei greatly 
sensitises the trypanosomes to cytotoxic pyrimidine analogues such as 5-
fluorouracil, 5-fluoro-2’deoxyuridine, 5-fluorodeoxycytidine and 5-fluorouridine 
(Table 7.1). The enhanced effect of 5-fluorouracil was also noted by Arakaki et 
al., (2008), who attributed it to inhibition of uracil uptake. Whilst this analogue 
is indeed a competitive inhibitor of uracil transport in T. brucei, none of these 
fluorinated pyrimidines would sufficiently inhibit uracil uptake in bloodstream 
forms at the EC50 values given in Table 7.1, especially not 5F-2’deoxyuridine or 
5F-2’deoxycytidine (Ali et al., 2013a). As an alternative explanation, we propose 
that these fluorinated pyrimidines enter the trypanosomes as prodrugs and 
subversive substrates for the pyrimidine salvage enzymes, are converted to 
nucleotides and incorporated into nucleic acids, as indeed is the case in 
mammalian cells (Longley et al., 2003) and as we have recently shown for 5-
fluorouracil in T. b. brucei (Ali et al., 2013a). This incorporation is more 
efficient in the absence of a newly synthesised pool of pyrimidine metabolites 
that would compete with the halogenated analogues at the level of each enzyme 
as well as for RNA and/or DNA polymerases. 
We thus conclude that an inhibitor of any one of the enzymes of the de 
novo pathway together with either an inhibitor of uracil/uridine uptake, or with 
a cytotoxic nucleoside analogue, would be a powerful and synergistic 
combination that would act on trypanosomes through both misincorporation of 
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false nucleotides, and by causing pyrimidine starvation through inhibition of 
pyrimidine carriers, and we found that trypanosome populations die much more 
quickly from a lack of pyrimidines than from a lack of purines (Ali et al., 2013b; 
De Koning & Diallinas, 2000). It can easily be speculated that kinetoplastid 
parasites, having evolved without the capacity to synthesise their own purines, 
must be relatively well-adapted to periods with low purine availability, as 
demonstrated by the reversibility of purine starvation-induced growth arrest (De 
Koning & Diallinas, 2000). In contrast, they have not needed to develop a 
mechanism to cope with a prolonged dearth of pyrimidines, being able to make 
sufficient amounts themselves, and trypanosomes are therefore unable to 
recover from even short periods of pyrimidine starvation. We did observe, 
consistently, increased expression of uridine phosphorylase, and an increase in 
uracil uptake capacity (both about two-fold), in pyrimidine-starved 
trypanosomes but this hardly constitutes a major upregulation of the pyrimidine 
salvage pathway and it is at best uncertain whether this is a regulated, 
physiological response to low pyrimidine levels. Indeed, the lack of a regulated 
response to the insufficient level of pyrimidine nucleotides was manifest in the 
major defects in DNA synthesis after only 24 hours, leading to fragmented and 
incomplete chromosomes. 
In summary, we have shown that neither pyrimidine uptake or de novo 
biosynthesis is essential in African trypanosomes but that a drug combination 
targeting both systems would be a very powerful and novel therapeutic approach 
against kinetoplastid parasites. 
 
 
 
CHAPTER EIGHT 
Genome analyses of Trypanosoma and Leishmania 
lines resistant to fluorinated pyrimidines 
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8.1 Introduction 
Pyrimidine analogues showed anti-metabolite activities against Trypanosoma and 
Leishmania parasites; therefore, new cell lines that were highly resistant to 
these analogues were generated as part of the investigation of pyrimidine 
metabolism as a drug target. The biochemical and metabolomic 
characterizations showed that the resistance mechanism to fluorinated 
pyrimidines varied between the indicated kinetoplastids. In recent years, the 
sequencing of whole genomes has become a possible avenue to investigate drug 
adaption in microorganisms such as bacteria (Feng et al., 2009; Howden et al., 
2008; Lescat et al., 2009; Mwangi et al., 2007), as well as protozoa such as 
Plasmodium species (Hunt et al., 2010; Martinelli et al., 2011). Despite the fact 
that the chromosome copy number was found to be diverse within different 
species and strains of Leishmania (Rogers et al., 2011), the whole genome of L. 
major resistant to miltefosine drug was generated and this allowed the 
identification of the resistance factors connected with miltefosine resistance in 
Leishmania (Adriano-Coelho et al., 2012). However, the genome of kinetoplastid 
parasites that were resistant to fluorinated pyrimidines has thus far not been 
examined. In order to identify genes potentially associated with resistance to 
fluorinated pyrimidines in kinetoplastid cells, the entire genomes of resistant 
strains were sequenced in parallel with their parental wild-type strains. Several 
alignment services have been used to analyze sequences, such as 
Illumina/Solexa, AB/SOLiD and Roche/454 (Langmead et al., 2009; Ley et al., 
2008; Li et al., 2008). We made Illumina paired-end sequencing libraries that 
were sequenced on Illumina HiSeq machines as described in Materials and 
Methods chapter (section 2.6.5), in collaboration with the Wellcome Trust 
Sanger Institute (Hinxton, UK). 
This generated high-quality genome sequences for kinetoplastids resistant to 
fluorinated pyrimidines, which were used to investigate the genetic variations 
amongst resistant lines and their background wild-type. For a given resistant 
line, single nucleotide polymorphisms (SNPs) were identified by comparison with 
parental wild-type strains (T. b. brucei strain 427, L. mexicana strain M379 and 
L. major strain Friedlin). Also read depth coverage was used to predict the 
amplifications or deletions of chromosomal regions, and other copy number 
variations (CNVs) against the background of each relative strain. 
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8.2 Genome analysis of T. b. brucei resistant to 
fluorinated pyrimidines 
The copy number of chromosomal domains was examined using read depth 
coverage for each chromosome of the resistant lines (Tbb-5FURes, Tbb-
5F2’dURes and Tbb-5FOARes) which were compared with BSF T. b. brucei s427 
parental wild-type. Any changes could obviously account for the complete loss of 
a particular metabolite or transport activity. The genome analysis data showed 
that neither medium scale nor large scale changes in copy number could be 
observed when the read depth of adapted lines were normalized against the 
whole genome of T. b. brucei strain 427 wild-type (Figure 8.1A&B) - i.e. no 
significant deletions or duplications were observed in the drug-resistant lines of 
T. b. brucei. These findings suggest that genomes of T. b. brucei bloodstream 
forms are very consistent. 
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Figure 8.1 Copy number sequencing analysis for all Trypanosoma chromosomes of T. b. 
brucei strain 427 wild-type, Tbb-5FURes, Tbb-5F2’dURes and Tbb-5FOARes. The eleven 
chromosomes have been mapped on a medium and large scale. A. The coverage was 
normalized against the median coverage of the whole genome for a given strain, the graph 
shows that the DNA sequence of individual strains is identical to parental line. The y-axis 
represents fold-change of coverage for a particular region of the chromosome compared to 
the genome-wide median coverage. y-axis: 1.0 is the "neutral" value, 1.5 would be a 50% 
increase in coverage [e.g. by duplication of one of the homologous chromosomes of a pair, 
creating a trisomy for the corresponding chromosome], and 0.5 would be a 50% reduction in 
coverage (loss of one of the two homologous chromosomes of a pair) the coverage of the 
parental wild-type strain is represented with a thick black line. B. Coverage relative to 
parental strain, essentially shows the difference between a coloured line (red line for Tbb-
5FURes, green line for Tbb-5F2’dURes and blue line for Tbb-5FOARes) and the parental 
black line of Plot A; this makes it easier to spot real changes in coverage in a drug-resistant 
line compared to the parental line, regardless of uneven coverage in the parental line 
(caused by varying degrees of repetitiveness or by sequence duplications not represented 
in the reference genome [e.g. VSG genes in T. brucei]; y-axis: 0 is the "neutral" value, 0.5 
would be a 50% increase in coverage, and -0.5 would be a 50% reduction in coverage. 
 
 
J. Ali 2013 Chapter 8 205 
 
8.3 Genome analysis of L. mexicana resistant to 5-
fluorouracil 
When L. mexicana cells were adapted to survive and proliferate in 500 μM of 5-
FU, four single cells were isolated and cloned from the population and 
designated intermediate adapted clones 1-4 to 5-FU (Int-Lmex-5FURes). 
Meanwhile, the rest of the culture was kept to grow under increased drug 
pressure until it became resistant to very high concentrations of 5-FU (up to 5 
mM); these cells were finally cloned out and designated Fin-Lmex-5FURes. We 
obtained four clones of intermediate strains (Lmex-Int-5FURes) and three clones 
of final adapted cells (Lmex-Fin-5FURes). [Note: in chapter 4 we only assessed 
clone Fin2-Lmex-5FURes]. The whole genome of each resistant clone was 
sequenced and compared with parental wild-type. The genome analysis of L. 
mexicana resistant to 5-fluorouracil (Int-Lmex-5FURes and Fin-Lmex-5FURes) 
showed different CNVs compared with L. mexicana M379-WT. Changes in 
chromosomes 3, 4, 8, 11, 22, 29, 31, 32 and 34 in drug resistance lines were 
observed in various clones; all other chromosomes are presumably normal 
diploid (Table 8.1). 
Chromosome 3: the Fin2-Lmex-5FURes strain had lost the start of this 
chromosome on one of its 2 homologous chromosomes (Figure 8.2; yellow line). 
 
Figure 8.2. The coverage on chromosome 3 normalized against the median coverage 
of the whole genome for indicated strains; the yellow line referred to Fin2-Lmex-5FURes 
strain, which lost the start of chromosome 3 on one of its 2 homologous chromosomes. 
The y-axis represents fold-change of coverage for a particular region of the 
chromosome compared to the genome-wide median coverage. y-axis: 1.0 is the 
"neutral" value, 1.5 would be a 50% increase in coverage [e.g. by duplication of one of 
the homologous chromosomes of a pair, creating a trisomy for the corresponding 
chromosome], and 0.5 would be a 50% reduction in coverage (loss of one of the two 
homologous chromosomes of a pair) the coverage of the parental WT strain is 
represented with a thick black line. 
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It could be speculated that, as the loss of the start of the polycistron on 
this chromosome is also likely to impact the transcription of the rest of this 
polycistron, this CNV could impact on the expression of all genes up to 
LmxM.03.0680, including eight hypothetical proteins (LmxM.03.0370, 
LmxM.03.0380, LmxM.03.0400, LmxM.03.0410, LmxM.03.0490, LmxM.03.0550, 
LmxM.03.0650 and LmxM.03.0660). These open reading frames (ORFs) started 
from 124,634 to 126,607 and their function was given as "unspecified product"; 
however, they were predicted to contain more than 4 Trans-Membrane domains 
(i.e. LmxM.03.0410 contains predicted 12 TM helices; Figure 8.3). 
 
Figure 8.3 The TMHMM Server v. 2.0 predicted 12 transmembrane helices 
for the protein encoded by gene LmxM.03.0410 located on chromosome 3 
of L. mexicana. 
Furthermore, Fin2-Lmex-5FURes and Fin3-Lmex-5FURes lost 
heterozygosity over the first 140 kb of chromosome 3, which is a difference from 
the parental line L. mexicana M379-WT and from Fin1-Lmex-5FURes. Only Fin2-
Lmex-5FURes showed a deletion of the first 90kb of the chromosome sequence in 
one of the two chromosomes (Figure 8.4). 
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Figure 8.4. Chromosome 3 of L. mexicana strains on Artemis entry; 1st row 
M379-WT, 2nd row Fin1-Lmex-5FURes, 3rd row Fin2-Lmex-5FURes and 4th 
row Fin3-Lmex-5FURes. The red arrow shows that Fin2 and 3 of Lmex-
5FURes lost heterozygosity over first 140 kb, but only the former lost the first 
90 kb of sequence in one of the two chromosomes. 
Chromosome 4: L. mexicana M379-WT and all the three Fin-Lmex-5FURes strains 
have increased coverage for chromosome 4, whereas the four Int-Lmex-5FURes 
strains have normal diploid coverage. However, Fin3-Lmex-5FURes has half the 
copy number for the start of the chromosome 4, and Fin2-Lmex-5FURes has 
double copy number up to ~35 kb (Figure 8.5A and B). This area includes: 
LmxM.04.0020 which encodes a pteridine transporter with 12 TM domains, but 
the coverage was amplification not deletion, so this CNV was unlikely to be 
linked to a loss of pyrimidine transport phenotype. Also this region contains 
LmxM.04.0250, which encodes RNA pseudouridylate synthase, the enzyme that 
catalyses the isomerisation of uridine to pseudouridine. This mechanism may 
relate to pyrimidine analogous metabolism but not to the pyrimidine uptake. 
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Figure 8.5 L. mexicana strains coverage on chromosome 4; A. M379-WT and Final 
resistant strains have higher coverage than the 4 intermediate drug-resistant lines. The y-
axis represents fold-change of coverage for a particular region of chromosome 4 
compared to the genome-wide median coverage. y-axis: 1.0 is the "neutral" value, 1.5 
would be a 50% increase in coverage and 0.5 would be a 50% reduction in coverage the 
coverage of the parental WT strain is represented with a black line. B. Fin2-Lmex-
5FURes has a roughly doubled coverage for the first ~35 kb of chromosome 4. Coverage 
relative to parental strain (window size = 40 kb), essentially shows the difference between 
a coloured line and the parental black line of Plot A; y-axis: 0 is the neutral value, 0.5 
would be a 50% increase in coverage, and -0.5 would be a 50% reduction in coverage. 
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Chromosome 8: surprisingly, there was higher coverage in chromosome 8 of L. 
mexicana M379-WT compared to the intermediate and final drug-resistant 
lines for a patch around position 1,456,000 that carries LmxM.08.0720, an 
amastin-like gene, which is transmembrane glycoprotein found on cell surface 
(Figure 8.6). This coverage has no link with the resistance to 5-fluorouracil 
since it was amplification on the parental wild-type strains. 
 
 
Figure 8.6 Coverage on chromosome 8. A. L. mexicana M379-WT showed 
higher coverage around position 1.456 Mbp (red arrow) in contrast to all 
other resistant strains. The y-axis represents fold-change of coverage for a 
particular region of chromosome 8 compared to the genome-wide median 
coverage. y-axis: 1.0 is the "neutral" value, 1.5 would be a 50% increase in 
coverage and 0.5 would be a 50% reduction in coverage the coverage of the 
parental WT strain is represented with a black line.  B. Artemis entry of 
chromosome 8 shows higher coverage for M379-WT compared with 
intermediate resistant strains around position 1,456,000 (inside the red box), 
which carries the amastin-like genes (underlined by a red thick line). 
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Chromosome 11: In figure 8.7, the normalized row sequence read depth shows 
that chromosome 11 has higher coverage in all Fin-Lmex-5FURes, particularly in 
Fin3-Lmex-5FURes, than the four intermediate drug-resistant lines and the 
parental line. This is of particular interest as chromosome 11 carries many 
transporter genes including amino acid transporter LmxM.11.0520 with 9 TM 
domains and a nucleobase transporter (NT4) LmxM.11.0550 with 11 TM domains. 
Amplification of NT4 in all Fin-Lmex-5FURes might somehow be due to the loss 
of uracil transport activity, which could cause an imbalance between purine and 
pyrimidine nucleotides. In L. major, the LmajNT4 specifically transports adenine 
(Ortiz et al., 2009b). The increased coverage of an amino acid transporter 
allowed us to speculate that the resistant cell lines increased pyrimidine 
biosynthesis to recover the loss of the uracil transporter, as the first two steps of 
pyrimidine biosynthesis depend on glutamine and aspartic acid, which are 
salvaged via amino acid transporters. 
 
Figure 8.7 Multiple chromosomal CNVs in the drug resistant of L. mexicana. A. The 
normalized row sequence coverage of chromosome 11 (red square) on a large scale. 
The y-axis represents fold-change of coverage for chromosomes 1-13 compared to 
the genome-wide large coverage, y-axis: 1.0 is the "neutral" value, 1.5 would be a 
50% increase in coverage and 0.5 would be a 50% reduction in coverage the 
coverage of the parental WT strain is represented with a black line. B. Coverage 
relative to parental strain L. mexicana M379-WT essentially shows the difference 
between a coloured line and the parental black line of Plot A; y-axis: 0 is the neutral 
value, 0.5 would be a 50% increase in coverage, and -0.5 would be a 50% reduction 
in coverage. 
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Chromosome 22: Int4-Lmex-5FURes was the only strain that displayed a 50% 
coverage reduction in a region of chromosome 22 that carries the gene 
LmxM.22.1290, which encodes a ribonucleoside-diphosphate reductase (Figure 
8.8A, B and C). These enzymes are crucial in purine and pyrimidine 
interconversions, so that the reduced coverage on this gene occurred very early 
as the changes were only on Int4-Lmex-5FURes. However, the CNV seems not to 
have been retained by the more highly adapted ‘Final’ strains. 
 
 
Figure 8.8 L. mexicana strains coverage on chromosome 22; Int4-Lmex-5FURes has 
50% coverage reduction; the region of chromosome 22 for Int4-Lmex-5FURes is 
underlined with a red line. A. The y-axis represents fold-change of coverage for a 
particular region of chromosome 22 compared to the genome-wide median coverage. y-
axis: 1.0 is the "neutral" value, 1.5 would be a 50% increase in coverage and 0.5 would 
be a 50% reduction in coverage the coverage of the parental WT strain is represented 
with a black line. B. Int4-Lmex-5FURes has 50% coverage reduction of chromosome 22. 
Coverage relative to parental strain (window size = 40kb), essentially shows the 
difference between a coloured line and the parental black line of Plot A; y-axis: 0 is the 
neutral value, 0.5 would be a 50% increase in coverage, and -0.5 would be a 50% 
reduction in coverage. C. Coverage on chromosome 22 of Int4-Lmex-5FURes; Artemis 
entry of chromosome 22 shows 50% coverage reduction compared with parental line 
and other intermediate resistant lines (inside a red circle), which carries the gene 
LmxM.22.1290 (highlighted gene). 
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Chromosome 29 has a slight increase in coverage in all Lmex-5FURes cell lines 
compared to the parental wild type particularly around position 786,000 kbp, 
which includes gene LmxM.29.2200. As this gene encodes a hypothetical 
protein without TM domains, we cannot here suggest whether/how this 
coverage may be associated with the resistance phenotype (Figure 8.9). 
Instead, the data appears to suggest that a reduced copy number is favourable 
for chromosome 29, upon exposure to fluoro-pyrimidines, but that this was not 
possible for the locus containing LmxM.29.2200, perhaps because this is 
encodes an essential protein. 
 
Figure 8.9 All intermediate and final resistant lines of Lmex-5FURes show 
reduced coverage on chromosome 29 compared with the parental line. 
However, the Artemis analysis shows a 50% coverage increase at location 
around 786 kbp (red arrow) compared with parental line, which carries the gene 
LmxM.29.2200 (highlighted gene). 
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Chromosome 31: the parental line appears to have a trisomy for a large 
section of chromosome 31 but none of the drug-resistant lines do (Figure 
8.10). 
 
Figure 8.10. Multiple chromosomal CNVs in L. mexicana M379-WT and 
resistant line. A. The normalized row sequence coverage of chromosome 31 
(marked region) on a large scale. The y-axis represents fold-change of 
coverage for chromosome 31 compared to the genome-wide large coverage, 
y-axis: 1.0 is the "neutral" value, 1.5 would be a 50% increase in coverage 
and 0.5 would be a 50% reduction in coverage the coverage of the parental 
WT strain is represented with a black line. B. Coverage relative to parental 
strain L. mexicana M379-WT essentially shows the difference between a 
coloured line and the parental black line of Plot A; y-axis: 0 is the neutral 
value, 0.5 would be a 50% increase in coverage, and -0.5 would be a 50% 
reduction in coverage. 
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Chromosome 32: All drug-resistant lines have double coverage in the region 
~916,000 - 1,175,000, compared to the parental line, which includes UDP-glc 4'-
epimerase (LmxM.32.2300) and UDP-N-acetylglucosamine pyrophosphorylase 
(LmxM.32.2520) this duplication must have happened quite early during drug-
adaptation (Figure 8.11). Interestingly, the level of UDP-N-acetyl-D-glucosamine 
was elevated in the metabolomic analyses after treatment with 5F2’dUrd 
(P=0.045 for L. mexicana and P=0.034 for L. major); it was also increased upon 
incubation with 5F-uracil and 5F-uridine, although this was not statistically 
significant (see Chapter 4). 
 
Figure 8.11. Resistant strains of L. mexicana have doubled coverage on 
chromosome 32 (red box). A. The y-axis represents fold-change of coverage for 
chromosome 32 compared to the genome-wide median coverage. y-axis: 1.0 is 
the "neutral" value, 1.5 would be a 50% increase in coverage and 0.5 would be a 
50% reduction in coverage the coverage of the parental WT strain is represented 
with a black line. B. All resistant strains show doubled coverage in region 0.916-
1.175 Mbp of chromosome 32. Coverage relative to parental strain, essentially 
shows the difference between a coloured line and the parental black line of Plot 
A; y-axis: 0 is the neutral value, 0.5 would be a 50% increase in coverage, and -
0.5 would be a 50% reduction in coverage. 
 
J. Ali 2013 Chapter 8 215 
 
Chromosome 34: Int2-Lmex-5FURes showed a 50% increased coverage around 
positions 1,790,000 - 1,890,000 (Figure 8.12). This region includes 
LmxM.34.5150, the biopterin transporter with 14 TM domains. As this coverage 
appeared only on Int2-Lmex-5FURes it is not associated with the high resistant to 
5-FU. 
 
Figure 8.12 Int-Lmex-5-FURes strain has 50% increased coverage around position 
1.79-1.89 Mbp (labelled in red). A. The y-axis represents fold-change of coverage for 
chromosome 34 compared to the genome-wide median coverage. y-axis: 1.0 is the 
"neutral" value, 1.5 would be a 50% increase in coverage and 0.5 would be a 50% 
reduction in coverage the coverage of the parental WT strain is represented with a 
black line. B. Int-Lmex-5-FURes strain shows 50% coverage in region 1.79-1.89 Mbp of 
chromosome 34. Coverage relative to parental strain essentially shows the difference 
between a coloured line and the parental black line of Plot A; y-axis: 0 is the neutral 
value, 0.5 would be a 50% increase in coverage, and -0.5 would be a 50% reduction in 
coverage. 
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Table 8.1: CNVs on L. mexicana strains 
Gene ID Gene product and function TMd strains Changes description 
Chromosome 3 
LmxM.03.0370 Unspecified product; unknown function 5 Fin2-Lmex-5FURes and  
Fin3-Lmex-5FURes 
Both strains have lost heterozygosity over first 
140 kb; only Fin2-Lmex-5FURes lost the first 
90 kb of sequence in one of the two 
chromosomes. 
LmxM.03.0380 6 
LmxM.03.0400 6 
LmxM.03.0410 12 
LmxM.03.0490 7 
LmxM.03.0550 5 
LmxM.03.0650 9 
LmxM.03.0660 9 
Chromosome 4 
LmxM.04.0020 Pteridine transporter (truncated) putative. 
Pteridine is a chemical compound composed of 
fused pyrimidine and pyrazine rings. 
12 Fin1-Lmex-5FURes, Fin2-
Lmex-5FURes , Fin3-Lmex-
5FURes and M379-WT  
Increased coverage (duplication) for chr. 4. 
Fin3-Lmex-5FURes has half the copy number 
for the start of chr. 4, Fin2- Lmex-5FURes has 
double copy number  
LmxM.04.0090 Hypothetical protein, conserved; unknown 
function. 
0 Fin1-Lmex-5FURes, Fin2-
Lmex-5FURes , Fin3-Lmex-
5FURes and M379-WT  
Increased coverage (duplication) for chr. 4. 
Fin3-Lmex-5FURes has half the copy number 
for the start of chr. 4, Fin2- Lmex-5FURes has 
double copy number  
LmxM.04.0250 RNA pseudouridylate synthase-like protein. 
Pseudouridine synthases catalyse the 
isomerisation of uridine to pseudouridine 
0 Fin2-Lmex-5FURes and Fin3-
Lmex-5FURes 
Halved reduction in coverage 
LmxM.04.0280 Adenosine monophosphate deaminase catalyzes 
the hydrolytic deamination of AMP into inosine 
monophosphate (IMP). 
0 Fin2-Lmex-5FURes and Fin3-
Lmex-5FURes 
Halved reduction in coverage 
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Table 8.1 continued CNVs on L. mexicana strains 
Gene ID Gene product and function TMd strains Changes description 
Chromosome 8 
LmxM.08.0720 Amastin-like protein, putative. Amastin surface 
glycoprotein family contains the eukaryotic 
surface glycoprotein amastin. 
3 L. mexicana M379-WT Higher coverage increase (amplification) 
Chromosome 11 
LmxM.11.0520 Amino acid transporter, putative. The best 
conserved region in this family is located in the 
second transmembrane segment. 
9 Fin1-Lmex-5FURes, Fin2-
Lmex-5FURes and Fin3-Lmex-
5FURes 
High increased coverage (amplification). 
LmxM.11.0550 Nucleobase transporter (NT4). These proteins 
enable the movement of hydrophilic nucleosides 
and nucleoside analogous across cell membranes. 
11 Fin1-Lmex-5FURes, Fin2-
Lmex-5FURes and Fin3-Lmex-
5FURes 
High increased coverage (amplification). 
Chromosome 22 
LmxM.22.1290 Ribonucleoside-diphosphate reductase small 
chain, putative, also known as ribonucleotide 
reductase (RNR). It catalyzes the formation of 
deoxyribonucleotides from ribonucleotides. The 
substrates for RNR are ADP, GDP, CDP and 
UDP. 
0 Int4-Lmex-5FURes 50% reduction in coverage. 
Chromosome 29 
LmxM.29.2200 Hypothetical protein, conserved; unknown 
function 
0 All FinLmex-5FURes and Int-
Lmex-5FURes strains 
Slight reduction in coverage. 
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Table 8.1 continued CNVs on L. mexicana strains 
Gene ID Gene product and function TMd strains Changes description 
Chromosome 32 
LmxM.32.2300 UDP-glc 4'-epimerase, putative; activity 
coenzyme binding. It catalyses the conversion of 
UDP-galactose to UDP-glucose during galactose 
metabolism. 
0 All FinLmex-5FURes and Int-
Lmex-5FURes strains 
Doubled increased in converge (amplification). 
LmxM.32.2520 UDP-N-acetylglucosamine pyrophosphorylase, 
putative. The enzyme catalyzes the chemical 
reaction UTP + N-acetyl-alpha-D-glucosamine 1-
phosphate  diphosphate + UDP-N-acetyl-D-
glucosamine 
0 All FinLmex-5FURes and Int-
Lmex-5FURes strains 
Doubled increased in converge (amplification). 
Chromosome 34 
LmxM.34.5150 Biopterin transporter. Biopterin is a coenzyme, it 
is an oxidized degradation product of 
tetrahydrobiopterin 
14 Int2-Lmex-5FURes 50% increased in coverage. 
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8.4 Genome analysis of L. major resistant to fluorinated 
pyrimidines. 
Strains of L. major promastigotes with high levels of resistance to fluorinated 
pyrimidine analogues were generated. One such strain was L. major resistant 
to 5-FU (Lmaj-5FURes) and the other strain was resistant to 5F-2’dUrd (Lmaj-
5F2’dURes). The extracted DNA from the adapted cell lines was full genome 
sequenced in parallel parental wild type (L. major sFriedlin-WT). The 
adapted L. major clones displayed CNVs on several different chromosomes (2, 
6, 12, 14, 18, 20, 31 and 33; see Table 8.2 for an overview). 
Chromosome 2: Lmaj-5FURes has apparently lost a section from chromosome 
2 around positions 97,000 - 110,000 carrying phosphoglycan 
galactosyltransferase genes (Figure 8.13A, B and C). It was reported that L. 
major has 8 copies of this gene in different chromosomes (Raymond et al., 
2012). Phosphoglycan β-1,3 galactosyltransferase plays a significant role in 
binding with side chain oligosaccharides (Dobson et al., 2003) and the lack of 
this activity prevented L. major infection of the sand fly vector (Butcher et 
al., 1996), but its association with pyrimidine antimetabolite resistance is not 
immediately clear and would require further investigation. 
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Figure 8.13. The Lmaj-5FURes strain has lost about 13 kbp of chromosome 2 which 
carries phosphoglycan galactosyltransferase genes. A. The y-axis represents fold-
change of coverage for chromosome 2 compared to the genome-wide median 
coverage. y-axis: 1.0 is the "neutral" value, 1.5 would be a 50% increase in coverage 
and 0.5 would be a 50% reduction in coverage the coverage of the parental WT strain 
is represented with a black line. B. Chromosome 2 region shows the coverage of 
Lmaj-5FURes. Coverage relative to parental strain essentially shows the difference 
between a coloured line and the parental black line of Plot A; y-axis: 0 is the neutral 
value, 0.5 would be a 50% increase in coverage, and -0.5 would be a 50% reduction 
in coverage. C. Lmaj-5FURes shows the coverage on chromosome 2 compared with 
parental line; Artemis entry of chromosome 2 shows 50% coverage reduction at 
location around 786 kbp (red mark) compared with the parental line, which carries the 
gene LmjF.02.0200 (highlighted gene). 
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Chromosome 6: Lmaj-5F2’dURes has double coverage in a region (around 
140,000) carrying ~3 genes: two genes are 60S ribosomal protein L19 
(LmjF.06.0410; LmjF.06.0415); one gene is a hypothetical protein 
(LmjF.06.0412; Figure 8.14 A, B and C). It is not clear how the amplified 
coverage of this gene on Lmaj-5F2’dURes might influence sensitivity to 5F-
2’dUrd, particularly since this gene (LmjF.06.0412) does not have any trans-
membrane domains, but may linked to unknown function of metabolomic 
enzymes. 
 
 
Figure 8.14. The Lmaj-5F2’dURes strain has double coverage for the region around 
140 kbp of chromosome 6, which carries about 3 genes. A. The y-axis represents fold-
change of coverage for chromosome 6 compared to the genome-wide median 
coverage. y-axis: 1.0 is the "neutral" value, 1.5 would be a 50% increase in coverage 
and 0.5 would be a 50% reduction in coverage the coverage of the parental WT strain 
is represented with a black line. B. Chromosome 6 shows the coverage of Lmaj-
5F2’dURes. Coverage relative to parental strain essentially shows the difference 
between a coloured line and the parental black line of Plot A; y-axis: 0 is the neutral 
value, 0.5 would be a 50% increase in coverage, and -0.5 would be a 50% reduction 
in coverage. C. Lmaj-5F2’dURes shows the coverage on chromosome 6 compared 
with parental line; Artemis entry of chromosome 6 shows double coverage at location 
around 140 kbp (red box) compared with parental line. 
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Chromosome 12: in Lamj-5FURes, apparent CNV for surface antigen protein, 
this coverage is very likely irrelevant to the pyrimidine uptake or metabolism 
(Figure 8.15). 
 
Figure 8.15. Artemis entry of chromosome 12 shows small reduction 
coverage for Lmaj-5FURes on chromosome 12 (red box) compared with 
parental line. 
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Chromosome 14: Lmaj5FURes has 50% reduction in coverage over region 
550,000 - 579,000 carrying 9 genes (Figure 8.16), including the gene encoded 
a pteridine transporter (LmjF.14.1355). This gene has only 3 TM domains; the 
other eight genes have various functions and are not linked to pyrimidine 
transporter since they have no TM domains, with exception of delta-4 fatty 
acid desaturase (LmjF.14.1340) which has 4 TM domains. Interestingly, one of 
these eight genes that is located in the same region is LmjF.14.1320. The 
gene encodes serine hydroxymethyl transferase, which may contribute to 
Lmaj-5FURes resistance to 5-FU, as the enzyme involved in the dTMP cycle. 
 
 
Figure 8.16. Lmaj-5FURes has 50% reduction in coverage for a region of ~29 kbp of 
chromosome 14, which carries 9 genes. A. The y-axis represents fold-change of 
coverage for chromosome 14 compared to the genome-wide median coverage. y-axis: 
1.0 is the "neutral" value, 1.5 would be a 50% increase in coverage and 0.5 would be a 
50% reduction in coverage the coverage of the parental WT strain is represented with a 
black line. B. Chromosome 14 shows 50% reduction in coverage. Coverage relative to 
parental strain essentially shows the difference between a coloured line and the parental 
black line of Plot A; y-axis: 0 is the neutral value, 0.5 would be a 50% increase in 
coverage, and -0.5 would be a 50% reduction in coverage. C. Lmaj-5FURes shows 50% 
reduction in coverage on chromosome 14 compared with parental line; Artemis entry of 
chromosome 14 shows the 50% reduction in coverage (red mark) compared with 
parental line. 
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Chromosome18: Lmaj5FURes has double coverage around position 704,000 
carrying one hypothetical gene LmjF.18.1570, which has no TM domains 
(Figure 8.17A, B and C). As the protein has no known function it is not 
possible to speculate on any role it may have in Lmaj-5-FURes resistance. 
 
 
Figure 8.17. Lmaj-5FURes strain has double coverage around position 704 kbp of 
chromosome 18, which encodes a hypothetical gene. A. The y-axis represents fold-
change of coverage for chromosome 18 compared to the genome-wide median 
coverage. y-axis: 1.0 is the "neutral" value, 1.5 would be a 50% increase in coverage 
and 0.5 would be a 50% reduction in coverage the coverage of the parental WT 
strain is represented with a black line. B. Chromosome 18 shows the coverage of 
Lmaj-5FURes. Coverage relative to parental strain essentially shows the difference 
between a coloured line and the parental black line of Plot A; y-axis: 0 is the neutral 
value, 0.5 would be a 50% increase in coverage, and -0.5 would be a 50% reduction 
in coverage. C. Lmaj-5FURes shows the coverage on chromosome 18 compared 
with parental line; Artemis entry of chromosome 18 shows doubled coverage at 
location around 704 kbp (red box) compared with the parental line. 
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Chromosome 20: Lmaj5FURes has 50% coverage around position 535,000 bp 
carrying two calpain-like cysteine peptidase genes; neither LmjF.20.1180 nor 
LmjF.20.1185 has TM domains (Figure 8.18). It was suggested that part of 
programmed cell death(Gonzalez et al., 2007) in L. major has been 
associated with cysteine proteinases (Arnoult et al., 2002), but this idea was 
criticized by (Mottram et al., 2004) when they claimed that L. major genome 
has no caspase genes. Here we believe that the calpain-like cysteine 
peptidase genes (LmjF.20.1180 and LmjF.20.1185) in Lmaj5FURes may in part 
be involved in L. major  mechanisms of resistance to 5-FU; however, we 
could not observe these changes in the other kinetoplastid resistance lines, 
which is in agreement with (Kaczanowski et al., 2011) findings when they 
conclude that the mechanisms of PCD in protozoa parasites are due to 
divergent evolution. 
 
 
Figure 8.18. Lmaj-5FURes strain has halved coverage around position 535 kbp of 
chromosome 20. A. Chromosome 20 shows 50% coverage. Coverage relative to parental 
strain essentially shows the difference between a coloured line and the parental black line 
of Plot A; y-axis: 0 is the neutral value, 0.5 would be a 50% increase in coverage, and -0.5 
would be a 50% reduction in coverage. B. Lmaj-5FURes shows halved coverage on 
chromosome 20 compared with parental line; Artemis entry of chromosome 20 (red box) 
compared with the parental line. 
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Chromosome 29: Lmaj-5F2’dURes has a 50% increase in coverage around 
position 770,000 compared to the parental line and Lmaj-5FURes; this locus 
carries two hypothetical genes, both have no TM domains (Figure 8.19). As 
before, the absence of any functional information on these genes makes it 
impossible to evaluate any role in fluoro-pyrimidine resistance. 
 
 
Figure 8.19. The Lmaj-52’dFURes strain has a 50% higher coverage around position 
770 kbp of chromosome 29, which carries two hypothetical genes. A. The y-axis 
represents fold-change of coverage for chromosome 29 compared to the genome-wide 
median coverage. y-axis: 1.0 is the "neutral" value, 1.5 would be a 50% increase in 
coverage and 0.5 would be a 50% reduction in coverage the coverage of the parental 
WT strain is represented with a black line. B. Chromosome 29 shows the coverage of 
Lmaj-5F2’dURes. Coverage relative to parental strain essentially shows the difference 
between a coloured line and the parental black line of Plot A; y-axis: 0 is the neutral 
value, 0.5 would be a 50% increase in coverage, and -0.5 would be a 50% reduction in 
coverage. C. Lmaj-5F2’dURes shows the coverage on chromosome 29 compared with 
parental line; Artemis entry of chromosome 29 shows a higher level of coverage for 
Lmaj5F-2’dUres (red box) compared with the parental line. 
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Chromosome 31: Both the parental line (L. major sFriedlin-WT) and Lmaj-
5FURes appear to have 5 copies of chromosome 31 whereas Lmaj-5F2’dURes 
has 4 copies. Among the potential genes of interest on this chromosome are 
three hypothetical genes LmjF.31.0030, LmjF.31.0040 and LmjF.31.0300, 
with 12, 11 and 12 TM domains, respectively. The parental line appears to 
have lost the first ~78 kb of this chromosome sequence from 3 of its 5 
chromosome copies. In addition, Lmaj-5FURes seems to have lost the region 
518,000 - 524,000 from two or three of its five chromosome copies, which 
carries gene LmjF.31.1280 (ABCC5) and borders gene LmjF.31.1290 (ABCC6) 
with 6 and 10 TM domains, respectively (Figure 8.20). 
 
 
Figure 8.20. Lmaj-5FURes strain has lost ~6 kbp from at least 2 of its 5 copies of 
chromosome 31. A. Chromosome 31 lost region 518-524 kbp. Coverage relative to 
parental strain essentially shows the difference between a coloured line and the 
parental black line of Plot A; y-axis: 0 is the neutral value, 0.5 would be a 50% 
increase in coverage, and -0.5 would be a 50% reduction in coverage. B. Lmaj-
5FURes shows the lost of chromosome 31. Coverage relative to parental strain 
essentially shows the difference between a coloured line and the parental black line of 
Plot A; y-axis: 0 is the neutral value, 0.5 would be a 50% increase in coverage, and -
0.5 would be a 50% reduction in coverage C. Lmaj-5FURes shows the loss of a 
section of chromosome 31 compared with parental line; Artemis entry of chromosome 
31 (red box) compared with the parental line. 
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Chromosome 33: Lmaj-5FURes has halved coverage around position 759,000 
which affects two genes: peptidase M20/M25/M40 LmjF.33.1610 and 
LmjF.33.1600, a hypothetical protein without any TM domains (Figure 8.21). 
 
 
Figure 8.21. Lmaj-5FURes strain has halved coverage around position 759 kbp of 
chromosome 33. A. Chromosome 33 shows halved coverage. Coverage relative to 
parental strain essentially shows the difference between a coloured line and the 
parental black line of Plot A; y-axis: 0 is the neutral value, 0.5 would be a 50% increase 
in coverage, and -0.5 would be a 50% reduction in coverage. B. Chromosome 33 
shows the coverage of Lmaj-5FURes. Coverage relative to parental strain essentially 
shows the difference between a coloured line and the parental black line of Plot A; y-
axis: 0 is the neutral value, 0.5 would be a 50% increase in coverage, and -0.5 would 
be a 50% reduction in coverage C. Lmaj-5FURes shows halved coverage on 
chromosome 33 compared with parental line; Artemis entry of chromosome 33 (red 
mark) compared with parental line. 
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Table 8.2: CNVs on L. major strains 
Gene ID Gene product and function TMd strains Changes description 
Chromosome 2 
LmjF.02.0200 Phosphoglycan beta 1,3 galactosyltransferase. Played a significant role in 
binding with side chain oligosaccharides 
1 Lmaj-5FURes Lost a region around 
positions 97-110 Kb 
(deletion) 
Chromosome 6 
LmjF.06.0410 
 
60S ribosomal protein L19, putative. Ribosomes are the particles that catalyse 
mRNA-directed protein synthesis in all organisms. 
0 Lmaj-5F2dURes Increased doubled 
coverage 
(amplification) LmjF.06.0415 
Chromosome 12 
LmjF.12.0960 Surface antigen protein 2, putative. Interacting selectively and non-covalently 
with any protein or protein complex. 
2 Lmaj-5FURes Reduction coverage 
(deletion) LmjF.12.0755 
Chromosome 14 
LmjF.14.1355 
 
Pteridine transporter. Pteridine is a chemical compound composed of fused 
pyrimidine and pyrazine rings. 
3 Lmaj-5FURes 50% reduction in 
coverage 
LmjF.14.1320 Serine hydroxymethyltransferase (SHMT) is a pyridoxal phosphate (PLP). 
SHMT catalyses the transfer of a hydroxymethyl group from N5, N10- 
methylene tetrahydrofolate to glycine, resulting in the formation of serine and 
tetrahydrofolate. 
0 Lmaj-5FURes 50% reduction in 
coverage 
LmjF.14.1340 Delta-4 fatty acid desaturase. A fatty acid desaturase is an enzyme that 
removes two hydrogen atoms from a fatty acid, creating a carbon/carbon 
double bond, so that it catalyses the insertion of a double bond at the delta 
position of fatty acids 
4 Lmaj-5FURes 50% reduction in 
coverage 
LmjF.14.1360 Inositol-3-phosphate synthase (INO1). Inositol phosphates play an important 
role in signal transduction. 
0 Lmaj-5FURes 50% reduction in 
coverage 
LmjF.14.1370 Tyrosyl-tRNA synthetase, putative. Catalyse the attachment of an amino acid 
to its cognate transfer RNA molecule in a highly specific two-step reaction. 
0 Lmaj-5FURes 50% reduction in 
coverage (deletion) 
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Table 8.2 continued: CNVs on L. major strains 
Gene ID Gene product and function TMd strains Changes description 
LmjF.14.1400 Phosphoglycan beta 1,3 galactosyltransferase, putative (SCGL). No abstract 
from Pfam or Gene Ontology; no function classes. This gene is not mapped 
to any metabolic pathway in KEGG. No EC number(s) registered for this 
gene. No essentiality data collected for this gene and/or its orthologs. 
1 Lmaj-5FURes 50% reduction in 
coverage 
LmjF.14.1410 Protein kinase, putative. Protein kinases are a group of enzymes that move a 
phosphate group onto proteins, in a process called phosphorylation.  
0 Lmaj-5FURes 50% reduction in 
coverage 
LmjF.14.1480 Glutathione-S-transferase/glutaredoxin, putative. Glutaredoxin functions as 
an electron carrier in the glutathione-dependent synthesis of 
deoxyribonucleotides by the enzyme ribonucleotide reductase. 
1 Lmaj-5FURes 50% reduction in 
coverage 
LmjF.14.1490 Synaptojanin (N-terminal domain). It dephosphorylates the D-5 position 
phosphate from phosphatidylinositol phosphates 
1 Lmaj-5FURes 50% reduction in 
coverage 
Chromosome 18 
LmjF.18.1570 Hypothetical protein, conserved.  0 Lmaj-5FURes Doubled coverage 
(amplification) 
Chromosome 20  
LmjF.20.1180 Calpain-like cysteine peptidase, putative. Members of the calpain family are 
believed to function in various biological processes. 
0 Lmaj-5FURes Halved reduction  in 
coverage 
LmjF.20.1185 
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Table 8.2: continued CNVs on L. major strains 
Gene ID Gene function TMd strains Changes description 
Chromosome 31 
LmjF.31.0030 Hypothetical protein, conserved. Un-specified function 12 Lmaj-5F2dURes WT and Lmaj-5FURes 
have 5 copies but Lmaj-
5F2dURes has 4 copies 
LmjF.31.0040 Hypothetical protein, conserved. Un-specified function 11 Lmaj-5F2dURes WT and Lmaj-5FURes 
have 5 copies but Lmaj-
5F2dURes has 4 copies 
LmjF.31.0300 Hypothetical protein, conserved. Un-specified function 12 Lmaj-5F2dURes WT and Lmaj-5FURes 
have 5 copies but Lmaj-
5F2dURes has 4 copies 
LmjF.31.1280 
 
ATP-binding cassette protein subfamily C, member 5, putative (ABCC5). It 
is main transmembrane structural unit of ATP-binding cassette transporter. 
6 Lmaj-5FURes Lost the region 518,000-
524,000 from 2 of its 5 
chromosome copies 
LmjF.31.1290 ATP-binding cassette protein subfamily C, member 6, putative (ABCC6). It 
is main transmembrane structural unit of ATP-binding cassette transporter. 
10 Lmaj-5FURes Its borders have been lost. 
Chromosome 33 
LmjF.33.1610 Peptidase M20/M25/M40, putative. It catalysed a reaction involves the 
release of an N-terminal amino acid, usually neutral or hydrophobic, from a 
polypeptide. 
0 Lmaj-5FURes Halved reduction in 
coverage, which effects 2 
genes 
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8.5 Single nucleotide polymorphisms (SNPs) in 
kinetoplastid resistant to fluorinated pyrimidines: 
As several hundreds of SNPs on each cell line resistant strain were observed 
they were summarized in tables below. The tables included the SNPs that 
were high-confidence and led to non-synonymous changes in coding 
sequences. This omits all low-confidence SNPs that led to non-synonymous 
changes in coding sequences, SNPs that lead to synonymous changes in coding 
sequences, and SNPs that lead to changes in UTRs. For T. b. brucei 
bloodstream forms three different resistant strains (Tbb-5FURes, Tbb-
5FOARes and Tbb-5F2’dURes) were considered and compared with 427-wild-
type. Regarding to Leishmania species; for L. mexicana there are 4 datasets 
for the intermediate 5-FU-resistance and 3 datasets for the final 5-FU-
resistance; and for L. major there is one dataset for 5-FU resistance and one 
dataset for 5F2’dUrd resistance.  
Our data included lists of which genomic position was found to have a high-
confidence SNP in each dataset. The collected information about each SNP 
was: the predicted number of transmembrane domains, the style of mapping 
sequence reads to the reference, whether SNP is deemed high confidence and 
the chromosome name and position of the SNPs. Next, for each strain we 
mention to the genotype of the reference sequence (data from GeneDB), the 
inferred diploid genotype of the parental strain (wild-type strain) and the 
inferred diploid genotype of the drug-resistant strain; we also list details 
regarding the indicated strain, as well as GeneID and description (gene 
product). For the SNPs information we include: position of open reading 
frame, the affected triplet in the reference sequence and the changed amino 
acid between wild-type and resistant line. The information also includes: 
whether the SNP call has passed the filtering  (should always be OK), lists 
whether the genotypes of the wild-type and the resistant line are different 
(should always be informative), lists the chromosomal location of SNP 
(whether it's in the subtelomere "end" or in the chromosome "cores" -not  
applicable for Leishmania), listing quality control indicators that relate to the 
mapping of the sequence reads to the reference, information on SNPs in 
protein coding  sequences, information on SNPs in 5'UTRs (length of 5'UTR as 
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defined by George Cross' data or 115 bp as default), information on SNPs in 
3'UTRs (length of 3'UTR as defined by George Cross' data or 480bp as default). 
In thesis the SNPs were summarized in tables each table has the following 
columns headings: 
Strains = the cell line; GeneID = gene identification; Gene product = the gene 
description from TriTrypDB; TM = Transmembrane domains; ORF = open 
reading frame position, GeneDB = the indicated nucleotide is taken from 
GeneDB; WT = the indicated nucleotide is from the parental wild-type strain 
of the indicated resistant line; Resis = the indicated nucleotide is from the 
resistant line; amino acid mutation = the variation between wild type and 
resistant line (should always be non_syn = non-synonym codon change); codon 
= the genetic code of the amino acid, the capital letter shows the changed 
nucleotide in parental WT based on GeneDB code, when it is the same it is 
located on regular strand and when it is complementary located on reverse 
strand; Change = the type of change based on the amino acid, these changes 
were given the following numbers: 0 = No change; 1 = The amino acid 
changed from negative charge (-) to positive charge (+); 2 = The amino acid 
changed from positive charge (+) to negative charge (-); 3 = The amino acid 
changed from negative charge (-) to neutral; 4 = The amino acid changed 
from positive charge to neutral; 5 = The amino acid changed from neutral to 
negative charge; 6 = The amino acid changed from neutral to positive charge; 
7 = The amino acid changed from negative charge to a different amino acid 
with negative charge; 8 = The amino acid changed from positive charge to a 
different amino acid with positive charge; 9 = The amino acid changed from 
neutral to a different neutral amino acid; 1S = The amino acid changed from 
stop codon to negative; 2S = The amino acid changed from stop codon to 
positive; 3S = The amino acid changed from stop codon to neutral; 4S = The 
amino acid changed from negative to stop codon; 5S = The amino acid 
changed from positive to stop codon; 6S = The amino acid changed from 
neutral to stop codon. 
We particularly looked for SNPs that have TMDs, and thus may be 
associated with changes in pyrimidine transport, and for SNPs in genes known 
to be associated with pyrimidine biosynthesis/metabolism. There was only 
one SNP that was present in all the T. b. brucei fluoro-pyrimidine resistant 
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lines, on chromosome Tb927_05_v4 position 991523 bp of GeneID 
Tb927.5.3170 (Table 8.3), which codes for a putative ribose phosphate 
pyrophosphokinase. However, another SNP occurred only on Tb927.2.3390 of 
Tbb-5FURes and Tbb-5F2’dURes, this gene encodes hypothetical protein and 
carries 10 transmembrane domains. The changes on this gene were different 
in the two strains (Table 8.3). In Table 8.4 we did pairwise blast comparisons 
to find similar genes that contained SNPs in multiple species (T. b. brucei, L. 
mexicana and L. major). The BLAST results show several hundreds of hits in 
each of the species; therefore, only the closest homologues, with TMDs 
and/or association with nucleotide metabolism, are listed in the Table. The 
most interesting finds included some hypothetical proteins from L. mexicana 
and L. major, as the only near-identical match is a 5 TMD-protein 
LmxM.03.0370 in L. mexicana and its counterpart LmjF.03.0370 in L. major. 
This gene was mutated in two of the final-adapted L. mexicana lines (Fin2-
Lmex-5FURes and Fin3-Lmex-5FURes) but in none of the intermediate lines. 
The L. major orthologue was also mutated in Lmaj5FURes, showing that the 
gene was independently targeted by high concentration of 5-FU in two 
different species of Leishmania. 
J. Ali 2013 Chapter 8 235 
 
Table 8.3: Genes that were mutated in multiple T. b. brucei fluoro-pyrimidine resistant lines, as compared to WT-s427. 
TMd Tbb-
WT 
Tbb-
5FURes 
Tbb-
5F2’dURes 
Tbb-
5FOARes 
GeneID Gene Description Tbb-5FURes Tbb-5F2’dURes Tbb-5FOARes Type of 
Change 
0 GT G G G Tb927.5.3170 
Ribose-phosphate 
pyrophosphokinase, putative 
nonsyn_Ala/Glu167Ala 0/3 
10 T GT GT T Tb927.2.3390 Hypothetical protein, conserved 
nonsyn_Ser131Arg/
Ser 
nonsyn_Lys650Lys 
/Asn 
No changes 6/0- 0/4 
Table 8.4: Pair-wise blast comparisons among kinetoplastids to identify the closest homologues of genes of particular interest, with TM domain(s) or 
associated with pyrimidine biosynthesis. This table identifies genes that were mutated in more than 1 species after treatment with fluorinated pyrimidines. 
L. mexicana versus L. major 
GeneID- L. major GeneID-L. mexicana Lmaj TMd Lmex TMd Identity % Gene product-L. major Gene product-L. mexicana 
LmjF.03.0370 LmxM.03.0370 5 5 79.04 Hypothetical protein, conserved Hypothetical protein, conserved 
LmjF.03.0370 LmxM.03.0380 5 6 27.98 Hypothetical protein, conserved Hypothetical protein, conserved 
LmjF.32.0810 LmxM.08_29.2570 3 0 27.49 Serine/threonine protein kinase, putative. Serine/threonine-protein kinase, putative. 
L. major   versus T. b. brucei 
GeneID L. major GeneID T. b. brucei Lmaj TMd Tbb TMd Identity% Gene product-L. major Gene product-T. b. brucei 
LmjF.17.0190 Tb927.4.3860 2 1 34.03 Receptor-type adenylate cyclase, putative 
Receptor-type adenylate cyclase 
GRESAG 4, putative 
LmjF.32.0810 Tb11.01.5650 3 3 49.3 Serine/threonine protein kinase, putative Protein kinase, putative 
LmjF.36.0910 Tb11.01.5650 2 3 33.57 
Mitogen-activated protein kinase-like 
protein 
Protein kinase, putative 
L. mexicana versus T. b. brucei 
GeneID L. mexicana GeneID T. b. brucei Lmex TMd Tbb TMd Identity% Gene product-L. mexicana Gene product-T. b. brucei 
LmxM.28.0890 Tb11.02.5720 0 0 66.31 
Ribonucleoside-diphosphate reductase 
large chain, putative 
Ribonucleoside-diphosphate reductase 
large chain 
LmxM.32.2290 Tb11.01.5650 2 3 44.44 Protein kinase, putative protein kinase, putative 
LmxM.30.0700 Tb11.01.6360 2 1 43.6 
ATP-dependent zinc metallopeptidase, 
putative; Clan MA(E), Family M41 
Metalloprotease, putative; cell division 
protein FtsH homologue, putative. 
LmxM.30.1270 Tb11.01.8700 10 7 28.39 P-glycoprotein e ABC transporter, putative 
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6.5.1 The high-confidence SNPs that lead to non-synonymous changes in coding sequences with ≥5 TM domains (summarized in tables 
8.5 – 8.8): 
Table 8.5: SNPs with ≥5 TM domains and known function genes, which are divided into groups based on the gene product; the blank gray 
line separates groups. This table lists the SNPs in identical (Gene ID) and/or highly similar genes (gene product description). NB: in the 
change column change is listed for both alleles of this gene. 
Strains Gene ID Gene product TM ORF GeneDB WT Resis. Amino acid mutation Codon Change 
Tbb-5FURes Tb11.02.3950 
ABC transporter, putative 
12 3620 T T GT nonsyn_Asn1207Asn/Thr aAc 0/9 
Tbb-5FURes Tb11.01.8700 7 1829 A A AC nonsyn_Leu610Leu/Arg cTt 0/6 
Lmex-Int1-
5FURes 
LmxM.27.0970 14 4151 G G AG nonsyn_Thr1384Met/Thr aCg 9/0 
Lmex-Int3-
5FURes 
LmxM.11.1290 13 3463 T T GT nonsyn_Phe1155Phe/Val Ttt 0/9 
Lmex-Int4-
5FURes 
LmxM.33.0990 9 53 G AG G nonsyn_Glu18Ala/Glu gAg 3/0 
           
Tbb-5F2dURes Tb927.2.6220 Adenosine transporter 2, 
putative 
10 1036 T T GT nonsyn_Leu346Leu/Val Ttg 0/9 
Tbb-5FOARes Tb927.2.6150 11 1342 G A AG nonsyn_Thr448Ala/Thr Gct 9/0 
           
Lmex-Int1-
5FURes 
LmxM.36.4480 
Transmembrane amino acid 
transporter protein- like 
protein 
11 1309 G G GT nonsyn_Ala437Ala/Ser Gcc 0/9 
Lmex-Int2-
5FURes 
11 1309 G G GT nonsyn_Ala437Ala/Ser Gcc 0/9 
Lmex-Int3-
5FURes 
11 1309 G G GT nonsyn_Ala437Ala/Ser Gcc 0/9 
Lmex-Int4-
5FURes 
11 5089 G G GT nonsyn_Leu/Val1697Leu Ctg 9/0 
Lmex-Fin1-
5FURes 
11 1309 G G GT nonsyn_Ala437Ala/Ser Gcc 0/9 
Lmex-Fin2-
5FURes 
11 1309 G G GT nonsyn_Ala437Ala/Ser Gcc 0/9 
Lmex-Fin3-
5FURes 
11 1309 G G GT nonsyn_Ala437Ala/Ser Gcc 0/9 
J. Ali 2013 Chapter 8 237 
 
Table 8.5 continued SNPs with ≥5 TM domains and known function genes 
Strains Gene ID Gene product TM ORF GeneDB WT Resis. Amino acid mutation Codon Change 
Tbb-5FOARes 
Tb927.3.4910 
Signal peptide peptidase, 
putative; aspartic 
peptidase. 
8 214 A AG G nonsyn_Ile/Val72Val Ata 9/0 
Tbb-5FOARes 8 689 G AG A nonsyn_Asp/Gly230Asp gGc 0/5 
           
Lmex-Int1-5FURes LmxM.30.0350 
Amino acid transporter, 
putative 
11 1421 G G CG nonsyn_Thr474Ser/Thr aCt 9/0 
Lmex-Int4-5FURes LmxM.30.0350 11 628 G G CG nonsyn_His/Tyr210Tyr Cat 9/0 
Lmex-Fin1-5FURes LmxM.30.0350 11 1421 G G CG nonsyn_Thr474Ser/Thr aCt 9/0 
Lmex-Fin1-5FURes LmxM.22.0230 10 557 T T AT nonsyn_Asn186Ile/Asn aAc 9/0 
Tbb-5F2dURes Tb11.02.4520 10 733 T T GT nonsyn_Thr245Pro/Thr Act 9/0 
Lmex-Int2-5FURes LmxM.27.1580 10 800 A A AG nonsyn_Asn267Asn/Ser aAc 0/9 
Lmex-Int3-5FURes LmxM.27.1580 10 800 A A AG nonsyn_Asn267Asn/Ser aAc 0/9 
Lmex-Int4-5FURes LmxM.27.1580 10 1198 A A AG nonsyn_Ile/Val400Ile Gtc 0/9 
           
Lmex-Int1-5FURes 
LmxM.32.3200 Cation transporter, putative 
6 934 T CT C nonsyn_Phe/Leu312Leu Ttc 9/0 
Lmex-Int2-5FURes 6 934 T CT C nonsyn_Phe/Leu312Leu Ttc 9/0 
Lmex-Int3-5FURes 6 934 T CT C nonsyn_Phe/Leu312Leu Ttc 9/0 
Lmex-Int4-5FURes 6 686 T CT C nonsyn_Glu229Ala/Glu gAg 3/0 
Lmex-Fin1-5FURes 6 934 T CT C nonsyn_Phe/Leu312Leu Ttc 9/0 
Lmex-Fin2-5FURes 6 934 T CT C nonsyn_Phe/Leu312Leu Ttc 9/0 
Lmex-Fin3-5FURes 6 934 T CT C nonsyn_Phe/Leu312Leu Ttc 9/0 
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Table 8.5 continued SNPs with ≥5 TM domains and known function genes 
Strains Gene ID Gene product TM ORF GeneDB WT Resis. Amino acid mutation Codon Change 
Lmex-Int4-5FURes 
LmxM.34.5150 
Biopterin transporter, 
putative 
14 392 T CT C nonsyn_Ala/Glu131Ala gCg 0/3 
Lmex-Fin1-5FURes 14 472 T CT C nonsyn_Phe/Leu158Leu Ttc 9/0 
           
Tbb-5F2dURes 
Tb11.02.3020 Sugar transporter, putative 
12 346 C C CT nonsyn_Pro116Pro/Ser Cca 0/9 
Tbb-5F2dURes 12 355 T T GT nonsyn_Leu119Leu/Val Ttg 0/9 
           
Lmex-Int2-5FURes 
LmxM.30.1270 P-glycoprotein e 
10 4250 A AG A nonsyn_Leu/Pro1417Leu cTg 0/9 
Lmex-Int2-5FURes 10 4092 C AC C nonsyn_Asp/Glu1364Glu gaG 7/0 
Lmex-Int2-5FURes 10 1702 C CT C nonsyn_Ala/Thr568Ala Gcc 0/9 
Lmex-Int3-5FURes 10 1702 C CT C nonsyn_Ala/Thr568Ala Gcc 0/9 
Lmex-Fin2-5FURes 10 1702 C CT C nonsyn_Ala/Thr568Ala Gcc 0/9 
Lmex-Fin3-5FURes 10 1702 C CT C nonsyn_Ala/Thr568Ala Gcc 0/9 
           
Lmex-Int1-5FURes LmxM.23.1510 Vacuolar proton 
translocating ATPase 
subunit A, putative 
6 1958 A A AG nonsyn_Glu653Glu/Gly gAg 0/3 
Lmex-Int1-5FURes LmxM.31.0920 6 365 T CT C nonsyn_Ala/Val122Ala gTg 0/9 
Lmex-Fin1-5FURes LmxM.07.0630 
Vacuolar-type Ca2+-
ATPase, putative 
10 2785 T T GT nonsyn_Cys929Cys/Gly Tgc 0/9 
           
Tbb-5FOARes Tb927.3.4220 Zn-finger domain 11 38 T GT T nonsyn_Asn/Thr13Asn aAt 0/9 
Lmex-Int1-5FURes LmxM.24.2270 
Zinc-finger multi-pass 
transmembrane protein 
5 505 A A AC nonsyn_Ser169Ala/Ser Tcg 9/0 
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Table 8.6: SNPs in genes of known function with ≥5 TM domains that occurred in only one strain (unique mutations). 
Strains Gene ID Gene product TM ORF  GeneDB WT Resis.  Amino acid mutation Codon Change 
Tbb-5FURes Tb11.01.8280 
CMP-sialic acid transporter, 
putative 
9 281 A A AC nonsyn_Leu94Leu/Arg cTt 0/6 
Tbb-5F2dURes Tb927.10.13900 UDP-galactose transporter 7 20 A A AC nonsyn_Leu7Leu/Arg cTt 0/6 
Tbb-5F2dURes Tb11.52.0018 
Phospholipid-transporting 
ATPase, putative 
8 3655 A A AC nonsyn_Phe1219Phe/Val Ttc 0/9 
Lmaj-5F2dURes LmjF.17.0600 P-type ATPase, putative 6 3142 T T GT nonsyn_Thr1048Pro/Thr Act 9/0 
Lmex-Int1-5FURes LmxM.21.1810 
GPI transamidase 
component GAA1, putative 
7 536 A A AC nonsyn_Lys179Lys/Thr aAg 0/4 
Lmex-Int1-5FURes LmxM.13.1210 Nucleobase transporter 11 493 A A AC nonsyn_Phe165Phe/Val Ttt 0/9 
Lmex-Int2-5FURes LmxM.18.0040 
Transporter, putative; major 
facilitator superfamily 
protein (MFS), putative 
11 103 A A AG nonsyn_Trp35Arg/Trp Tgg 6/0 
Lmex-Int4-5FURes LmxM.06.0080 
Serine/threonine protein 
kinase, putative; protein 
kinase, putative 
6 1011 T T GT nonsyn_STOP/Tyr337Tyr taC 3S/0 
Lmex-Fin1-5FURes LmxM.24.1090 
Hypothetical predicted 
multipass transmembrane 
protein 
10 1402 G AG G nonsyn_Ile/Val468Val Gtc 9/0 
Lmex-Fin2-5FURes LmxM.23.0830 Na/H antiporter-like protein 12 2248 A A AC nonsyn_Phe750Phe/Val Ttt 0/9 
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Table 8.7: SNPs in genes of unknown function with ≥5 TM domains that are found in multiple resistant strains; mutations are divided into 
groups based on gene ID. 
Strains Gene ID Gene product TM ORF  GeneDB WT Resis. Amino acid mutation Codon Change 
Tbb-5FOARes 
Tb927.3.4110 
Hypothetical protein, 
conserved 
14 1176 C CT C nonsyn_Ile/Met392Met atG 9/0 
Tbb-5F2dURes 14 1176 C CT C nonsyn_Ile/Met392Met atG 9/0 
           
Tbb-5F2dURes 
Tb11.18.0010 
Hypothetical protein, 
conserved 
7 136 T CT T nonsyn_Pro/Ser46Ser Tcc 9/0 
Tbb-5F2dURes 7 142 A AG A nonsyn_Gly/Ser48Ser Agt 9/0 
Tbb-5F2dURes 7 151 A AG A nonsyn_Gly/Ser51Ser Agt 9/0 
           
Lmex-Int1-5FURes 
LmxM.10.0380  Unspecified product 
 12 1455 C CG C nonsyn_Ile/Met485Met atG 9/0 
Lmex-Fin2-5FURes  12 1455 C CG C nonsyn_Ile/Met485Met atG 9/0 
Lmex-Fin3-5FURes  12 1455 C CG C nonsyn_Ile/Met485Met atG 9/0 
           
Lmex-Int1-5FURes 
LmxM.17.1440 
Hypothetical protein, 
unknown function 
 20 479 T CT T nonsyn_Ala/Val160Val gTc 9/0 
Lmex-Int2-5FURes  20 479 T CT T nonsyn_Ala/Val160Val gTc 9/0 
Lmex-Int3-5FURes  20 479 T CT T nonsyn_Ala/Val160Val gTc 9/0 
Lmex-Int4-5FURes  20 1028 T CT T nonsyn_Leu343Leu/Pro cTg 0/9 
Lmex-Fin1-5FURes  20 479 T CT T nonsyn_Ala/Val160Val gTc 9/0 
Lmex-Fin2-5FURes  20 479 T CT T nonsyn_Ala/Val160Val gTc 9/0 
Lmex-Fin3-5FURes  20 479 T CT T nonsyn_Ala/Val160Val gTc 9/0 
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Table 8.7 continued SNPs in genes of unknown function with ≥5 TM domains 
Strains Gene ID Gene product TM ORF  GeneDB WT Resis.  Amino acid mutation Codon Change 
Lmex-Int1-5FURes 
LmxM.30.0030 
hypothetical protein, 
conserved 
 14 857 C T CT nonsyn_Asp286Asp/Gly gGc 0/3 
Lmex-Int4-5FURes  14 3745 C T CT nonsyn_Ile/Leu1249Leu Tta 9/0 
Lmex-Fin1-5FURes  14 857 C T CT nonsyn_Asp286Asp/Gly gGc 0/3 
           
Lmex-Int1-5FURes 
LmxM.32.0710 
hypothetical protein, 
conserved 
 10 730 T T CT nonsyn_Trp244Arg/Trp Tgg 6/0 
Lmex-Fin2-5FURes 10  191 T CT C nonsyn_Ala/Val64Ala gTt 0/9 
           
Lmex-Int1-5FURes 
LmxM.32.1940 
hypothetical protein, 
conserved 
 9 2438 C AC C nonsyn_STOP/Ser813Ser tCg 3S/0 
Lmex-Int2-5FURes  9 2438 C AC C nonsyn_STOP/Ser813Ser tCg 3S/0 
Lmex-Int3-5FURes  9 2438 C AC C nonsyn_STOP/Ser813Ser tCg 3S/0 
Lmex-Int4-5FURes  9 3028 C AC C nonsyn_His/Asn1010Asn Cac 9/0 
Lmex-Fin1-5FURes  9 2438 C AC C nonsyn_STOP/Ser813Ser tCg 3S/0 
Lmex-Fin2-5FURes  9 2438 C AC C nonsyn_STOP/Ser813Ser tCg 3S/0 
Lmex-Fin3-5FURes  9 2438 C AC C nonsyn_STOP/Ser813Ser tCg 3S/0 
           
Lmex-Int2-5FURes 
LmxM.30.0800 
Hypothetical protein, 
conserved 
 5 1457 C CT C nonsyn_Asn/Ser486Ser aGc 9/0 
Lmex-Int2-5FURes  5 892 A A AC nonsyn_Phe298Phe/Val Ttt 0/9 
Lmex-Int2-5FURes  5 125 C CT C nonsyn_Glu/Gly42Gly gGg 3/0 
Lmex-Int3-5FURes  5 892 A A AC nonsyn_Phe298Phe/Val Ttt 0/9 
Lmex-Int3-5FURes  5 125 C CT C nonsyn_Glu/Gly42Gly gGg 3/0 
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Table 8.7 continued SNPs in genes of unknown function with ≥5 TM domains 
Strains Gene ID Gene product TM ORF  GeneDB WT Resis.  Amino acid mutation Codon Change 
Lmex-Int1-5FURes 
LmxM.34.3190 
Hypothetical protein, 
conserved 
 5 521 T T CT nonsyn_Glu174Glu/Gly gAg 0/3 
Lmex-Int4-5FURes  5 1343 A AG G nonsyn_Ala/Gly448Ala gGt 9/0 
Lmex-Int4-5FURes  5 1334 C AC A nonsyn_Ala/Gly445Gly gCg 9/0 
Lmex-Fin1-5FURes  5 2588 A AG G nonsyn_Leu/Ser863Ser tTg 9/0 
Lmex-Fin1-5FURes  5 2438 C AC A nonsyn_Gly/Val813Val gGc 9/0 
           
Lmex-Int4-5FURes 
LmxM.33.1070 
Hypothetical protein, 
conserved 
 9 935 G CG G nonsyn_Gln312Gln/Arg cAg 0/6 
Lmex-Int4-5FURes  9 437 T CT T nonsyn_Gln146Leu/Gln cAg 9/0 
Lmex-Int4-5FURes  9 1265 C AC C nonsyn_Cys/Tyr422Cys tAc 0/9 
           
Lmex-Fin1-5FURes 
LmxM.24.1451 
Hypothetical protein, 
conserved 
 11 2480 C AC A nonsyn_Ala/Glu827Glu gCa 5/0 
Lmex-Fin1-5FURes  11 3187 A AG G nonsyn_Ala/Thr1063Ala Aca 0/9 
Lmex-Fin1-5FURes  11 4384 G AG G nonsyn_Gly/Ser1462Gly Ggt 9/0 
Lmex-Fin1-5FURes  11 5806 G GT G nonsyn_Cys/Gly1936Gly Ggt 9/0 
           
Lmex-Fin1-5FURes 
LmxM.26.2590 
Hypothetical protein, 
conserved 
 9 1562 G AG A nonsyn_His/Arg521His cGt 0/4 
Lmex-Fin3-5FURes  9 1562 G AG A nonsyn_His/Arg521His cGt 0/4 
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Table 8.7 continued SNPs in genes of unknown function with ≥5 TM domains 
Strains Gene ID Gene product TM ORF  GeneDB WT Resis.  Amino acid mutation Codon Change 
Lmex-Fin1-5FURes 
LmxM.30.0300 
Hypothetical protein, 
conserved 
 12 3030 T CT T nonsyn_Ile/Met1010Ile atA 0/9 
Lmex-Fin1-5FURes  12 3026 C CG C nonsyn_Ala/Gly1009Gly gGg 9/0 
Lmex-Fin1-5FURes 12 2531 G GT G nonsyn_Ala/Glu844Ala gCa 0/3 
Lmex-Fin1-5FURes  12 818 C CT C nonsyn_Asn/Ser273Ser aGc 9/0 
Lmex-Fin1-5FURes  12 454 C CT C nonsyn_Gly/Ser152Gly Ggc 0/9 
           
Lmex-Fin1-5FURes 
LmxM.30.0310 
Hypothetical protein, 
conserved 
 12 3032 T CT T nonsyn_Asp/Gly1011Asp gAc 0/5 
Lmex-Fin1-5FURes  12 1792 C CT C nonsyn_Ile/Val598Val Gtt 9/0 
Lmex-Fin1-5FURes  12 1171 T CT T nonsyn_Gly/Ser391Ser Agt 9/0 
           
Lmex-Fin2-5FURes 
LmxM.03.0370 
Hypothetical protein, 
conserved 
 5 665 C C A nonsyn_Thr222Asn aCt 9 
Lmex-Fin3-5FURes  5 665 C C A nonsyn_Thr222Asn aCt 9 
           
Lmex-Fin2-5FURes 
LmxM.03.0380 Unspecified product 
 6 692 C CT T nonsyn_Phe/Ser231Phe tCc 0/9 
Lmex-Fin3-5FURes  6 692 C CT T nonsyn_Phe/Ser231Phe tCc 0/9 
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Table 8.8: SNPs with ≥5 TM domains in genes of unknown function; these mutations are unique for the indicated strain only. 
Strains Gene ID Gene product TM ORF  GeneDB WT Resis.  Amino acid mutation Codon Change 
Tbb-5F2’dURes 
Tb927.2.3390 
Hypothetical protein, 
conserved 
10 1950 T T GT nonsyn_Lys650Lys/Asn aaA 0/4 
Tb927.2.4470 8 2353 A A AC nonsyn_Leu785Leu/Val Ttg 0/9 
Tb927.3.3500 8 241 T T GT nonsyn_Phe81Phe/Val Ttt 0/9 
Tb927.4.320 8 53 A A AC nonsyn_Leu18Leu/Arg cTt 0/6 
Tb927.8.4360 12 2166 A A AC nonsyn_Asp722Asp/Glu gaT 0/7 
Tb927.8.6730 6 652 C CT C nonsyn_Ala/Thr218Ala Gct 9/0 
Tb11.01.6760 6 1639 A A AC nonsyn_Leu547Leu/Val Ttg 0/9 
           
Tbb-5FOARes 
Tb927.3.4200 Hypothetical protein, 
conserved 
4 224 A AG A nonsyn_Met/Thr75Met aTg 0/9 
Tb927.3.4200 4 205 T CT C nonsyn_Met/Val69Val Atg 9/0 
           
Lmaj-5FURes 
LmjF.03.0370 Hypothetical protein, 
conserved 
 5 859 A A C nonsyn_Thr287Pro Acc 9 
LmjF.32.2310  9 790 A A AC nonsyn_Ser264Ala/Ser Tcg 9/0 
           
Lmaj-5F2dURes 
LmjF.08.0190 
Hypothetical protein, 
conserved 
13 2116 G G AG nonsyn_Val706Ile/Val Gtt 9/0 
LmjF.25.1160 9 1438 T T GT nonsyn_Ser480Arg/Ser Agc 6/0 
LmjF.26.0520 5 2335 T T CT nonsyn_Lys779Glu/Lys Aag 2/0 
           
Lmex-Int1-
5FURes 
LmxM.01.0440 Hypothetical protein, 
conserved 
 10 421 C CT C nonsyn_Phe/Leu141Leu Ctc 9/0 
LmxM.27.1510  5 1376 T T GT nonsyn_Val459Gly/Val gTg 9/0 
           
Lmex-Int4-
5FURes 
LmxM.14.0640 
Hypothetical protein, 
conserved 
6  904 T AC C nonsyn_Pro/Ser302Pro Ccg 0/9 
LmxM.14.0730  7 427 C CT C nonsyn_Pro/Ser143Pro Ccg 0/9 
LmxM.33.1270  13 4196 T CT T nonsyn_Asp/Gly1399Asp gGc 0/5 
LmxM.34.3320  5 2423 T CT T nonsyn_Ala/Glu808Glu gCg 5/0 
           
Fin2-Lmex-
5FURes 
LmxM.34.2810b Hypothetical protein, 
conserved 
 11 530 T T CT nonsyn_Tyr177Cys/Tyr tAt 9/0 
LmxM.25.0790  6 3503 A AG A nonsyn_Asp/Gly1168Asp gAc 0/5 
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6.5.2 The high-confidence SNPs that lead to non-synonymous changes in coding sequences, but with no TM domains (summarized in tables 
8.9 and 8.10): 
Table 8.9: SNPs that are associated with the pyrimidine biosynthesis and salvage pathways; the gray line divides the groups based on gene function 
Strains 
Gene ID ORF GDB WT Resist 
strain  
A.A. mutation Codon Type 
change 
Gene product and function 
Tbb-5FURes 
Tb927.5.3170 500 G GT G nonsyn_Ala/Glu167Ala gCa 0/3 
Ribose-phosphate diphospho-kinase 
(RPPK), also known as phosphoribosyl 
diphosphate synthetase (EC:2.7.6.1), 
catalyses the transfer of an intact 
diphosphate (PP) group from ATP to 
ribose-5-phosphate (R-5-P), which results 
in the formation of AMP and 5-phospho-
D-ribosyl-1-diphosphate (PRPP). 
Tbb-5F2’dURes 
Tbb-5FOARes 
          
Tbb-5F2dURes Tb11.02.5720 2042 A A AC nonsyn_Ile681Ile/ Ser aTt 0/9 Ribonucleotide reductase (RNR) catalyzes 
the formation of deoxyribonucleotides 
from ribonucleotides. The substrates for 
RNR are ADP, GDP, CDP and UDP. 
Lmex-Int3-5FURes 
LmxM.28.0890 1918 C C AC nonsyn_Arg640Arg/Ser Cgc 0/4 Lmex-Fin2-5FURes 
Lmex-Fin3-5FURes 
          
Tbb-5F2dURes Tb927.10.880 1088 T T GT nonsyn_Leu363Leu/Arg cTt 0/6 
Thymidine kinase, putative, TK catalyses 
the reaction: deoxythymidine + ATP = 
deoxythymidine 5’-phosphate + ADP. 
Thymidine kinases introduce 
deoxythymidine into the DNA.  
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Table 8.9 continued SNPs that are associated with the pyrimidine biosynthesis and salvage pathways; the gray line divides the groups based on 
gene function 
Strains 
Gene ID ORF GDB WT Resist 
strain  
A.A. mutation Codon Type 
change 
Gene product and function 
Lmaj-5F2dURes LmjF.30.1960 1522 T T GT nonsyn_STOP508STOP/Glu Tag 0/1S 
RNA pseudouridylate synthase-like 
protein. Members of this family are 
involved in modifying bases in RNA 
molecules. They carry out the 
conversion of uracil bases to 
pseudouridine 
          
Lmex-Fin1-5FURes LmxM.16.0550 434 T T GT nonsyn_Gln145Pro/Gln cAg 9/0 
Orotidine 5'-phosphate decarboxylase/ 
orotate phosphoribosyl transferase, 
putative (UTPase). It catalyses the last 
step in the de novo biosynthesis of 
pyrimidines. 
          
Lmex-Fin3-5FURes LmxM.10.1010 601 T T CT nonsyn_Thr201Ala/Thr Acc 9/0 
Nucleoside phosphorylase-like 
protein. Members of this family 
include: Uridine phosphorylase, which 
catalyses the cleavage of uridine into 
uracil and ribose-1-phosphate, the 
products of the reaction are used in the 
rescue of pyrimidine bases for 
nucleotide synthesis 
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Table 8.10: SNPs in genes, without TMDs, involved in nucleotide metabolism, with unique mutation for the indicated strain only. 
Strains Gene ID ORF GDB WT 
Resist 
strain  
A.A. mutation Codon 
Type 
change 
Gene function  
Tbb-5FURes Tb927.8.3800 1000 T T GT nonsyn_Ser334Arg/ Ser Agt 6/0 
Nucleoside phosphatase, putative; guanosine 
diphosphatase, putative. Nucleoside 
diphosphatase activity as well as guanosine-
diphosphatase activity 
Tbb-5F2dURes Tb927.10.5510 1498 T T GT nonsyn_Leu500Leu/ Val Ttg 0/9 
Endonuclease/exonuclease/phosphatase, 
putative. This is a structural domain found in the 
large family of proteins including magnesium 
dependent endonucleases and many 
phosphatases involved in intracellular signalling 
Tbb-5F2dURes Tb927.10.6090 632 A A AC nonsyn_Leu211Leu/ Arg cTt 0/6 
tRNA pseudouridine synthase A. Pseudouridine 
synthase activity and RNA binding. 
Tbb-5F2dURes Tb927.10.11100 683 T T GT nonsyn_Glu228Ala/ Glu gAg 3/0 
Deoxyribodipyrimidine photolyase, putative; 
DNA repair enzymes, putative. They bind to 
DNA containing pyrimidine dimers. These 
enzymes catalyse dimer splitting into the 
constituent monomers. 
Lmaj-5F2dURes LmjF.23.1590 788 C C CT nonsyn_Ser263Leu/ Ser tCa 9/0 
Oxidoreductase-like protein. This group of 
enzymes utilise NADP or NAD. 
Lmex-Fin1-5FURes LmxM.36.0330 497 T T GT nonsyn_Glu166Ala/ Glu gAg 3/0 
Ribonuclease HII is involved in the degradation 
of the ribonucleotide moiety on RNA-DNA 
hybrid molecules carrying out endonucleolytic 
cleavage to 5'-phospo-monoester. 
Lmex-Fin1-5FURes LmxM.34.4800 281 G G AG nonsyn_Arg94His/ Arg cGc 4/0 
AMP deaminase, putative. It catalyzes the 
hydrolytic deamination of AMP into IMP. 
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8.6 Discussion 
The generation of genome sequences for trypanosomes and for 
Leishmania species resistant to fluorinated pyrimidines showed numerous 
changes in each resistant strain. The data showed that the genomes of Tbb-
5FURes, Tbb-5FOARes and Tbb-5F2’dURes contained 2561, 2581 and 2605 
SNPs, respectively. Out of these SNPs only 697, 135, and 755 SNPs were 
considered as high-confidence and led to non-synonymous changes in coding 
sequences, respectively. None of these changes was found in all 
trypanosomes resistant strains with two exceptions: one occurred on gene 
Tb927.5.3170, which encodes phosphate pyrophosphokinase. This SNP is 
probably associated with resistance to fluoro-pyrimidines; the second one 
occurred on Tb927.2.3390, only on Tbb-5FURes and Tbb-5F2’dURes. Although 
this gene encodes hypothetical protein and has unknown function, it carries 
10 transmembrane domains. The SNPs on this gene were different in the two 
strains: on Tbb-5FURes the change was from serine at position 131 to arginine 
or serine, and on Tbb-5F2’dURes was from lysine on position 650 to lysine or 
asparagine. As both 5-FU and 5F2’dUrd share the same transporter (TbU3) on 
plasma membrane of bloodstream form of T. b. brucei, the SNPs on this gene 
could be a part of the adaption, particularly as we found a 76 ± 6% reduction 
of 5-FU uptake by Tbb-5FURes compared with Tbb-WT. None of the 
chromosomes of trypanosomes resistance strains has shown copy number 
variations (CNVs), consistent with the general view that Trypanosoma 
species, in contrast, to Leishmania species, do not easily undergo CNVs 
(Bingle et al., 2001;Gaunt et al., 2003). 
For the resistant Leishmania strains the number of SNPs was also very 
considerable. The four intermediate strains of L. mexicana resistant to 5-FU 
(Lmex-5FURes-Int -1,2,3,4) showed 849, 868, 618 and 1018 SNPs; out of these 
SNPs changes the data showed only 204, 197, 138 and 208 SNPs were high-
confidence and led to non-synonymous changes in coding sequences, 
respectively. Similarly numbers of SNPs were observed in the genomes of the 
three final strains of L. mexicana with very high levels of resistance to 5-FU, 
(Lmex-5FURes-Fin 1,2,3) which showed 1748, 953 and 926 SNPs, respectively. 
The numbers of SNPs that were high-confidence and led to non-synonymous 
changes in coding sequences were 447, 210 and 208 SNPs, respectively. SNPs 
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changes were also observed in the genome of L. major with resistance to 
fluorinated pyrimidines. The number of SNPs in Lmaj-5FURes and Lmaj-
5F2’dURes were 212 and 466, but the high-confidence SNPs, which led to 
non-synonymous changes in coding sequences, were 74 and 116, respectively. 
Out of thousands of SNPs in all the resistant Leishmania strains, there was 
only one gene independently targeted by 5-FU in both L. mexicana and L. 
major, and this was a hypothetical protein identified as LmxM.03.0370 and 
LmjF.03.0370, respectively. Interestingly, the gene carries a 5 TMD-protein, 
which might be a candidate gene for 5-FU resistance in Leishmania spp. 
On the other side, several reductions and elevations have been 
observed on a whole chromosome or chunk of it on Leishmania resistant 
strains. Therefore, we recommend further investigation on the suspected 
genes that were known or unknown function and potentially associated with 
resistance to fluorinated pyrimidines. 
 
 
 
CHAPTER NINE 
General discussion  
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Kinetoplastid parasites including: Trypanosoma brucei brucei, T. b. 
gambiense, T. b. rhodesiense, T. vivax, and T. congolense, as well as 
Leishmania mexicana, L. major, L. donovani, L. braziliensis, and L. 
infantum, cause a number of medical and veterinary conditions all over the 
world. As the pathogens have become resistant to most of the drugs currently 
used, new therapeutic strategies are urgently needed. Since kinetoplastid 
parasites must continue to divide at a rapid rate, purine and pyrimidine 
nucleotide metabolism is one obvious drug target. However, no purine-based 
chemotherapy has successfully emerged against kinetoplastid parasites. The 
pathway of pyrimidine nucleotide metabolism is rather more diverse in 
protozoan parasites. Kinetoplastid parasites possess both salvage and 
biosynthesis routes for pyrimidines (Al-Salabi et al., 2007; De Koning et al., 
2005; Papageorgiou et al., 2005) and some enzymes of the pyrimidine inter-
conversion pathways may be good drug targets. For instance, bloodstream 
forms of trypanosomes are unable to incorporate tritium cytosine or cytidine 
into their nucleotide pool, leaving CTP synthetase as the only route to obtain 
cytidine nucleotides; inhibition of the enzyme declined the growth in vivo 
and in vitro (Fijolek et al., 2007; Hofer et al., 2001). Another target in the 
pyrimidine pathways is RNAi knockdown of dUTPase, the inhibition of which 
reduces proliferation and leads to DNA damage (Castillo-Acosta et al., 2008, 
2013). Furthermore, knockout of DHFR-TS is lethal in T. b. brucei 
(Sienkiewicz et al., 2008). In L. donovani, UMP synthase was found to be 
essential for in vitro growth in the absence of added pyrimidines (French et 
al., 2011). 
Few studies on pyrimidine uptake by kinetoplastid parasites have been 
performed; procyclic forms of T. b. brucei (De Koning & Jarvis, 1998; Gudin 
et al., 2006) and promastigotes of L. major (Papageorgiou et al., 2005) 
showed high affinity transporters for uracil, identified as TbU1 and LmajU1, 
respectively. The incomplete information about pyrimidine permease in 
kinetoplastid and the lack of information about individual pyrimidine 
metabolism inside the cells hinder efforts to develop a pyrimidine-based 
chemotherapy, as well as making it difficult to judge the relative importance 
of salvage and synthesis. Because of that, detailed study of pyrimidine 
transport and metabolism in kinetoplastid parasites is crucial, and the 
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identification of pyrimidine analogues against Trypanosoma and Leishmania 
species are of great interest. 
Characterization of pyrimidine transport activities in bloodstream 
forms of T. b. brucei found that these cells express a high affinity uracil 
transporter (TbU3) that has a very similar substrate profile compared to TbU1 
in procyclic forms. This would usually be indicative of a similar structure for 
the two transport proteins, but the gene identifications and protein 
structures are as yet unknown. Of the two, TbU3 has more steric limitations 
than TbU1 when it comes to binding nucleosides rather than nucleobases – 
either in the binding site itself or in extracellular access to it, as reflected in 
its much lower affinity for uridine. Furthermore, the lower affinity for 4-
thiouracil by TbU3 is likely to reflect a stronger hydrogen bond at the 4-keto 
group than was the case for TbU1, as a result of a subtle shift in position or a 
different amino acid facing this group. However, while procyclic forms 
expressed TbU1, with high affinity for uracil and uridine, these cells also 
express a separate uridine transporter, TbU2 (Gudin et al., 2006), giving 
uridine salvage clearly more importance in this life-cycle stage. Bloodstream 
forms of T. b. brucei expressed only TbU3, which had high affinity and 
efficiency for uracil, but very low affinity for uridine and 2’-deoxyuridine. In 
addition, thymidine was taken up by the bloodstream forms, although 
inefficiently, through a P1-type nucleoside transporter, TbT1. The affinity to 
thymidine was identical when we assessed the uptake of the nucleoside into 
trypanosomes grown under in vivo or in vitro conditions. Uptake of uridine, 
2’-deoxyuridine, cytidine and 2’-deoxycytidine can all be measured but 
displays very low affinity and efficiency compared to [3H]-uracil transport, 
and unlikely to play any significant role in pyrimidine metabolism in vivo. 
The evidence showed that the nucleobases and nucleosides of 
pyrimidines were taken up by Leishmania cells via different transporters. We 
demonstrated that L. mexicana expressed at least two pyrimidine transport 
activities, the first being a pyrimidine nucleobase transporter (LmexU1) 
responsible for uracil uptake and well inhibited by uridine, but not by 
thymidine and adenosine. The second was a nucleoside transporter 
(LmexNT1) sensitive to uridine, thymidine and adenosine, but with low 
affinity for uracil. For promastigotes of L. major, it was demonstrated that 
these promastigotes also expressed a high affinity uracil transporter (LmajU1) 
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that was inhibited by uridine (Papageorgiou et al., 2005). However, in this 
species two distinct nucleoside transport activities were observed: the high 
affinity uridine transporter (LmajNT1), which was sensitive to uridine, uracil, 
inosine and adenine; and the low affinity uridine transporter (LmajNT2), 
which has low affinity to uridine and was insensitive to uracil, inosine and 
adenine. Both activities are inhibited by 2’-deoxyuridine, thymidine and 
adenosine. Of importance, the anticancer drug 5-fluorouracil was an 
excellent substrate for all the kinetoplastid uracil transporters TbU1, TbU3, 
LmajU1 and LmexU1. 
It appears that bloodstream forms of Trypanosoma brucei and 
promastigotes of Leishmania are virtually identical with respect to the 
toxicity of pyrimidine analogues against kinetoplastid parasites. For instance, 
5-FU, 5-FOA, 5F-2’dUrd, 5F-2’dCyd and 5F-Urd were much more active 
against all of the kinetoplastid species than any of the other halogenated 
pyrimidines tested. However, the effect of 5F-Urd and 5-FOA was an 
exception. While L. major cells were very sensitive to 5F-Urd, T. b. brucei 
and L. mexicana cells were resistant to the drug. For T. b. brucei, we mostly 
attributed that to the poor uptake, as well as the low activity of uridine 
phosphorylase; in L. mexicana the promastigotes catalyzed the drug to 5F-
2’dUrd and we linked the resistance to the rapid conversion of 5F-2’dUrd to 
5F-dUMP that lead to the absence of the metabolite responsible for inhibition 
of TS. For 5-FOA, it seems that trypanosomes are sensitive to the drug at 
micromolar level, but Leishmania species were resistant to high 
concentrations. This finding was consistent with French et al., 2011, who 
found that pyrimidine auxotrophic of L. donovani were not able to 
incorporate orotate into nucleotide pool when the cells exposed to 100 μM 
orotate as sole pyrimidine source. 
Fluorinated pyrimidines such as 5-fluorouracil, 5-fluoroorotic acid, 5-
fluoro-2’deoxy- (uridine or cytidine) and 5-chloro-2deoxyuridine displayed 
anti-trypanosomal activity in the micromolar range. The study induced 
resistance to 5-FU, 5-FOA and 5F-2’dUrd by in vitro exposure of T. b. brucei 
BSF s427-WT to stepwise increasing concentrations of the compounds. When 
the trypanosomes became resistance to high concentrations of the drugs the 
new strains were cloned out, which resulted in the clonal lines Tbb-5FURes, 
Tbb-5FOARes and Tbb-5F2’dURes with resistance factors 131, 83 and 825, 
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respectively. Tbb-5FURes cells were cross-resistant to other pyrimidine 
nucleobase analogues, but not to pyrimidine nucleoside analogues; and vies 
versa Tbb-5F2’dURes cells were cross-resistant to pyrimidine nucleoside 
analogues, but not to pyrimidine nucleobase analogues. Interestingly, when 
the uptake of natural pyrimidines was assessed in resistant Trypanosoma 
clones the results showed that the uptake of natural pyrimidines was not 
significantly changed. Although the uptake of [3H]-5-fluroruracil and [3H]-
orotic acid were reduced by 76% and 68% in the Tbb-5FURes and Tbb-5FOARes 
cell lines, respectively, we can assume that the reduction in these transport 
rates is small and most likely only one contributing factor to the very high 
levels of resistance observed in the resistant lines. The results indicate that 
the mechanisms of resistance to high levels of pyrimidine analogues in 
trypanosomes were related to changes in pyrimidine metabolic processes 
rather than drug transport. Therefore, we assessed the metabolism and mode 
of action of effective pyrimidine analogues using metabolomic assessments of 
trypanosomes clonal lines adapted to high concentrations of these pyrimidine 
analogues, and of the sensitive Trypanosoma s427-WT. 
Detailed characterization of metabolomic and incorporation of 
pyrimidine analogues in nucleic acids by trypanosomes was performed. 
Incubation with 100 μM of 5-FU or 5-FOA led to the same fluorinated 
metabolites in bloodstream forms of s427-WT and finally converted to 5F-
UMP. Considerable amounts of fluorinated-uridine nucleotides were detected 
in metabolomic extracts, as well as 5F-UDP-glucose or -galactose, and 5F-
UDP-N-acetylglucosamine, but no trace of 5-fluoro-2’deoxyuridine 
nucleotides was observed. These pyrimidine metabolites have also been 
observed to achieve lower levels in trypanosomes resistant to fluorinated 
pyrimidine nucleobases, which is consistent with reduced uptake of [3H]-
pyrimidine nucleobase transport, the reductions in the level of pyrimidine 
metabolites in resistant clones (Tbb-5FURes and Tbb-5FOARes) and the 
reduced rate of [3H]-pyrimidine nucleobase uptake could make major 
contributions in resistance mechanism to 5-FU and 5-FOA. Furthermore, the 
intracellular level of dUMP was elevated in trypanosomes of the resistant 
lines and s427-WT after treatment with 5-FU, which is possibly attributed to 
an inhibition of thymidylate synthase and/or an allosteric effect of a 
fluorinated nucleotide on ribonucleoside-diphosphate reductase. Although 
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fluorinated cytidine nucleotides were not detected in the trypanosomes 
extract after 5-FU or 5-FOA treatment, significant amounts of 5F-UMP and 
low levels of 5F-CMP were detected in digested RNA. The reason for the 
apparently more sensitive detection of fluorinated nucleotides in the 
digested RNA was attributed to a much more concentrated mono-nucleotide 
pool for HPLC/MS analysis. However, no fluorinated metabolites were 
observed in digested DNA after exposing trypanosomes to 5-FU or 5F-2’dUrd, 
which seems to differentiate the mechanism of action in trypanosomes from 
the actions in Homo sapiens cells; however, we can rule out that very small 
amounts of fluorinated deoxynucleotides were incorporated into DNA, below 
the detection level. We also could not observe any effect on glycosylation of 
T. b. brucei membrane proteins. To sum up, the analysis showed that 5-FU 
and 5-FOA trypanocidal activities are multifactorial, they are incorporated 
into a large number of metabolites such as precursors for lipid biosynthesis, 
sugar metabolism and VSG glycosylation or GPI anchors (Donelson, 2003), but 
likely exert toxicity through incorporation into RNA, and the resistance 
mechanism was possibly by preventing their incorporation into the nucleotide 
pool. 
Intracellular levels of 5F-2’dUrd were not different between s427-WT 
and Tbb-5F2’dURes cells, confirming that the resistance mechanism is based 
on metabolism rather than reduced uptake of the drug. Significant amounts 
of 2’-deoxyuridine monophosphate were observed in 5F-2’dUrd-exposed 
trypanosomes, but neither fluorinated uridine ribonucleotides nor fluorinated 
2’deoxyuridine nucleotides were detected apart from 5F-dUMP, and the lack 
of any incorporation of 5F-deoxynucleotides into DNA digests appears to 
support these findings. This strongly suggests that the mechanism of action of 
5F-2’dUrd is the inhibition of dihydrofolate reductase-thymidylate synthase 
by the drug itself or the low level of 5F-dUMP; this hypothesis was strongly 
supported when the effect was rescued by excess extracellular thymidine. 
Particularly, thymidine nucleotide levels were not significantly different in 
s427-WT and Tbb-5F2’dURes cells after treatment with 5F-2’dUrd. In 
addition, the affinity and efficiency of thymidine uptake was significantly 
increased in 5F-2’dURes comparing with s427-WT, which clearly showed that 
thymidine salvage contributes to 5F-2’dUrd resistance. As the intracellular 
levels of 5F-2’dUrd were not different between s427-WT and Tbb-5F2’dURes 
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cells, we conclude that the resistance mechanism is based on metabolism 
rather than reduced uptake of the drug. 
At 100 μM 5F-2’dCtd-exposed trypanosomes displayed almost the same 
metabolomic alterations as with 5F-2’dUrd. Particularly, the later was clearly 
detected after trypanosomes were exposed to 5F-2’dCyd; and another strong 
indication was the cross-resistance between these analogues. Therefore, we 
can conclude that 5F-2’dUrd and 5F-2’dCtd have an identical mode of action, 
and are not incorporated into nucleic acids but act as prodrugs by inhibiting 
thymidylate synthase as 5F-2’dUrd and/or 5F-dUMP.  
Compared with 5-FU and 5FOA, there were very low levels of 
fluorinated metabolites (5F-Urd, 5F-UMP, 5F-UDP and 5F-UDP-glucose) in 
s427-WT cells exposed to 100 μM of 5-fluorouridine. Trypanosomes were 
insensitive to the drug and the absence of toxicity may be the result of the 
non-detectable level of 5F-UTP, as a result of which the drug was not 
incorporated into RNA. 
The study presented an updated model of pyrimidine salvage in 
bloodstream forms of T. brucei, provided by a library of hidden Markov model 
(HMM)-based profiles for pyrimidine synthesis and salvage enzymes. Selected 
parasite proteomes were scanned with this library, with Homo sapiens and 
Mus musculus serving as references. The analysis clearly separated 
trypanosomatids from the apicomplexans, mainly because of the presence of 
TK, UDP-glucose pyrophosphorylase and UDP-glucose epimerase and the 
absence of orotate reductase and DHOD. The main distinction between T. 
brucei and its mammalian hosts was dUTPase, DHODH and UP. These 
kinetoplastid dUTPases have been classified together with several prokaryotic 
and bacteriophage dUTPases into an all-αNTP pyrophosphatase superfamily 
(Moroz et al., 2005). Similarly, trypanosomal UP has an unusual quaternary 
structure. DHOD (1.3.5.2) is indeed absent from the T. b. brucei genome, its 
function in the pyrimidine biosynthesis pathway instead being performed by 
DHOD (1.3.3.1) (Arakaki et al., 2008), which the HMM analysis correctly 
predicts. 
While fluorinated pyrimidines (nucleobases and deoxynucleosides) have 
different trypanocides effects (Figure 9.1A), in Leishmania species, fluoro-
pyrimidines have largely the same mechanism of action (Figure 9.1B). 
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Antifolates like methotrexate and pyrimethamine, which inhibit dihydrofolate 
reductase (DHFR): the inhibition of thymidine synthesis from dUMP. Although 
these antifolates and the fluoro-pyrimidine analogues act on different 
enzymes of the folate cycle, their activities may well be complementary, as 
in the highly successful, synergistic antimalarial combination 
Sulfadoxine/pyrimethamine (Fansidar®), where sulfadoxine inhibits folate 
biosynthesis. The fact that 5F-2’dUrd additionally inhibits both thymidine 
uptake and thymidine kinase, should potentiate the action of any antifolates 
against Leishmania. The problem with antifolate therapy of Leishmania has 
mostly been the potential for pteridine reductase (PTR1) to reduce 
dihydrofolate to tetrahydrofolate when DHFR is inhibited, providing a bypass 
(Bello et al., 1994; Wang et al., 1997), but a joint administration of a DHFR 
and fluoro-pyrimidine would not be successfully compensated for by 
upregulation of PTR1. Therefore, the effects of fluorinated pyrimidines as 
anti-leishmanial agents were investigated.  
Although Leishmania promastigotes showed different mechanisms of 
resistance to fluorinated pyrimidine analogues, through loss of different 
transporters, mostly, there were many close similarities between the cellular 
effects of fluorinated pyrimidine analogues (5-FU, 5F-2’dUrd and 5F-Urd; 
Figure 9.1B), indicating a common mode of action on L. mexicana and L. 
major. The specific difference was the effect of 5F-Urd, particularly in that 
L. mexicana was extremely resistant to the compound, whereas the other 
species was very sensitive. While both species generate 5F-2’dUrd from 5F-
Urd by the double action of uridine phosphorylase (with 5-FU as intermediate 
product), this is more rapidly converted by thymidine kinase to 5F-dUMP in L. 
mexicana than in L. major, explaining both the absence of the substrate and 
the higher level of the product in L. mexicana promastigotes. The other 
evidence is that the level of 5F-2’dUrd was below detection limit in L. 
mexicana treated with 5-FU, which shows the rapid conversion of 5F-2’dUrd 
to 5F-dUMP by promastigotes of this species. We also found that thymidine 
nucleotide levels in L. major are substantially reduced relative to untreated 
controls, but are not significantly different in L. mexicana. We conclude that 
the biosynthesis of thymidine is substantially inhibited in L. major, through 
inhibition of both TS in the de novo pathway by 5F-dUMP and TK in the 
salvage pathway by 5F-2’dUrd, whereas there is no inhibition of TK in L. 
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mexicana due to the absence of 5F-2’dUrd, allowing a bypass from the 
inhibition of TS and a sufficient synthesis of thymidine nucleotides. This 
interpretation is corroborated by the fact that LmajNT1 has only low affinity 
for thymidine, allowing at best a poor rate of salvage, whereas LmexNT1 
displays a Km of 4.2 ± 0.4 μM for thymidine, identical to its affinity for 
uridine. 
 
Figure 9.1: The possible mode of action of fluorinated pyrimidines in A. Trypanosoma brucei 
and B. Leishmania spp. Abbreviations: FUMP, FUDP, FUTP: fluorouridine -5'-mono-, di-, and 
triphosphate, respectively; FdUMP, FdUDP, FdUTP: fluorodeoxyuridine-5'-mono-, di-, and 
triphosphate, respectively; dUMP: deoxyuridine-5'-monophosphate; dTMP, dTDP, dTTP: 
deoxythymidine-5'-mono-, di-, and triphosphate, respectively; 5-FU: 5fluorouracil; 5FUrd: 
5fluorouridine; 5FdUrd: 5fluoro-2’deoxyuridine; Thd: thymidine; TS: thymidylate synthase; TK 
thymidine kinase. 
To understand in which way effective pyrimidine analogues rely on 
salvage enzymes or transporters, resistance was induced to 5-FU and 5F-
2’dUrd by in vitro exposure of L. mexicana and L. major to stepwise 
increasing concentrations of the compounds. The lines generated from these 
cells were Lmex-5FURes and Lmaj-5FURes, which had adapted to 5-FU, and 
Lmex-5F2’dURes and Lmaj-5F2’dURes which had adapted to 5F-2’dUrd, 
respectively. Our biochemical assessment showed that the main mechanism 
of resistance against the anti-leishmanial activity of pyrimidine analogues was 
the loss of pyrimidine transport/s. Leishmania cells become resistant to high 
concentrations of fluorinated deoxynucleosides faster than to fluorinated 
nucleobases. Lmex-5FURes and Lmaj-5FURes were unable to take up uracil, 
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this clearly shows that Leishmania-5FURes cells have lost their uracil 
transport activity completely (LmexU1 and LmajU1). In addition, Leishmania 
cells adapted to 5-FU were not cross-resistance to fluorinated nucleosides, as 
evidenced by that the rate of uridine uptake in these strains was identical to 
their wild-type counterparts. Moreover, in Lmaj-5FURes the rate of uridine 
uptake exceeded its metabolic usage, resulting in a high initial rate of 
transport, and a lower secondary rate representing uridine metabolism, 
which became rate limiting for overall uptake after a few minutes, which 
could be due to up-regulation of LmajNT1/LmajNT2. Although Lmex-
5F2’dURes cells were very resistant to 5-FU, the uracil rate of uptake by 
Lmex-5F2’dURes was equal to promastigotes of L. mexicana-WT, here we 
suggest that the high level of resistance of Lmex-5F2’dURes to 5-FU is due to 
changes in 5-FU metabolism, particularly the part of the pyrimidine 
metabolomic pathway shared by 5-FU and 5F-2’dUrd, i.e. thymidine kinase 
and thymidylate synthase. Lmaj-5F2’dURes cells are resistant to all 
fluorinated pyrimidine nucleosides, but are not at all cross-resistant to 5-FU, 
also the uptake of uridine and uracil was equally reduced in Lmaj-5F2’dURes. 
This is possibly attributed to the loss of both the LmajU1 and the uracil-
insensitive nucleoside transporter (LmajNT2). 
In conclusion, the sensitivity and cross-resistance to fluorinated 
pyrimidines was similar among kinetoplastid cells, but the mechanism of 
resistance to these analogues is totally different within trypanosomes and 
Leishmania cells. All resistant Leishmania promastigotes responded to 
increased concentrations of pyrimidine analogues by a significant or complete 
reduction in the transport capacity for natural pyrimidines, that is the cause 
of their resistance to high concentrations of fluorinated pyrimidines. The 
apparent ease by which Leishmania promastigotes ‘loose’ a pyrimidine 
transport activity is possibly related to the fact that they have several, 
whereas bloodstream trypanosomes express only TbU3. It could be speculated 
that this reflects the fact that T. b. brucei bloodstream forms express only 
one pyrimidine transporter (TbU3), whereas the Leishmania promastigotes 
express one pyrimidine nucleobase transporter in addition to at least one 
pyrimidine nucleoside transporter, of which the resistant lines loose only one. 
While this is an attractive notion, it must be remembered that pyrimidine 
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salvage is not an essential function for growth of bloodstream trypanosomes 
(Ali et al., 2013b) and promastigotes of Leishmania (French et al., 2011). 
The metabolism of fluorinated pyrimidines inside the promastigotes of 
L. mexicana and L. major was also investigated using metabolomic analysis. 
Promastigotes of Leishmania converted 5-FU and 5-FUrd to 5-F2’dUrd, which 
was phosphorylated by TK to produce 5F-dUMP. We also found that 5F-2’dUrd 
can be converted to 5-FU, the reaction by uridine phosphorylase clearly being 
reversible. No 5F-dUDP or 5F-dUTP nor 5F-UMP, 5F-UDP and 5F-UTP were 
detected after Leishmania cells exposure to these fluorinated pyrimidines. 
The analysis produced no evidence for the incorporation of fluorinated 
pyrimidines into nucleic acids. Consistent with this conclusion we found that 
5F-dUMP was most likely not a substrate for thymidylate kinase. The most 
important effect observed in Leishmania species treated with fluorinated 
pyrimidines was a massive increase in dUMP intensity that was due to the 
inhibition of TS, which converts dUMP to dTMP. This elevation caused an 
imbalance between deoxyuridine nucleotides and thymidine nucleotides, as 
well as a disturbance in the level of purine and pyrimidine derivatives. In 
addition, we found that accumulation of 5F-2’dUrd inhibited thymidine 
kinase. In general, we suggest that fluorinated pyrimidines inhibited: 
thymidylate synthase by accumulation of 5F-dUMP, and thymidine kinase by 
5F-2’dUrd. 
Although 5-FU and 5F-2’dUrd produced the same fluorinated 
metabolites and have identical mode of action against promastigotes of L. 
mexicana and L. major, the mechanism of resistance to these drugs was very 
different among Leishmania cells. For example, promastigotes of Leishmania 
became resistant to 5F-2’dUrd faster than to 5-FU. The most common 
observation between kinetoplastid was that trypanosomes and leishmanias 
resistant to 5F-2’dUrd became highly cross-resistant to 5F-2’dCyd. Alamar 
blue assay data showed some cross-resistance among pyrimidine nucleobase 
and nucleoside analogues in Leishmania cells. The most interesting data was 
the investigation of pyrimidine uptake in Leishmania resistant cells. The 
promastigotes of Leishmania resistant to 5-FU were completely insensitive to 
uracil, and resistant strains to 5F-2’dUrd were unable to take up uridine. 
Further investigations on resistant strains of Leishmania cells showed that: 
Lmex-5FURes and Lmaj-5FURes have lost their uracil transport activities, 
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LmexU1 and LmajU1, respectively; and Lmex-5F2’dURes and Lmaj-5F2’dURes 
have lost the nucleoside transporter, LmexNT1 and LmajNT1, respectively. In 
contrast, the fluoro-pyrimidine-resistant trypanosome lines did not display a 
significant loss of transport activity. 
It has long been established that kinetoplastid parasites biosynthesise 
pyrimidines and produce UMP, as the end-product of the 6-step biosynthesis 
pathway, while at the same time salvaging several pyrimidine nucleobases 
and nucleosides using transporters and different interconversions enzymes 
such as cytidine deaminase, uridine phosphorylase and uracil 
phosphoribosyltransferase (Li et al., 2007); this also generally leads to the 
production of UMP. From UMP the cell can then make all pyrimidine 
ribonucleotides and 2’deoxyribonucleotides that it requires. Therefore, this 
study attempted to assess the essentiality of pyrimidine biosynthesis and 
salvage in T. b. brucei bloodstream forms in vitro and in vivo; we exclude 
Leishmania species from this assessment as (Wilson et al., 2012) have 
addressed this issue in L. donovani. 
Pyrimidine uptake was not essential for T. b. brucei bloodstream forms 
as growth rates were unchanged in pyrimidine-free medium. The essentiality 
of the de novo pyrimidine biosynthesis pathway was studied by knocking out 
the PYR6-5 gene that produces a fusion product of orotate 
phosphoribosyltransferase (OPRTase; PYR5) and orotidine monophosphate 
decarboxylase (OMPDCase; PYR6), the two final enzymes of the 6-step 
pyrimidine biosynthesis pathway. Pyrimidine biosynthesis was essential for 
growth in the absence of an extracellular pyrimidine source. Flow cytometry 
showed that pyrimidine starvation caused incomplete DNA content in newly 
divided cells. The phenotype could be rescued by the addition of uracil, with 
uridine, 2’deoxyuridine, and cytidine also allowing a diminished growth rate 
and density; thymidine, thymine, cytosine and 2’-deoxycytidine did not allow 
growth, even at 1 mM. PYR6-5-/- were more sensitive to a number of 
cytotoxic pyrimidine analogues. The knockout cells adapted by increasing 
their rate of uracil uptake and, when growing on uridine, by upregulation of 
uridine phosphorylase. Survival of PYR6-5-/- trypanosomes in vivo was tested 
in mice; the infection developed much more slowly than the parental 
trypanosome line but the pyrimidine auxotrophs were able to establish and 
maintain a reduced parasitaemia. We conclude that trypanosomes lacking de 
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novo pyrimidine biosynthesis are highly dependent on an extracellular 
pyrimidine source, preferring uracil, and display reduced infectivity even 
though trypanosomes lacking de novo pyrimidine biosynthesis are completely 
dependent on an extracellular pyrimidine source. As T. brucei are able to 
salvage sufficient pyrimidines from the host environment, the pyrimidine 
biosynthesis pathway is not a viable drug target, although any interruption of 
pyrimidine supply was lethal. Neither pyrimidine uptake or de novo 
biosynthesis is essential in African trypanosomes but a drug combination 
targeting both systems would be a very powerful approach to novel therapy. 
Despite the fact that the genomic data analysis of kinetoplastid 
resistance to fluorinated pyrimidines showed many changes, in T. b. brucei 
strains resistant to pyrimidine analogues (Tbb-5FURes, Tbb-5FOARes and Tbb-
5F2’dURes) there was only one common SNP in all resistance strains, which 
occurred in gene Tb927.5.3170, which encodes ribose phosphate 
pyrophosphokinase. However, these resistant strains have not shown any copy 
number variations. In addition, SNP occurred on Tb927.2.3390, but only on 
Tbb-5FURes and Tbb-5F2’dURes. This gene encodes hypothetical protein and 
carries 10 transmembrane domains. Therefore, they could cause a part of the 
adaption to fluoro-pyrimidines, particularly as we found a 76 ± 6% reduction 
of 5-FU uptake by Tbb-5FURes compared with T. b. brucei wild-type. 
Leishmania spp have also shown many SNPs in the resistant cells, but 
only one common SNP appeared in L. mexicana and L. major as a result of  
exposure to a high concentration of 5-FU; this gene encoded an unknown 
protein with five putative trans-membrane domains. Regarding to copy 
number variation in resistant Leishmania strains, it seems that multiple 
changes occurred in the entire chromosomes or parts thereof, compared to 
the wild-type cells. We recommend further investigations to identify the 
specific changes that led to high resistance to fluorinated pyrimidines, using 
the SNPs observed in multiple resistant lines as starting points. 
The main findings of this thesis are: 
 Bloodstream forms of T. b. brucei expressed only one pyrimidine 
transport protein, a high affinity uracil transporter (TbU3), which has 
high affinity and efficiency for uracil, but very low affinity for uridine 
and 2’-deoxyuridine. Thymidine is also taken up by the bloodstream 
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forms, although inefficiently, through a P1-type nucleoside 
transporter, TbT1 (Chapter 3). 
 L. mexicana promastigotes expressed at least two pyrimidine transport 
activities, the first being a pyrimidine nucleobase transporter 
(LmexU1) responsible for uracil uptake and well inhibited by uridine, 
but not by thymidine and adenosine. The second was a nucleoside 
transporter (LmexNT1) sensitive to uridine, thymidine and adenosine, 
but with low affinity for uracil. L. major promastigotes also expressed 
a high affinity uracil transporter (LmajU1) that was inhibited by 
uridine. They also expresses two distinct nucleoside transport 
activities: a high affinity uridine transporter (LmajNT1), which was 
sensitive to uridine, uracil, inosine and adenine; and a low affinity 
uridine transporter (LmajNT2), which has low affinity to uridine and 
was insensitive to uracil, inosine and adenine. Both these activities are 
inhibited by 2’-deoxyuridine, thymidine and adenosine (Chapter 4). 
 Trypanosoma brucei bloodstream forms and Leishmania promastigotes 
are more sensitive to fluorinated pyrimidines (5-FU, 5-F2’dUrd and 5-
FOA and 5F-Urd) than to other halogenated pyrimidines (Chapters 3 
and 4). 
 The mechanisms of resistance to high levels of pyrimidine analogues in 
trypanosomes were mostly related to changes in pyrimidine metabolic 
processes, possibly by preventing their incorporation into the 
nucleotide pool. However, the main mechanism of resistance against 
anti-leishmanial activity of pyrimidine analogues was the loss of 
pyrimidine transporters (Chapters 3 and 4). 
 While bloodstream forms resistant to 5-FU showed only a 76% 
reduction in 5-FU uptake, resistant strains of Leishmania spp 
completely lost their natural pyrimidine transporters. Leishmania cells 
resistant to 5-FU had lost uracil transport activity (LmexU1 and 
LmajU1), and cells that were resistant to 5F-2’dUrd had lost uridine 
transport activity (LmexNT1, LmajNT1 and LmajNT2) (Chapters 3 and 
4). 
 In T. b. brucei, 5-FU and 5-FOA are incorporated into a large number 
of metabolites such as precursors for lipid biosynthesis, sugar 
metabolism and VSG glycosylation or GPI anchors, but likely exert their 
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toxicity, at least in part, through incorporation into RNA as significant 
amounts of 5F-UMP and low levels of 5F-CMP were detected in digested 
RNA (Chapter 5). 
 5F-2’dUrd and 5F2d’Cyd have a common a mode of action on 
trypanosomes, they inhibit dihydrofolate reductase-thymidylate 
synthase, either as 5F-2’dUrd or the low levels present of the 
metabolite 5F-dUMP; this hypothesis was proven when the effect of 5F-
2’dUrd was rescued by excess extracellular thymidine (Chapter 5). 
 Promastigotes of Leishmania converted 5-FU and 5-FUrd to 5-F2’dUrd, 
which was phosphorylated by TK to produce 5F-dUMP. Therefore, we 
suggest that fluorinated pyrimidines have a common mode of anti-
leishmanial action through (a) inhibiting thymidylate synthase by 
accumulation of 5F-dUMP, and (b) thymidine kinase by 5F-2’dUrd 
(Chapter 6). 
 Trypanosomes that were made pyrimidine auxotrophic by disruption of 
the OMPDCase gene adapted by increasing their rate of uracil uptake 
and, when growing on uridine, by upregulation of uridine 
phosphorylase (Chapter 7). 
 Trypanosomes lacking de novo pyrimidine biosynthesis are highly 
dependent on an extracellular pyrimidine source, preferring uracil, 
and display reduced infectivity (Chapter 7). 
 In all the T. b. brucei strains resistant to pyrimidine analogues (Tbb-
5FURes, Tbb-5FOARes and Tbb-5F2’dURes) there was only one common 
SNP, which occurred in gene Tb927.5.3170, which encodes ribose 
phosphate pyrophosphokinase (Chapter 8). 
 A further SNP of interest occurred on Tb927.2.3390, but only on Tbb-
5FURes and Tbb-5F2’dURes. This gene encodes for a hypothetical 
protein and carries 10 transmembrane domains (Chapter 8).  
 Only one common SNP appeared in L. mexicana and L. major as a 
result of exposure to a high concentration of 5-FU; this gene encoded 
an unknown protein with five putative trans-membrane domains 
(Chapter 8). 
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Appendix I: Standard HMI-9 and HMI-9-tmd media. Without adding serum 
Compounds HMI-9 (mg/L) HMI-9-tmd (mg/L) 
CaCl2 165 165 
KCl 330 330 
KNO3 0.076 0.076 
MgSO4 97.67 97.67 
NaCl 4500 4500 
NaHCO3 3000 3000 
NaH2PO4.H2O 125 125 
Na2SeO3.5H2O 0.0112 0.0112 
Glucose 4500 4500 
Phenol Red 15 15 
HEPES 5958 5958 
β-mercaptoethanol 14.3 M 14.3 M 
Bathocuproine disulfonate.Na2 28.225 28.225 
Alanine 25 25 
Arginine. HCl 84 84 
Asparagine 25 25 
Aspartic acid 30 30 
Cysteine 181.74 181.74 
Cystine 91.24 91.24 
Glutamic acid 75 75 
Glutamine 584 584 
Glycine 30 30 
Histidine.HCl.H2O 42 42 
Isoleucine 105 105 
Leucine 105 105 
Lysine. HCl 146 146 
Methionine 30 30 
Phenylalanine 66 66 
Proline 40 40 
Serine 42 42 
Threonine 95 95 
Tryptophan 16 16 
Tyrosine 104.2 104.2 
Valine 94 94 
B12 0.013 0.013 
Biotin 0.013 0.013 
D-Ca pantothenate 4 4 
Choline chloride 4 4 
Folic Acid 4 4 
Inositol 7.2 7.2 
Niacinamide 4 4 
Pyridoxal. HCl 4 4 
Riboflavin 0.4 0.4 
Thiamine. HCl 4 4 
Pyruvate. Na 220 220 
Hypoxanthine 136.1 136.1 
 Thymidine 20.176 0 
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Appendix II: Structures of natural pyrimidines and their analogues 
Nucleobases 
   
 
 
Uracil 
 
Cytosine 
 
Thymine 
    
 
5-Fluorouracil 
 
5-Chlorouracil 
 
5-Bromouracil 
 
5-Iodouracil 
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Appendix II: continued structures of natural pyrimidines and their analogues 
Nucleobases    
 
5-Fluoroorotic acid 
 
5-Fluorocytosine 
 
1-methyl uracil 
 
2-Thiouracil 
 
4-Thiouracil 
 
5,6-dihydrouracil 
 
6-Azauracil 
 
6-methyluracil 
    
 
3-deazauracil 
 
2-mercaptopyrimidine 
 
4 (3H)pyrimidinone 
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Appendix II: continued structures of natural pyrimidines and their analogues 
Nucleosides    
 
 
Uridine 
 
Cytidine 
 
Thymidine 
 
5-Fluorouridine 
 
5-Chlorouridine 
 
5-Bromouridine 
 
5-Iodouridine 
 
5-Fluorocytidine 
 
2-Thiouridine 
 
4-Thiouridine 
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Appendix II: continued structures of natural pyrimidines and their analogues 
Deoxynucleosides    
 
 
2’-deoxyuridine 
 
2’deoxycytidine 
 
2’deoxythymidine 
    
 
5-Fluoro-2’deoxyuridine 
 
5-Chloro-
2’deoxyuridine 
 
5-Bromo-
2’deoxyuridine 
 
5-Iodo-2’deoxyuridine 
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Appendix II: continued structures of natural pyrimidines and their analogues 
Deoxynucleosides    
 
5-Fluoro-2’deoxycytidine 
 
2’,3’-dideoxyuridine 
 
2’,5’-dideoxyuridine 
 
5’-deoxyuridine 
 
5’-deoxy-5-fluorouridine 
 
3’-deoxyuridine 
 
3’-deoxythymidine 
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Appendix III: Kinetic characterization of pyrimidine and purine uptakes in kinetoplastid wild-type cells (Km and Vmax values). 
[
3
H]-Substrates T. b. brucei bloodstream forms L. mexicana  promastigotes L. major promastigotes 
Uracil Km (μM) Vmax (pmol∙10
7
 cells
-1∙s-1) Efficiency Km (μM) Vmax (pmol∙10
7
 cells
-1∙s-1) Efficiency Km (μM) Vmax (pmol∙10
7
 cells
-1∙s-1) Efficiency 
1
st
 repeat 0.45 0.26  18.9 0.072     
2
nd
 repeat 0.68 0.18  35.3 0.08     
3
rd
 repeat 1.08 0.17  34.9 0.11     
4
th
 repeat 0.42 0.05        
5
th
 repeat 0.32 0.10        
6
th
 repeat 0.28 0.07        
Mean 0.54 0.14 0.25 29.7 0.088 0.0029 0.32 0.68 2.15 
SE 0.11 0.03  4.41 0.01  0.07 0.15  
N 6 6  3 3     
[
3
H]-Substrates T. b. brucei bloodstream forms L. mexicana  promastigotes L. major promastigotes 
Uridine Km (μM) Vmax (pmol∙10
7
 cells
-1∙s-1) Efficiency Km (μM) Vmax (pmol∙10
7
 cells
-1∙s-1) Efficiency Km (μM) Vmax (pmol∙10
7
 cells
-1∙s-1) Efficiency 
1
st
 repeat 3397 8.0  8.96 0.79  2.17 0.044  
2
nd
 repeat 10348 17.0  9.10 0.28  2.59 0.026  
3
rd
 repeat 14810 23.1  5.79 0.28  4.6 0.038  
4
th
 repeat    3.88 0.22     
5
th
 repeat    8.01 0.067     
Mean 9518 16 0.0016 7.2 0.33 0.046 3.12 0.036 0.011 
SE 2711 4  0.9 0.11  0.61 0.004  
N 3 3  5 5  3 3  
[
3
H]-Substrates T. b. brucei bloodstream forms L. mexicana  promastigotes L. major promastigotes 
Thymidine Km (μM) Vmax (pmol∙10
7
 cells
-1∙s-1) Efficiency Km (μM) Vmax (pmol∙10
7
 cells
-1∙s-1) Efficiency Km (μM) Vmax (pmol∙10
7
 cells
-1∙s-1) Efficiency 
1
st
 repeat 1084 0.082  3.69 0.765     
2
nd
 repeat 677.1 0.048  5.21 1.13     
3
rd
 repeat 1959 0.070  3.84 0.66     
Mean 1240 0.067 5.42E-05 4.24 0.85 0.20    
SE 309 0.008  0.39 0.12     
N 3 3  3 3     
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Appendix III continued Kinetic characterization of pyrimidine and purine uptakes in kinetoplastid wild-type cells (Km ,Vmax values). 
 [
3
H]-Substrates T. b. brucei bloodstream forms L. mexicana  promastigotes L. major promastigotes 
2’deoxyuridine Km (μM) Vmax (pmol∙10
7
 cells
-1∙s-1) Efficiency Km (μM) Vmax (pmol∙10
7
 cells
-1∙s-1) Efficiency Km (μM) Vmax (pmol∙10
7
 cells
-1∙s-1) Efficiency 
1
st
 repeat 558 0.26        
2
nd
 repeat 746 0.57        
3
rd
 repeat 1110 3.15        
Mean 804.7 1.32 0.0016       
SE 132.3 0.74        
N 3 3        
[
3
H]-Substrates T. b. brucei bloodstream forms L. mexicana  promastigotes L. major promastigotes 
Uridine + 1mM 
Uracil 
Km (μM) Vmax (pmol∙10
7
 cells
-1∙s-1) Efficiency Km (μM) Vmax (pmol∙10
7
 cells
-1∙s-1) Efficiency Km (μM) Vmax (pmol∙10
7
 cells
-1∙s-1) Efficiency 
1
st
 repeat    4.12 0.32     
2
nd
 repeat    3.654 0.15     
3
rd
 repeat    4.539 0.477     
Mean    4.1 0.32 0.078    
SE    0.20 0.075     
N    3 3     
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Appendix III continued Kinetic characterization of pyrimidine and purine uptakes in kinetoplastid wild-type cells (Km ,Vmax values). 
[
3
H]-Substrates T. b. brucei bloodstream forms L. mexicana  promastigotes L. major promastigotes 
Adenosine Km (μM) Vmax (pmol∙10
7
 cells
-1∙s-1) Efficiency Km (μM) Vmax (pmol∙10
7
 cells
-1∙s-1) Efficiency Km (μM) Vmax (pmol∙10
7
 cells
-1∙s-1) Efficiency 
1
st
 repeat    0.80 1.64     
2
nd
 repeat    1.18 0.96     
3
rd
 repeat    0.50 0.79     
Mean    0.83 1.13 1.35    
SE    0.16 0.21     
N    3 3     
[
3
H]-Substrates T. b. brucei bloodstream forms L. mexicana  promastigotes L. major promastigotes 
5-Fluorouracil Km (μM) Vmax (pmol∙10
7
 cells
-1∙s-1) Efficiency Km (μM) Vmax (pmol∙10
7
 cells
-1∙s-1) Efficiency Km (μM) Vmax (pmol∙10
7
 cells
-1∙s-1) Efficiency 
1
st
 repeat 2.57 0.24        
2
nd
 repeat 2.55 0.29        
Mean 2.56 0.27 0.105       
SE 0.008 0.015        
N 2 2        
[
3
H]-Substrates T. b. brucei bloodstream forms L. mexicana  promastigotes L. major promastigotes 
Inosine Km (μM) Vmax (pmol∙10
7
 cells
-1∙s-1) Efficiency Km (μM) Vmax (pmol∙10
7
 cells
-1∙s-1) Efficiency Km (μM) Vmax (pmol∙10
7
 cells
-1∙s-1) Efficiency 
1
st
 repeat 1.168 0.06092        
2
nd
 repeat 0.532 0.05303        
3
rd
 repeat 0.9837 0.1114        
Mean 0.89 0.075        
SE 0.15 0.015        
N 3 3        
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Appendix IV: Substrate profiles of the pyrimidine transporters (Ki values) in Kinetoplastid wild type cells 
Inhibitors/[
3
H]-substrate T. b. brucei bloodstream forms L. mexicana  promastigotes L. major  promastigotes 
Uracil Uracil Uridine Thymidine Uracil Uridine  Thymidine Uracil Uridine  Thymidine 
 1
st
 repeat  2.1 >2500  16.52 >2500  3.61  
 2
nd
 repeat  1.38 >2500  33.61 >2500  1.00  
 3
rd
 repeat  1.54 >2500  15.29 >2500  2.78  
 4
th
 repeat     50.97     
 5
th
 repeat     12.20     
Mean   1.67 >2500  25.72 >2500  2.46  
SE   0.18 0  6.56 0  0.63  
N   3 3  5 3  3  
Inhibitors/[
3
H]-substrate T. b. brucei bloodstream forms L. mexicana  promastigotes L. major  promastigotes 
Uridine  Uracil Uridine Thymidine Uracil Uridine  Thymidine Uracil Uridine  Thymidine 
 1
st
 repeat ≥10000  178.28 3.52  7.51    
 2
nd
 repeat ≥10000  130.94 0.79  5.29    
 3
rd
 repeat ≥10000  288.67 2.31  5.11    
 4
th
 repeat    1.47      
Mean  ≥10000  199.3 2.02  5.97 10.9   
SE  0  38.2 0.51  0.63 3.2   
N  3  3 4  3    
Inhibitors/[
3
H]-substrate T. b. brucei bloodstream forms L. mexicana  promastigotes L. major  promastigotes 
Thymidine  Uracil Uridine Thymidine Uracil Uridine  Thymidine Uracil Uridine  Thymidine 
 1
st
 repeat >10000   >10000 10.17   139.24  
 2
nd
 repeat >10000   >10000 4.09   81.12  
 3
rd
 repeat >10000   >10000 15.24     
 4
th
 repeat          
 5
th
 repeat          
Mean  >10000   >10000 9.8  >200 110.18  
SE  0   0 2.6  0 20.55  
N  3   3 3   2  
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Appendix IV: continued Substrate profiles of the pyrimidine transporters (Ki values) in Kinetoplastid wild type cells 
Inhibitors/[
3
H]-substrate T. b. brucei bloodstream forms L. mexicana  promastigotes L. major  promastigotes 
2’Deoxyuridine  Uracil Uridine Thymidine Uracil Uridine  Thymidine Uracil Uridine  Thymidine 
 1
st
 repeat 578.98  367.26 15.24 5.94   9.25  
 2
nd
 repeat 1715.79  169.61 4.73 9.07   4.98  
 3
rd
 repeat 1935.16  422.29 7.83 6.59   23.11  
 4
th 
repeat   322.40       
Mean  1147  320.4 9.27 7.20   12.45  
SE  343  47 2.55 0.78   4.47  
N  3  4 3 3   3  
Inhibitors/[
3
H]-substrate T. b. brucei bloodstream forms L. mexicana  promastigotes L. major  promastigotes 
Cytidine  Uracil Uridine Thymidine Uracil Uridine Thymidine Uracil Uridine Thymidine 
 1
st
 repeat   >10000  66.61 94.71    
 2
nd
 repeat   >10000  54.23 78.12    
 3
rd
 repeat   >10000  114.80 72.94    
Mean    >10000  78.55 81.92 >200   
SE    0  15.09 5.36    
N    3  3 3    
Inhibitors/[
3
H]-substrate T. b. brucei bloodstream forms L. mexicana  promastigotes L. major  promastigotes 
Thymine  Uracil Uridine Thymidine Uracil Uridine Thymidine Uracil Uridine Thymidine 
 1
st
 repeat >2500  >1000 983.44      
 2
nd
 repeat >2500  >1000 163.25      
 3
rd
 repeat >2500  >1000 542.86      
Mean  >2500  >1000 563.19      
SE  0  0 193.5      
N  3  3 3      
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Appendix IV: continued Substrate profiles of the pyrimidine transporters (Ki values) in Kinetoplastid wild type cells 
Inhibitors/[
3
H]-substrate T. b. brucei bloodstream forms L. mexicana  promastigotes L. major  promastigotes 
Cytosine  Uracil Uridine Thymidine Uracil Uridine Thymidine Uracil Uridine Thymidine 
 1
st
 repeat >2500   >5000      
 2
nd
 repeat >2500   >5000      
 3
rd
 repeat >2500   >5000      
Mean  >2500   >5000   >200   
SE  0   0   0   
N  3   3      
Inhibitors/[
3
H]-substrate T. b. brucei bloodstream forms L. mexicana  promastigotes L. major  promastigotes 
5-Fluorouracil  Uracil Uridine Thymidine Uracil Uridine  Thymidine Uracil Uridine  Thymidine 
 1
st
 repeat 7.76  >1000 72.14 >5000     
 2
nd
 repeat 5.18  >1000 48.06 >5000     
 3
rd
 repeat 10.68  >1000 48.85 >5000     
Mean  7.9  >1000 56.35 >5000  0.66   
SE  1.3  0 6.45 0  0.14   
N  3  3 3 3     
Inhibitors/[
3
H]-substrate T. b. brucei bloodstream forms L. mexicana  promastigotes L. major  promastigotes 
5Fl-2’dUrd  Uracil Uridine Thymidine Uracil Uridine  Thymidine Uracil Uridine  Thymidine 
 1
st
 repeat     6.91     
 2
nd
 repeat     7.25     
 3
rd
 repeat     6.81     
Mean      7     
SE      0.11     
N      3     
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Appendix IV: continued Substrate profiles of the pyrimidine transporters (Ki values) in Kinetoplastid wild type cells 
Inhibitors/[
3
H]-substrate T. b. brucei bloodstream forms L. mexicana promastigotes L. major  promastigotes 
Adenine  Uracil Uridine Thymidine Uracil Uridine  Thymidine Uracil Uridine  Thymidine 
 1
st
 repeat    314.70 >1000   10.06  
 2
nd
 repeat    416.00 >1000   3.66  
 3
rd
 repeat    134.73 >1000   1.56  
Mean     288.48 >1000  >200 5.09  
SE     67.15 0   2.09  
N     3 3   3  
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Appendix IV: continued Substrate profiles of the pyrimidine transporters (Ki values) in Kinetoplastid wild type cells 
Inhibitors/[
3
H]-substrate T. b. brucei bloodstream forms L. mexicana promastigotes L. major  promastigotes 
Adenosine  Uracil Uridine Thymidine Uracil Uridine  Thymidine Uracil Uridine  Thymidine 
 1
st
 repeat   2.102 2770.36 0.19 0.18  3.02  
 2
nd
 repeat   1.79 946.07 0.58 0.34  1.84  
 3
rd
 repeat   3.006 4817.89 0.40 0.23  0.92  
 4
th
 repeat    6379.60      
Mean    2.3 3728 0.39 0.25  1.93  
SE    0.3 1026 0.09 0.04  0.49  
N    3 4 3 3  3  
Inhibitors/[
3
H]-substrate T. b. brucei bloodstream forms L. mexicana promastigotes L. major  promastigotes 
Hypoxanthine  Uracil Uridine Thymidine Uracil Uridine  Thymidine Uracil Uridine  Thymidine 
 1
st
 repeat >1000         
 2
nd
 repeat >1000   >500      
 3
rd
 repeat >1000   >500      
Mean  >1000   >500   >200   
SE  0   0   0   
N  3   2      
Inhibitors/[
3
H]-substrate T. b. brucei bloodstream forms L. mexicana promastigotes L. major  promastigotes 
Inosine  Uracil Uridine Thymidine Uracil Uridine  Thymidine Uracil Uridine  Thymidine 
 1
st
 repeat   0.863  559.55 615.22  0.15  
 2
nd
 repeat   3.28  1364.14 582.35  0.14  
 3
rd
 repeat   0.638  1107.52 722.07  0.13  
Mean    1.6  1010.4 639.88  0.14  
SE    0.6  193.74 34.44  0.004  
N    3  3 3  3  
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Appendix V: The EC50 values of effective pyrimidine analogues on Kinetoplastid strains using Alamar Blue assay 
 
T. b. brucei bloodstream forms L. mexicana promastigotes L. major promastigotes 
s427-WT Tbb5FURes Tbb5FdURes Tbb5FOARes sM379-WT Lmex5FURes Lmex5FdURes sF-WT Lmaj5FURes Lmaj5FdURes 
5-Fluorouracil          
1
st
 repeat 36.3 3746 80.4 459 9.2 1162 1850 11.2 165 15.8 
2
nd
repeat 33 5905 75 408 10.7 1658 854.8 11 140 12.8 
3
rd
 repeat 40 4873 73 446 7.4 1559 1163 7 160 11.3 
4
th
 repeat 34.4 5303  458.6 9.9 1119 2500 8.5 129 10.5 
5
th
 repeat  4479  589.5   2500 7.3 161  
6
th
 repeat  3933  328.8    8.1 149  
7
th
 repeat        6.7   
           
Mean ± SE 35.9±1.5 4706±307 76.1±2.2 448.3±31.6 9.3±0.6 1374.5± 123 1773±301 8.5±0.6 150±6.2 12.6±1.0 
 
T. b. brucei bloodstream forms L. mexicana promastigotes L. major promastigotes 
s427-WT Tbb5FURes Tbb5FdURes Tbb5FOARes sM379-WT Lmex5FURes Lmex5FdURes sF-WT Lmaj5FURes Lmaj5FdURes 
5Fluoro-2’deoxyuridine          
1
st
 repeat 4.8 2.7 4512 38 1.4 0.56 > 5000 1.7 6.9 582 
2
nd
repeat 5.2 3.4 3763 28 1.13 1.3 > 5000 1.6 7 248 
3
rd
 repeat 5.6 4 4610 33 1.3 1.5 > 5000 1.2 4 314 
4
th
 repeat 5.22 3.3  29.2 1.5 2 > 5000 2.2 6.4  
5
th
 repeat  2.4  32.9 1.3 2 >5000 2 6.3  
6
th
 repeat    24.8 1.7   1.4 3.4  
7
th
 repeat     1.5   1.8   
8
th
 repeat     1.3      
9
th
 repeat     1.7      
Mean ± SE 5.2±0.2 3.16±0.25 4295±267 30.98±1.7 1.4±0.06 1.47±0.23 >5000 1.7±0.1 6.12 ± 0.48 381 ± 83 
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Appendix V: continued the IC50 values of effective pyrimidine analogues on Kinetoplastid strains using Alamar Blue assay 
 
T. b. brucei bloodstream forms L. mexicana promastigotes L. major promastigotes 
s427-WT Tbb5FURes Tbb5FdURes Tbb5FOARes sM379-WT Lmex5FURes Lmex5FdURes sF-WT Lmaj5FURes Lmaj5FdURes 
5Fluoro-uridine          
1
st
 repeat >5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 18.7 103 2044 
2
nd
repeat >5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 15.3 86 650 
3
rd
 repeat >5000 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 22 170 1003 
4
th
 repeat        14.2   
5
th
 repeat        17.4 81  
6
th
 repeat        17   
7
th
 repeat        22   
Mean ± SE >5000 >5000 >5000 >5000 >5000 >5000 >5000 18±1.6 110 ± 17.7 1232 ± 341 
 
T. b. brucei bloodstream forms L. mexicana promastigotes L. major promastigotes 
s427-WT Tbb5FURes Tbb5FdURes Tbb5FOARes sM379-WT Lmex5FURes Lmex5FdURes sF-WT Lmaj5FURes Lmaj5FdURes 
5Fluoro-orotic acid          
1
st
 repeat 12.5 94 13.6 1459 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 
2
nd
repeat 13 96 13.2 1240 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 
3
rd
 repeat 14.2 97 13.3 884.5 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 
4
th
 repeat 16.8 108  1412       
5
th
 repeat  93  1410       
6
th
 repeat    1109       
7
th
 repeat    730       
Mean ± SE 14.1±0.9 97.6±2.4 13.3±0.12 1177.7±99. >5000 >5000 >5000 >5000 >5000 >5000 
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Appendix V: continued the IC50 values of effective pyrimidine analogues on Kinetoplastid strains using Alamar Blue assay 
 
T. b. brucei bloodstream forms L. mexicana promastigotes L. major promastigotes 
s427-WT Tbb5FURes Tbb5FdURes Tbb5FOARes sM379-WT Lmex5FURes Lmex5FdURes sF-WT Lmaj5FURes Lmaj5FdURes 
5Fluoro-2’deoxycytidine          
1
st
 repeat 46 65 > 5000 124 19.8 22 > 5000 39 13.8 5392 
2
nd
repeat 51 53 > 5000 108 12.6 26 > 5000 41 16 3070 
3
rd
 repeat 43.6 46 > 5000 131 21.6 24 > 5000 34 21.2 3148 
4
th
 repeat 57  > 5000 102 17.9  > 5000    
5
th
 repeat    166 17      
6
th
 repeat     13.2      
7
th
 repeat     19      
Mean ± SE 49.4±3.0 54.6±4.5 >5000 126.2±10 17.3±1.8 24±0.94 >5000 38±1.6 17±1.79 3870±621 
 
T. b. brucei bloodstream forms L. mexicana promastigotes L. major promastigotes 
s427-WT Tbb5FURes Tbb5FdURes Tbb5FOARes sM379-WT Lmex5FURes Lmex5FdURes sF-WT Lmaj5FURes Lmaj5FdURes 
5-Chloro-2’deoxyuridine          
1
st
 repeat 51 4 21.9 104 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 
2
nd
repeat 53.8 3.9 20.2 98 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 
3
rd
 repeat 57 3.8 23.7 73 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 
4
th
 repeat  3  76       
5
th
 repeat    106       
Mean ± SE 54±1.7 3.67±0.19 21.9±1.0 91.4±6.2 >5000 >5000 >5000 >5000 >5000 >5000 
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Appendix V: continued the IC50 values of effective pyrimidine analogues on Kinetoplastid strains using Alamar Blue assay 
 T. b. brucei bloodstream forms L. mexicana promastigotes L. major promastigotes 
s427-WT Tbb5FURes Tbb5FdURes Tbb5FOARes sM379-WT Lmex5FURes Lmex5FdURes sF-WT Lmaj5FURes Lmaj5FdURes 
6-Azauracil          
1
st
 repeat 1000 163 1015 1561 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 
2
nd
repeat 875 155 1200 1352 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 
3
rd
 repeat 1000 153 1095 1151 > 5000 > 5000 > 5000 > 5000 > 5000 > 5000 
4
th
 repeat    1484       
Mean ± SE 958±34 157±2.49 1103±43.7 1387±77.7 >5000 >5000 >5000 >5000 >5000 >5000 
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